

Exhibit B

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

The parties reserve all objections to any exhibit or portion thereof listed by either party. By listing an exhibit, the parties do not waive any objection. The parties reserve the right to object depending upon the admission of testimony or other exhibits. The parties the right to supplement this exhibit list after reviewing each other's exchanged exhibit list.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5000	Email from D. Uelmen to J. Hudnall, et al re: Physician Panel Agenda	BPV-17-01-00000105	BPV-17-01-00000107	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #1
5001	Dec. 2004 Dear Doctor Letter	BPV-17-01-00000188	BPV-17-01-00000189	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5002	Feb. 4, 2005 Conference FDA and BPV re DCL and Recovery Retrieivable (K031328)	BPV-17-01-00000208	BPV-17-01-00000209	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5003	Feb. 8, 2005 Conference FDA and BPV re Recovery Retrieivable (K031328)	BPV-17-01-00000210	BPV-17-01-00000211	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5004	Recovery Filter IFU 2003	BPV-17-01-00000246	BPV-17-01-00000248	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5005	Recovery Filter DFMEA 070010, Rev. 2 DFMEA070010 Rev. 2 Recovery Filter DFMEA 070010, Rev. 2	BPV-17-01-00000249	BPV-17-01-00000262	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5006	Design Review Assessment Status Memo	BPV-17-01-00000297	BPV-17-01-00000302	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 901
5007	Oct 18, 2002 letter to the FDA responding to the questions posed by Dr. Harvey at the FDA about RNF	BPV-17-01-00000334	BPV-17-01-00000340	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403
5008	ETR-04-08-04 (G2 Arm Fatigue Testing Report) ETR-04-08-04 (G2 Arm Fatigue Testing Report)	BPV-17-01-00000781	BPV-17-01-00000787	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5009	TM1133800 (G2 Filter Arm Fatigue Test Method)	BPV-17-01-00001481	BPV-17-01-00001487	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5010	Recovery Filter Fault Tree Analysis	BPV-17-01-00002121	BPV-17-01-00002127	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5011	SPA-04-04-01 (Remedial Action Plan re RNF Fractures)	BPV-17-01-00002137	BPV-17-01-00002140	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5012	HHE of Dr. Ciavarella July 9, 2004	BPV-17-01-00002145	BPV-17-01-00002145	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5013	May 21, 2002 Memo from Doug Uelmen (re Fracture Investigation)	BPV-17-01-00002207	BPV-17-01-00002216	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5014	ETR-04-06-06 (RF Migration Resistance DOE and Hook Radius Change)	BPV-17-01-00002240	BPV-17-01-00002270	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5015	ETR-04-10-21 (G2® Acute Animal Feasibility Study)	BPV-17-01-00002335	BPV-17-01-00002344	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5016	ETR-02-12-01, Rev. 00 (Recovery Filter Magnetic Resonance Safety and Compatibility Report)	BPV-17-01-00002345	BPV-17-01-00002369	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5017	Aug. 5, 1999 R&D Technical Report RNF Migration Study, Design Verification (RD-RPT-100)	BPV-17-01-00002650	BPV-17-01-00002655	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403
5018	RD-RPT-104 (Analysis of RNF Migration Resistance) (FEA)	BPV-17-01-00002656	BPV-17-01-00002662	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5019	RNF Wire Tensile Test Report	BPV-17-01-00003453	BPV-17-01-00003466	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5020	Aug. 9, 1999 RD-RPT-102 RNF Radial Strength Report	BPV-17-01-00003667	BPV-17-01-00003672	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2
5021	ETR-04-10-04 (Feasibility: RNF v. G2 and Competitive Product -- migration resistance)	BPV-17-01-00003783	BPV-17-01-00003792	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5022	RD-LNB-087 Laboratory Notebook	BPV-17-01-00004149	BPV-17-01-00004290	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5023	Aug. 12, 1999 RD-RPT-095 Test Results for RD-SOP-057 Simulated Use	BPV-17-01-00004856	BPV-17-01-00004863	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5024	Recovery Filter DFMEA 070010, Rev. 4 Recovery Filter DFMEA 070010, Rev. 4	BPV-17-01-00007573	BPV-17-01-00007595	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2
5025	ETR-05-03-01 G1A Jugular/Subclavian System Design Verification and Validation Phase 2 Report	BPV-17-01-00008669	BPV-17-01-00008680	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5026	ETR-05-05-21 G1A Jugular/Subclavian System Design Verification and Validation Phase 3 Report	BPV-17-01-00008682	BPV-17-01-00008688	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5027	ETR-05-03-02 G1A Acute Animal Study Report	BPV-17-01-00008690	BPV-17-01-00008694	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5028	Recovery Filter G1A Femoral System-Design Failure Mode and Effect Analysis (DFMEA070022, Rev. 4)	BPV-17-01-00009033	BPV-17-01-00009056	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5029	ETR-05-03-11 (G2 Migration Resistance Evaluation of NEPG Manufactured Filters)	BPV-17-01-00009213	BPV-17-01-00009225	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5030	Lab notebook 7013 (Recovery Arm Fatigue Feasibility)	BPV-17-01-00009320	BPV-17-01-00009331	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5031	Lab notebook 7013 (Recovery Arm Fatigue Feasibility) Lab notebook 7013 (Recovery Arm Fatigue Feasibility)	BPV-17-01-00009381	BPV-17-01-00009398	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2
5032	ETR-05-01-06 (G2® Femoral System Acute Animal Study Report) (followed TPR-04-12-20)	BPV-17-01-00013631	BPV-17-01-00013639	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5033	TPR-04-12-20 (Protocol for Animal Model Evaluation of G2)	BPV-17-01-00013788	BPV-17-01-00013799	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5034	G1A Filter and Femoral Delivery System PPS Revision 0	BPV-17-01-00013929	BPV-17-01-00013958	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5035	G1A Filter and Femoral Delivery System PPS Revision 1	BPV-17-01-00014097	BPV-17-01-00014126	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5036	ETR-05-02-11 (Chronic Animal Model Evaluation of Recovery G1A Femoral System Report) (followed TPR-04-09-11)	BPV-17-01-00014227	BPV-17-01-00014257	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5037	ETR-05-02-02 (Effects of Changes to the Recovery Filter & The Femoral Delivery System on Filter Stresses Based on FEA Analysis)	BPV-17-01-00014259	BPV-17-01-00014286	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5038	Dec 5, 2003 Recovery Filter Design Review Materials	BPV-17-01-00014488	BPV-17-01-00014824	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2
5039	12.04.03 Special Design Review Objectives for Recovery FMR Launch	BPV-17-01-00014490	BPV-17-01-00014496	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5040	Aug. 11, 1999 RD-RPT-094 Pusher Wire Integrity Test Report	BPV-17-01-00014566	BPV-17-01-00014570	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5041	Aug. 18, 1999 RD-RPT-103 RNF Clot Trapping Efficiency Report	BPV-17-01-00014588	BPV-17-01-00014592	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5042	TM1134800 (G2® Filter Migration Resistance Testing Test Method)	BPV-17-01-00015103	BPV-17-01-00015112	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5043	RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 511)	BPV-17-01-00019372	BPV-17-01-00019375	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402
5044	ETR-05-05-21 (G2® DV&V Report Phase III [for jugular system])	BPV-17-01-00021183	BPV-17-01-00021189	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5045	ETR-05-03-02 (Recovery Filter Jugular/Subclavian System Acute Animal Study Report)	BPV-17-01-00021191	BPV-17-01-00021195	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5046	MAUDE and sales data through Q1 2004	BPV-17-01-00023746	BPV-17-01-00023752	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 801; 802; MIL #1
5047	Aug. 2004 Altran Report (Preliminary SEM of Failed Hooks and Legs) (Fracture)	BPV-17-01-00024471	BPV-17-01-00024496	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5048	RA-STD-002, Rev. 08	BPV-17-01-00024667	BPV-17-01-00024684	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5049	Recovery Filter DFMEA (DFMEA070010, Rev. 2)	BPV-17-01-00024687	BPV-17-01-00024700	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5050	Sept. 2004 Altran Report (Draft Failure Analysis for 11 Complaint Filters) (Fracture)	BPV-17-01-00024718	BPV-17-01-00024794	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5051	Sept. 2004 Altran Report (Draft Evaluation of Two Production Lot Filters and One Test Piece) (Fracture)	BPV-17-01-00024795	BPV-17-01-00024828	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 801; 802; MIL #1
5052	Feb. 14, 2005 Conference FDA and BPV re DDL and Recovery Retrievable (K031328)	BPV-17-01-00025340	BPV-17-01-00025342	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5053	Recovery Filter Design/Development Files Recovery Filter Design/Development Files Cover Sheet	BPV-17-01-00025839	BPV-17-01-00026584	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403
5054	NMT Filter Drawing RD-10261, Rev. 00 (Arms Up)	BPV-17-01-00025912	BPV-17-01-00025912	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5055	RD-SOP-033 (Rotating-Beam Corrosion Fatigue Testing of Nitinol Wire)	BPV-17-01-00026034	BPV-17-01-00026055	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5056	RD-RPT-029 Technical Review of Phase I Development Activities for RNF (Sept. 2, 1997)	BPV-17-01-00026097	BPV-17-01-00026100	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2
5057	Dec. 30, 1997 RD-RPT-038 Corrosion Fatigue Testing Report	BPV-17-01-00026101	BPV-17-01-00026108	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5058	March 23, 1998 RD-RPT-041 Feasibility Animal Study Summary Results	BPV-17-01-00026109	BPV-17-01-00026116	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5059	April 13, 1998 RD-RPT-045 Feasibility Animal Study Summary Results	BPV-17-01-00026136	BPV-17-01-00026147	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5060	June 17, 1999 RD-RPT-085 Determination of Optimum Welding Parameters Report	BPV-17-01-00026193	BPV-17-01-00026210	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5061	Feb. 15, 2000 RD-RPT-115 Straight .013" Pusher Wire Deployment Testing and Analysis	BPV-17-01-00026268	BPV-17-01-00026276	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5062	Oct. 16, 2001 R&D Technical Report Evaluation of RNF Hook Strength Test (RD-RPT-162)	BPV-17-01-00026324	BPV-17-01-00026329	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5063	June 15, 2000 RD-RPT-123 Creep Evaluation of RNF	BPV-17-01-00026338	BPV-17-01-00026352	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5064	June 11, 2001 RD-RPT-158 RNF Recovery Sheath Bioburden Test Report	BPV-17-01-00026353	BPV-17-01-00026357	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2
5065	Arms Up Design History File Table of Contents Table of Contents for Removable Nitinol Filter Design History File (Phase II)	BPV-17-01-00026359	BPV-17-01-00026361	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2
5066	RM-0045, Nitinol Sleeve RM-0045, Nitinol Sleeve	BPV-17-01-00027145	BPV-17-01-00027148	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2
5067	Nov. 24, 2004 Email FDA to BPV re Recovery IFU and DDL	BPV-17-01-00029512	BPV-17-01-00029516	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5068	Recovery IFU Supporting Documentation	BPV-17-01-00029787	BPV-17-01-00029799	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5069	Recovery Filter Fact Book, Volume 01 of 13 Recovery Filter Fact Book, Volume 01 of 13 Cover Sheet for Recovery Filter Fact Book, volume 1 of 13	BPV-17-01-00030232	BPV-17-01-00030315	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #2
5070	NMT Design Inputs, Rev. 03 10/04/99	BPV-17-01-00030283	BPV-17-01-00030295	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5071	Sept. 1997 NMT Design Input Approval	BPV-17-01-00030295	BPV-17-01-00030306	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5072	Recovery Filter Fact Book, Volume 02 of 13 Recovery Filter Fact Book, Volume 02 of 13 Project 7081 Fact Book, Volume 2 of 13	BPV-17-01-00030316	BPV-17-01-00030526	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5073	Recovery Filter Fact Book, Volume 03 of 13 Recovery Filter Fact Book, Volume 03 of 13 Fact Book Project 7081 - Volume 3 of 13	BPV-17-01-00030527	BPV-17-01-00030882	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5074	RD-RPT-025 (Test Report for Biocompatibility for SNF)	BPV-17-01-00030532	BPV-17-01-00030538	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5075	Recovery Filter Fact Book, Volume 04 of 13 Recovery Filter Fact Book, Volume 04 of 13	BPV-17-01-00030883	BPV-17-01-00031020	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5076	Recovery Filter Fact Book, Volume 05 of 13 Recovery Filter Fact Book, Volume 05 of 13	BPV-17-01-00031021	BPV-17-01-00031049	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5077	Recovery Product Development Operating Plan	BPV-17-01-00031047	BPV-17-01-00031049	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5078	Recovery Filter Fact Book, Volume 06 of 13 Recovery Filter Fact Book, Volume 06 of 13	BPV-17-01-00031050	BPV-17-01-00031500	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5079	RD-SOP-035.03 (SOP re migration resistance testing NMT) R&D SOP: RD-SOP-035.3, IVC Filter Migration Study	BPV-17-01-00031053	BPV-17-01-00031061	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5080	May 13, 1998 RD-SOP-048 In-Vivo Evaluation of Thrombogenic Response to RNF Implant	BPV-17-01-00031077	BPV-17-01-00031082	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2
5081	RNF Animal Experiment Notes, Feasibility Animal Experiment	BPV-17-01-00031083	BPV-17-01-00031085	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5082	RNF Animal Experiment Notes, Feasibility Animal Experiment	BPV-17-01-00031087	BPV-17-01-00031098	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5083	RNF Animal Experiment Notes, Feasibility Animal Experiment	BPV-17-01-00031099	BPV-17-01-00031113	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5084	RNF Animal Experiment Notes, Feasibility Animal Experiment	BPV-17-01-00031114	BPV-17-01-00031122	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5085	RD-SOP-050.00, RNF Design Verification: In-vivo Occlusion Migration Resistance and Deployment Study	BPV-17-01-00031123	BPV-17-01-00031133	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5086	RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 379)	BPV-17-01-00031135	BPV-17-01-00031136	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5087	Data Sheet for RD-SOP-050.00 (Animal 379)	BPV-17-01-00031137	BPV-17-01-00031146	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5088	Data Sheet for RD-SOP-050.00 (Animal 511)	BPV-17-01-00031151	BPV-17-01-00031160	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5089	RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558)	BPV-17-01-00031162	BPV-17-01-00031164	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5090	RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance Data Sheets (animal #558)	BPV-17-01-00031165	BPV-17-01-00031174	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5091	Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for Permanent Indication	BPV-17-01-00031183	BPV-17-01-00031195	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5092	RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal Experiment Notes (animal #747)	BPV-17-01-00031197	BPV-17-01-00031348	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5093	RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term Removal Indication	BPV-17-01-00031349	BPV-17-01-00031360	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5094	RNF Animal Experiment Notes, Feasibility Animal Experiment	BPV-17-01-00031361	BPV-17-01-00031419	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5095	RD-SOP-053.00, RNF Hook Creep Study	BPV-17-01-00031420	BPV-17-01-00031424	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5096	June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol	BPV-17-01-00031425	BPV-17-01-00031431	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5097	July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	BPV-17-01-00031482	BPV-17-01-00031487	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402
5098	Recovery Filter Fact Book, Volume 07 of 13 Recovery Filter Fact Book, Volume 07 of 13	BPV-17-01-00031501	BPV-17-01-00031903	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5099	Aug. 20, 1999 RD-RPT-088 In-Vivo Testing of RNF for Permanent Use and Early Removal	BPV-17-01-00031503	BPV-17-01-00031511	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5100	RNF Pivotal Animal Clinical Study, Permanent Implant In-Situ Sacrifice Data Sheets (Animal #32)	BPV-17-01-00031601	BPV-17-01-00031882	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5101	RNF Pivotal Animal Clinical Study Permanent Implant Data Sheets (Animal #48)	BPV-17-01-00031883	BPV-17-01-00031891	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5102	Recovery Filter Fact Book, Volume 08 of 13	BPV-17-01-00031904	BPV-17-01-00032274	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5103	NMT Medical R&D Technical Report Document #RD-RPT-089, Creep Study of RNF Hooks	BPV-17-01-00031906	BPV-17-01-00031910	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5104	July 30, 1999 RD-RPT-091 RNF Wire Integrity Report	BPV-17-01-00031965	BPV-17-01-00031970	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5105	Aug. 13, 1999 RD-RPT-093 Crimp and Bond Integrity Test Report	BPV-17-01-00032065	BPV-17-01-00032071	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5106	Aug. 4, 1999 R&D Technical Report EnduraTEC Corrosion/Fatigue Testing of RNF Filters, Design Verification (RD-RPT-099)	BPV-17-01-00032217	BPV-17-01-00032220	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5107	Recovery Filter Fact Book, Volume 09 of 13	BPV-17-01-00032275	BPV-17-01-00032551	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5108	Aug. 9, 1999 R&D Technical Report RNF Hook Strength, Design Verification (RD-RPT-101)	BPV-17-01-00032375	BPV-17-01-00032386	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5109	Aug. 23, 1999 R&D Technical Report Analysis of RNF Migration Resistance (RD-RPT-104)	BPV-17-01-00032545	BPV-17-01-00032551	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5110	Recovery Filter Fact Book, Volume 10 of 13	BPV-17-01-00032552	BPV-17-01-00032804	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5111	Final Pathology Report: In-vivo Evaluation of the RNF for Permanent & Intra-Procedural Removal Indications - A Study of 15 Sheep	BPV-17-01-00032555	BPV-17-01-00032567	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5112	In-Vivo Evaluation of the Removable Nitinol Filter System for Permanent & Intra-Procedural Removal Indications	BPV-17-01-00032689	BPV-17-01-00032694	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5113	Final Pathology Report: In-vivo Evaluation for Permanent Indication (Vena Cava Filters in 8 sheep)	BPV-17-01-00032698	BPV-17-01-00032706	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5114	Pathology Report: In-vivo Evaluation of the RNF for Long-term Removal Indications (Pathology Associates)	BPV-17-01-00032758	BPV-17-01-00032773	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5115	Recovery Filter Fact Book, Volume 11 of 13	BPV-17-01-00032805	BPV-17-01-00033163	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5116	April 24, 2000 RD-RPT-121 In-Vivo Technical Testing of RNF for Long-Term Removal	BPV-17-01-00032807	BPV-17-01-00032817	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5117	In-Vivo Evaluation of the Removable Nitinol Filter System for Long-Term Removal Indication	BPV-17-01-00032818	BPV-17-01-00032822	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5118	Pivotal Animal Clinical Study: RNF Filter Implant Data Sheets (Animal #26)	BPV-17-01-00032829	BPV-17-01-00033134	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5119	Recovery Filter Fact Book, Volume 12 of 13	BPV-17-01-00033164	BPV-17-01-00034065	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5120	Recovery Filter DFMEA 070010, Rev. 3	BPV-17-01-00033286	BPV-17-01-00033302	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5121	Recovery Filter Fact Book, Volume 13 of 13	BPV-17-01-00034066	BPV-17-01-00034647	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5122	March 28, 2003 Design Review Report	BPV-17-01-00034436	BPV-17-01-00034437	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5123	Design Review II Summary of Design Verification Studies	BPV-17-01-00034445	BPV-17-01-00034446	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5124	Oct. 16, 2003 Risk Assessment RA070011, Rev. 0	BPV-17-01-00034493	BPV-17-01-00034505	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5125	FM-0010.02 FM-0010.02 Recovery Filter FMEA: Implant and Delivery System	BPV-17-01-00034523	BPV-17-01-00034527	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5126	Guidance for Industry and FDA Reviewers/Staff - Guidance for Cardiovascular Intravascular Filter 510(k) Submissions	BPV-17-01-00034593	BPV-17-01-00034604	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5127	November 26, 1999 FDA Guidance for Cardiovascular Intravascular Filter 510(k) Submissions	BPV-17-01-00034593	BPV-17-01-00034604	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5128	Dec. 20, 2002 Design Review Assessment Status (Phase 1)	BPV-17-01-00034616	BPV-17-01-00034621	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5129	Design Review Element -- Compliance to Design Input (validating statistical relevance of migration testing)	BPV-17-01-00034622	BPV-17-01-00034630	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5130	FIR-04-09-01 (Recovery Filter Fractures) (includes some Altran Reports)	BPV-17-01-00034657	BPV-17-01-00034855	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5131	FIR-04-09-01 Failure Investigation report - Recovery Filter	BPV-17-01-00034669	BPV-17-01-00034680	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5132	SPA-04-12-01: Addendum 2 (Remedial Action Plan re RNF Migration)	BPV-17-01-00034857	BPV-17-01-00034858	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5133	G2 Filter Stability Rationale (includes info re FEA and fatigue resistance)	BPV-17-01-00035612	BPV-17-01-00035614	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5134	RNF Design Review Summary Table Sept. 19, 2002	BPV-17-01-00035870	BPV-17-01-00035871	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5135	12.09.03 Special Design Review Meeting Minutes	BPV-17-01-00036291	BPV-17-01-00036292	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5136	CAE FEA (Nonlinear Structural Simulation of RNF Filter Device Delivery Tube Insertion)	BPV-17-01-00037348	BPV-17-01-00037356	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5137	Recovery Filter DFMEA 070010, Rev. 0	BPV-17-01-00037462	BPV-17-01-00037476	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5138	DFMEA070010 Rev. 4	BPV-17-01-00038701	BPV-17-01-00038724	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5139	June 25, 2004 Multidisciplinary Focus Group Meeting Transcript	BPV-17-01-00039242	BPV-17-01-00039305	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5140	Memo re RNF Inventory Swap-Out (inventory exchange) for G2	BPV-17-01-00039452	BPV-17-01-00039452	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5141	Summary of Feb. 12, 2005 Bariatric Surgeon Meeting Summary of Feb. 12, 2005	BPV-17-01-00039917	BPV-17-01-00039919	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5142	Jan. 10, 2005 Conference FDA and BPV re DDL and Recovery Retrievable (K031328)	BPV-17-01-00043382	BPV-17-01-00043402	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5143	Dec. 2004 BPV begins distributing DDL	BPV-17-01-00043383	BPV-17-01-00043402	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5144	Feb. 8, 2005 Fax BPV to FDA re DDL and Recovery Retrievable (K031328)	BPV-17-01-00043415	BPV-17-01-00043416	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5145	Jan. 14, 2004 Design Review Meeting Minutes Response (From Rob Carr to File)	BPV-17-01-00043534	BPV-17-01-00043535	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5146	TPR-05-01-13 (G2® DV&V Protocol)	BPV-17-01-00044081	BPV-17-01-00044116	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5147	RA-STD-002, Rev. 08	BPV-17-01-00044635	BPV-17-01-00044653	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5148	Article re Long-Term Retrieval of RNF Article entitled A New Optional Vena Canva Filter: Retrievable at 12 Weeks in An Animal Model	BPV-17-01-00044725	BPV-17-01-00044734	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5149	Dr. Asch Article re Asch Study Article entitled Initial Experiences in Humans with a New Retrievable Inferior Vena Cava Filter	BPV-17-01-00044735	BPV-17-01-00044744	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
5150	8/25/2005 - FDA Conference Call Meeting Minutes	BPV-17-01-00045092	BPV-17-01-00045094	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5151	Feb. 28, 2005 Conference FDA and BPV re new submission	BPV-17-01-00045869	BPV-17-01-00045871	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5152	March 2005 Emails with FDA	BPV-17-01-00045872	BPV-17-01-00045877	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5153	Oct. 13, 2005 Email FDA to BPV re G2 Filter - Jugular Subclavian Delivery Kit (K052578)	BPV-17-01-00046358	BPV-17-01-00046362	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5154	Revised 03/03 -- F-8020 Rev.0 (Bard Peripheral Technologies)	BPV-17-01-00047425	BPV-17-01-00047440	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5155	Oct. 14, 2005 Letter FDA to BPV re G2 Filter - Jugular Subclavian Delivery Kit (K052578)	BPV-17-01-00048142	BPV-17-01-00048144	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5156	TPR-05-01-05 (G2 Filter Arm Fatigue DV&V Protocol)	BPV-17-01-00050276	BPV-17-01-00050285	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5157	Data Sheet (for G2® DV&V Migration Resistance Testing in 28mm IVC)	BPV-17-01-00050526	BPV-17-01-00050535	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5158	2001 Bard acquires filter line from NMT	BPV-17-01-00051623	BPV-17-01-00051624	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL # 2
5159	December 10, 1999 Letter from FDA re Recovery K993809	BPV-17-01-00051625	BPV-17-01-00051626	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5160	ETR-02-06-02 (Failure Investigation Report re Fracture in Asch Study) (with Rob Carr memo)	BPV-17-01-00052601	BPV-17-01-00052615	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	MIL #2
5161	RD-RPT-128 (Investigation re Asch patient migration)	BPV-17-01-00052622	BPV-17-01-00052628	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5162	RD-SOP-059.00 (SOP re Wire Integrity)	BPV-17-01-00053552	BPV-17-01-00053561	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5163	In-Vivo Evaluation of the Removal Nitinol Filter System for Permanent & Intra-Procedural Removal Indications	BPV-17-01-00053920	BPV-17-01-00053928	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5164	July 8, 2003 Fax IMPRA to FDA re Recovery Retrievable (K031328)	BPV-17-01-00054002	BPV-17-01-00054076	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5165	July 1, 2003 Email FDA to BPV re Recovery Retrievable (K031328)	BPV-17-01-00054093	BPV-17-01-00054093	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1; MIL #2
5166	July 23, 2003 Email FDA to BPV re Recovery Retrievable (K031328)	BPV-17-01-00054098	BPV-17-01-00054101	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #2
5167	July 23, 2003 Letter BPV to FDA re Recovery Retrievable (K031328)	BPV-17-01-00054109	BPV-17-01-00054110	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5168	July 24, 2003 Letter BPV to FDA re Recovery Retrievable (K031328)	BPV-17-01-00054127	BPV-17-01-00054139	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5169	Apr. 25, 2003 Recovery Retrievable Abbreviated 510(k) (K031328)	BPV-17-01-00054947	BPV-17-01-00055252	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5170	Patient 33 Note (w/fracture) (submitted to FDA)	BPV-17-01-00055205	BPV-17-01-00055205	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5171	RD-SOP-071.00 (SOP re Hook Strength)	BPV-17-01-00056338	BPV-17-01-00056344	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5172	Aug. 2, 1999 RD-RPT-092 Weld Integrity Report	BPV-17-01-00056386	BPV-17-01-00056393	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5173	RD-RPT-088 (Report on RNF In-vivo Testing for Permanent Use and Early Removal) (followed SOP-051)	BPV-17-01-00056477	BPV-17-01-00056485	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5174	NMT Due Dilligence Materials from Bard Sept. 24, 2001	BPV-17-01-00056704	BPV-17-01-00056719	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 901; MIL #2
5175	Hand-written Annotations on response to FDA of Aug. 30, 2002	BPV-17-01-00056930	BPV-17-01-00056930	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5176	November 27, 2002 Letter from FDA re Recovery K022236	BPV-17-01-00057704	BPV-17-01-00057707	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
5177	Nov. 27, 2002 FDA Clearance Letter re Recovery Permanent (K022236) (Substantial Equivalence)	BPV-17-01-00057709	BPV-17-01-00057711	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5178	Oct. 25, 2002 Letter IMPRA to FDA re Recovery (K022236)	BPV-17-01-00057722	BPV-17-01-00057728	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5179	Oct. 4, 2002 Letter FDA to IMPRA re Recovery (K022236)	BPV-17-01-00057740	BPV-17-01-00057742	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5180	Draft response to October 3, 2002 FDA Teleconference	BPV-17-01-00057744	BPV-17-01-00057748	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5181	September 30, 2002 Fax from FDA	BPV-17-01-00057750	BPV-17-01-00057751	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5182	Aug. 30, 2002 Letter IMPRA to FDA re Recovery (K022236)	BPV-17-01-00057755	BPV-17-01-00057917	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5183	August 30, 2002 Draft Letter to FDA	BPV-17-01-00057755	BPV-17-01-00057771	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5184	September 1997 NMT Cyclic Polarization Testing of Seven Sets of Wire	BPV-17-01-00057784	BPV-17-01-00057870	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5185	RD-SOP-058.00, RNF Weld Integrity, Design Verification	BPV-17-01-00057881	BPV-17-01-00057905	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5186	August 5, 2002 Letter from FDA re Recovery K022236	BPV-17-01-00057919	BPV-17-01-00057930	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5187	Aug. 5, 2002 Letter FDA to IMPRA re Recovery (K022236)	BPV-17-01-00057926	BPV-17-01-00057930	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5188	July 10, 2002 Recovery 510(k) Application Letter	BPV-17-01-00057935	BPV-17-01-00057937	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5189	July 10, 2002 IMPRA Recovery Permanent Special 510(k) (K022236)	BPV-17-01-00057953	BPV-17-01-00058037	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5190	July 8, 2002 Recovery 510(k) Submission (partial)	BPV-17-01-00057953	BPV-17-01-00058037	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5191	November 27, 2002 Letter from FDA re Recovery K022236	BPV-17-01-00057953	BPV-17-01-00057953	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5192	July 25, 2003 Abbreviated Recovery 510(k) Submission K031328	BPV-17-01-00058038	BPV-17-01-00058038	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5193	Feb. 28, 2005 Letter BPV to FDA re FDA AI re Recovery Retrievable (K031328)	BPV-17-01-00058041	BPV-17-01-00058074	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5194	Feb. 8, 2005 Letter FDA to BPV re Recovery Retrievable (K031328)	BPV-17-01-00058077	BPV-17-01-00058077	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5195	Nov. 30, 2004 Letter FDA to BPV re Recovery IFU and DDL	BPV-17-01-00058079	BPV-17-01-00058081	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5196	Oct. 5, 2004 Letter BPV to FDA re Recovery IFU and DDL	BPV-17-01-00058083	BPV-17-01-00058120	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5197	July 25, 2003 FDA Clearance Letter re Recovery Retrievable (K031328) (Substantial Equivalence)	BPV-17-01-00058122	BPV-17-01-00058124	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5198	August 29, 2002 Email to FDA	BPV-17-01-00058715	BPV-17-01-00058720	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5199	August 26, 2002 email re FDA letter response	BPV-17-01-00058778	BPV-17-01-00058796	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5200	Draft Clinical Testing Questions	BPV-17-01-00058779	BPV-17-01-00058796	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5201	Feb. 29, 2000 Letter NMT to FDA re Recovery (K993809)	BPV-17-01-00058895	BPV-17-01-00058895	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5202	Feb. 10, 2000 Conference FDA and NMT re Recovery (K993809)	BPV-17-01-00058907	BPV-17-01-00058930	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5203	Notes re Asch Live Case	BPV-17-01-00059057	BPV-17-01-00059059	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5204	Aug. 12, 2002 Conference IMPRA and FDA re Recovery (K022236)	BPV-17-01-00059159	BPV-17-01-00059193	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5205	August 12, 2002 FDA teleconference	BPV-17-01-00059159	BPV-17-01-00059175	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5206	RNF Brochure Timeless Performance Complete Compliance Folder	BPV-17-01-00060382	BPV-17-01-00060413	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
5207	RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558)	BPV-17-01-00061162	BPV-17-01-00061164	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5208	G2 Filter Sales Training Manual G2 Filter Sales Training Manual	BPV-17-01-00061944	BPV-17-01-00062024	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5209	Dec. 17, 2002 Letter BPV to FDA requesting conference re Recovery Retrievable	BPV-17-01-00062069	BPV-17-01-00062070	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5210	RD-RPT-122 Migration Study of 30-31 mm Leg span	BPV-17-01-00067976	BPV-17-01-00067979	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 901; MIL #2
5211	June 9, 2000 R&D Technical Report Fatigue Evaluation of RNF (RD-RPT-120)	BPV-17-01-00068038	BPV-17-01-00068061	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5212	RD-RPT-126 (Lake Region SNF Migration Resistance Study)	BPV-17-01-00068118	BPV-17-01-00068122	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5213	SOP-RD-006 (NMT SOP re Design Control)	BPV-17-01-00068128	BPV-17-01-00068160	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5214	Dec. 10, 1999 Letter FDA to NMT re Recovery (K993809)	BPV-17-01-00069470	BPV-17-01-00069471	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5215	Nov. 1, 1999 NMT's Recovery Filter System Special 510(k) (K993809)	BPV-17-01-00069501	BPV-17-01-00069604	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 901
5216	RD-LNB-097 (Misc. Vena Cava Filter Research Projects; Includes Results of Early NMT Competitive Migration Testing) Lab Notebook	BPV-17-01-00069978	BPV-17-01-00070029	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5217	RD-SOP-035.02 (SOP re migration resistance testing NMT)	BPV-17-01-00070037	BPV-17-01-00070044	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5218	Data Sheet for Early NMT Competitive Migration Testing (raw data) Lab Notebook 097 RD-LNB-097	BPV-17-01-00070050	BPV-17-01-00070072	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5219	June 23, 1998 NMT Memo re Removable Filter Concepts	BPV-17-01-00070679	BPV-17-01-00070688	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5220	June 15, 1998 Memo re Removable Filter Issues	BPV-17-01-00070715	BPV-17-01-00070716	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5221	June 1, 1999 NMT Meeting Minutes	BPV-17-01-00072602	BPV-17-01-00072604	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5222	January 7, 1999 NMT Meeting Minutes	BPV-17-01-00072605	BPV-17-01-00072606	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5223	April 14, 2000 NMT RNF Design Review II Minutes	BPV-17-01-00072607	BPV-17-01-00072610	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5224	June 12, 1998 NMT Meeting Minutes	BPV-17-01-00072614	BPV-17-01-00072616	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5225	April 30, 1998 NMT RNF Meeting Minutes	BPV-17-01-00072620	BPV-17-01-00072625	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5226	RNF Meeting Notes RNF Meeting notes	BPV-17-01-00072631	BPV-17-01-00072634	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5227	April 30, 1998 Memo re Justification for Restarting Pivotal Animal Study	BPV-17-01-00073163	BPV-17-01-00073165	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5228	April 8, 1998 Memo re Summary of Animal Experiments to be Performed for RNF	BPV-17-01-00073166	BPV-17-01-00073168	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5229	RNF Meeting Notes RNF Meeting notes	BPV-17-01-00073184	BPV-17-01-00073186	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5230	RD-RPT-137 (SNF Substantial Equivalence Report)	BPV-17-01-00081987	BPV-17-01-00081998	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5231	Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release	BPV-17-01-00082624	BPV-17-01-00082803	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5232	RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-116	BPV-17-01-00083886	BPV-17-01-00083889	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5233	RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT)	BPV-17-01-00084683	BPV-17-01-00084689	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5234	RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT)	BPV-17-01-00084690	BPV-17-01-00084693	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5235	Recovery Filter DFMEA070010 Rev. 1	BPV-17-01-00089681	BPV-17-01-00089694	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5236	Email from Hudson to Benware re Starguide testing	BPV-17-01-00091149	BPV-17-01-00091149	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5237	Draft Starguide Report	BPV-17-01-00092792	BPV-17-01-00092795	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5238	Slides from Bariatric Surgeons Panel Meeting on Feb. 12, 2005	BPV-17-01-00097071	BPV-17-01-00097103	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5239	Jan. 21, 2005 Conference FDA and BPV re DDL and Recovery Retrievable (K031328)	BPV-17-01-00097135	BPV-17-01-00097137	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5240	MAUDE and Sales data through Q2 2005	BPV-17-01-00097492	BPV-17-01-00097525	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5241	MAUDE and Sales Data through Q2 2004	BPV-17-01-00097589	BPV-17-01-00097622	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5242	Sep. 28, 2004 Conference FDA and BPV re Recovery IFU and DDL	BPV-17-01-00097730	BPV-17-01-00097733	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5243	Sep. 17, 2004 FDA Contact Report re Recovery IFU and DDL	BPV-17-01-00097745	BPV-17-01-00097746	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5244	Mar. 24, 2005 Conference FDA and BPV re DCL and Modified Recovery (K050558)	BPV-17-01-00097998	BPV-17-01-00098003	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5245	Jan. 27, 2005 Conference BPV and FDA Phoenix Investigator re DCL and Recovery Retrievable (K031328)	BPV-17-01-00098579	BPV-17-01-00098582	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5246	Aug. 5, 2005 Conference FDA and BPV re G2 Everest Study (G050134)	BPV-17-01-00098772	BPV-17-01-00098774	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5247	May 11, 2005 BPV began distributing DCL	BPV-17-01-00100782	BPV-17-01-00100784	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5248	TD-00012 (Characterization of G2® Filter Migration Resistance When Legs are Crossed)	BPV-17-01-00101562	BPV-17-01-00101567	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106
5249	SPA-04-04-01 (Revised Remedial Action Plan re RNF Fractures)	BPV-17-01-00101586	BPV-17-01-00101587	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5250	Nov. 28, 2004 Internal BPV Email chain re Recovery IFU and DDL	BPV-17-01-00102072	BPV-17-01-00102075	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5251	ETR-04-03-19 (RNF Radial Strength v. Competitive Product)	BPV-17-01-00103828	BPV-17-01-00103850	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5252	ETR-04-03-02 (RNF v. Competitive Product -- migration resistance)	BPV-17-01-00103851	BPV-17-01-00103863	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5253	HHE of Dr. Ciavarella November 17, 2004	BPV-17-01-00103875	BPV-17-01-00103878	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5254	DOPQ0700020, Rev. 4	BPV-17-01-00107427	BPV-17-01-00107568	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5255	FDA concurrence letter for K940489	BPV-17-01-00109425	BPV-17-01-00109426	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5256	NMT's 510(k) (K940489) for the Modified SNF	BPV-17-01-00109427	BPV-17-01-00109533	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5257	FDA concurrence letter for K944353	BPV-17-01-00109956	BPV-17-01-00109957	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5258	NMT's 510(k) (K944353) to the Simplified SNF (Straight Line System)	BPV-17-01-00109958	BPV-17-01-00110134	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5259	Recovery Filter Design/Development Files	BPV-17-01-00110331	BPV-17-01-00111349	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5260	NMT's 510(k) (K912144) for the SNF for antecubital insertion	BPV-17-01-00112374	BPV-17-01-00112440	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5261	Letter from FDA to NMT regarding K912144	BPV-17-01-00112410	BPV-17-01-00112411	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5262	Letter from NMT to FDA regarding K912144 and FDA's June 25, 1991 questions	BPV-17-01-00112412	BPV-17-01-00112420	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5263	Letter from Hogan & Hartson to FDA regarding K912144	BPV-17-01-00112421	BPV-17-01-00112440	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5264	Letter from Hogan & Hartson to FDA regarding K940489 and FDA's March 4, 1994 questions	BPV-17-01-00112451	BPV-17-01-00112453	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5265	Letter from FDA to Hogan & Hartson regarding K940489	BPV-17-01-00112454	BPV-17-01-00112455	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5266	FDA concurrence letter for K963016	BPV-17-01-00112560	BPV-17-01-00112561	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5267	Letter from Hogan & Hartson to FDA regarding October 7, 1996 conference	BPV-17-01-00112562	BPV-17-01-00112564	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5268	NMT's 510(k) (K963016) for modifications to the SNF (submitted by Hogan & Hartson)	BPV-17-01-00112585	BPV-17-01-00112742	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5269	NMT's 510(k) (K970099) for modifications to the SNF and SNF/Straight Line System	BPV-17-01-00112743	BPV-17-01-00112934	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5270	Revised Recovery Filter IFU as of December 2004	BPV-17-01-00112988	BPV-17-01-00112990	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5271	NMT Sept. 12, 2000 Memo re Clinical Discussion of Migration from Asch Study	BPV-17-01-00114162	BPV-17-01-00114164	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5272	Nov. 23, 2009 BPV's Eclipse Filter System Special 510(k) (K093659)	BPV-17-01-00116991	BPV-17-01-00117153	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5273	Jan. 14, 2010 FDA Clearance Letter Eclipse Filter (K093659) (Substantial Equivalence)	BPV-17-01-00117156	BPV-17-01-00117158	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5274	July 2, 2008 Letter BPV to FDA Responses re AI Demand re G2 Express (K080668)	BPV-17-01-00117260	BPV-17-01-00117783	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5275	June 25, 2008 Conference FDA and BPV re AI Demand re G2 Express (K080668)	BPV-17-01-00117271	BPV-17-01-00117272	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5276	TD-00272 (Addendum to TD-00192 Product Comparisons through Finite Element Analysis and Testing by William James Harrison, WJH Engineering)	BPV-17-01-00118350	BPV-17-01-00118353	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5277	TD-00553 (Finite Element Analysis Comparing the G2/G2 Express Filter with Two Loading Scenarios)	BPV-17-01-00118354	BPV-17-01-00118364	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5278	G2 IFU PK5100030, Rev. 2 08/05 (Femoral)	BPV-17-01-00118365	BPV-17-01-00118368	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5279	G2 IFU (Femoral) PK5100030 Rev. 3 09/05	BPV-17-01-00118369	BPV-17-01-00118372	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5280	G2 IFU PK5014091, Rev. 0 09/05 (Jugular)	BPV-17-01-00118373	BPV-17-01-00118377	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5281	G2 IFU PK5100030, Rev. 4 04/06 (Femoral)	BPV-17-01-00118378	BPV-17-01-00118381	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5282	G2 IFU PK5100030, Rev. 5 10/06 (Femoral)	BPV-17-01-00118382	BPV-17-01-00118385	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5283	G2 IFU (Femoral) PK5250500 Rev. 0 01/08	BPV-17-01-00118386	BPV-17-01-00118389	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5284	G2 IFU PK5260600, Rev. 0 01/08 (Jugular)	BPV-17-01-00118390	BPV-17-01-00118397	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5285	G2 IFU PK5250500, Rev. 1 07/09 (Femoral)	BPV-17-01-00118398	BPV-17-01-00118401	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5286	G2 IFU PK5260600, Rev. 1 07/09 (Jugular)	BPV-17-01-00118402	BPV-17-01-00118409	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5287	Project 8041: Design History File; Everest- Recovery G2, Vol. 1 of 2	BPV-17-01-00118539	BPV-17-01-00118728	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5288	Sept. 6, 2005 EVEREST Clinical Study Protocol	BPV-17-01-00118623	BPV-17-01-00118694	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5289	Project 8041: Design History File; Everest- Recovery G2, Vol. 2 of 2	BPV-17-01-00118729	BPV-17-01-00118973	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5290	TD-00456 (EVEREST Study Final Report)	BPV-17-01-00118807	BPV-17-01-00118902	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5291	Project File; Project 8002: G2 Recovery Filter; Jugular/Subclavian System, Vol. 1 of 3	BPV-17-01-00118974	BPV-17-01-00119449	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5292	Project File; Project 8002: G2 Recovery Filter; Jugular/Subclavian System, Vol. 2 of 3	BPV-17-01-00119450	BPV-17-01-00119908	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5293	Project File; Project 8002: G2 Recovery Filter; Jugular/Subclavian System, Vol. 3 of 3	BPV-17-01-00119909	BPV-17-01-00120436	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5294	Fact Book; Project 8027: US: G2 Filter System (RF-310F) OUS Recovery Filter System (RF-210F), Vol. 1 of 2	BPV-17-01-00120437	BPV-17-01-00120902	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5295	G2 Filter Project Initiation Request Form (Project 8027)	BPV-17-01-00120454	BPV-17-01-00120455	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5296	G2 Filter Product Performance Specification, v.2	BPV-17-01-00120471	BPV-17-01-00120502	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5297	G2 Filter Regulatory and Clinical Strategy Determination (Jan. 2005)	BPV-17-01-00120511	BPV-17-01-00120522	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5298	G2 Filter Drawings and Labels	BPV-17-01-00120558	BPV-17-01-00120574	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5299	Fact Book; Project 8027: US: G2 Filter System (RF-310F) OUS Recovery Filter System (RF-210F), Vol. 2 of 2	BPV-17-01-00120903	BPV-17-01-00121313	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5300	TPR-04-09-11 An Acute and Chronic In-Vivo Evaluation of the Bard Recovery Filter (G2)	BPV-17-01-00120906	BPV-17-01-00120921	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5301	ETR-05-01-06 Animal Model Evaluation of Recovery Filter G1A Femoral System Report	BPV-17-01-00120922	BPV-17-01-00120931	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5302	TPR 05-01-13 G1A Recovery Filter Femoral System Design Verification and Validation Protocol	BPV-17-01-00120932	BPV-17-01-00120960	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5303	ETR-05-02-05 (G2® DV&V summary testing)	BPV-17-01-00120961	BPV-17-01-00120982	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5304	ETR 05-02-11 G1A Recovery Filter Femoral System Chronic Animal Study Report	BPV-17-01-00120983	BPV-17-01-00121014	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5305	RA070025 Risk Assessment for the G1A Filter, v.1	BPV-17-01-00121020	BPV-17-01-00121035	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5306	DFMEA070022, v.1 (for the G1A)	BPV-17-01-00121036	BPV-17-01-00121060	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5307	PFMEA for the G1A Recovery Filter Femoral System	BPV-17-01-00121061	BPV-17-01-00121074	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5308	PV-RF210F G1A Process Qualification Final Report, G1A Filters, RF210F	BPV-17-01-00121077	BPV-17-01-00121088	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5309	ETR 05-03-11 Migration Resistance Evaluation of "New England Precision Grinding" G1A Manufactured Filters (RF210F) and Multiple Loading	BPV-17-01-00121089	BPV-17-01-00121101	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5310	FIR 05-03-05 G1A Filter (RF210F) Process Qualification Failure Investigation for "Crossed or Twisted Leg"	BPV-17-01-00121102	BPV-17-01-00121109	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5311	Stability Rationale for G1A	BPV-17-01-00121155	BPV-17-01-00121158	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5312	E05-009 Adoption for the G1A Recovery Filter Femoral System, v.0	BPV-17-01-00121159	BPV-17-01-00121167	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5313	Phase 0 Design Review G1A Recovery Filter Femoral Delivery System	BPV-17-01-00121189	BPV-17-01-00121214	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5314	Phase 1 Design Review G1A Recovery Filter Femoral Delivery System	BPV-17-01-00121215	BPV-17-01-00121225	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5315	Phase 2 Design Review G1A Recovery Filter Femoral Delivery System	BPV-17-01-00121226	BPV-17-01-00121255	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5316	Phase 3 Design Review (Design Review 3 & 4) G1A Recovery Filter Femoral Delivery System	BPV-17-01-00121256	BPV-17-01-00121286	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5317	G1A Authorization for Market Release (Domestic)	BPV-17-01-00121306	BPV-17-01-00121308	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5318	G2 Filter Internal Product Information Bulletin (Sept. 7, 2005)	BPV-17-01-00121309	BPV-17-01-00121309	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5319	Recovery Filter Internal Product Information Bulletin (Sept. 7, 2005)	BPV-17-01-00121310	BPV-17-01-00121310	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5320	Dec. 4, 2006 Conference FDA and BPV re future G2 Filter Retrievable Traditional 510(k)	BPV-17-01-00122493	BPV-17-01-00122493	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5321	Dec. 11, 2007 Conference FDA and BPV re G2 Everest Study (G051304)	BPV-17-01-00122495	BPV-17-01-00122495	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5322	Nov. 2, 2005 FDA Grants Full Approval of G2 Everest Study (G051304)	BPV-17-01-00122502	BPV-17-01-00122502	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5323	Aug. 8, 2005 FDA Grants BPV Conditional Approval for G2 Everest Study (G050134)	BPV-17-01-00122505	BPV-17-01-00122508	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5324	July 8, 2005 BPV's original IDE submission re G2 Everest Study (G050134)	BPV-17-01-00122544	BPV-17-01-00122829	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5325	Oct. 3, 2005 Letter BPV to FDA re G2 Everest Study (G051034) and Conditional Approval	BPV-17-01-00122845	BPV-17-01-00122932	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5326	Aug. 25, 2005 Conference FDA and BPV re G2 Everest Study (G050134) and Conditional Approval	BPV-17-01-00122930	BPV-17-01-00122932	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5327	Dec. 2, 2005 Letter BPV to FDA re G2 Everest Study (G051304) Notice of IDE Change	BPV-17-01-00123040	BPV-17-01-00123067	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5328	July 11, 2006 Lettre BPV to FDA re G2 Everest Study (G051304) IDE Supplement	BPV-17-01-00123071	BPV-17-01-00123152	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5329	June 21, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement	BPV-17-01-00123153	BPV-17-01-00123175	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5330	June 21, 2006 Letter BPV to FDA re G2 Everest Study (G051304)	BPV-17-01-00123183	BPV-17-01-00123210	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5331	Dec. 6, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement	BPV-17-01-00123217	BPV-17-01-00123217	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5332	Dec. 8, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement	BPV-17-01-00123233	BPV-17-01-00123249	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5333	Feb. 2, 2007 Letter BPV to FDA re G2 Everest Study (G051304) Annual Progress Report	BPV-17-01-00123269	BPV-17-01-00123351	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5334	Sept. 21, 2007 Letter FDA to BPV Questions re G2 Everest Study (G051304)	BPV-17-01-00123402	BPV-17-01-00123405	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5335	Aug. 23, 2007 Letter BPV to FDA re G2 Everest Study (G051304) Annual Progress Report	BPV-17-01-00123427	BPV-17-01-00123474	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5336	Oct. 25, 2007 Letter BPV to FDA re Responses to FDA re G2 Everest Study (G051304)	BPV-17-01-00123498	BPV-17-01-00123562	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5337	Mar. 12, 2008 Letter FDA to BPV re G2 Everest Study (G051304) Closing IDE	BPV-17-01-00123564	BPV-17-01-00123565	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5338	Feb. 12, 2008 Letter BPV to FDA re G2 Everest Study (G051304) Final IDE Report	BPV-17-01-00123573	BPV-17-01-00123588	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5339	Jan. 15, 2008 FDA Clearance Letter G2 Filter Retrievable (K073090) (Substantial Equivalence)	BPV-17-01-00123590	BPV-17-01-00123592	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5340	Oct. 31, 2007 BPV's G2 Filter Retrievable Traditional 510(k) (K073090)	BPV-17-01-00123629	BPV-17-01-00125197	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5341	ETR-06-05-02 G2 Filter Clot Trapping Efficiency Report	BPV-17-01-00123824	BPV-17-01-00123837	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5342	Special 510(k) Submission K050558- 3/2/2005	BPV-17-01-00125198	BPV-17-01-00125334	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5343	Aug. 29, 2005 FDA Clearance Letter re G2 Permanent (K050558) (Substantial Equivalence)	BPV-17-01-00125199	BPV-17-01-00125201	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5344	July 28, 2005 Letter FDA to BPV re AI re Modified Recovery (K050558)	BPV-17-01-00125220	BPV-17-01-00125222	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5345	June 3, 2005 Email BPV to FDA re proposed IDE G2 Everest Study	BPV-17-01-00125226	BPV-17-01-00125285	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5346	Apr. 28, 2005 Letter FDA to BPV 30 day extension re FDA AI re Modified Recovery (K050558)	BPV-17-01-00125288	BPV-17-01-00125288	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5347	Apr. 27, 2005 Letter BPV to FDA 30 day extension re FDA AI re Modified Recovery (K050558)	BPV-17-01-00125289	BPV-17-01-00125289	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5348	Mar. 30, 2005 Letter FDA to BPV re Modified Recovery (K050558)	BPV-17-01-00125312	BPV-17-01-00125314	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5349	Mar. 2, 2005 BPV's Modified Recovery Filter Special 510(k) (K050558)	BPV-17-01-00125335	BPV-17-01-00125415	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5350	June 3, 2005 Letter BPV to FDA re Modified Recovery conversion Traditional 510(k) (K050558)	BPV-17-01-00125416	BPV-17-01-00125615	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5351	May 6, 2005 Conference FDA and BPV re Modified Recovery (K050558)	BPV-17-01-00125422	BPV-17-01-00125424	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5352	Aug. 10, 2005 Letter BPV to FDA Responses to AI re G2 (K050558)	BPV-17-01-00125616	BPV-17-01-00125633	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5353	Nov. 25, 2005 FDA Clearance Letter G2 Filter - Jugular (K052578) (Substantial Equivalence)	BPV-17-01-00125637	BPV-17-01-00125639	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5354	Sept. 19, 2005 BPV's G2 Filter - Jugular Subclavian Delivery Kit Special 510(k) (K052578)	BPV-17-01-00125658	BPV-17-01-00125749	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5355	Sept. 21, 2005 Letter BPV to FDA re G2 Filter - Jugular Subclavian Delivery Kit (K052578)	BPV-17-01-00125750	BPV-17-01-00125772	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5356	Oct. 25, 2005 Letter BPV to FDA Responses to FDA AI Demand re G2 Filter - Jugular (K052578)	BPV-17-01-00125782	BPV-17-01-00125876	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5357	Oct. 14, 2005 Conference FDA and BPV re G2 Filter - Jugular Subclavian Delivery Kit (K052578)	BPV-17-01-00125799	BPV-17-01-00125801	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5358	Oct. 14, 2005 Email FDA to BPV re G2 Filter - Jugular Subclavian Delivery Kit (K052578)	BPV-17-01-00125804	BPV-17-01-00125805	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5359	Nov. 14, 2005 Conference FDA and BPV re Responses re G2 Filter - Jugular (K052578)	BPV-17-01-00125891	BPV-17-01-00125892	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5360	Nov. 16, 2005 Letter BPV to FDA Responses to FDA AI Demand re G2 Filter - Jugular (K052578)	BPV-17-01-00125893	BPV-17-01-00125923	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5361	Sept. 25, 2006 BPV's G2 Filter - Femoral Delivery Kit Special 510(k) (K062887)	BPV-17-01-00125963	BPV-17-01-00126062	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5362	Oct. 26, 2006 FDA Clearance Letter G2 Filter - Femoral Delivery Kit (K062887)	BPV-17-01-00126184	BPV-17-01-00126187	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5363	G2 Filter System Brochure	BPV-17-01-00126318	BPV-17-01-00126321	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5364	G2 Filter System Patient Questions & Answers	BPV-17-01-00126336	BPV-17-01-00126341	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5365	Dr. Binkert Article re EVEREST Study G2 Filter Prospective, Multicenter Study	BPV-17-01-00127751	BPV-17-01-00127755	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5366	May 8, 2008 Letter BPV to FDA Responses to AI Demand re G2 Express (K080668)	BPV-17-01-00130268	BPV-17-01-00130441	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5367	June 26, 2008 Letter BPV to FDA Request 30 Day Extension re G2 Express (K080668)	BPV-17-01-00130442	BPV-17-01-00130448	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5368	July 30, 2008 FDA Clearance Letter G2 Express Filter (K080668) (Substantial Equivalence)	BPV-17-01-00130450	BPV-17-01-00130452	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5369	July 1, 2008 Letter FDA to BPV Granting Extension re G2 Express (K080668)	BPV-17-01-00130459	BPV-17-01-00130459	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5370	June 6, 2008 Letter FDA to BPV re AI Demand re G2 Express (K080668)	BPV-17-01-00130460	BPV-17-01-00130463	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5371	May 6, 2008 Letter FDA to BPV Granting extension re G2 Express (K080668)	BPV-17-01-00130468	BPV-17-01-00130468	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5372	Apr. 8, 2008 Letter FDA to BPV re AI Demand re G2 Express (K080668)	BPV-17-01-00130470	BPV-17-01-00130473	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5373	Mar. 7, 2008 BPV's G2 Express Filter Special 510(k) (K080668)	BPV-17-01-00130498	BPV-17-01-00130730	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5374	Sept. 29, 2008 Letter BPV to FDA re Responses to FDA AI Demand re G2X (K082305)	BPV-17-01-00130734	BPV-17-01-00130838	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5375	May 5, 2008 Letter BPV to FDA Request 30 day extension re G2 Express (K080668)	BPV-17-01-00131255	BPV-17-01-00131261	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5376	Oct. 31, 2008 FDA Clearance Letter G2X Filter (K082305) Substantial Equivalence	BPV-17-01-00131282	BPV-17-01-00131284	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5377	Sept. 4, 2008 Email FDA to BPV re FDA AI Demand re G2X (K082305)	BPV-17-01-00131294	BPV-17-01-00131295	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5378	Sept. 8, 2008 Letter FDA to BPV re FDA AI Demand re G2X (K082305)	BPV-17-01-00131298	BPV-17-01-00131299	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5379	Aug. 12, 2008 BPV's G2X Filter Special 510(k) (K082305)	BPV-17-01-00131320	BPV-17-01-00131596	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5380	G2 Express Filter Design/Development Files	BPV-17-01-00132051	BPV-17-01-00135828	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 801; 802
5381	Conference between FDA and BPV regarding I050537	BPV-17-01-00132282	BPV-17-01-00132284	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5382	G2 Express BR-8058 Biocompatibility Requirements G2 Express BR-8058 Biocompatibility Requirements	BPV-17-01-00132372	BPV-17-01-00132448	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5383	G2 Express Flat Plate Fatigue and Corrosion Testing TR-07-02-12 G2X Flat Plate Fatigue Test Various G2 Express Testing	BPV-17-01-00133001	BPV-17-01-00133027	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5384	G2 Express Feasibility Acute Animal study Report TR-07-05-18	BPV-17-01-00133028	BPV-17-01-00133050	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5385	G2 Express Filter Arm Fatigue Comparison TR-07-07-04	BPV-17-01-00133064	BPV-17-01-00133077	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5386	G2 Express v. G2 Tilt Assessment in Varying Cava Sizes TD-00463	BPV-17-01-00133078	BPV-17-01-00133080	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5387	G2 IFU PK5100085, Rev. 0 (Femoral)	BPV-17-01-00137389	BPV-17-01-00137392	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5388	G2 IFU (Jugular) PK5100090 Rev. 0 03/09	BPV-17-01-00137393	BPV-17-01-00137400	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5389	G2 IFU PK5014091, Rev. 2 10/08 (Jugular)	BPV-17-01-00137425	BPV-17-01-00137432	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5390	G2 IFU PK5100085, Rev. 2 (Femoral)	BPV-17-01-00137437	BPV-17-01-00137440	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5391	G2 IFU PK5260600, Rev. 2 10/09 (Jugular)	BPV-17-01-00137441	BPV-17-01-00137448	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5392	Recovery G2 Filter system 1 G2 filter system: indicated for retrieval	BPV-17-01-00137620	BPV-17-01-00137621	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403
5393	2008 - G2 Filter system: Patient Q+A 2008 - G2 Filter system: Patient Q+A	BPV-17-01-00137624	BPV-17-01-00137637	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403
5394	10/2009 - G2 IFU 10-2009	BPV-17-01-00137638	BPV-17-01-00137645	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5395	G2 DFMEA (Recovery Jugular) 070021, Rev. 0	BPV-17-01-00139544	BPV-17-01-00139562	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5396	G2 DFMEA (Recovery Jugular) 070021, Rev. 1	BPV-17-01-00139563	BPV-17-01-00139577	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5397	G2 DFMEA (Recovery Jugular) 070021, Rev. 2	BPV-17-01-00139578	BPV-17-01-00139592	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5398	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 3	BPV-17-01-00139593	BPV-17-01-00139607	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5399	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 4	BPV-17-01-00139608	BPV-17-01-00139622	FRE 401; 402; 403; 602; 702; 703; 801; 802	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5400	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 5	BPV-17-01-00139623	BPV-17-01-00139637	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5401	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 6	BPV-17-01-00139638	BPV-17-01-00139652	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5402	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 7	BPV-17-01-00139653	BPV-17-01-00139667	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5403	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 6 Signature page	BPV-17-01-00139668	BPV-17-01-00139668	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5404	G2 DFMEA (G2 Jugular) 070021, Rev. 7	BPV-17-01-00139669	BPV-17-01-00139684	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5405	G2 DFMEA (G2 Jugular) 070021, Rev. 8	BPV-17-01-00139685	BPV-17-01-00139686	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5406	G2 DFMEA (G2 Jugular) 070021, Rev. 9	BPV-17-01-00139687	BPV-17-01-00139704	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5407	G2 DFMEA (Femoral) 070022, Rev. 0	BPV-17-01-00139705	BPV-17-01-00139726	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5408	G2 DFMEA (Femoral) 070022, Rev. 1	BPV-17-01-00139727	BPV-17-01-00139749	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5409	G2 DFMEA (Femoral) 070022, Rev. 2	BPV-17-01-00139750	BPV-17-01-00139782	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5410	G2 DFMEA (Femoral) 070022, Rev. 3	BPV-17-01-00139783	BPV-17-01-00139823	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5411	G2 DFMEA (Femoral) 070022, Rev. 4	BPV-17-01-00139824	BPV-17-01-00139864	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5412	G2 DFMEA (Femoral) 070022, Rev. 5	BPV-17-01-00139866	BPV-17-01-00139907	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5413	G2 DFMEA (Femoral) 070031, Rev. 0	BPV-17-01-00139908	BPV-17-01-00139940	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5414	G2 DFMEA (Femoral) 070031, Rev. 1	BPV-17-01-00139941	BPV-17-01-00139973	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5415	G2 DFMEA (Femoral) 070031, Rev. 2	BPV-17-01-00139974	BPV-17-01-00140006	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5416	G2 DFMEA (Femoral) 070031, Rev. 3	BPV-17-01-00140007	BPV-17-01-00140047	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5417	G2 DFMEA (Femoral) 070031, Rev. 4	BPV-17-01-00140048	BPV-17-01-00140088	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5418	G2 DFMEA (Femoral) 070031, rev. 5	BPV-17-01-00140090	BPV-17-01-00140128	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5419	G2 DFMEA (Femoral) 070031, Rev. 6	BPV-17-01-00140129	BPV-17-01-00140160	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5420	Society of Interventional Radiology Responds to FDA Blood Clot Device (IVC Filter) Advisory	BPV-17-01-00140458	BPV-17-01-00140458	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 801; 802
5421	Aug. 23, 2010 Letter from SIR to Shuren Aug. 23, 2010 Letter from SIR to Shuren	BPV-17-01-00140459	BPV-17-01-00140462	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 801; 802
5422	FDA Safety Advisory	BPV-17-01-00140479	BPV-17-01-00140479	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5423	Dec. 17, 2009 Email from Schulz to Moffett Nicholson documents received from Bard 2/11/11	BPV-17-01-00141514	BPV-17-01-00141515	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 801; 802; MIL #2
5424	Dec. 15, 2009 Email from Schulz to Moffett	BPV-17-01-00141516	BPV-17-01-00141516	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5425	Nov. 9, 2009 Email from Chavez to Nicholson	BPV-17-01-00141517	BPV-17-01-00141519	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 801; 802
5426	Nov. 9, 2009 Email from Nicholson to Chavez	BPV-17-01-00141520	BPV-17-01-00141522	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 801; 802
5427	Dec. 9, 2009 Email from Schulz to Rhinehart	BPV-17-01-00141523	BPV-17-01-00141524	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403
5428	Chart reflecting information on complaint files	BPV-17-01-00141525	BPV-17-01-00141538	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5429	Dec. 1, 2009 Email from Chavez to DelioCox	BPV-17-01-00141539	BPV-17-01-00141541	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5430	Dec. 8, 2009 Email from Schulz to Nicholson	BPV-17-01-00141542	BPV-17-01-00141542	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5431	Dec. 7, 2009 email chain with FDA re IVC filters	BPV-17-01-00141543	BPV-17-01-00141549	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5432	Dec. 2, 2009 email chain with FDA re Nicholson and Meridian®	BPV-17-01-00141592	BPV-17-01-00141595	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5433	FDA re Removing Retrievable Inferior Vena Cava Filters: Initial Communication	BPV-17-01-00141621	BPV-17-01-00141621	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5434	Establishment Inspection Report -- May 20, 2003 Establishment Inspection Report -- May 20, 2003	BPV-17-01-00141829	BPV-17-01-00141838	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5435	Establishment Inspection Report -- April 5, 2006 Establishment Inspection Report -- April 5, 2006	BPV-17-01-00141839	BPV-17-01-00141852	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5436	Establishment Inspection Report -- May 4, 2009 Establishment Inspection Report -- May 4, 2009	BPV-17-01-00141853	BPV-17-01-00141875	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5437	Eclipse(Femoral) 12.09 - PK100600 Rev. 0a IFU	BPV-17-01-00142881	BPV-17-01-00142887	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5438	G2 Express (femoral) IFU 02.08 - PK5022940 Rev. 0	BPV-17-01-00142916	BPV-17-01-00142919	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5439	G2X(Femoral) 06.09 - PK5100060 Rev. 4 IFU	BPV-17-01-00142962	BPV-17-01-00142971	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5440	CQA-STD-24 Rev 08 -- Standard for Product Complaint Handling	BPV-17-01-00143084	BPV-17-01-00143100	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5441	SOPQ0153100 Rev 00 -- BPV Complaint Handling System	BPV-17-01-00143101	BPV-17-01-00143129	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5442	sopq0153100 Rev 01 -- BPV Complaint Handling System	BPV-17-01-00143130	BPV-17-01-00143156	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5443	sopq0153100 Rev 02 -- BPV Complaint Handling System	BPV-17-01-00143157	BPV-17-01-00143182	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5444	sopq0153100 Rev 03 -- BPV Complaint Handling System	BPV-17-01-00143183	BPV-17-01-00143198	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5445	sopq0153100 Rev 04 -- BPV Complaint Handling System	BPV-17-01-00143199	BPV-17-01-00143215	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5446	sopq0153100 Rev 05 -- BPV Complaint Handling System	BPV-17-01-00143216	BPV-17-01-00143232	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5447	sopq0153100 Rev 06 -- BPV Complaint Handling System	BPV-17-01-00143233	BPV-17-01-00143252	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5448	sopq0153100 Rev 07 -- BPV Complaint Handling System	BPV-17-01-00143253	BPV-17-01-00143272	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5449	sopq0153100 Rev 08 -- BPV Complaint Handling System	BPV-17-01-00143273	BPV-17-01-00143290	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5450	sopq0153100 Rev 09 -- BPV Complaint Handling System	BPV-17-01-00143291	BPV-17-01-00143307	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5451	sopq0153100 Rev 10 -- BPV Complaint Handling System	BPV-17-01-00143308	BPV-17-01-00143324	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5452	sopq0153100 Rev 11 -- BPV Complaint Handling System	BPV-17-01-00143325	BPV-17-01-00143342	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5453	sopq0153100 Rev 12 -- BPV Complaint Handling System	BPV-17-01-00143343	BPV-17-01-00143364	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5454	sopq0153100 Rev 13 -- BPV Complaint Handling System	BPV-17-01-00143365	BPV-17-01-00143387	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5455	sopq0153100 Rev 14 -- BPV Complaint Handling System	BPV-17-01-00143388	BPV-17-01-00143415	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5456	sopq0153100 Rev 15 -- BPV Complaint Handling System PMA Related	BPV-17-01-00143416	BPV-17-01-00143443	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5457	sopq0153100 Rev 16 -- BPV Complaint Handling System PMA Related	BPV-17-01-00143444	BPV-17-01-00143457	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5458	SOPQ0153100 Rev 17 -- BPV Complaint Handling System PMA Related	BPV-17-01-00143458	BPV-17-01-00143471	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5459	SOPQ0153100 Rev 18 -- BPV Complaint Handling System PMA Related	BPV-17-01-00143472	BPV-17-01-00143487	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5460	SOPQ0700200 Rev 00 -- Complaint Investigation Procedures	BPV-17-01-00143627	BPV-17-01-00143631	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5461	sopq0700200 Rev 01 -- Complaint Investigation Procedures	BPV-17-01-00143632	BPV-17-01-00143636	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5462	sopq0700200 Rev 02 -- Complaint Investigation Procedures	BPV-17-01-00143637	BPV-17-01-00143641	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5463	sopq0700200 Rev 03 -- Complaint Investigation Procedures	BPV-17-01-00143642	BPV-17-01-00143646	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5464	sopq0700200 Rev 04 -- Complaint Investigation Procedures	BPV-17-01-00143647	BPV-17-01-00143652	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5465	sopq0700200 Rev 05 -- Complaint Investigation Procedures	BPV-17-01-00143653	BPV-17-01-00143659	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5466	sopq0700200 Rev 06 -- Complaint Investigation Procedures	BPV-17-01-00143660	BPV-17-01-00143666	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5467	sopq0700200 Rev 07 -- Complaint Investigation Procedures	BPV-17-01-00143667	BPV-17-01-00143674	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5468	sopq0700200 Rev 08 -- Complaint Investigation Procedures PMA Related	BPV-17-01-00143675	BPV-17-01-00143684	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5469	sopq0700200 Rev 09 -- Complaint Investigation Procedures PMA Related	BPV-17-01-00143685	BPV-17-01-00143694	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5470	sopq0700200 Rev 10 -- Complaint Investigation Procedures PMA Related	BPV-17-01-00143695	BPV-17-01-00143700	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5471	SOPQ0700200 Rev 11 -- Complaint Investigation Procedures PMA Related	BPV-17-01-00143701	BPV-17-01-00143704	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5472	SOPQ0700200 Rev 12 -- Complaint Investigation Procedures PMA Related	BPV-17-01-00143705	BPV-17-01-00143708	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5473	sopq0735600 Rev 0 -- Failure Investigation	BPV-17-01-00143709	BPV-17-01-00143713	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5474	sopq0735600 Rev 1 -- Failure Investigation	BPV-17-01-00143714	BPV-17-01-00143718	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5475	sopq0735600 Rev 2 -- Failure Investigation	BPV-17-01-00143719	BPV-17-01-00143724	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5476	sopq0735600 Rev 3 -- Failure Investigation	BPV-17-01-00143725	BPV-17-01-00143730	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5477	sopq0735600 Rev 4 -- Failure Investigation	BPV-17-01-00143731	BPV-17-01-00143736	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5478	sopq0735600 Rev 5 -- Investigation Procedure	BPV-17-01-00143737	BPV-17-01-00143749	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5479	sopq0735600 Rev 6 -- Investigation Procedure	BPV-17-01-00143750	BPV-17-01-00143762	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5480	SOPQ0735600 Rev 7 -- Investigation Procedure PMA Related	BPV-17-01-00143763	BPV-17-01-00143778	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5481	sopq1402000 Rev 5 -- Subject Product Analysis and Remedial Action Assessment sopq1402000 Rev 5 -- Subject Product Analysis and Remedial Action Assessment	BPV-17-01-00143815	BPV-17-01-00143823	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5482	sopq1413000 Rev 15 -- CAPA Procedure PMA Related sopq1413000 Rev 15 -- CAPA Procedure PMA Related	BPV-17-01-00144100	BPV-17-01-00144118	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5483	sopq1417500 Rev 1 -- Statistical Complaint Trending Procedure PMA Related sopq1417500 Rev 1 -- Statistical Complaint Trending Procedure PMA Related	BPV-17-01-00144123	BPV-17-01-00144126	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5484	Recovery Cone® Removal System IFU and related documentation	BPV-17-01-00144315	BPV-17-01-00144318	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5485	Recovery Cone® IFU and related documentation	BPV-17-01-00144389	BPV-17-01-00144525	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5486	Dec. 17, 2009 Letter from BPV to FDA re Eclipse Filter System Response to FDA Questions (K093659)	BPV-17-01-00145607	BPV-17-01-00145616	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5487	Dec. 17, 2009 Letter BPV to FDA re Responses to FDA AI Demand re Eclipse (K093659)	BPV-17-01-00145607	BPV-17-01-00145616	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5488	June 21, 2010 Letter from BPV to FDA re Eclipse Filter System Response to FDA Questions (K101431)	BPV-17-01-00145617	BPV-17-01-00145633	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5489	Meridian Filter System -- Femoral Delivery Kit Special 510(k) (K112497), Aug. 27, 2011 (Vol. I & II)	BPV-17-01-00147141	BPV-17-01-00147592	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
5490	Sept. 30, 2011 Letter from FDA to BPV re Meridian Filter System -- Femoral Delivery Kit Special 510(k) (K112497)	BPV-17-01-00147593	BPV-17-01-00147597	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5491	Sept. 30, 2011 Letter from FDA to BPV re Meridian Filter System -- Femoral Special 510(k) (K112497)	BPV-17-01-00147593	BPV-17-01-00147597	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5492	Letter from BPV to FDA re Meridian Filter System Response to FDA Questions, Sept. 30, 2011	BPV-17-01-00147598	BPV-17-01-00147607	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5493	Oct. 24, 2011 Letter from FDA to BPV re Meridian Filter System -- Femoral Delivery Kit Special 510(k) (K112497) (Substantial Equivalence)	BPV-17-01-00147608	BPV-17-01-00147610	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5494	Oct. 24, 2011 Letter re Meridian Filter System (K112497) (Substantial Equivalence)	BPV-17-01-00147608	BPV-17-01-00147610	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5495	Meridian IFU (Femoral) 2011.01 - PK5372100 rev. 1	BPV-17-01-00147635	BPV-17-01-00147646	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5496	Meridian IFU (Femoral) 2011.02 - PK5372100 rev. 2	BPV-17-01-00147647	BPV-17-01-00147658	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5497	Meridian IFU (Femoral) 2011.06 - PK5372100 rev. 3	BPV-17-01-00147659	BPV-17-01-00147670	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5498	Meridian(Femoral) 08.11 - PK5372100 Rev. 4 IFU	BPV-17-01-00147671	BPV-17-01-00147682	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5499	Meridian IFU (Jugular) 2011.06 - PK5372400 rev. 2	BPV-17-01-00147707	BPV-17-01-00147718	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5500	Meridian IFU (Jugular) 2011.08 - PK5372400 rev. 3	BPV-17-01-00147719	BPV-17-01-00147730	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5501	Meridian Jugular Subclavian Delivery Kit Traditional 510(k) (K102511) August 31, 2010	BPV-17-01-00150192	BPV-17-01-00151045	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5502	CQA-STD-24 Rev 0 -- Standard for Product Complaint Handling	BPV-17-01-00152637	BPV-17-01-00152661	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5503	CQA-STD-24 Rev 1 -- Standard for Product Complaint Handling	BPV-17-01-00152662	BPV-17-01-00152677	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5504	CQA-STD-24 Rev 2 -- Standard for Product Complaint Handling	BPV-17-01-00152678	BPV-17-01-00152694	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5505	CQA-STD-24 Rev 3 -- Standard for Product Complaint Handling	BPV-17-01-00152695	BPV-17-01-00152713	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5506	CQA-STD-24 Rev 4 -- Standard for Product Complaint Handling	BPV-17-01-00152714	BPV-17-01-00152734	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5507	CQA-STD-24 Rev 5 -- Standard for Product Complaint Handling	BPV-17-01-00152735	BPV-17-01-00152822	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5508	CQA-STD-24 Rev 6 -- Standard for Product Complaint Handling	BPV-17-01-00152823	BPV-17-01-00152838	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5509	CQA-STD-24 Rev 7 -- Standard for Product Complaint Handling	BPV-17-01-00152839	BPV-17-01-00152855	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5510	Recovery Filter Subject Product Analysis Migration SPA-04-12-01 Addendum I SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration) Recovery Filter Subject Product Analysis: Migration (SPA-04-12-01) Addendum I	BPV-17-01-00153231	BPV-17-01-00153234	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5511	Attachment A to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration) Attachment A to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration)	BPV-17-01-00153235	BPV-17-01-00153289	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5512	Attachment B to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration) Attachment B to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration)	BPV-17-01-00153344	BPV-17-01-00153410	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5513	Attachment C to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration) Attachment C to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration)	BPV-17-01-00153411	BPV-17-01-00153470	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5514	Attachment D to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration) Attachment D to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration)	BPV-17-01-00153471	BPV-17-01-00153474	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5515	Attachment E to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration) Attachment E to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration)	BPV-17-01-00153475	BPV-17-01-00153478	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5516	Attachment F to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration) Attachment F to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration)	BPV-17-01-00153479	BPV-17-01-00153483	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5517	Attachment G to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration) Attachment G to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration)	BPV-17-01-00153484	BPV-17-01-00153489	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5518	Attachment H to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration) Attachment H to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF Migration)	BPV-17-01-00153490	BPV-17-01-00153494	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5519	July 12, 2004 Addendum to the Recovery; Filter Migration Events Spreadsheet (by Doug Uelmen) July 12, 2004 Addendum to the Recovery; Filter Migration Events Spreadsheet (by Doug Uelmen)	BPV-17-01-00153557	BPV-17-01-00153557	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5520	June 25, 2004 Multidisciplinary Focus Group Meeting PPT Slides June 25, 2004 Multidisciplinary Focus Group Meeting PPT Slides	BPV-17-01-00153561	BPV-17-01-00153564	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5521	June 25, 2004 Multidisciplinary Focus Group Meeting PPT Slides June 25, 2004 Multidisciplinary Focus Group Meeting PPT Slides	BPV-17-01-00153565	BPV-17-01-00153565	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5522	June 25, 2004 Multidisciplinary Focus Group Meeting PPT Slides June 25, 2004 Multidisciplinary Focus Group Meeting PPT Slides	BPV-17-01-00153569	BPV-17-01-00153572	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5523	ETR-04-03-05 (RNF Characterization testing comparing GFO v. NMT manufactured filters) (followed TPR-04-02-02) ETR-04-03-05, Rev. 0 (GFO and NMT Manufactured Recovery; Filters Migration Resistance Comparison, Phase 1)	BPV-17-01-00153717	BPV-17-01-00153723	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5524	March 10, 2004 Health Hazard Evaluation	BPV-17-01-00153751	BPV-17-01-00153762	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5525	Action Items from March 4, 2004 RNF Migration Meeting	BPV-17-01-00153895	BPV-17-01-00153895	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5526	TPR-04-02-02 (Protocol for RNF Migration Testing v. Competitive) Test Protocol Number TPR-04-02-02 (Rev. 0) -- Characterization of the Recovery Filter (RF) - Migration Resistance	BPV-17-01-00153896	BPV-17-01-00153909	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5527	March 26, 2014 Recovery Filter Migration Physician Review Panel PPT	BPV-17-01-00154014	BPV-17-01-00154047	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; MIL #2
5528	Agenda for Feb. 12, 2004 RNF Migration Meeting	BPV-17-01-00154048	BPV-17-01-00154049	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5529	2004 Notebook of Materials re Migration (includes various meeting minutes)	BPV-17-01-00154190	BPV-17-01-00154256	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5530	IFU Comparison Chart IFU Comparison Chart	BPV-17-01-00154520	BPV-17-01-00154564	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1; MIL #2
5531	March 4, 2004 RNF Migration Meeting Minutes	BPV-17-01-00154665	BPV-17-01-00154667	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5532	April 16, 2004 RNF Migration Meeting Minutes	BPV-17-01-00154730	BPV-17-01-00154731	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #2
5533	Feb. 2004 Notebook of Materials re Migration (includes various meeting minutes)	BPV-17-01-00155031	BPV-17-01-00155073	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 801; 802; MIL #1
5534	Picture of Clot from Feb. 2004 RNF Migration	BPV-17-01-00155041	BPV-17-01-00155045	FRE 401; 402; 403; Cond.	401; 402; 403; 801; 802; MIL #1
5535	G2 Caudal Migration Failure Investigation Presentation Slides	BPV-17-01-00155091	BPV-17-01-00155170	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5536	Meeting Summary from Filter Expert Panel June 1, 2006	BPV-17-01-00155135	BPV-17-01-00155137	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5537	June 2006 Expert Panel Meeting Slides	BPV-17-01-00155139	BPV-17-01-00155170	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5538	June 19, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes	BPV-17-01-00155174	BPV-17-01-00155204	FRE 401; 402; 403; Cond.	
5539	G2 Caudal Migration Failure Investigation Report Aug. 4, 2005 G2 Filter Caudal Migration Failure Investigation Report (FIR-06-01-01) G2 Caudal Migration Failure Investigation Report	BPV-17-01-00155205	BPV-17-01-00155221	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL # 1
5540	BPV Quality Manual Rev. 0	BPV-17-01-00158946	BPV-17-01-00158969	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5541	BPV Quality Manual Rev 1	BPV-17-01-00158970	BPV-17-01-00158993	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5542	BPV Quality Manual Rev 2	BPV-17-01-00158994	BPV-17-01-00159017	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5543	BPV Quality Manual Rev 3	BPV-17-01-00159018	BPV-17-01-00159041	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5544	BPV Quality Manual Rev 4	BPV-17-01-00159042	BPV-17-01-00159065	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5545	BPV Quality Manual Rev 5	BPV-17-01-00159066	BPV-17-01-00159089	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5546	BPV Quality Manual - DOPQ0700300 Rev 6 BPV Quality Manual - DOPQ0700300 Rev 6	BPV-17-01-00159090	BPV-17-01-00159114	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5547	SOPN0700080, Rev. 0 (Design Review)	BPV-17-01-00160805	BPV-17-01-00160814	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5548	Standard Operating Procedure / Division Operating Procedure - SOPN0700080 Rev 6	BPV-17-01-00160860	BPV-17-01-00160869	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5549	Department of Health and Human Services NOI 2003 Notice of Inspection	BPV-17-01-00162796	BPV-17-01-00162800	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5550	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-31 Rev 1	BPV-17-01-00162811	BPV-17-01-00162820	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5551	Standard Operating Procedures / Division Operating Procedures -- DOPQ1102100 Rev 12	BPV-17-01-00162958	BPV-17-01-00162960	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5552	Establishment Inspection Report -- FDA July 2011	BPV-17-01-00162961	BPV-17-01-00162984	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5553	Standard Operating Procedures / Division Operating Procedures -- SOPQ1413000 Rev 15	BPV-17-01-00163288	BPV-17-01-00163306	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5554	Standard Operating Procedures / Division Operating Procedures -- DOPQ0700000 Rev 8	BPV-17-01-00163323	BPV-17-01-00163324	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5555	Standard Operating Procedures / Division Operating Procedures -- DOPQ0700020 Rev 13	BPV-17-01-00163540	BPV-17-01-00163544	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5556	Standard Operating Procedures / Division Operating Procedures -- DOPQ0700040 Rev 4	BPV-17-01-00163565	BPV-17-01-00163569	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5557	Standard Operating Procedures / Division Operating Procedures -- DOPQ0700300 Rev 5	BPV-17-01-00163890	BPV-17-01-00163913	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5558	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-54 Rev 00	BPV-17-01-00166650	BPV-17-01-00166686	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5559	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-54 Rev 01	BPV-17-01-00166687	BPV-17-01-00166724	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5560	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-R002 Rev 11	BPV-17-01-00166749	BPV-17-01-00166776	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5561	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-R002 Rev 12	BPV-17-01-00166777	BPV-17-01-00166806	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5562	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-R002 Rev 13	BPV-17-01-00166807	BPV-17-01-00166837	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5563	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-R002 Rev 14	BPV-17-01-00166838	BPV-17-01-00166868	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5564	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-R002 Rev 15	BPV-17-01-00166869	BPV-17-01-00166901	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5565	Standard Operating Procedures / Division Operating Procedures -- RA-STD-002 Rev 10	BPV-17-01-00166947	BPV-17-01-00166968	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5566	Standard Operating Procedures / Division Operating Procedures -- RA-STD-002 Rev 9	BPV-17-01-00166969	BPV-17-01-00166987	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5567	Lab notebook 7102 (G2 Express ELF Test) Lab Notebook LAB-7102 JOB	BPV-17-01-00167982	BPV-17-01-00168036	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5568	Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 0	BPV-17-01-00169138	BPV-17-01-00169139	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5569	Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 1	BPV-17-01-00169140	BPV-17-01-00169142	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5570	Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 2	BPV-17-01-00169143	BPV-17-01-00169145	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5571	Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 3	BPV-17-01-00169146	BPV-17-01-00169148	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5572	Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 4	BPV-17-01-00169149	BPV-17-01-00169152	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5573	Standard Operating Procedures / Division Operating Procedures - SOPN0700180 Rev 5	BPV-17-01-00169153	BPV-17-01-00169156	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5574	Standard Operating Procedures / Division Operating Procedures - SOPQ0700190 Rev 0	BPV-17-01-00169157	BPV-17-01-00169164	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5575	Standard Operating Procedures / Division Operating Procedures - SOPQ0700190 Rev 1	BPV-17-01-00169165	BPV-17-01-00169172	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5576	Standard Operating Procedures / Division Operating Procedures - SOPQ0700190 Rev 2	BPV-17-01-00169173	BPV-17-01-00169180	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5577	Standard Operating Procedures / Division Operating Procedures - SOPQ0700190 Rev 3	BPV-17-01-00169181	BPV-17-01-00169188	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5578	Standard Operating Procedures / Division Operating Procedures - SOPQ1417500 Rev 0	BPV-17-01-00169268	BPV-17-01-00169271	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5579	Standard Operating Procedures / Division Operating Procedures - SOPQ1417500 Rev 1	BPV-17-01-00169272	BPV-17-01-00169275	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5580	Standard Operating Procedures / Division Operating Procedures - CQA-STD-15 rev 2	BPV-17-01-00169295	BPV-17-01-00169304	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5581	02.28.13 Letter from FDA to BPV re PRESERVE Study 522_Eclipse	BPV-17-01-00171669	BPV-17-01-00171670	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
5582	02.28.13 Letter from FDA to BPV re PRESERVE Study 522_G2	BPV-17-01-00171671	BPV-17-01-00171672	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
5583	02.28.13 Letter from FDA to BPV re PRESERVE Study 522_G2X	BPV-17-01-00171673	BPV-17-01-00171674	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
5584	02.28.13 Letter from FDA to BPV re PRESERVE Study 522_Recovery	BPV-17-01-00171675	BPV-17-01-00171676	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5585	02.28.13 Letter from FDA to BPV re PRESERVE Study 522_Simon Nitinol	BPV-17-01-00171677	BPV-17-01-00171678	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
5586	May 20, 2010 BPV's Eclipse Filter Special 510(k) (K101431)	BPV-17-01-00171679	BPV-17-01-00171793	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5587	June 18, 2010 Letter FDA to BPV re FDA AI Demand re Eclipse (K101431)	BPV-17-01-00171794	BPV-17-01-00171796	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5588	Dec. 15, 2009 Letter FDA to BPV re FDA AI Demand re Eclipse (K093659)	BPV-17-01-00171797	BPV-17-01-00171799	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5589	June 22, 2010 -- FDA Clearance Letter for Eclipse Filter (K101431) (Substantial Equivalence)	BPV-17-01-00171815	BPV-17-01-00171817	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5590	Meridian Clearance August 24, 2011 (K102511)	BPV-17-01-00171818	BPV-17-01-00171820	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5591	FDA CONTACT REPORT 11-18-2010_Meridian 510(k)	BPV-17-01-00171821	BPV-17-01-00171821	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5592	FDA CONTACT REPORT 2-4-2011_MERIDIAN AI Letter and DENALI IDE	BPV-17-01-00171822	BPV-17-01-00171822	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5593	Aug. 14, 2009 Conference FDA and BPV re future Eclipse Filter 510(k)	BPV-17-01-00171823	BPV-17-01-00171824	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5594	FDA CONTACT REPORT December 3 2010_Denali pre-IDE supplement & Meridian AI Response	BPV-17-01-00171825	BPV-17-01-00171828	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5595	FDA CONTACT REPORT December 7 2010_Denali IDE and Meridian AI Response	BPV-17-01-00171829	BPV-17-01-00171829	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5596	FDA CONTACT REPORT December 8 2010_Meridian AI_Fatigue	BPV-17-01-00171830	BPV-17-01-00171832	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5597	Dec. 8, 2010 FDA Contact Report re Meridian	BPV-17-01-00171830	BPV-17-01-00171832	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5598	Feb. 10, 2011 FDA Contact Report (Denali Pre IDE)	BPV-17-01-00171833	BPV-17-01-00171835	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5599	Feb. 10, 2011 FDA Contact Report (Meridian)	BPV-17-01-00171836	BPV-17-01-00171838	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5600	FDA CONTACT REPORT Feb 16 2010_ Prophylactic Indication	BPV-17-01-00171839	BPV-17-01-00171840	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5601	Feb. 17, 2011 (Meridian)	BPV-17-01-00171841	BPV-17-01-00171844	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5602	FDA CONTACT REPORT January 7 2010 FINAL	BPV-17-01-00171845	BPV-17-01-00171849	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5603	Jan. 8, 2010 (Meridian Pre IDE)	BPV-17-01-00171850	BPV-17-01-00171853	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5604	FDA CONTACT REPORT June 29 2010_ASLT for IDE	BPV-17-01-00171854	BPV-17-01-00171854	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5605	FDA CONTACT REPORT March 31 2009 Pre-IDE Meeting Minutes_G2 Platinum	BPV-17-01-00171855	BPV-17-01-00171856	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5606	FDA CONTACT REPORT May 17 2011_Meridian	BPV-17-01-00171857	BPV-17-01-00171864	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5607	May 17, 2011 (Meridian)	BPV-17-01-00171857	BPV-17-01-00171864	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5608	May 20, 2010 (Denali Pre IDE)	BPV-17-01-00171865	BPV-17-01-00171867	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5609	May 5, 2010 (Denali Pre IDE)	BPV-17-01-00171868	BPV-17-01-00171871	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5610	Nov. 12, 2010 (Meridian)	BPV-17-01-00171872	BPV-17-01-00171873	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5611	FDA CONTACT REPORT Nov 17 2009 CRT Online	BPV-17-01-00171874	BPV-17-01-00171874	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5612	Nov. 17, 2009 (Filters and future submissions)	BPV-17-01-00171875	BPV-17-01-00171876	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5613	FDA CONTACT REPORT June 22 2011_Meridian	BPV-17-01-00171877	BPV-17-01-00171879	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5614	June 22, 2011 (Meridian)	BPV-17-01-00171877	BPV-17-01-00171879	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5615	FDA CONTACT REPORT September 27 2011_IVC Filter Discussion and Meridian	BPV-17-01-00171880	BPV-17-01-00171881	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5616	Standard Operating Procedure / Division Operating Procedure - R-004 Rev 03	BPV-17-01-00178223	BPV-17-01-00178253	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5617	Standard Operating Procedure / Division Operating Procedure - SOPR0700000 Rev.17	BPV-17-01-00178537	BPV-17-01-00178552	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5618	Standard Operating Procedure / Division Operating Procedure - SOPR0700010 Rev. 12	BPV-17-01-00178594	BPV-17-01-00178606	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5619	Preserve Materials 12-8-10 IVC Filter study	BPV-17-01-00178867	BPV-17-01-00179006	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5620	Bard.Preserve.LOI Bard.Preserve.LOI	BPV-17-01-00178911	BPV-17-01-00178911	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5621	ETR-06-08-29, Rev. 0 (Caudal Migration Test Method Development and G2 Filter Resistance Test Report)	BPV-17-01-00180551	BPV-17-01-00180573	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5622	TPR-06-08-29, Rev. 0 (Caudal Migration Test Method Development and G2 Filter Resistance Test Protocol)	BPV-17-01-00180858	BPV-17-01-00180869	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5623	Recovery Filter Product Performance Specification (PPS070016 Rev. 0)	BPV-17-01-00186068	BPV-17-01-00186094	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5624	Filter Action Items PPT	BPV-17-01-00188512	BPV-17-01-00188512	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5625	Design History File: 8088 Platinum - G2 Compliant	BPV-17-01-00188517	BPV-17-01-00188517	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5626	Spreadsheet of Complications	BPV-17-01-00188520	BPV-17-01-00188520	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5627	BPV EIR 2007 -- Establishment Inspection Report -- FDA January 2007	BPV-17-01-00189119	BPV-17-01-00189123	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5628	BPV EIR 2007 -- Establishment Inspection Report -- FDA January 2009	BPV-17-01-00189124	BPV-17-01-00189130	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5629	Nov. 28 2011 EIR -- Establishment Inspection Report -- FDA August 2011	BPV-17-01-00189131	BPV-17-01-00189143	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5630	Bard Signed Agreement Bard Signed Agreement	BPV-17-01-00189810	BPV-17-01-00189811	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5631	DOPN0700010, Rev. 0 (DOP re Risk Assessment)	BPV-17-01-00189812	BPV-17-01-00189818	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5632	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 00	BPV-17-01-00190036	BPV-17-01-00190046	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5633	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 01	BPV-17-01-00190047	BPV-17-01-00190057	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5634	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 02	BPV-17-01-00190058	BPV-17-01-00190068	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5635	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 03	BPV-17-01-00190069	BPV-17-01-00190079	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5636	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 04	BPV-17-01-00190080	BPV-17-01-00190089	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5637	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 05	BPV-17-01-00190090	BPV-17-01-00190106	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5638	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 06	BPV-17-01-00190107	BPV-17-01-00190128	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5639	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 07	BPV-17-01-00190129	BPV-17-01-00190151	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5640	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 08	BPV-17-01-00190152	BPV-17-01-00190174	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5641	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 09	BPV-17-01-00190175	BPV-17-01-00190198	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5642	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 10	BPV-17-01-00190199	BPV-17-01-00190222	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5643	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 11	BPV-17-01-00190223	BPV-17-01-00190247	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5644	Standard Operating Procedure / Division Operating Procedure - SOPN0700120 Rev 12	BPV-17-01-00190248	BPV-17-01-00190272	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5645	QMBR--April 2013	BPV-17-01-00191230	BPV-17-01-00191297	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5646	QMBR--Nov. 2013	BPV-17-01-00191684	BPV-17-01-00191763	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802
5647	TD-03970 -- Eclipse and G2X Migration Resistance Test Data	BPV-17-01-00193315	BPV-17-01-00193321	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5648	Jan. 5, 2015 FDA 483 Letter to BPV.pdf	BPV-17-01-00193330	BPV-17-01-00193336	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5649	July 13, 2015 FDA Warning Letter to Bard.pdf	BPV-17-01-00193337	BPV-17-01-00193348	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	MIL #3
5650	Nov. 25, 2014 FDA 483 Letter to Glens Falls.pdf	BPV-17-01-00193349	BPV-17-01-00193358	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5651	GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Letter.pdf	BPV-17-01-00193359	BPV-17-01-00193361	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5652	GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Exhibit 1.pdf	BPV-17-01-00193362	BPV-17-01-00193371	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5653	GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Exhibit 2.pdf	BPV-17-01-00193372	BPV-17-01-00193414	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5654	GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Exhibit 3.pdf	BPV-17-01-00193415	BPV-17-01-00193418	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5655	GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Attachments\09-01.pdf	BPV-17-01-00194696	BPV-17-01-00194698	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5656	GFO FDA 483 Response (2) Jan 15 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00195057	BPV-17-01-00195064	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5657	GFO FDA 483 Response (2) Jan 15 2015 Update\Exhibit 1.pdf	BPV-17-01-00195065	BPV-17-01-00195078	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5658	GFO FDA 483 Response (2) Jan 15 2015 Update\Exhibit 2.pdf	BPV-17-01-00195079	BPV-17-01-00195081	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5659	GFO FDA 483 Response (2) Jan 15 2015 Update\Exhibit 3.pdf	BPV-17-01-00195082	BPV-17-01-00195091	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5660	GFO FDA 483 Response (3) Feb 18 2015 Update\FDA Response Document Receipt, FedEx Tracking and Letter.pdf	BPV-17-01-00195325	BPV-17-01-00195332	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5661	GFO FDA 483 Response (3) Feb 18 2015 Update\Exhibit 1.pdf	BPV-17-01-00195333	BPV-17-01-00195355	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5662	GFO FDA 483 Response (3) Feb 18 2015 Update\Exhibit 2.pdf	BPV-17-01-00195356	BPV-17-01-00195358	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5663	GFO FDA 483 Response (3) Feb 18 2015 Update\Exhibit 3.pdf	BPV-17-01-00195359	BPV-17-01-00195371	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5664	GFO FDA 483 Response (4) Mar 16 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00195511	BPV-17-01-00195521	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5665	GFO FDA 483 Response (4) Mar 16 2015 Update\Exhibit 1.pdf	BPV-17-01-00195522	BPV-17-01-00195541	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5666	GFO FDA 483 Response (4) Mar 16 2015 Update\Exhibit 2.pdf	BPV-17-01-00195542	BPV-17-01-00195544	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5667	GFO FDA 483 Response (4) Mar 16 2015 Update\Exhibit 3.pdf	BPV-17-01-00195545	BPV-17-01-00195560	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5668	GFO FDA 483 Response (5) Apr 17 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00195699	BPV-17-01-00195709	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5669	GFO FDA 483 Response (5) Apr 17 2015 Update\Exhibit 1.pdf	BPV-17-01-00195710	BPV-17-01-00195733	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5670	GFO FDA 483 Response (5) Apr 17 2015 Update\Exhibit 2.pdf	BPV-17-01-00195734	BPV-17-01-00195736	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5671	GFO FDA 483 Response (5) Apr 17 2015 Update\Exhibit 3.pdf	BPV-17-01-00195737	BPV-17-01-00195756	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5672	GFO FDA 483 Response (6) May 6 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00196023	BPV-17-01-00196033	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5673	GFO FDA 483 Response (6) May 6 2015 Update\Exhibit 1.pdf	BPV-17-01-00196034	BPV-17-01-00196056	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5674	GFO FDA 483 Response (6) May 6 2015 Update\Exhibit 2.pdf	BPV-17-01-00196057	BPV-17-01-00196059	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5675	GFO FDA 483 Response (6) May 6 2015 Update\Exhibit 3.pdf	BPV-17-01-00196060	BPV-17-01-00196079	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5676	GFO FDA 483 Response (7) Jun 19 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00196357	BPV-17-01-00196366	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5677	GFO FDA 483 Response (7) Jun 19 2015 Update\Exhibit 1.pdf	BPV-17-01-00196367	BPV-17-01-00196395	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5678	GFO FDA 483 Response (7) Jun 19 2015 Update\Exhibit 2.pdf	BPV-17-01-00196396	BPV-17-01-00196399	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5679	GFO FDA 483 Response (7) Jun 19 2015 Update\Exhibit 3.pdf	BPV-17-01-00196400	BPV-17-01-00196422	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5680	GFO FDA 483 Response (8) July 17 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00199457	BPV-17-01-00199467	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5681	GFO FDA 483 Response (8) July 17 2015 Update\Exhibit 1.pdf	BPV-17-01-00199468	BPV-17-01-00199496	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5682	GFO FDA 483 Response (8) July 17 2015 Update\Exhibit 2.pdf	BPV-17-01-00199497	BPV-17-01-00199500	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5683	GFO FDA 483 Response (8) July 17 2015 Update\Exhibit 3.pdf	BPV-17-01-00199501	BPV-17-01-00199523	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5684	BPV FDA 483 Response Cover letter and response January 26, 2014	BPV-17-01-00199543	BPV-17-01-00199555	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5685	BPV FDA 483 Response 1 - Attachments.pdf	BPV-17-01-00199556	BPV-17-01-00199800	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5686	Jan. 2015 Retrospective Review of Death Complaints	BPV-17-01-00199738	BPV-17-01-00199772	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5687	Jan. 2015 Retrospective Review of Death Complaints (Serious Injury v. Malfunction)	BPV-17-01-00199773	BPV-17-01-00199800	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 801; 802; MIL #3
5688	BPV FDA 483 Response 2 - Attachments.pdf	BPV-17-01-00199801	BPV-17-01-00199868	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5689	BPV FDA 483 Response 3 - Attachments.pdf	BPV-17-01-00199869	BPV-17-01-00199958	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5690	BPV FDA 483 Update Response February 26, 2015.pdf	BPV-17-01-00199959	BPV-17-01-00200155	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5691	BPV FDA 483 Update Response March 26, 2015.pdf	BPV-17-01-00200156	BPV-17-01-00200338	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5692	BPV FDA 483 Update Response April 24, 2015.pdf	BPV-17-01-00200339	BPV-17-01-00200353	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5693	BPV FDA 483 Update Response May 22, 2015.pdf	BPV-17-01-00200354	BPV-17-01-00200370	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5694	BPV FDA 483 Update Response June 25, 2015.pdf	BPV-17-01-00200371	BPV-17-01-00200383	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5695	Bard Warning Letter Response (August 3 2015) 01 Cover Letter.pdf	BPV-17-01-00200384	BPV-17-01-00200390	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5696	Bard Warning Letter Response (August 3 2015) 02 Warning Letter Response.pdf	BPV-17-01-00200391	BPV-17-01-00200451	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5697	Bard Warning Letter Response (August 3 2015) 03 Appendix 0.pdf	BPV-17-01-00200452	BPV-17-01-00200463	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5698	Bard Warning Letter Response (August 3 2015) 04 Appendix 1.pdf	BPV-17-01-00200464	BPV-17-01-00200606	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5699	Bard Warning Letter Response (August 3 2015) 05 Appendix 2.pdf	BPV-17-01-00200607	BPV-17-01-00200636	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5700	Bard Warning Letter Response (August 3 2015) 06 Appendix 3.pdf	BPV-17-01-00200637	BPV-17-01-00200715	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5701	Bard Warning Letter Response (August 3 2015) 10 Appendix 7.pdf	BPV-17-01-00201984	BPV-17-01-00201990	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5702	Bard Warning Letter Response (August 3 2015) 11 Appendix 8.pdf	BPV-17-01-00201991	BPV-17-01-00202163	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5703	October 6 2015 Update Response to Warning Letter Issued July 13 2015.pdf	BPV-17-01-00202253	BPV-17-01-00202341	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5704	September 3 2015 Update Response to Form 483 issued January 5 2015.pdf	BPV-17-01-00202342	BPV-17-01-00202353	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5705	September 3 2015 Update Response to Form 483 issued November 25 2014.pdf	BPV-17-01-00202354	BPV-17-01-00202873	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5706	September 3 2015 Update Response to Warning Letter issued July 13 2015.pdf	BPV-17-01-00202874	BPV-17-01-00203376	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; MIL #3
5707	Recovery Cone Materials -- 001_Recovery Cone 510(k)_FINAL.pdf	BPV-17-01-00203377	BPV-17-01-00203857	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5708	Recovery Cone Materials -- FW Continued Distribution of the Recovery Cone Removal System.msg	BPV-17-01-00203888	BPV-17-01-00203893	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5709	Recovery Cone Materials -- RC15 Customer Letter.pdf	BPV-17-01-00204002	BPV-17-01-00204003	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5710	Recovery Cone Materials -- Recovery Cone Customer Letter.pdf	BPV-17-01-00204004	BPV-17-01-00204006	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5711	Recovery® Cone IFU and related documentation	BPV-17-01-00204007	BPV-17-01-00204138	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5712	FDA Submissions and Correspondence Files Regarding Recovery® Cone	BPV-17-01-00204139	BPV-17-01-002040230	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5713	Recovery Cone Materials -- Dr Bilek letter.pdf	BPV-17-01-00204144	BPV-17-01-00204150	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5714	Recovery Cone Materials -- FDA Meeting K152136 Recovery Cone_Question 8.pdf	BPV-17-01-00204184	BPV-17-01-00204190	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5715	July 13 2015 FDA Warning Letter to Bard (unredacted)	BPV-17-01-00204231	BPV-17-01-00204243	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5716	October 6 2015 Update Response to 483 Issued November 25 2014.pdf	BPV-17-01-00204244	BPV-17-01-00204480	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5717	November 20 2015 Update Response to Form 483 issued November 25 2014.pdf	BPV-17-01-00205167	BPV-17-01-00205852	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5718	November 20 2015 Update Response to Warning Letter issued July 13 2015.pdf	BPV-17-01-00205853	BPV-17-01-00206168	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5719	Sept. 2015 Retrospective Review re Follow Up	BPV-17-01-00206131	BPV-17-01-00206168	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5720	RE Bard Peripheral Vascular - clarification question.msg	BPV-17-01-00206170	BPV-17-01-00206171	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5721	FDA response letter 121415.pdf	BPV-17-01-00206172	BPV-17-01-00206175	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5722	FDA Warning Letter Materials -- December 22 2015 GFO 483 Update Submission.pdf	BPV-17-01-00206782	BPV-17-01-00206981	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5723	FDA Warning Letter Materials -- December 22 2015 WL Update Response.pdf	BPV-17-01-00206982	BPV-17-01-00207267	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5724	Internal Quality Audit Worksheet (attached to FDA WL response Dec. 2015)	BPV-17-01-00207022	BPV-17-01-00207267	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5725	FDA Warning Letter Materials -- Transmittal Letter.pdf	BPV-17-01-00207268	BPV-17-01-00207268	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5726	FDA 483 #2020394 BPV February 2016.PDF	BPV-17-01-00207269	BPV-17-01-00207271	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5727	FDA 483 GFO March 2016.PDF	BPV-17-01-00207272	BPV-17-01-00207274	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5728	Recovery Cone Materials - K152136 Letter SE FINAL_Sent001.pdf	BPV-17-01-00207285	BPV-17-01-00207286	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5729	Denali Design Input Summary Rev. 2	BPV-17-01-00209120	BPV-17-01-00209268	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5730	Denali 510(k) submission (K130366) -- Narrative Submission.pdf	BPV-17-01-00213103	BPV-17-01-00213188	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
5731	Denali 510(k) submission (K130366) -- Appendices Part 1.pdf	BPV-17-01-00213189	BPV-17-01-00213688	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5732	Denali 510(k) submission (K130366) -- Appendices Part 2.pdf	BPV-17-01-00213689	BPV-17-01-00214187	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5733	Denali 510(k) submission (K130366) -- Appendices Part 3.pdf	BPV-17-01-00214188	BPV-17-01-00214587	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5734	Denali 510(k) submission (K130366) -- Appendices Part 4.pdf	BPV-17-01-00214588	BPV-17-01-00215017	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
5735	Denali 510(k) submission (K130366) -- Appendices Part 5.pdf	BPV-17-01-00215018	BPV-17-01-00215973	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5736	Denali 510(k) submission (K130366) -- Appendices Part 6.pdf	BPV-17-01-00215974	BPV-17-01-00216073	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
5737	Denali 510(k) submission (K130366) -- Appendices Part 7.pdf	BPV-17-01-00216074	BPV-17-01-00216173	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5738	Denali 510(k) submission (K130366) -- Appendices Part 8.pdf	BPV-17-01-00216174	BPV-17-01-00216473	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
5739	Denali 510(k) submission (K130366) -- Appendices Part 9.pdf	BPV-17-01-00216474	BPV-17-01-00216873	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5740	Denali 510(k) submission (K130366) -- Appendices Part 10 Section 1.pdf	BPV-17-01-00216874	BPV-17-01-00217094	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
5741	Denali 510(k) (K130366) Clearance Letter dated May 15, 2013.pdf	BPV-17-01-00217095	BPV-17-01-00217097	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5742	Denali 510(k) submission (K130366) -- Appendices Part 10 Section 2.pdf	BPV-17-01-00217098	BPV-17-01-00217321	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5743	Denali Special 510(k) (K143208).pdf	BPV-17-01-00217322	BPV-17-01-00217528	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
5744	Dec. 9, 2014 Denali Clearance Letter (K143208).PDF	BPV-17-01-00217529	BPV-17-01-00217530	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5745	Dec. 30, 2010 IDE for Denali	BPV-17-01-00217546	BPV-17-01-00219372	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5746	Aug. 9, 2011 BPV 5th IDE Supplement	BPV-17-01-00219373	BPV-17-01-00220196	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5747	Oct. 3, 2011 BPV 7th IDE Supplement	BPV-17-01-00220197	BPV-17-01-00220258	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5748	Nov. 11, 2011 BPV 9th IDE Supplement	BPV-17-01-00220259	BPV-17-01-00220290	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5749	Denali Materials – Clinical Study Materials – Denali Final Clinical Study Report.pdf	BPV-17-01-00221894	BPV-17-01-00221985	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
5750	Standard Operating Procedures / Division Operating Procedures – CQA-STD-54.doc	BPV-17-01-00222487	BPV-17-01-00222522	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5751	Standard Operating Procedures / Division Operating Procedures – CQA-STD-R002.doc Rev 15	BPV-17-01-00222558	BPV-17-01-00222589	FRE 401; 402; 403; Cond.	
5752	G2 DFMEA (Femoral) 070022, Rev. 6	BPV-17-01-00223198	BPV-17-01-00223237	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5753	G2 DFMEA (Femoral) 070031, Rev. 7	BPV-17-01-00223238	BPV-17-01-00223268	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5754	DFMEAs – Exam Key (Parts I & Part II).pdf	BPV-17-01-00223502	BPV-17-01-00223510	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5755	DFMEAs – TD-04451 Rev 0.pdf	BPV-17-01-00223511	BPV-17-01-00223607	FRE 401; 402; 403; 602; 702; 703; 801; 802	
5756	Audit Materials – Assessment Report 7766817 7737901A.pdf	BPV-17-01-00223608	BPV-17-01-00223627	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5757	Audit Materials – Assessment Report 78787507864713 9-13-13.pdf	BPV-17-01-00223628	BPV-17-01-00223654	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5758	Audit Materials – BSI Assessment Report 8043354 9-19-14A.pdf	BPV-17-01-00223655	BPV-17-01-00223673	FRE 401;402; 403; 801; 802	401; 402; 403; 801; 802
5759	Audit Materials – AUD-14-11-14 Final Report.pdf	BPV-17-01-00223674	BPV-17-01-00223676	FRE 401;402; 403; 801; 802	401; 402; 403; 407
5760	Audit Materials – 2015 BSI Assessment Report.pdf	BPV-17-01-00223677	BPV-17-01-00223696	FRE 401;402; 403; 801; 802	401; 402; 403; 407
5761	Audit Materials – AUD-15-12-04 Complaint Audit Final Report.pdf	BPV-17-01-00223697	BPV-17-01-00223699	FRE 401;402; 403; 801; 802	401; 402; 403; 407
5762	QMBR--April 2014	BPV-17-01-00227622	BPV-17-01-00227697	FRE 401;402; 403; 801; 802	401; 402; 403; MIL #1
5763	QMBR--Nov. 2014	BPV-17-01-00228135	BPV-17-01-00228203	FRE 401;402; 403; 801; 802	401; 402; 403; MIL #1
5764	QMBR--May 2015	BPV-17-01-00228633	BPV-17-01-00228713	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5765	QMBR--Oct. 2015	BPV-17-01-00229057	BPV-17-01-00229141	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5766	QMBR--Feb. 2016	BPV-17-01-00229415	BPV-17-01-00229492	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	403; MIL #1
5767	May 10, 2013 FDA email to BPV re revised IFU	BPV-17-01-00229493	BPV-17-01-00229494	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5768	April 6, 2013 email from FDA requesting additional information	BPV-17-01-00229495	BPV-17-01-00229498	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5769	Denali Materials – K130366 FDA Correspondence – K130366 Femoral IFU FDA comments.pdf	BPV-17-01-00229499	BPV-17-01-00229510	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5770	Denali Materials – K130366 FDA Correspondence – K130366 Patient Brochure FDA comments.pdf	BPV-17-01-00229511	BPV-17-01-00229512	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5771	May 6, 2013 email to FDA responding to questions	BPV-17-01-00229537	BPV-17-01-00229613	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5772	Denali Materials – K130366 FDA Correspondence – Denali Femoral IFU_PE rate of 1.1%.pdf	BPV-17-01-00229546	BPV-17-01-00229557	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5773	Denali Materials – K130366 FDA Correspondence – Denali Femoral IFU_PE rate of 1.6%.pdf	BPV-17-01-00229558	BPV-17-01-00229569	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5774	Denali Materials – K130366 FDA Correspondence – Denali IFU Clinical Experience red-lines.docx	BPV-17-01-00229570	BPV-17-01-00229574	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5775	Denali Materials – K130366 FDA Correspondence – Denali Jugular IFU_PE rate of 1.1%.pdf	BPV-17-01-00229575	BPV-17-01-00229586	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5776	Denali Materials – K130366 FDA Correspondence – Denali Jugular IFU_PE rate of 1.6%.pdf	BPV-17-01-00229587	BPV-17-01-00229598	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5777	April 24, 2013 email to FDA responding to questions	BPV-17-01-00229624	BPV-17-01-00229651	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5778	April 15, 2013 email to FDA responding to questions	BPV-17-01-00229652	BPV-17-01-00229767	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5779	Denali Materials – K130366 FDA Correspondence – Femoral IFU Red-line.pdf	BPV-17-01-00229669	BPV-17-01-00229704	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5780	Denali Materials – K130366 FDA Correspondence – Femoral IFU.pdf	BPV-17-01-00229705	BPV-17-01-00229716	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5781	Denali Materials – K130366 FDA Correspondence – Femoral Label Set.pdf	BPV-17-01-00229717	BPV-17-01-00229717	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5782	Denali Materials – K130366 FDA Correspondence – Jugular IFU Red-line.pdf	BPV-17-01-00229718	BPV-17-01-00229750	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5783	Denali Materials – K130366 FDA Correspondence – Jugular IFU.pdf	BPV-17-01-00229751	BPV-17-01-00229762	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5784	Denali Materials – K130366 FDA Correspondence – Jugular Label Set.pdf	BPV-17-01-00229763	BPV-17-01-00229763	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5785	Denali Materials – K130366 FDA Correspondence – Patient Brochure and Implant Card.pdf	BPV-17-01-00229764	BPV-17-01-00229767	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5786	May 6, 2013 email to FDA responding to questions	BPV-17-01-00229784	BPV-17-01-00229799	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5787	Denali Materials – K130366 FDA Correspondence – Femoral IFU FDA 050213.pdf	BPV-17-01-00229788	BPV-17-01-00229799	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5788	May 8, 2013 email to FDA with redlined IFU	BPV-17-01-00229823	BPV-17-01-00229838	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5789	Denali Materials – K130366 FDA Correspondence – Denali IFU Clinical Experience red-lines.docx	BPV-17-01-00229834	BPV-17-01-00229838	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5790	May 14, 2013 emails with FDA re animal study description in 510(k) summary	BPV-17-01-00229839	BPV-17-01-00229853	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5791	May 10, 2013 email to FDA with revised 510(k) summary	BPV-17-01-00229854	BPV-17-01-00229868	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5792	April 15, 2013 email to FDA responding to questions	BPV-17-01-00229894	BPV-17-01-00229998	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5793	March 14-19 emails with FDA re Denali 510(k)	BPV-17-01-00230014	BPV-17-01-00230021	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5794	Denali Materials – Clinical Study Materials – Denali Final Clinical Study Report.pdf	BPV-17-01-00230031	BPV-17-01-00230122	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5795	Feb. 16, 2011 BPV IDE Supplement #1 appendices	BPV-17-01-00230123	BPV-17-01-00230269	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407
5796	Feb. 16, 2011 BPV IDE Supplement #1	BPV-17-01-00230270	BPV-17-01-00230281	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5797	Jan. 31, 2012 IDE Annual Report	BPV-17-01-00230629	BPV-17-01-00230644	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5798	Nov. 13, 2012 BPV 13th IDE Supplement	BPV-17-01-00230655	BPV-17-01-00230749	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5799	March 1, 2013 BPV response to FDA questions re annual IDE report	BPV-17-01-00230755	BPV-17-01-00230831	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5800	Jan. 10, 2013 BPV Annual IDE Report	BPV-17-01-00230832	BPV-17-01-00230904	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5801	Jan. 30, 2014 BPV IDE Annual Report	BPV-17-01-00230921	BPV-17-01-00230999	FRE 401; 402; 403; 602; 702; 703; 801; 802	401; 402; 403; 407;
5802	Jan. 30, 2015 BPV Annual IDE Report	BPV-17-01-00231017	BPV-17-01-00231170	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5803	Jan. 29, 2016 BPV IDE Final Annual Report	BPV-17-01-00231188	BPV-17-01-00231623	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5804	Sept. 9, 2011 FDA letter conditional approval of IDE	BPV-17-01-00231734	BPV-17-01-00231736	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5805	Feb. 7, 2013 FDA Letter with questions re IDE annual report	BPV-17-01-00231737	BPV-17-01-00231739	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5806	March 17, 2011 FDA letter with conditional approval of IDE	BPV-17-01-00231740	BPV-17-01-00231741	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5807	Dec. 14, 2012 FDA Letter approving IDE change	BPV-17-01-00231742	BPV-17-01-00231746	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5808	Feb. 16, 2016 FDA email re final IDE and annual report	BPV-17-01-00231748	BPV-17-01-00231749	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5809	Feb. 26, 2016 FDA letter closing Denali IDE	BPV-17-01-00231750	BPV-17-01-00231750	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5810	Feb. 18, 2016 BPV email responding to questions of Feb. 16	BPV-17-01-00231751	BPV-17-01-00231756	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5811	Audit Materials – Bard PV Re-assessment Report 10-19-2010.pdf	BPV-17-01-00234048	BPV-17-01-00234063	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5812	Audit Materials – Assessment Report 7597321B 12-15-11.pdf	BPV-17-01-00234064	BPV-17-01-00234078	FRE 401; 402; 403; 801; 802	401; 402; 403
5813	Audit Materials – AUD-16-03-02 Complaint Files Internal Audit Report	BPV-17-01-00234079	BPV-17-01-00234083	FRE 401; 402; 403; 801; 802	401; 402; 403
5814	BPV Response - March 11, 2016.pdf	BPV-17-01-00234084	BPV-17-01-00234190	FRE 401; 402; 403; 801; 802	401; 402; 403; MIL #3
5815	483 Response March 22, 2016.pdf	BPV-17-01-00234191	BPV-17-01-00234264	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5816	RE BPV 483 Response.msg	BPV-17-01-00234266	BPV-17-01-00234271	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5817	Additional materials related to the FDA Warning Letter and 483s	BPV-17-01-00234310	BPV-17-01-00234394	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5818	BPV 483 Response Update 20160414.pdf	BPV-17-01-00234378	BPV-17-01-00234394	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3;
5819	Denali (Femoral) 2011.08 - PK5410500 rev. 1 IFU	BPV-17-01-00236429	BPV-17-01-00236436	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5820	Denali (Femoral) 2012.02 - PK5410500 rev. 2 IFU	BPV-17-01-00236437	BPV-17-01-00236446	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5821	Denali (Femoral) 2013.03 - PK5410500 rev. 3 IFU	BPV-17-01-00236447	BPV-17-01-00236458	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5822	Denali (Femoral) 2013.04 - PK5410500 rev. 4 IFU	BPV-17-01-00236459	BPV-17-01-00236470	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5823	Denali (Jugular) 2011.08 - PK5380500 rev. 1 IFU	BPV-17-01-00236471	BPV-17-01-00236478	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5824	Denali (Jugular) 2012.02 - PK5380500 rev. 2 IFU	BPV-17-01-00236479	BPV-17-01-00236490	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5825	Denali (Jugular) 2013.03 - PK5380500 rev. 3 IFU	BPV-17-01-00236490	BPV-17-01-00236502	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5826	Denali (Jugular) 2013.04 - PK5380500 rev. 4 IFU	BPV-17-01-00236503	BPV-17-01-00236514	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5827	G2X (Femoral) 2008.06 - PK5100060 rev. 1 IFU	BPV-17-01-00236515	BPV-17-01-00236526	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5828	Meridian (Femoral) 2013.02 - PK5372100 rev. 5 IFU	BPV-17-01-00236551	BPV-17-01-00236562	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5829	Meridian (Jugular) 2013.02 - PK5372400 rev. 4 IFU	BPV-17-01-00236563	BPV-17-01-00236574	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5830	Denali Materials – Clinical Study Materials – Audits – Denali audit March 2013.pdf	BPV-17-01-00236637	BPV-17-01-00236641	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5831	Denali Materials – Clinical Study Materials – Audits – Denali audit Septmber 2011.pdf	BPV-17-01-00236642	BPV-17-01-00236644	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5832	Denali Materials – Clinical Study Materials – Audits – Denali site Audit.pdf	BPV-17-01-00236645	BPV-17-01-00236650	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5833	Establishment Inspection Reports (EIRs) – AUD-14-02-01 EIR Feb 2014.pdf	BPV-17-01-00237045	BPV-17-01-00237050	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5834	Establishment Inspection Reports (EIRs) – FDA Establishment Inspection Report Dated 2.19.16.pdf	BPV-17-01-00237051	BPV-17-01-00237086	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5835	FDA Warning Letter Materials – BPV 483 Response Update 20160527.pdf	BPV-17-01-00237087	BPV-17-01-00237120	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3;
5836	FDA Warning Letter Materials – Signed Final - Cover and Response to FDA's 5-25-16 Letter.pdf	BPV-17-01-00237121	BPV-17-01-00237126	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3;
5837	SNF Materials – K963014 Clearance Letter.pdf	BPV-17-01-00237177	BPV-17-01-00237178	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5838	SNF Materials – K970099 Clearance Letter.pdf	BPV-17-01-00237179	BPV-17-01-00237181	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5839	SNF Materials – All Filter Data 8-20-12 Draft.xls	BPV-17-01-00237456	BPV-17-01-00237456	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5840	SNF Materials – Competitor Rate Analysis.xls 8-22-12.xls	BPV-17-01-00237457	BPV-17-01-00237457	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5841	SNF Materials – Filter Analysis 8-23-12.PPTX	BPV-17-01-00237458	BPV-17-01-00237458	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5842	FDA Warning Letter Materials – Feb. 3, 2016 updated response to Warning Letter	BPV-17-01-00237516	BPV-17-01-00237884	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3;
5843	FDA Warning Letter Materials – May 25, 2016 Letter from FDA with follow-up re Warning Letter	BPV-17-01-00237885	BPV-17-01-00237887	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5844	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-24 Rev 9.pdf	BPV-17-01-00237888	BPV-17-01-00238002	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5845	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-24 Rev 10.pdf	BPV-17-01-00238003	BPV-17-01-00238114	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5846	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-24 Rev 11.pdf	BPV-17-01-00238115	BPV-17-01-00238233	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5847	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-54 Rev 3.pdf	BPV-17-01-00238234	BPV-17-01-00238304	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5848	G2 DFMEA (G2 Jugular) 070021, Rev. 10	BPV-17-01-00261441	BPV-17-01-00261441	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5849	SOPN0700120 Rev 13.docx	BPV-17-01-00261442	BPV-17-01-00261468	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5850	SOPN0700120 Rev 14.docx	BPV-17-01-00261469	BPV-17-01-00261494	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5851	TD-04698 Re_Retrospective IVC Filter Review.pdf	BPV-17-01-00261496	BPV-17-01-00261505	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3;
5852	FDA Communications -- FDA Ltr Denali IVC Filter 9.28.16.pdf	BPV-17-01-00261506	BPV-17-01-00261508	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5853	FDA Communications -- FDA Ltr Denali -Juglar Sub Del Sys 9.28.16.pdf	BPV-17-01-00261509	BPV-17-01-00261511	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5854	FDA Communications -- 001_SimonNitinolFilterSystem_PS140002.pdf	BPV-17-01-00261512	BPV-17-01-00261512	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5855	FDA Communications -- PS140002A7 - Bard Peripheral Perivascular - email receipt.msg	BPV-17-01-00261513	BPV-17-01-00261514	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5856	FDA Communications -- RE PRESERVE - please provide contact for SAEs.msg	BPV-17-01-00261515	BPV-17-01-00261521	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5857	FDA Communications -- 001_Denali Special 510(k).pdf	BPV-17-01-00261522	BPV-17-01-00261590	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5858	FDA Communications -- Acceptance Review From FDA.pdf	BPV-17-01-00261591	BPV-17-01-00261591	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5859	FDA Communications -- FDA Decision Letter - Bard Peripheral Perivascular - PS140002A7.msg	BPV-17-01-00261592	BPV-17-01-00261592	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5860	FDA Communications -- PS140002.A7 - OTHER2 - 8.3.16.pdf	BPV-17-01-00261593	BPV-17-01-00261594	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5861	FDA Communications -- FW K160866 Review Complete.msg	BPV-17-01-00261595	BPV-17-01-00261595	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5862	FDA Communications -- K160866.510kSummary.Final_Sent001.pdf	BPV-17-01-00261596	BPV-17-01-00261598	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5863	FDA Communications -- K160866.IFU.FINAL_Sent001.pdf	BPV-17-01-00261599	BPV-17-01-00261599	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5864	FDA Communications -- K160866.Letter.SE.FINAL_Sent001.pdf	BPV-17-01-00261600	BPV-17-01-00261601	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5865	FDA Communications -- RE K160866 Special 510(k) to add 2-year study data to label (1).msg	BPV-17-01-00261602	BPV-17-01-00261603	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5866	FDA Communications -- Femoral IFU Redlined.docx	BPV-17-01-00261604	BPV-17-01-00261621	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5867	FDA Communications -- RE K160866 Special 510(k) to add 2-year study data to label (2).msg	BPV-17-01-00261622	BPV-17-01-00261626	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5868	FDA Communications -- Femoral IFU Updated Redlines.docx	BPV-17-01-00261627	BPV-17-01-00261643	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5869	FDA Communications -- RE K160866 Special 510(k) to add 2-year study data to label (3).msg	BPV-17-01-00261644	BPV-17-01-00261646	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5870	FDA Communications -- Femoral IFU FDA comments.docx	BPV-17-01-00261647	BPV-17-01-00261664	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5871	FDA Communications -- RE K160866 Special 510(k) to add 2-year study data to label.msg	BPV-17-01-00261665	BPV-17-01-00261669	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5872	FDA Warning Close Out Letter	BPV-17-01-00261679	BPV-17-01-00261680	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5873	FDA Establishment Inspection Report EIR (01/05/2015)	BPV-17-01-00261714	BPV-17-01-00261739	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5874	Bard filter rate information December 2016	BPV-17-01-00261741	BPV-17-01-00261741	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	MIL #1
5875	Bard filter rate information December 2016	BPV-17-01-00261742	BPV-17-01-00261742	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	MIL #1
5876	COOKFOIA Materials downloaded from Cook Medical IVC Filter Litigation PACER Docket (FDA Price Memos)	BPV-17-01-00262219	BPV-17-01-00262449	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5877	1996 Memo from Veronica Price	BPV-17-01-00262283	BPV-17-01-00262292	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5878	2004 Memo from Veronica Price	BPV-17-01-00262399	BPV-17-01-00262408	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5879	April 11, 2006 Letter to FDA re Caudal Migration	BPV-COMP-00004805	BPV-COMP-00004817	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; MIL #1
5880	March 23, 2006 Letter to FDA re G2 Caudal Migration	BPV-COMP-TW-00000716	BPV-COMP-TW-00000717	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; MIL #1
5881	May 11, 2006 Letter to FDA re Caudal Migration	BPV-COMP-TW-00000797	BPV-COMP-TW-00000799	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; MIL #1
5882	May 12, 2004 Email from Carr re RNF jigs	BPVE-01-00009906	BPVE-01-00009907	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5883	July 26, 2005 Conference FDA and BPV re Modified Recovery (K050558)	BPVE-01-00034138	BPVE-01-00034138	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5884	May, 27, 2005 Conference FDA and BPV re Modified Recovery (K050558)	BPVE-01-00034167	BPVE-01-00034168	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5885	Conference between BPV and FDA regarding K050558	BPVE-01-00081180	BPVE-01-00081181	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5886	Aug. 29, 2005 Email BPV to FDA re G2 (K050558)	BPVE-01-00154718	BPVE-01-00154723	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5887	Aug. 19, 2005 Email BPV to FDA re G2 (K050558)	BPVE-01-00155084	BPVE-01-00155088	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5888	July 28, 2005 Conference FDA and BPV re AI re Modified Recovery (K050558)	BPVE-01-00155254	BPVE-01-00155255	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5889	Aug. 22, 2005 Email BPV to FDA re G2 (K050558)	BPVE-01-00155392	BPVE-01-00155396	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5890	G2 IFU PK5100030, Rev. 0 05/08 (Femoral)	BPVE-01-00156395	BPVE-01-00156398	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5891	July 27, 2005 Email chain BPV and FDA re Modified Recovery (K050558)	BPVE-01-00157774	BPVE-01-00157777	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5892	Email from BPV to FDA regarding K050558	BPVE-01-00155084	BPVE-01-00155091	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5893	Conference between FDA and BPV regarding K050558	BPVE-01-00034167	BPVE-01-00034168	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5894	Email from BPV to FDA K050558	BPVE-01-00155392	BPVE-01-00155400	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5895	Email from BPV to FDA regarding K050558	BPVE-01-00155510	BPVE-01-00155522	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5896	Conference between BPV and FDA regarding K050558	BPVE-01-00155254	BPVE-01-00155255	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5897	Email chain between BPV and FDA regarding K050558	BPVE-01-00157774	BPVE-01-00157777	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5898	Conference between BPV and FDA regarding K050558	BPVE-01-00156137	BPVE-01-00156141	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5899	July 26, 2005 Contact Report, BPV and FDA regarding K050558	BPVE-01-00159552	BPVE-01-00159552	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5900	Oct. 21, 2005 Conference FDA and BPV re G2 Everest Study (G051034) and future submission	BPVE-01-00275704	BPVE-01-00275704	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5901	ETR-04-03-10 (RNF Characterization testing Migration Resistance when Legs are Crossed or Hooks Removed)	BPVE-01-00276108	BPVE-01-00276118	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5902	Article Entitled "US FDA Clinical Data Summary of the Simon Nitinol Filter Article Entitled "US FDA Clinical Data Summary of the Simon Nitinol Filter	BPVE-01-00280772	BPVE-01-00280787	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5903	Email from BPV to FDA regarding K031328 and DCL	BPVE-01-00290753	BPVE-01-00290753	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5904	Jan. 22, 2005 Email from BPV to FDA re DCL and Recovery Retrievable (K031328)	BPVE-01-00303306	BPVE-01-00303318	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5905	March 24, 2005, Meeting with FDA Agenda	BPV-17-01-00039306	BPV-17-01-00039308	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5906	PPT with Summary of Design Modifications for G2 PPT with Summary of Design Modifications for G2	BPVE-01-00324256	BPVE-01-00324262	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5907	PPT Entitled Recovery Filter Design Enhancements (re G2)	BPVE-01-00324300	BPVE-01-00324317	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5908	G2 IFU PK5100030, Rev. 1 05/08 (Femoral)	BPVE-01-00364587	BPVE-01-00364590	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5909	ETR-04-03-18 (RNF Characterization testing of Migration Resistance when Filter is Tilted)	BPVE-01-00375842	BPVE-01-00375847	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5910	Email from Benware to Hudson, Carr (cc to Fitzpatrick) enclosing final Starguide Report	BPVE-01-00414580	BPVE-01-00414586	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5911	EPRO-02-01 (BPT SOP re DFMEA)	BPVE-01-00424142	BPVE-01-00424154	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5912	Testing PPT re Migration Testing in 2004	BPVE-01-00424853	BPVE-01-00424898	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5913	June 9, 2005 email with Dear Colleague Letter Tracking Chart	BPVE-01-00427547	BPVE-01-00427620	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5914	June 7, 2005 email with Dear Colleague Letter Tracking Chart	BPVE-01-00428174	BPVE-01-00428176	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5915	May 11, 2005 Dear Colleague Letter	BPVE-01-00429852	BPVE-01-00429854	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5916	Dear Colleague Letter DCL Tracking Chart	BPVE-01-00430092	BPVE-01-00430161	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5917	Data Chart used by Natalie Wong in May 2004 email chain with Doug Uelmen regarding draft data set for statistician	BPVE-01-00435200	BPVE-01-00435201	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5918	May 27, 2004 Email chain between Natalie Wong and Doug Uelmen regarding draft data set for statistician	BPVE-01-00436072	BPVE-01-00436076	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5919	U.S. Patent No. US 6,258,026 B1 for "Removable Embolus Blood Clot Filter and Filter Delivery Unit", submitted by Ravenscroft et al., dated 7/10/2001	BPVE-01-00503712	BPVE-01-00503720	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5920	Reformatted version of the data chart used by Natalie Wong in May 2004 email chain with Doug Uelmen regarding draft data set for statistician.	BPVE-01-00511131	BPVE-01-00511132	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5921	Graphs and statistical summary forwarded to Doug Uelmen by Natalie Wong in May 2004 email chain.	BPVE-01-00511142	BPVE-01-00511143	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5922	Dec. 9, 2004 email re Dear Doctor Letter	BPVE-01-00531407	BPVE-01-00531408	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5923	September 2010 Letter to Clinicians re FDA PHN	BPVE-01-00582009	BPVE-01-00582009	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5924	Sept 2, 2010 Bard Filter Clinical Overview to Sales Force (Cover Letter Packet)	BPVE-01-00602630	BPVE-01-00602670	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5925	G2X IFU (Jugular) 2008.07 - PK5100070 rev. 1	BPVE-01-00635351	BPVE-01-00635362	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5926	G2X IFU (Jugular) 2009.06 - PK5100070 rev. 4	BPVE-01-00678895	BPVE-01-00678906	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5927	G2 Risk Benefit Analysis (RBA-0003, Rev. 2)	BPVE-01-00687949	BPVE-01-00687954	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5928	TP-07-12-01 (DV& V Flat Plate Fatigue and Corrosion Examination Test Protocol G2 Express Filter)	BPVE-01-00689527	BPVE-01-00689536	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5929	TR-07-12-01 (Test Report re G2 Express DV& V Flat Plate Fatigue and Corrosion)	BPVE-01-00689537	BPVE-01-00689554	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5930	TM1141300 (Filter Wire Weld Tensile Strength Testing)	BPVE-01-00738469	BPVE-01-00738475	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5931	G2X (Jugular) 2009.10 - PK5100070 rev. 5 IFU	BPVE-01-00738603	BPVE-01-00738626	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5932	QMBR--Jan. 2011	BPVE-01-00752804	BPVE-01-00752862	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5933	April 24, 2009 email noting withdrawal of G2® Expand 510(k)	BPVE-01-00756463	BPVE-01-00756463	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5934	TP 07-02-12 (Flat Plate Fatigue Testing Protocol)	BPVE-01-00769120	BPVE-01-00769127	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5935	TD-00275 (Comparison of Nonsymmetrical Loading on the G2 Filter Device in Two Orientations Using FEA by William James Harrison, WJH Engineering)	BPVE-01-00817105	BPVE-01-00817112	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5936	TD-00468 (G2 Flat Plate Baseline Characterization Test Analysis of Detached Arm)	BPVE-01-00817119	BPVE-01-00817121	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5937	TD-00192 (Product Comparisons through Finite Element Analysis and Testing by William James Harrison, WJH Engineering)	BPVE-01-00818418	BPVE-01-00818444	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5938	April 3, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-00958858	BPVE-01-00958859	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5939	March 31, 2006 Meeting Minutes re G2 caudal migration	BPVE-01-00958862	BPVE-01-00958865	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5940	Powerpoint slide regarding filter failure investigations	BPVE-01-00987656	BPVE-01-00987656	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5941	April 11, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01023545	BPVE-01-01023547	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5942	January 7, 2010 FDA Powerpoint Presentation	BPVE-01-01-059923	BPVE-01-01-059923	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5943	Filters Complaint History PPT	BPVE-01-01081449	BPVE-01-01081468	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5944	June 25, 2004 Multidisciplinary Focus Group Meeting Summary	BPVE-01-01089531	BPVE-01-01089535	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5945	April 2006 letter to FDA re G2 caudal migration	BPVE-01-01189125	BPVE-01-01189126	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5946	QMBR--July 2006	BPVE-01-01247634	BPVE-01-01247733	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5947	QMBR--Dec. 2005	BPVE-01-01251390	BPVE-01-01251428	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5948	April 1, 2009 letter from FDA requesting additional information re G2® for prophylactic indication	BPVE-01-01288903	BPVE-01-01288906	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5949	ETR-06-05-02 (Test report re G2® Clot Trapping Efficiency)	BPVE-01-01341174	BPVE-01-01341187	FRE 401; 402; 403; Cond.	
5950	TP-07-07-04 (G2® Express Filter Arm Fatigue Comparison Study)	BPVE-01-01366605	BPVE-01-01366609	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5951	Nov. 16, 2010 email to FDA enclosing fatigue testing info re Meridian	BPVE-01-01404251	BPVE-01-01404291	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5952	QMBR--Jan. 2007	BPVE-01-01514237	BPVE-01-01514293	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5953	TR-07-08-16 (G2® Express Acute GLP Animal Study Report)	BPVE-01-01558318	BPVE-01-01558336	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5954	June 30, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01655405	BPVE-01-01655405	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5955	May 9, 2006 Email from Natalie Wong to Brian Hudson forwarding responses to FDA requests for information.	BPVE-01-01656254	BPVE-01-01656263	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5956	June 12, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01656285	BPVE-01-01656286	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5957	June 21, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01656342	BPVE-01-01656343	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5958	March 3, 2006 Caudal Migration Meeting Minutes	BPVE-01-01656463	BPVE-01-01656465	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5959	April 18, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01656607	BPVE-01-01656609	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5960	April 28, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01658660	BPVE-01-01658661	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5961	May 18, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01658763	BPVE-01-01658764	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5962	TD-00060 (formerly ETR-04-05-06) (RNF Characterization testing of Migration Resistance in Oval and D shaped IVC)	BPVE-01-01692728	BPVE-01-01692763	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5963	November 20, 2008 Presentation entitled "G2 and G2X Fracture Analysis"	BPVE-01-01750592	BPVE-01-01750610	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5964	TM1141700 (Filter Flat Plate Fatigue Test Method)	BPVE-01-01785500	BPVE-01-01785516	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5965	QMBR--Feb. 2008	BPVE-01-01823827	BPVE-01-01823868	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5966	Oct. 26, 2010 Letter from FDA to BPV re Meridian Jugular (K102511)	BPVE-01-01977697	BPVE-01-01977704	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5967	G2 Risk Benefit Analysis (RBA-0003, Rev. 0)	BPVE-01-01981272	BPVE-01-01981274	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5968	Meridian (Jugular) 2010.10 - PK5372400 rev. 0 IFU	BPVE-01-02030224	BPVE-01-02030235	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5969	Email chain with McDermott and Allen re G2 Investigators Meeting and Sale of RNF and G2	BPVEFILTER-01-00001808	BPVEFILTER-01-00001808	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	403; 801; 802
5970	HHE re G2 Caudal Migration Febuary 15, 2006	BPVEFILTER-01-00008355	BPVEFILTER-01-00008357	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5971	February 8, 2006 Email re Micky Graves	BPVEFILTER-01-00010053	BPVEFILTER-01-00010055	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901
5972	Feb. 12, 2004 email re sales communique and rate information	BPVEFILTER-01-00010245	BPVEFILTER-01-00010289	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5973	Feb. 1, 2011 Letter from FDA to BPV re Meridian Jugular (K102511)	BPVEFILTER-01-00016497	BPVEFILTER-01-00016501	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5974	Complication Rate Chart	BPVEFILTER-01-00037664		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901; MIL #1
5975	QMBR Jan. 2010	BPVEFILTER-01-00043094	BPVEFILTER-01-00043094	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5976	QMBR Feb. 2009	BPVEFILTER-01-00043106	BPVEFILTER-01-00043106	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5977	QMBR May 2011	BPVEFILTER-01-00043457	BPVEFILTER-01-00043457	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5978	QMBR April 2012	BPVEFILTER-01-00043466	BPVEFILTER-01-00043466	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5979	QMBR Sept. 2012	BPVEFILTER-01-00043467	BPVEFILTER-01-00043467	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5980	Eclipse (Jugular) 2010.02 - PK5100700 rev. 1 IFU	BPVEFILTER-01-00050423	BPVEFILTER-01-00050434	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5981	G2X (Jugular) 2009.03 - PK5100100 rev. 0 IFU	BPVEFILTER-01-00050447	BPVEFILTER-01-00050458	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5982	Complication Rate Chart (2010) – page from BPVEFILTER-01-00050487	BPVEFILTER-01-00050487	BPVEFILTER-01-00050487	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5983	EVEREST Adjudication Manual of Operations	BPVEFILTER-01-00051397	BPVEFILTER-01-00051464	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5984	TPR-06-05-02 (SOP re G2® Clot Trapping Efficiency)	BPVEFILTER-01-00079006	BPVEFILTER-01-00079013	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5985	Meridian (Jugular) 2011.08 - PK5372400 rev. 3 IFU	BPVEFILTER-01-00106442	BPVEFILTER-01-00106454	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5986	May 17, 2011 PPT to FDA re Meridian®	BPVEFILTER-01-00136505		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5987	May 17, 2011 PPT to FDA re Meridian	BPVEFILTER-01-00136505	BPVEFILTER-01-00136505	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5988	Filters Complaint History PPT	BPVEFILTER-01-00206819	BPVEFILTER-01-00206819	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5989	FM1287100 Rev. 0 (MDR Reportability Guidelines)	BPVEFILTER-01-00220237	BPVEFILTER-01-00220251	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5990	FM1287100 Rev. 2 (MDR Reportability Guidelines)	BPVEFILTER-01-00223960	BPVEFILTER-01-00223974	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5991	FM1287100 Rev. 5 (MDR Reportability Guidelines)	BPVEFILTER-01-00224213	BPVEFILTER-01-00224222	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5992	FM1287100 Rev. 1 (MDR Reportability Guidelines)	BPVEFILTER-01-00263062	BPVEFILTER-01-00263074	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5993	TD-04382 Rev. 1 (List of Actions for MDR and Complaint Handling in Response to WL and 483)	BPVEFILTER-01-00263396	BPVEFILTER-01-00263407	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5994	TD-04316 Nov. 4, 2015 FDA and Bard Teleconference	BPVEFILTER-01-00263409	BPVEFILTER-01-00263418	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5995	TD-04326 Oct. 26, 2015 FDA and Bard Teleconference	BPVEFILTER-01-00263419	BPVEFILTER-01-00263422	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5996	FM1287100 Rev. 3 (MDR Reportability Guidelines)	BPVEFILTER-01-00264236	BPVEFILTER-01-00264250	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5997	FM1287100 Rev. 0 (MDR Reportability Guidelines)	BPVEFILTER-01-00264871	BPVEFILTER-01-00264885	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5998	Feb. 1, 2011 FDA Conditional Approval of IDE with 31 questions	BPVEFILTER-01-00367553	BPVEFILTER-01-00367563	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5999	August 2010 Letter to Clinicians re FDA PHN	BPVEFILTER-01-00496214	BPVEFILTER-01-00496214	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6000	March 21, 2011 ernal from FDA re Questions 18 and 24	BPVEFILTER-01-00703650	BPVEFILTER-01-00703657	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6001	May 5, 2010 email enclosing PPT slides for meeting	BPVEFILTER-01-00703843	BPVEFILTER-01-00703877	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6002	Filters Complaint History PPT	BPVEFILTER-01-01081449	BPVEFILTER-01-01081449	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6003	May 13, 2010 email and meeting minutes re Denali Pre-IDE	BPVEFILTER-01-01110191	BPVEFILTER-01-011101916	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6004	Sept. 30, 2011 email to FDA enclosing responses to AI (K112497)	BPVEFILTER-01-01138155	BPVEFILTER-01-01138155	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6005	March 19, 2010 email to FDA enclosing Denali Pre-IDE	BPVEFILTER-01-01138499	BPVEFILTER-01-01138571	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6006	June 16, 2011 email from custodial file of Joni Creal with Appendix 1-6	BPVEFILTER-01-01138842	BPVEFILTER-01-01138951	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6007	March 16, 2011 email confirming FDA re biocompatibility	BPVEFILTER-01-01141999	BPVEFILTER-01-01142002	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6008	Nov. 3, 2011 letter from FDA requesting more info	BPVEFILTER-01-01153526	BPVEFILTER-01-01153528	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6009	June 27, 2011 email from custodial file of Joni Creal with Appendix 14 Part A	BPVEFILTER-01-01156092	BPVEFILTER-01-01156185	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6010	Dec. 10, 2010 email to FDA confirming Denali regulatory strategy	BPVEFILTER-01-01165336	BPVEFILTER-01-01165336	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6011	Feb. 22, 2011 email to FDA re biocompatibility questions 27-31	BPVEFILTER-01-01166624	BPVEFILTER-01-01166624	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6012	Dec. 4, 2012 email and attachment to FDA responding to informal quesitons	BPVEFILTER-01-01170973	BPVEFILTER-01-01170977	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6013	Dec. 27, 2010 Letter from BPV to FDA re Meridian	BPVEFILTER-01-01201729	BPVEFILTER-01-01201779	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6014	March 11, 2011 email to FDA with proposed response to Nos. 18 and 24	BPVEFILTER-01-01205839	BPVEFILTER-01-01205845	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6015	Feb. 22, 2011 email with FDA re chromosomal aberration testing (Question 3 from Feb. 1 letter)	BPVEFILTER-01-01853704	BPVEFILTER-01-01853705	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6016	Nov. 5, 2015 email to Chad Modra re FDA and MDRs	BPVEFILTER-07-00088570	BPVEFILTER-07-00088570	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6017	Dec. 3, 2009 Meridian Pre-IDE Meeting Request	BPVEFILTER-08-00026072	BPVEFILTER-08-00026125	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6018	May 20-23, 2011 email chain re deficiencies 8 and 9	BPVEFILTER-08-00065051	BPVEFILTER-08-00065053	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6019	June 27, 2011 email from custodial file of Joni Creal with Appendix 3-5	BPVEFILTER-08-00074784	BPVEFILTER-08-00074827	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6020	22 -- - June 27, 2011 email from custodial file of Joni Creal with Appendix 1 & 2	BPVEFILTER-08-00075953	BPVEFILTER-08-00076043	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6021	May 23, 2011 Letter to FDA re Meridian FDA Questions Feb. 1, 2011 Nos 1-7, 10-13	BPVEFILTER-08-00076994	BPVEFILTER-08-00077147	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6022	May 23, 2011 Letter to FDA (Appendix 6)	BPVEFILTER-08-00077067	BPVEFILTER-08-00077067	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6023	May 23, 2011 Letter from BPV to FDA (Appendix 8)	BPVEFILTER-08-00077146	BPVEFILTER-08-00077146	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6024	May 23, 2011 Letter from BPV to FDA (Appendix 8)	BPVEFILTER-08-00076994	BPVEFILTER-08-00077147	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6025	August 17, 2011 email with FDA re Meridian IFU changes	BPVEFILTER-08-00077841	BPVEFILTER-08-00077854	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6026	June 27, 2011 email from custodial file of Joni Creal with Appendix 12 & 13	BPVEFILTER-08-00080312	BPVEFILTER-08-00080407	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6027	June 27, 2011 email from custodial file of Joni Creal with Appendix 10 & 11	BPVEFILTER-08-00081986	BPVEFILTER-08-00082031	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6028	Native Attachment	BPVEFILTER-08-00081986	BPVEFILTER-08-00081986	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6029	June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9	BPVEFILTER-08-00083555	BPVEFILTER-08-00083592	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6030	24 -- - June 27, 2011 email from custodial file of Joni Creal with Appendix 6 & 7	BPVEFILTER-08-00085241	BPVEFILTER-08-00085294	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6031	Dec. 27, 2010 Appendices to Letter to FDA	BPVEFILTER-11-00002394	BPVEFILTER-11-00002960	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6032	RNF Filter Drawing SA-0030, Rev. 00	BPVEFILTER-11-00027120	BPVEFILTER-11-00027120	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6033	NMT Table of Contents for RNF Design History File Phase II (Arms Up)	BPVEFILTER-11-00224944	BPVEFILTER-11-00224947	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6034	December 20, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page	BPVEFILTER-11-00237600	BPVEFILTER-11-00237600	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6035	August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page	BPVEFILTER-11-00237601	BPVEFILTER-11-00237601	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6036	June 7, 2010 FDA Contact Report (Denali Pre-IDE Meeting)	BPVEFILTER-11-00254025	BPVEFILTER-11-00254027	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6037	Nov. 5, 2015 email to Chad Modra re FDA and MDRs	BPVEFILTER-13-00000701	BPVEFILTER-13-00000703	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6038	Nov. 30, 2015 email chain with FDA re MDR Reporting	BPVEFILTER-13-00001127	BPVEFILTER-13-00001130	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6039	TM1139500 Caudal Migration Push Test Method	BPVEFILTER-15-00006980	BPVEFILTER-15-00006991	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6040	TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Test Method	BPVEFILTER-20-00039633	BPVEFILTER-20-00039643	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6041	TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol	BPVEFILTER-20-00046765	BPVEFILTER-20-00046772	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6042	G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU	BPVEFILTER-22-00013682	BPVEFILTER-22-00013689	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6043	June 2014 Clinical Evaluation Report of SNF Filter	BPVEFILTER-30-00230977	BPVEFILTER-30-00231013	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6044	June 27, 2011 email from custodial file of Joni Creal with Appendix 14 Part B	BPVEFILTER-35-00027113	BPVEFILTER-35-00027173	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6045	December 20, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes	BPVEFILTER-35-00097831	BPVEFILTER-35-00097838	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6046	August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes	BPVEFILTER-35-00097856	BPVEFILTER-35-00097876	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6049	2007.02.20 Response to Questions about the Recall of G2 Filter System- Jugular/ Subclavian Delivery Kit	FDA_PRODUCTION_00000000	FDA_PRODUCTION_00000000	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6050	2006.12.01 Health Hazard Evaluation - Updated	FDA_PRODUCTION_00000000	FDA_PRODUCTION_00000000	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6051	2006.12.22 G2 Filter System – Jugular/ Subclavian Delivery Kit	FDA_PRODUCTION_00000000	FDA_PRODUCTION_00000000	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6052	2008.10.23 Summary and Termination Validation	FDA_PRODUCTION_00000002	FDA_PRODUCTION_00000000	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6053	2008.09.22 Bard Peripheral Vascular (BPV) Recalls	FDA_PRODUCTION_00000003	FDA_PRODUCTION_00000000	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6054	2007.01.16 Bard G2 Filter System – Jugular/ Subclavian Delivery Kit	FDA_PRODUCTION_00000003	FDA_PRODUCTION_00000000	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6055	2006.12.20 Urgent Production Recall Notification	FDA_PRODUCTION_00000003	FDA_PRODUCTION_00000000	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6056	2007.02.02 Recall Z-0393-2007 Bard G2 Filter System – Jugular/ Subclavian Delivery Kit, Catalog Number RF-320J	FDA_PRODUCTION_00000003	FDA_PRODUCTION_00000000	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6057	2006.12.12 Recall Enterprise System Recall Details	FDA_PRODUCTION_00000004	FDA_PRODUCTION_00000000	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6058	K050558	FDA_PRODUCTION_00000004	FDA_PRODUCTION_00000003	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6059	Aug. 29, 2005 Fax BPV to FDA re G2 (K050558)	FDA_PRODUCTION_00000015	FDA_PRODUCTION_00000001	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6060	Aug. 26, 2005 Fax FDA to BPV re G2 (K050558)	FDA_PRODUCTION_00000015	FDA_PRODUCTION_00000001	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6061	Aug. 22, 2005 Internal FDA memo reviewing BPV's Responses to FDA AI re G2 (K050558)	FDA_PRODUCTION_00000016	FDA_PRODUCTION_00000001	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6062	Aug. 22, 2005 Bard email to FDA enclosing revised IFU	FDA_PRODUCTION_0000017	FDA_PRODUCTION_0000017	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6063	July 26, 2005 FDA Reviewer Memo for G2 510(k) (K050558)	FDA_PRODUCTION_0000017	FDA_PRODUCTION_0000017	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6064	July 26, 2005 Internal FDA memo re BPV Responses to FDA AI re Modified Recovery (K050558)	FDA_PRODUCTION_0000017	FDA_PRODUCTION_0000017	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6065	May 2, 2005 Interna FDA memo reviewing animal study re Modified Recovery (K050558)	FDA_PRODUCTION_0000018	FDA_PRODUCTION_0000018	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6066	Apr. 19, 2005 BPV's Informal Responses to FDA AI Letter re Modified Recovery (K050558)	FDA_PRODUCTION_0000019	FDA_PRODUCTION_0000019	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6067	BPV's Informal Responses to FDA AI Letter re Modified Recovery (K050558)	FDA_PRODUCTION_0000019	FDA_PRODUCTION_0000019	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6068	March 28, 2005 FDA Reviewer Memo for G2 510(k) (K050558)	FDA_PRODUCTION_0000020	FDA_PRODUCTION_0000020	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6069	Mar. 29, 2005 Internal FDA memo re Modified Recovery (K050558)	FDA_PRODUCTION_0000020	FDA_PRODUCTION_0000020	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6070	2005.08.29 Summary of Safety and Effectiveness	FDA_PRODUCTION_0000037	FDA_PRODUCTION_0000037	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6071	Maude Adverse Event Report: Bard Peripheral Vascular Bard G2 Filter System Femoral IVC Filter	FDA_PRODUCTION_0000095	FDA_PRODUCTION_0000095	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6072	2006.12.22 G2 Filter System – Jugular/ Subclavian Delivery Kit	FDA_PRODUCTION_0000098	FDA_PRODUCTION_0000098	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6073	FDA file re Recovery; Filter obtained from FOIA services	FDA_PRODUCTION_0000100	FDA_PRODUCTION_0000100	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6074	Nov. 29, 2004 FDA Reviewer Memo re Dear Doctor Letter	FDA_PRODUCTION_0000101	FDA_PRODUCTION_0000101	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6075	Nov. 10, 2004 FDA Internal Memo re Dear Doctor Letter	FDA_PRODUCTION_0000101	FDA_PRODUCTION_0000101	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6076	Nov. 10, 2004 Internal FDA Email chain re Recovery IFU and DDL	FDA_PRODUCTION_0000102	FDA_PRODUCTION_0000102	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6077	July 25, 2003 Internal FDA Memo re Recovery Retrievable (K031328)	FDA_PRODUCTION_0000120	FDA_PRODUCTION_0000120	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6078	July 22, 2004 Internal FDA Memorandum re Recovery Retrievable (K031328)	FDA_PRODUCTION_0000120	FDA_PRODUCTION_0000120	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6079	Internal FDA Memorandum re Recovery Retrievable (K031328)	FDA_PRODUCTION_0000120	FDA_PRODUCTION_0000120	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6080	July 17, 2003 Email strings re FDA request for information concerning sterilization	FDA_PRODUCTION_0000122	FDA_PRODUCTION_0000122	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6081	Email chain FDA and BPV re Recovery Retrievable (K031328)	FDA_PRODUCTION_00001288		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6082	FDA_PRODUCTION_00001288 -- July 2, 2003 Email chain FDA and BPV re Recovery Retrievable (K031328)	FDA_PRODUCTION_0000128	FDA_PRODUCTION_0000128	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6083	July 2003 FDA Internal Reviewer Memo re Recovery; Filter 510(k)	FDA_PRODUCTION_0000136	FDA_PRODUCTION_0000136	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6084	FDA file re Eclipse Filter obtained from FOIA services	FDA_PRODUCTION_0000137	FDA_PRODUCTION_0000137	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6085	K022236.pdf	FDA_PRODUCTION_0000154	FDA_PRODUCTION_0000154	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6086	K080669 - 510K G2 Express Filter System.pdf	FDA_PRODUCTION_0000168	FDA_PRODUCTION_0000168	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6087	K101431 - Eclipse.pdf	FDA_PRODUCTION_0000211	FDA_PRODUCTION_0000211	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6088	K894703.pdf	FDA_PRODUCTION_0000227	FDA_PRODUCTION_0000227	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6089	Product Development Cycle PPT	Public Document		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6090	Selected medical records for York Hospital study patient 87	YH04460	YH04460	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6091	Selected medical records for York Hospital study patient 87	YH04464	YH04464	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6092	Selected medical records for York Hospital study patient 87	YH04560	YH04565	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6093	Selected medical records for York Hospital study patient 87	YH04598	YH04601	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6094	Selected medical records for York Hospital study patient 87	YH04654	YH04655	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6095	Selected medical records for York Hospital study patient 87	YH04684	YH04686	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6096	Selected medical records for York Hospital study patient 87	YH04748	YH04749	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6097	York Hospital procedure log from surgical suite	YH04750	YH04759	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6098	York Hospital procedure log from interventional radiology suite	YH04760	YH04761	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6099	Selected records for York Hospital study patient 40	YH04768	YH04768	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6100	Selected medical records for York Hospital study patient 87	YH04780	YH04780	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6101	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04804	YH04806	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6102	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04813	YH04815	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6103	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04833	YH04835	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6104	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04851	YH04853	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6105	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04941	YH04943	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6106	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04953	YH04955	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6107	Selected medical records for York Hospital Study patient 36	YH05019	YH05020	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6108	Selected records for York Hospital study patient 40	YH05042	YH05045	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6109	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH05042	YH05044	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6110	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH05125	YH05132	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6111	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH05190	YH05191	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6112	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH05214	YH05215	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6113	Selected medical records for York Hospital Study patient 76	YH05274	YH05274	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6114	Selected medical records for York Hospital Study patient 76	YH05276	YH05277	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6115	Selected medical records for York Hospital Study patient 77	YH05278	YH05283	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6116	Selected medical records for York Hospital Study patient 84	YH05326	YH05327	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6117	Selected medical records for York Hospital study patient 85	YH05328	YH05329	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6118	Selected medical records for York Hospital study patient 85	YH05333	YH05337	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6119	Selected medical records for York Hospital study patient 85	YH05342	YH05344	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6120	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH05353	YH05355	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6121	Selected medical records for York Hospital study patient 87	YH05358	YH05360	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6122	Letters from FDA to Dr. Nicholson regarding complaints	YH05361	YH05370	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6123	Letter from FDA to Dr. Nicholson regarding complaint	YH05371	YH05371	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6124	Letter from FDA to Dr. Nicholson regarding MedWatch report	YH05372	YH05374	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6125	Email between York Hospital researchers regarding assessment of rate of fracture	YH05733	Yh05735	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6126	York Hospital November 11, 2009, Meeting Minutes	YH05943	YH05953	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6127	York Hospital January 14, 2009, Meeting Minutes	YH06002	YH06014	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6128	Letter from York Hospital to Dr. Nicholson regarding IRB review and oversight of York Hospital Study	YH06023	YH06023	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6129	Letter from Schulz to Moffett regarding visit at York	YH06475	YH06475	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6130	Email from Bard to York Hospital regarding York Hospital Study	YH06477	YH06477	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6131	Emails between Bard and Barbara Delio-Cox regarding York Hospital Study	YH06478	YH06478	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6132	Emails between Bard and Barbara Delio-Cox regarding York Hospital Study	YH06488	YH06490	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6133	Emails between York Hospital employees regarding meeting with Dr. Nicholson and FDA	YH06640	YH06641	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6134	Emails between York Hospital employees about non-consenting patients	YH06683	YH06684	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6135	Chart of York Hospital study patients	YH06741	YH06742	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6136	Chart of York Hospital study patients	YH06743	YH06744	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6137	Selected medical records for York Hospital Study patient 86	YH11131	YH11131	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6138	Selected medical records for York Hospital Study patient 86	YH11139	YH11140	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6139	Selected medical records for York Hospital study patient 85	YH12110	YH12114	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6140	Emails between York Hospital and Dr. Nicholson regarding press coverage of publication of York Hospital Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6141	Emails between Dr. Nicholson and FDA regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6142	Email from FDA to Dr. Nicholson regarding Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6143	York Hospital Study Protocol	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6144	Emails between York Hospital researchers regarding study protocol	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6145	Emails between Dr. Nicholson and colleague regarding study publication Dec. 17, 2009 Email to Nicholson re Embolized Filters	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6146	Email from FDA to Dr. Nicholson regarding Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6147	Email from Archives of Internal Medicine to Dr. Nicholson	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6148	Email from Bard to Dr. Nicholson regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6149	Email from Dr. Nicholson to co-author of York Hospital Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6150	Email from FDA to Dr. Nicholson regarding Bard IVC filters	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6151	Email from York Hospital to Dr. Nicholson attaching surgical procedure log	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6152	Emails between York Hospital and Dr. Nicholson regarding number of Bard filters used at the hospital	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6153	Email from JAMA to Dr. Nicholson regarding publication of York Hospital Study manuscript	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6154	Email to Nicholson from Walcott regarding FDA MedWatch Report	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6155	Email from Delio Cox to Walcott regarding fracture report	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6156	Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6157	Email from Dr. Nicholson to FDA regarding Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6158	Email from Bard to Dr. Nicholson regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6159	Email from FDA to Dr. Nicholson regarding Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6160	Email from Bard to Dr. Nicholson regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6161	Emails between York Hospital and Dr. Nicholson regarding HIPAA	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6162	Email from York Hospital to Dr. Nicholson regarding patients in study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6163	Email from NEJM to Dr. Nicholson	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6164	Email from Bard to Dr. Nicholson regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6165	Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6166	Email from Dr. Nicholson to FDA regarding Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6167	Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6168	Email from FDA to Dr. Nicholson regarding Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6169	Email from Dr. Nicholson to FDA regarding Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6170	Emails between Dr. Nicholson and the Archives of Internal Medicine regarding publication of York Hospital Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6171	Email from Dr. Nicholson to FDA regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6172	Email from Dr. Nicholson to FDA regarding Study	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6173	Note from Dr. Nicholson to an editor attaching table of his study patients	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6174	Draft of Dr. Nicholson article	YORK_SUBPOENA_B_NICHOLSON	YORK_SUBPOENA_B_NICHOLSON	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6175	Email from Dr. Nicholson to Christopher Tuohy regarding statistical analysis of York Hospital Study	YORK_SUBPOENA_Tuohy_00	YORK_SUBPOENA_Tuohy_00	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6176	Deposition of Carol Vierling, taken May 11, 2016, Exhibit 122			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6177	Deposition of Carol Vierling, taken May 11, 2016, Exhibit 212			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6178	Deposition of Carol Vierling, taken May 11, 2016, Exhibit 226			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901; MIL #2
6179	Deposition of Carol Vierling, taken May 11, 2016, Exhibit 227			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901; MIL #2
6180	Deposition of Carol Vierling, taken May 11, 2016, Exhibit 236			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6181	Deposition of Carol Vierling, taken May 11, 2016, Exhibit 240			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #2
6182	Deposition of Carol Vierling, taken May 11, 2016, Exhibit 244			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #2
6183	Deposition of Carol Vierling, taken May 11, 2016, Exhibit 245			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6184	Deposition of Carol Vierling, taken May 11, 2016, Exhibit 247			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6185	Deposition of Kay Fuller, taken January 11, 2016, Exhibit 140			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6186	Deposition of Kay Fuller, taken January 11, 2016, Exhibit 153			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6187	Deposition of Kay Fuller, taken January 11, 2016, Exhibit 161			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6188	Deposition of Kay Fuller, taken January 11, 2016, Exhibit 164			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6189	Deposition of Kay Fuller, taken January 11, 2016, Exhibit 168			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6190	Deposition of Carol Vierling, taken May 5, 2011, Exhibit 226			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6191	Deposition of Carol Vierling, taken May 5, 2011, Exhibit 242			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6192	Deposition of Carol Vierling, taken May 5, 2011, Exhibit 247			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6193	Deposition of Mary Edwards, taken August 19, 2016, Exhibit 355			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6194	Deposition of Mary Edwards, taken August 19, 2016, Exhibit 356			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6195	Deposition of Mary Edwards, taken August 19, 2016, Exhibit 357			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6196	Deposition of Mary Edwards, taken August 19, 2016, Exhibit 358			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6197	Deposition of Mary Edwards, taken August 19, 2016, Exhibit 360			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6198	Deposition of Dr. David Ciavarella, taken November 12, 2013, Exhibit 21			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6199	Deposition of Dr. David Ciavarella, taken November 12, 2013, Exhibit 23			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6200	Deposition of Dr. David Ciavarella, taken November 12, 2013, Exhibit 35			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6201	Deposition of Dr. David Ciavarella, taken November 12, 2013, Exhibit 39			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6202	Deposition of Gin Schulz, taken January 30, 2014, Exhibit 2			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6203	Deposition of Gin Schulz, taken January 30, 2014, Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6204	Deposition of Gin Schulz, taken January 30, 2014, Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6205	Deposition of Gin Schulz, taken January 30, 2014, Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6206	Deposition of Gin Schulz, taken January 30, 2014, Exhibit 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6207	Deposition of Gin Schulz, taken January 30, 2014, Exhibit 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6208	Deposition of Robert Ferrara, taken April 7, 2017, Exhibit 3			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; 901
6209	Deposition of Robert Ferrara, taken April 7, 2017, Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; MIL #1
6230	Deposition of Scott Trerotola, M.D., taken 1/20/17, Exhibit 688			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6231	Deposition of S. William Stavropoulos, M.D., taken 2/1/2017, Exhibit 827			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6232	2011.05.23 deposition of Robert Ritchie Exhibit 1	BPV-DEP-00009657	BPV-DEP-00009852	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106
6233	2011.05.23 deposition of Robert Ritchie Exhibit 2	BPV-DEP-00009853	BPV-DEP-00009907	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6234	2011.05.23 deposition of Robert Ritchie Exhibit 3	BPV-DEP-00009908	BPV-DEP-00009908	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6235	2011.05.23 deposition of Robert Ritchie Exhibit 4	BPV-DEP-00009909	BPV-DEP-00009933	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6236	2011.05.23 deposition of Robert Ritchie Exhibit 5	BPV-DEP-00009934	BPV-DEP-00009937	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6237	2011.05.23 deposition of Robert Ritchie Exhibit 6	BPV-DEP-00009938	BPV-DEP-00009950	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6238	2011.05.23 deposition of Robert Ritchie Exhibit 7	BPV-DEP-00009951	BPV-DEP-00009955	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6239	2011.05.23 deposition of Robert Ritchie Exhibit 8	BPV-DEP-00009956	BPV-DEP-00009956	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6240	2011.05.23 deposition of Robert Ritchie Exhibit 9	BPV-DEP-00009957	BPV-DEP-00009971	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6241	2011.05.23 deposition of Robert Ritchie Exhibit 10	BPV-DEP-00009972	BPV-DEP-00009977	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6242	2011.05.23 deposition of Robert Ritchie Exhibit 11	BPV-DEP-00009978	BPV-DEP-00009979	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6243	2011.05.24 deposition of Robert McMeeking Exhibit 1	BPV-DEP-00009534	BPV-DEP-00009602	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6244	2011.05.24 deposition of Robert McMeeking Exhibit 2	BPV-DEP-00009603	BPV-DEP-00009606	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6245	2011.05.24 deposition of Robert McMeeking Exhibit 3	BPV-DEP-00009607	BPV-DEP-00009635	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6246	2011.05.24 deposition of Robert McMeeking Exhibit 4	BPV-DEP-00009636	BPV-DEP-00009640	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6247	2011.05.24 deposition of Robert McMeeking Exhibit 5	BPV-DEP-00009641	BPV-DEP-00009642	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6248	2011.05.24 deposition of Robert McMeeking Exhibit 6	BPV-DEP-00009643	BPV-DEP-00009647	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6249	2011.05.24 deposition of Robert McMeeking Exhibit 7	BPV-DEP-00009648	BPV-DEP-00009656	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6250	2012.04.02 deposition of Robert Ritchie Exhibit 01	BPV-DEP-00010222	BPV-DEP-00010225	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 701; 801; 802; 901; MIL #1
6251	2012.04.02 deposition of Robert Ritchie Exhibit 02	BPV-DEP-00010226	BPV-DEP-00010226	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6252	2012.04.02 deposition of Robert Ritchie Exhibit 03	BPV-DEP-00010227	BPV-DEP-00010227	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; MIL #1
6253	2012.04.02 deposition of Robert Ritchie Exhibit 04	BPV-DEP-00010228	BPV-DEP-00010229	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802;
6254	2012.04.02 deposition of Robert Ritchie Exhibit 05	BPV-DEP-00010230	BPV-DEP-00010230	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 901; MIL #1;
6255	2012.04.02 deposition of Robert Ritchie Exhibit 06	BPV-DEP-00010231	BPV-DEP-00010231	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802;

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6256	2012.04.02 deposition of Robert Ritchie Exhibit 07	BPV-DEP-00010232	BPV-DEP-00010256	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802;
6257	2012.04.02 deposition of Robert Ritchie Exhibit 08	BPV-DEP-00010257	BPV-DEP-00010284	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6258	2012.04.02 deposition of Robert Ritchie Exhibit 09	BPV-DEP-00010285	BPV-DEP-00010305	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6259	2012.04.02 deposition of Robert Ritchie Exhibit 10	BPV-DEP-00010306	BPV-DEP-00010368	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1;
6260	2012.04.02 deposition of Robert Ritchie Exhibit 11	BPV-DEP-00010369	BPV-DEP-00010404	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1;
6261	2014.04.22 McMeeking Depo Exhibit 01	BPV-DEP-00028338	BPV-DEP-00028342	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802;
6262	2014.04.22 McMeeking Depo Exhibit 02	BPV-DEP-00028343	BPV-DEP-00028358	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
6263	2014.04.22 McMeeking Depo Exhibit 03	BPV-DEP-00028359	BPV-DEP-00028359	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802;
6264	2014.04.22 McMeeking Depo Exhibit 04	BPV-DEP-00028360	BPV-DEP-00028360	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
6265	2014.04.22 McMeeking Depo Exhibit 05	BPV-DEP-00028361	BPV-DEP-00028361	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802;
6266	2014.04.22 McMeeking Depo Exhibit 06	BPV-DEP-00028362	BPV-DEP-00028362	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
6267	2014.04.22 McMeeking Depo Exhibit 07	BPV-DEP-00028363	BPV-DEP-00028363	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
6268	2014.05.08 Ritchie Depo Exhibit 01	BPV-DEP-00028466	BPV-DEP-00028527	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802;
6269	2014.05.08 Ritchie Depo Exhibit 02	BPV-DEP-00028528	BPV-DEP-00028588	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802;
6270	2014.05.08 Ritchie Depo Exhibit 03	BPV-DEP-00028589	BPV-DEP-00028590	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1;
6271	2014.05.08 Ritchie Depo Exhibit 04	BPV-DEP-00028591	BPV-DEP-00028592	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 901; MIL #1;
6272	2014.05.08 Ritchie Depo Exhibit 05	BPV-DEP-00028593	BPV-DEP-00028593	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1;
6273	2014.05.08 Ritchie Depo Exhibit 06	BPV-DEP-00028594	BPV-DEP-00028617	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802;
6274	2014.05.08 Ritchie Depo Exhibit 07	BPV-DEP-00028618	BPV-DEP-00028678	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1;
6275	2014.06.13 Parisian Depo Exhibit 01	BPV-DEP-00041040	BPV-DEP-00041045	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1;
6276	2014.06.13 Parisian Depo Exhibit 02	BPV-DEP-00041046	BPV-DEP-00041048	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1;
6277	2014.06.13 Parisian Depo Exhibit 03	BPV-DEP-00041049	BPV-DEP-00041052	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6278	2014.06.13 Parisian Depo Exhibit 04	BPV-DEP-00041053	BPV-DEP-00041242	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6279	2014.06.13 Parisian Depo Exhibit 05	BPV-DEP-00041243	BPV-DEP-00041460	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6280	2014.06.13 Parisian Depo Exhibit 06	BPV-DEP-00041461	BPV-DEP-00041624	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6281	2014.06.13 Parisian Depo Exhibit 07	BPV-DEP-00041625	BPV-DEP-00041640	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6282	2014.06.13 Parisian Depo Exhibit 08	BPV-DEP-00041641	BPV-DEP-00041657	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
6283	2014.06.13 Parisian Depo Exhibit 09	BPV-DEP-00041658	BPV-DEP-00041662	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6284	2014.06.13 Parisian Depo Exhibit 10	BPV-DEP-00041663	BPV-DEP-00041667	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6285	2014.06.13 Parisian Depo Exhibit 11	BPV-DEP-00041668	BPV-DEP-00041761	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6286	2014.06.13 Parisian Depo Exhibit 12	BPV-DEP-00041762	BPV-DEP-00041837	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802; 901
6287	2014.06.13 Parisian Depo Exhibit 13	BPV-DEP-00041838	BPV-DEP-00041865	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802; 901
6288	2014.06.13 Parisian Depo Exhibit 14	BPV-DEP-00041866	BPV-DEP-00041866	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6289	2014.06.13 Parisian Depo Exhibit 15	BPV-DEP-00041867	BPV-DEP-00041867	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6290	2014.06.13 Parisian Depo Exhibit 16	BPV-DEP-00041868	BPV-DEP-00041904	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6291	2014.06.13 Parisian Depo Exhibit 17	BPV-DEP-00041905	BPV-DEP-00041908	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6292	2014.06.13 Parisian Depo Exhibit 18	BPV-DEP-00041909	BPV-DEP-00041924	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6293	2014.09.25 Parisian Depo Exhibit 01	BPV-DEP-00031113	BPV-DEP-00031123	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6294	2014.09.25 Parisian Depo Exhibit 02	BPV-DEP-00031124	BPV-DEP-00031317	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6295	2014.09.25 Parisian Depo Exhibit 03	BPV-DEP-00031318	BPV-DEP-00031318	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6296	2014.09.25 Parisian Depo Exhibit 04	BPV-DEP-00031319	BPV-DEP-00031336	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6297	2014.09.25 Parisian Depo Exhibit 05	BPV-DEP-00031337	BPV-DEP-00031341	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6298	2014.12.18 Parisian Depo - CD	BPV-DEP-00035522	BPV-DEP-00035523	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6299	2014.12.18 Parisian Depo Exhibit 01	BPV-DEP-00035096	BPV-DEP-00035339	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6300	2014.12.18 Parisian Depo Exhibit 02	BPV-DEP-00035340	BPV-DEP-00035344	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6301	2014.12.18 Parisian Depo Exhibit 03	BPV-DEP-00035345	BPV-DEP-00035360	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6302	2014.12.18 Parisian Depo Exhibit 04	BPV-DEP-00035361	BPV-DEP-00035382	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6303	2014.12.18 Parisian Depo Exhibit 05	BPV-DEP-00035383	BPV-DEP-00035388	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6304	2014.12.18 Parisian Depo Exhibit 06	BPV-DEP-00035389	BPV-DEP-00035397	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6305	2014.12.18 Parisian Depo Exhibit 07	BPV-DEP-00035398	BPV-DEP-00035400	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6306	2014.12.18 Parisian Depo Exhibit 08	BPV-DEP-00035401	BPV-DEP-00035405	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6307	2014.12.18 Parisian Depo Exhibit 09	BPV-DEP-00035406	BPV-DEP-00035469	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6308	2014.12.18 Parisian Depo Exhibit 10	BPV-DEP-00035470	BPV-DEP-00035470	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6309	2014.12.18 Parisian Depo Exhibit 11	BPV-DEP-00035471	BPV-DEP-00035475	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6310	2014.12.18 Parisian Depo Exhibit 12	BPV-DEP-00035476	BPV-DEP-00035498	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6311	2014.12.18 Parisian Depo Exhibit 13	BPV-DEP-00035499	BPV-DEP-00035501	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6312	2014.12.18 Parisian Depo Exhibit 14	BPV-DEP-00035502	BPV-DEP-00035502	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6313	2014.12.18 Parisian Depo Exhibit 15	BPV-DEP-00035503	BPV-DEP-00035521	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 403; 404(b); 410; 609; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6314	2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert Deposition Exhibit 01	BPV-DEP-00043190	BPV-DEP-00043194	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6315	2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert Deposition Exhibit 02	BPV-DEP-00043195	BPV-DEP-00043199	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6316	2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert Deposition Exhibit 03	BPV-DEP-00043200	BPV-DEP-00043204	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6317	2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert Deposition Exhibit 04	BPV-DEP-00043205	BPV-DEP-00043327	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6318	2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert Deposition Exhibit 05	BPV-DEP-00043328	BPV-DEP-00043445	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6319	2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert Deposition Exhibit 06	BPV-DEP-00043446	BPV-DEP-00043532	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6320	2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert Deposition Exhibit 07	BPV-DEP-00043533	BPV-DEP-00043542	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6321	2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert Deposition Exhibit 08	BPV-DEP-00043543	BPV-DEP-00043552	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6322	2015.04.24 Arnold, Robin - Mcmeeking, Ph.D., Robert Deposition Exhibit 09	BPV-DEP-00043553	BPV-DEP-00043560	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6323	2015.05.01 Robert Ritchie Deposition Exhibit 01	BPV-DEP-00045670	BPV-DEP-00045673	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
6324	2015.05.01 Robert Ritchie Deposition Exhibit 02	BPV-DEP-00045674	BPV-DEP-00045675	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6325	2015.05.01 Robert Ritchie Deposition Exhibit 03	BPV-DEP-00045676	BPV-DEP-00045679	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6326	2015.05.01 Robert Ritchie Deposition Exhibit 04	BPV-DEP-00045680	BPV-DEP-00045681	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6327	2015.05.01 Robert Ritchie Deposition Exhibit 05	BPV-DEP-00045682	BPV-DEP-00045687	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6328	2015.05.05 Suzanne Parisian Deposition Exhibit 01	BPV-DEP-00045828	BPV-DEP-00045833	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6329	2015.05.05 Suzanne Parisian Deposition Exhibit 02	BPV-DEP-00045834	BPV-DEP-00045839	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6330	2015.05.05 Suzanne Parisian Deposition Exhibit 03	BPV-DEP-00045840	BPV-DEP-00046029	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6331	2015.05.05 Suzanne Parisian Deposition Exhibit 04	BPV-DEP-00046030	BPV-DEP-00046293	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6332	2015.05.05 Suzanne Parisian Deposition Exhibit 05	BPV-DEP-00046294	BPV-DEP-00046309	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6333	2015.05.05 Suzanne Parisian Deposition Exhibit 06	BPV-DEP-00046310	BPV-DEP-00046343	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 901
6334	2015.05.05 Suzanne Parisian Deposition Exhibit 07	BPV-DEP-00046344	BPV-DEP-00046357	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6335	2015.05.05 Suzanne Parisian Deposition Exhibit 08	BPV-DEP-00046358	BPV-DEP-00046792	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6336	2015.05.05 Suzanne Parisian Deposition Exhibit 09	BPV-DEP-00046793	BPV-DEP-00046810	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6337	2015.05.05 Suzanne Parisian Deposition Exhibit 10	BPV-DEP-00046811	BPV-DEP-00046811	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6338	2015.05.05 Suzanne Parisian Deposition Exhibit 11	BPV-DEP-00046812	BPV-DEP-00046814	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6339	2015.05.05 Suzanne Parisian Deposition Exhibit 12	BPV-DEP-00046815	BPV-DEP-00046815	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6340	2015.05.05 Suzanne Parisian Deposition Exhibit 13	BPV-DEP-00046816	BPV-DEP-00046816	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901
6341	2015.05.05 Suzanne Parisian Deposition Exhibit 14	BPV-DEP-00046817	BPV-DEP-00046826	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901
6342	2016.07.21 Derek Muehrcke Exhibit 01	BPV-DEP-00065247	BPV-DEP-00065251	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6343	2016.07.21 Derek Muehrcke Exhibit 02	BPV-DEP-00065252	BPV-DEP-00065264	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6344	2016.07.21 Derek Muehrcke Exhibit 03	BPV-DEP-00065265	BPV-DEP-00065266	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6345	2016.07.21 Derek Muehrcke Exhibit 04	BPV-DEP-00065267	BPV-DEP-00065272	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6346	2016.07.21 Derek Muehrcke Exhibit 05	BPV-DEP-00065273	BPV-DEP-00065275	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6347	2016.07.21 Derek Muehrcke Exhibit 06	BPV-DEP-00065276	BPV-DEP-00065276	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6348	2016.07.21 Derek Muehrcke Exhibit 07	BPV-DEP-00065277	BPV-DEP-00065277	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6349	2016.07.21 Derek Muehrcke Exhibit 08	BPV-DEP-00065278	BPV-DEP-00065287	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6350	2016.07.21 Derek Muehrcke Exhibit 09	BPV-DEP-00065288	BPV-DEP-00065294	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6351	2016.07.21 Derek Muehrcke Exhibit 10	BPV-DEP-00065295	BPV-DEP-00065295	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6352	2016.07.21 Derek Muehrcke Exhibit 11	BPV-DEP-00065296	BPV-DEP-00065307	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6353	2016.07.21 Derek Muehrcke Exhibit 12	BPV-DEP-00065308	BPV-DEP-00065308	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6354	2016.07.21 Derek Muehrcke Exhibit 13	BPV-DEP-00065309	BPV-DEP-00065309	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6355	2016.07.21 Derek Muehrcke Exhibit 14	BPV-DEP-00065310	BPV-DEP-00065314	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6356	2016.07.21 Derek Muehrcke Exhibit 15	BPV-DEP-00065315	BPV-DEP-00065317	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6357	2016.07.21 Derek Muehrcke Exhibit 16	BPV-DEP-00065318	BPV-DEP-00065318	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	403; 702; 703; 801; 802; MIL #1
6358	2016.07.21 Derek Muehrcke Exhibit 17	BPV-DEP-00065319	BPV-DEP-00065327	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6359	2016.07.21 Derek Muehrcke Exhibit 18	BPV-DEP-00065328	BPV-DEP-00065328	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6360	2016.07.21 Derek Muehrcke Exhibit 19	BPV-DEP-00065329	BPV-DEP-00065349	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6361	2016.07.21 Derek Muehrcke Exhibit 20	BPV-DEP-00065350	BPV-DEP-00065351	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	702; 703; 801; 802
6362	2016.07.26 Rebecca Betensky Exhibit 01	BPV-DEP-00065517	BPV-DEP-00065521	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6363	2016.07.26 Rebecca Betensky Exhibit 02	BPV-DEP-00065522	BPV-DEP-00065551	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6364	2016.07.26 Rebecca Betensky Exhibit 03	BPV-DEP-00065552	BPV-DEP-00065589	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6365	2016.07.26 Rebecca Betensky Exhibit 04	BPV-DEP-00065590	BPV-DEP-00065590	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6366	2016.07.26 Rebecca Betensky Exhibit 05	BPV-DEP-00065591	BPV-DEP-00065610	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 901
6367	2016.07.26 Rebecca Betensky Exhibit 06	BPV-DEP-00065611	BPV-DEP-00065611	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6368	2016.08.17 Mark Eisenberg Exhibit 01	BPV-DEP-00066353	BPV-DEP-00066357	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6369	2016.08.17 Mark Eisenberg Exhibit 02	BPV-DEP-00066358	BPV-DEP-00066358	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #2
6370	2016.08.17 Mark Eisenberg Exhibit 03	BPV-DEP-00066359	BPV-DEP-00066364	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6371	2016.08.17 Mark Eisenberg Exhibit 04	BPV-DEP-00066365	BPV-DEP-00066368	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6372	2016.08.17 Mark Eisenberg Exhibit 05	BPV-DEP-00066369	BPV-DEP-00066406	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6373	2016.08.17 Mark Eisenberg Exhibit 06	BPV-DEP-00066407	BPV-DEP-00066488	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6374	2016.08.17 Mark Eisenberg Exhibit 07	BPV-DEP-00066489	BPV-DEP-00066508	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403
6375	2017.01.31 Wilson, Mark Exhibit 795			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6376	2017.01.31 Wilson, Mark Exhibit 796			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6377	2017.01.31 Wilson, Mark Exhibit 797			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403
6378	2017.01.31 Wilson, Mark Exhibit 798			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6379	2017.01.31 Wilson, Mark Exhibit 800			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901
6380	2017.01.31 Wilson, Mark Exhibit 801			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6381	2017.01.31 Wilson, Mark Exhibit 802			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6382	2017.01.31 Wilson, Mark Exhibit 803			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6383	2017.06.09 Robert Ritchie Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6384	2017.06.09 Robert Ritchie Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 404(b); 410; 609; 702; 703; 801; 802; MIL #1
6385	2017.06.09 Robert Ritchie Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; MIL #1
6386	2017.06.09 Robert Ritchie Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6387	2017.06.09 Robert Ritchie Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901; MIL #1
6388	2017.06.09 Robert Ritchie Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6389	2017.06.09 Robert Ritchie Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6390	2017.06.09 Robert Ritchie Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6391	2017.06.09 Robert Ritchie Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6392	2017.06.09 Robert Ritchie Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6393	2017.06.09 Robert Ritchie Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6394	2017.06.17 Kinney, MD, Thomas B Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703
6395	2017.06.17 Kinney, MD, Thomas B Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6396	2017.06.17 Kinney, MD, Thomas B Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6397	2017.06.17 Kinney, MD, Thomas B Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6398	2017.06.17 Kinney, MD, Thomas B Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6399	2017.06.17 Kinney, MD, Thomas B Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6400	2017.06.17 Kinney, MD, Thomas B Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6401	2017.06.17 Kinney, MD, Thomas B Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6402	2017.06.17 Kinney, MD, Thomas B Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6403	2017.06.17 Kinney, MD, Thomas B Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6404	2017.06.17 Kinney, MD, Thomas B Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 702; 703; 801; 802; MIL #1
6405	2017.06.17 Kinney, MD, Thomas B Exhibit 11r			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 702; 703; 801; 802; MIL #1
6406	2017.06.17 Kinney, MD, Thomas B Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 702; 703; 801; 802; MIL #1
6407	2017.06.17 Kinney, MD, Thomas B Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6408	2017.06.17 Kinney, MD, Thomas B Exhibit 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6409	2017.06.17 Kinney, MD, Thomas B Exhibit 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 702; 703; 801; 802; MIL #1
6410	2017.06.17 Kinney, MD, Thomas B Exhibit 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 702; 703; 801; 802; MIL #1
6411	2017.06.17 Kinney, MD, Thomas B Exhibit 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6412	2017.06.17 Kinney, MD, Thomas B Exhibit 18			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6413	2017.06.17 Kinney, MD, Thomas B Exhibit 19			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6414	2017.06.17 Kinney, MD, Thomas B Exhibit 20			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6415	2017.06.17 Kinney, MD, Thomas B Exhibit 21			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6416	2017.06.17 Kinney, MD, Thomas B Exhibit 22			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6417	2017.06.21- Filter MDL- David A Garcia Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	407; 801; 802
6418	2017.06.21- Filter MDL- David A Garcia Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	407; 801; 802
6419	2017.06.21- Filter MDL- David A Garcia Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	407; 801; 802
6420	2017.06.21- Filter MDL- David A Garcia Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6421	2017.06.21- Filter MDL- David A Garcia Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6422	2017.06.21- Filter MDL- David A Garcia Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6423	2017.06.21- Filter MDL- David A Garcia Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6424	2017.06.21- Filter MDL- David A Garcia Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6425	2017.06.21- Filter MDL- David A Garcia Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6426	2017.06.21- Filter MDL- David A Garcia Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6427	2017.06.21- Filter MDL- David A Garcia Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6428	2017.06.21- Filter MDL- David A Garcia Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6429	2017.06.21 Suzanne Parisian, MD Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6430	2017.06.21 Suzanne Parisian, MD Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1; MIL #2
6431	2017.06.21 Suzanne Parisian, MD Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6432	2017.06.21 Suzanne Parisian, MD Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6433	2017.06.21 Suzanne Parisian, MD Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6434	2017.06.21 Suzanne Parisian, MD Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6435	2017.06.21 Suzanne Parisian, MD Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6436	2017.06.21 Suzanne Parisian, MD Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6437	2017.07.06 Mark Eisenberg, MD Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403
6438	2017.07.06 Mark Eisenberg, MD Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6439	2017.07.06 Mark Eisenberg, MD Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6440	2017.07.06 Mark Eisenberg, MD Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6441	2017.07.06 Mark Eisenberg, MD Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6442	2017.07.06 Mark Eisenberg, MD Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6443	2017.07.06 Mark Eisenberg, MD Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6444	2017.07.06 Mark Eisenberg, MD Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6445	2017.07.06 Mark Eisenberg, MD Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6446	2017.07.06 Mark Eisenberg, MD Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6447	2017.07.06 Mark Eisenberg, MD Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6448	2017.07.06 Mark Eisenberg, MD Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6449	2017.07.06 Mark Eisenberg, MD Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6450	2017.07.06 Robert McMeeking, PhD Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6451	2017.07.06 Robert McMeeking, PhD Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6452	2017.07.06 Robert McMeeking, PhD Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6453	2017.07.06 Robert McMeeking, PhD Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6454	2017.07.06 Robert McMeeking, PhD Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6455	2017.07.06 Robert McMeeking, PhD Exhibit 05a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #3
6456	2017.07.06 Robert McMeeking, PhD Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802
6457	2017.07.06 Robert McMeeking, PhD Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6458	2017.07.06 Robert McMeeking, PhD Exhibit 07a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6459	2017.07.06 Robert McMeeking, PhD Exhibit 07b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6460	2017.07.06 Robert McMeeking, PhD Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6461	2017.07.06 Robert McMeeking, PhD Exhibit 08a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6462	2017.07.06 Robert McMeeking, PhD Exhibit 08b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6463	2017.07.06 Robert McMeeking, PhD Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802
6464	2017.07.06 Robert McMeeking, PhD Exhibit 09a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
6465	2017.07.06 Robert McMeeking, PhD Exhibit 09b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6466	2017.07.06 Robert McMeeking, PhD Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6467	2017.07.06 Robert McMeeking, PhD Exhibit 10a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6468	2017.07.06 Robert McMeeking, PhD Exhibit 10b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6469	2017.07.06 Robert McMeeking, PhD Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6470	2017.07.06 Robert McMeeking, PhD Exhibit 11a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6471	2017.07.06 Robert McMeeking, PhD Exhibit 11b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6472	2017.07.06 Robert McMeeking, PhD Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6473	2017.07.06 Robert McMeeking, PhD Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6474	2017.07.06 Robert McMeeking, PhD Exhibit 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6475	2017.07.06 Robert McMeeking, PhD Exhibit 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6476	2017.07.06 Robert McMeeking, PhD Exhibit 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6477	2017.07.06 Robert McMeeking, PhD Exhibit 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6478	2017.07.06 Robert McMeeking, PhD Exhibit 18			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6479	2017.07.07 Roberts, MD, Anne Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802
6480	2017.07.07 Roberts, MD, Anne Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6481	2017.07.07 Roberts, MD, Anne Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6482	2017.07.07 Roberts, MD, Anne Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6483	2017.07.07 Roberts, MD, Anne Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6484	2017.07.07 Roberts, MD, Anne Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6485	2017.07.07 Roberts, MD, Anne Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6486	2017.07.07 Roberts, MD, Anne Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6487	2017.07.07 Roberts, MD, Anne Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6488	2017.07.07 Roberts, MD, Anne Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6489	2017.07.07 Roberts, MD, Anne Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6490	2017.07.07 Roberts, MD, Anne Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6491	2017.07.07 Roberts, MD, Anne Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6492	2017.07.07 Roberts, MD, Anne Exhibit 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6493	2017.07.07 Roberts, MD, Anne Exhibit 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6494	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6495	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6496	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6497	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6498	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6499	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6500	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 404(b); 407; 408(a); 410; 411; 501; 502; 601; 602; 609; 701; 702; 703; 801; 802; 901; 902; 1001-1004; 1005; MIL 1; MIL #2; MIL#3; MIL #4; MIL #5
6501	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6502	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6503	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6504	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6505	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6506	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6507	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6508	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6509	2017.07.11 Kalva, MD, Sanjeeva Prasad Exhibit 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; MIL #1
6510	2017.07.24 Derek Muehrcke Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6511	2017.07.24 Derek Muehrcke Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6512	2017.07.24 Derek Muehrcke Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6513	2017.07.24 Derek Muehrcke Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6514	2017.07.24 Derek Muehrcke Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6515	2017.07.24 Derek Muehrcke Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6516	2017.07.24 Derek Muehrcke Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6517	2017.07.24 Derek Muehrcke Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6518	2017.07.24 Derek Muehrcke Exhibit 34			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1; MIL #2
6519	2017.07.24 Derek Muehrcke Exhibit 35			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6520	2017.07.24 Derek Muehrcke Exhibit 36			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
6521	2017.07.24 Derek Muehrcke Exhibit 37			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
6522	2017.07.24 Derek Muehrcke Exhibit 38			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
6523	2017.07.24 Derek Muehrcke Exhibit 39			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6524	2017.07.26 Sims, James Matthew Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6525	2017.07.31 David A Kessler, MD Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6526	2017.07.31 David A Kessler, MD Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6527	2017.07.31 David A Kessler, MD Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6528	2017.07.31 David A Kessler, MD Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6529	2017.07.31 David A Kessler, MD Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6530	2017.07.31 David A Kessler, MD Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6531	2017.07.31 David A Kessler, MD Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6532	2017.07.31 David A Kessler, MD Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6533	2017.07.31 David A Kessler, MD Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6534	2017.07.31 David A Kessler, MD Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6535	2017.07.31 David A Kessler, MD Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6536	2017.07.31 David A Kessler, MD Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6537	2017.07.31 David A Kessler, MD Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6538	2017.08.04 Robert Ritchie Exhibit 6007			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6539	2017.08.04 Robert Ritchie Exhibit 6008			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6540	2017.08.04 Robert Ritchie Exhibit 6009			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6541	2017.08.04 Robert Ritchie Exhibit 6010			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6542	2017.08.04 Robert Ritchie Exhibit 6011			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6543	2017.08.04 Robert Ritchie Exhibit 6012			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6544	2017.08.04 Robert Ritchie Exhibit 6013			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6545	2017.08.04 Robert Ritchie Exhibit 6014			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6546	2017.08.07 Darren Hurst, MD Exhibit 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6547	2017.08.07 Darren Hurst, MD Exhibit 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6548	2017.08.07 Darren Hurst, MD Exhibit 18			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6549	2017.08.07 Darren Hurst, MD Exhibit 19			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6550	2017.08.07 Darren Hurst, MD Exhibit 20			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6551	2017.08.07 Darren Hurst, MD Exhibit 21			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6552	2017.08.07 Darren Hurst, MD Exhibit 22			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6553	2017.08.07 Darren Hurst, MD Exhibit 23			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6554	2017.08.07 Darren Hurst, MD Exhibit 24			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6555	2017.08.07 Darren Hurst, MD Exhibit 25			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6556	2017.08.07 Darren Hurst, MD Exhibit 26			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6557	2017.08.16 White, Lora Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6558	2017.08.16 White, Lora Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6559	2017.08.16 White, Lora Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6560	2017.08.16 White, Lora Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6561	2017.08.16 White, Lora Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6562	2017.08.16 White, Lora Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6563	2017.08.16 White, Lora Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6564	2017.08.16 White, Lora Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6565	2017.08.16 White, Lora Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6566	2017.08.16 White, Lora Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6567	2017.08.16 White, Lora Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6568	2011.03.21 Deposition of William Nicholson, Exhibit 01.pdf	BPV-DEP-00047917	BPV-DEP-00047922	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6569	2011.03.21 Deposition of William Nicholson, Exhibit 02.pdf	BPV-DEP-00047923	BPV-DEP-00047929	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6570	2011.03.21 Deposition of William Nicholson, Exhibit 03.pdf	BPV-DEP-00047930	BPV-DEP-00047942	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6571	2011.03.21 Deposition of William Nicholson, Exhibit 04.pdf	BPV-DEP-00047943	BPV-DEP-00047945	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6572	2011.03.21 Deposition of William Nicholson, Exhibit 05.pdf	BPV-DEP-00047946	BPV-DEP-00047952	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6573	2011.03.21 Deposition of William Nicholson, Exhibit 06.pdf	BPV-DEP-00047953	BPV-DEP-00047963	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6574	2011.03.21 Deposition of William Nicholson, Exhibit 07.pdf	BPV-DEP-00047964	BPV-DEP-00047965	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6575	2011.03.21 Deposition of William Nicholson, Exhibit 08.pdf	BPV-DEP-00047966	BPV-DEP-00047966	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6576	2011.03.21 Deposition of William Nicholson, Exhibit 09.pdf	BPV-DEP-00047967	BPV-DEP-00047971	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6577	2011.03.21 Deposition of William Nicholson, Exhibit 10.pdf	BPV-DEP-00047972	BPV-DEP-00047978	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6578	2011.03.21 Deposition of William Nicholson, Exhibit 11.pdf	BPV-DEP-00047979	BPV-DEP-00047991	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6579	2011.03.21 Deposition of William Nicholson, Exhibit 12.pdf	BPV-DEP-00047992	BPV-DEP-00048036	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6580	2011.03.21 Deposition of William Nicholson, Exhibit 13.pdf	BPV-DEP-00048037	BPV-DEP-00048046	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6581	2011.03.21 Deposition of William Nicholson, Exhibit 14.pdf	BPV-DEP-00048047	BPV-DEP-00048048	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6582	2011.03.21 Deposition of William Nicholson, Exhibit 15.pdf	BPV-DEP-00048049	BPV-DEP-00048072	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6583	2011.03.21 Deposition of William Nicholson, Exhibit 16.pdf	BPV-DEP-00048073	BPV-DEP-00048074	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6584	2011.03.21 Deposition of William Nicholson, Exhibit 17.pdf	BPV-DEP-00048075	BPV-DEP-00048076	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6585	2011.03.21 Deposition of William Nicholson, Exhibit 18.pdf	BPV-DEP-00048077	BPV-DEP-00048091	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6586	2011.03.21 Deposition of William Nicholson, Exhibit 19.pdf	BPV-DEP-00048092	BPV-DEP-00048094	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6587	2011.03.21 Deposition of William Nicholson, Exhibit 20.pdf	BPV-DEP-00048095	BPV-DEP-00048097	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6588	2011.03.21 Deposition of William Nicholson, Exhibit 21.pdf	BPV-DEP-00048098	BPV-DEP-00048098	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6589	2011.03.21 Deposition of William Nicholson, Exhibit 22.pdf	BPV-DEP-00048099	BPV-DEP-00048099	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6590	2011.03.21 Deposition of William Nicholson, Exhibit 23.pdf	BPV-DEP-00048100	BPV-DEP-00048122	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6591	2011.03.21 Deposition of William Nicholson, Exhibit 25.pdf	BPV-DEP-00048123	BPV-DEP-00048123	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6592	2011.03.21 Deposition of William Nicholson, Exhibit 26.pdf	BPV-DEP-00048124	BPV-DEP-00048124	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6593	2011.03.21 Deposition of William Nicholson, Exhibit 27.pdf	BPV-DEP-00048125	BPV-DEP-00048126	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6594	2011.03.21 Deposition of William Nicholson, Exhibit 28.pdf	BPV-DEP-00048127	BPV-DEP-00048130	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6595	2011.03.21 Deposition of William Nicholson, Exhibit 29.pdf	BPV-DEP-00048131	BPV-DEP-00048132	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6596	2011.03.21 Deposition of William Nicholson, Exhibit 30.pdf	BPV-DEP-00048133	BPV-DEP-00048133	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6597	2011.03.21 Deposition of William Nicholson, Exhibit 31.pdf	BPV-DEP-00048134	BPV-DEP-00048134	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6598	2011.03.21 Deposition of William Nicholson, Exhibit 32.pdf	BPV-DEP-00048135	BPV-DEP-00048136	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6599	2011.03.21 Deposition of William Nicholson, Exhibit 33.pdf	BPV-DEP-00048137	BPV-DEP-00048137	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6600	2011.03.21 Deposition of William Nicholson, Exhibit 34.pdf	BPV-DEP-00048138	BPV-DEP-00048139	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6601	2011.03.21 Deposition of William Nicholson, Exhibit 35.pdf	BPV-DEP-00048140	BPV-DEP-00048141	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6602	2011.03.21 Deposition of William Nicholson, Exhibit 36.pdf	BPV-DEP-00048142	BPV-DEP-00048143	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6603	2011.03.21 Deposition of William Nicholson, Exhibit 37.pdf	BPV-DEP-00048144	BPV-DEP-00048144	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6604	2011.03.21 Deposition of William Nicholson, Exhibit 38.pdf	BPV-DEP-00048145	BPV-DEP-00048147	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6605	2011.03.21 Deposition of William Nicholson, Exhibit 39.pdf	BPV-DEP-00048148	BPV-DEP-00048149	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6606	2011.03.21 Deposition of William Nicholson, Exhibit 40.pdf	BPV-DEP-00048150	BPV-DEP-00048150	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6607	2011.03.21 Deposition of William Nicholson, Exhibit 41.pdf	BPV-DEP-00048151	BPV-DEP-00048151	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6608	2011.03.21 Deposition of William Nicholson, Exhibit 42.pdf	BPV-DEP-00048152	BPV-DEP-00048170	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6609	2011.03.21 Deposition of William Nicholson, Exhibit 43.pdf	BPV-DEP-00048171	BPV-DEP-00048171	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6610	2011.03.21 Deposition of William Nicholson, Exhibit 44.pdf	BPV-DEP-00048172	BPV-DEP-00048173	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6611	2011.03.21 Deposition of William Nicholson, Exhibit 45.pdf	BPV-DEP-00048174	BPV-DEP-00048175	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6612	2011.03.21 Deposition of William Nicholson, Exhibit 46.pdf	BPV-DEP-00048176	BPV-DEP-00048180	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6613	2011.03.21 Deposition of William Nicholson, Exhibit 47.pdf	BPV-DEP-00048181	BPV-DEP-00048181	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6614	2011.03.21 Deposition of William Nicholson, Exhibit 48.pdf	BPV-DEP-00048182	BPV-DEP-00048182	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6615	2011.10.04 Nicholson Defendant Exhibit 1.pdf	BPV-DEP-00048333	BPV-DEP-00048333	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6616	2011.10.04 Nicholson Plaintiff Exhibit 1.pdf	BPV-DEP-00048334	BPV-DEP-00048338	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6617	2011.10.04 Nicholson Plaintiff Exhibit 2.pdf	BPV-DEP-00048339	BPV-DEP-00048376	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6618	2011.04.28 Delio-Cox Exhibit 01.pdf	BPV-DEP-00048475	BPV-DEP-00048475	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6619	2011.04.28 Delio-Cox Exhibit 02.pdf	BPV-DEP-00048476	BPV-DEP-00048476	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6620	2011.04.28 Delio-Cox Exhibit 03.pdf	BPV-DEP-00048477	BPV-DEP-00048477	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6621	2011.04.28 Delio-Cox Exhibit 04.pdf	BPV-DEP-00048478	BPV-DEP-00048478	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6622	2011.04.28 Delio-Cox Exhibit 05.pdf	BPV-DEP-00048479	BPV-DEP-00048479	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6623	2011.04.28 Delio-Cox Exhibit 06.pdf	BPV-DEP-00048480	BPV-DEP-00048480	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6624	2011.04.28 Delio-Cox Exhibit 07.pdf	BPV-DEP-00048481	BPV-DEP-00048481	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6625	2011.04.28 Delio-Cox Exhibit 08.pdf	BPV-DEP-00048482	BPV-DEP-00048482	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6626	2011.04.28 Delio-Cox Exhibit 09.pdf	BPV-DEP-00048483	BPV-DEP-00048483	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6627	2011.04.28 Delio-Cox Exhibit 10.pdf	BPV-DEP-00048484	BPV-DEP-00048484	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6628	2011.04.28 Delio-Cox Exhibit 11.pdf	BPV-DEP-00048485	BPV-DEP-00048485	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6629	2011.04.28 Delio-Cox Exhibit 12.pdf	BPV-DEP-00048486	BPV-DEP-00048486	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6630	2011.04.28 Delio-Cox Exhibit 13.pdf	BPV-DEP-00048487	BPV-DEP-00048487	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6631	Exhibit 1 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6632	Exhibit 2 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6633	Exhibit 3 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6634	Exhibit 4 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6635	Exhibit 8 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6636	Exhibit 9 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
6637	Exhibit 10 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6638	Exhibit 11 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
6639	Exhibit 12 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6640	Exhibit 13 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6641	Exhibit 14 of Kush Desai Deposition, taken 6/6/2017.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6642	Deposition of Natalie Wong, taken 10/18/2016, Exhibit 537			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6835	"Should you worry about the radiation from CT scans?" https://www.washingtonpost.com/national/health-science/how-much-to-worry-about-the-radiation-from-ct-scans/2016/01/04/8dfb80cc-8a30-11e5-be39-0034bb576eeestory.html?utmterm=.67f42f94c11d Accessed on February 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6836	2016 Revised ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism. https://www.acr.org/~media/a569be8f18ae4cfaa2868b6e0984dbd8.pdf Accessed January 16, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6837	Aarabi B, Harrop JS, Tator CH, Alexander M, Dettori JR, Grossman RG, Fehlings MG, Mirvis SE, Shanmuganathan K, Zacherl KM, Burau KD, Frankowski RF, Toups E, Shaffrey CI, Guest JD, Harkema SJ, Habashi NM, Andrews P, Johnson MM, Rosner MK. Predictors of Pulmonary Complications in Blunt Traumatic Spinal Cord Injury. J Neurosurg Spine. 2012 Sep;17(1 Suppl):38-45. doi: 10.3171/2012.4.AOSpine1295.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6838	Abtahian F, Hawkins BM, Ryan DP. Inferior vena cava filter usage, complications, and retrieval rate in cancer patients. Am J Med 2014; 127:1111-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6839	ACR Appropriateness Criteria® radiologic management of inferior vena cava filters. Available at: http://guidelines.gov/content.aspx?id=15730#Section420 .	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6840	ACR SIR, Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism (2014)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6841	ACR-SIR Practice guideline on informed consent for image-guided procedures 2011 https://www.sirweb.org/globalassets/aasociety-of-interventional-radiology-home-page/practice-resources/standards_pdfs/final_acr_doc7109ed01.pdf	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6842	ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism. Revised 2016.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6843	ACR-SIR-SPR Practice Parameter on Informed Consent for Image-Guided Procedures. Revised 2016. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/InformedConsent-ImagGuided.pdf	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6844	Adair JD, Harvey KP, Mahmood A. Inferior vena cava filter migration to right ventricle with destruction of tricuspid valve: a case report. J Trauma. 2008 Feb;64(2):509-11. doi: 10.1097/TA.0b013e318058251c.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6845	Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral Apixaban for the Treatment of Acute Thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6846	Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6847	Ahmad I, Yeddula K, Wicky S, Kalva SP. Clinical sequelae of thrombus in an inferior vena cava filter. Cardiovasc Intervent Radiol. 2010 Apr;33(2):285-9. doi: 10.1007/s00270-009-9664-x. Epub 2009 Aug 18.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6848	Alam M, Levine TB. Echocardiographic features of embolized inferior venacaval filter to the right ventricle: a case report. Angiology. 1993 Apr;44(4):338-40.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6849	Albrecht RM, Garwe T, Carter SM, Maurer AJ. Retrievable inferior vena cava filters in trauma patients: factor that influence removal rate and an argument for institutional protocols. Am J Surg 2012; 203:297-302.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6850	Albright HL. Thrombophlebitis: The Problem of Treatment. N Engl J Med. 1947 Jun 19;236(25):928-33. doi: 10.1056/NEJM194706192362502.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6851	Allen CJ, Murray CR, Meizoso JP, Ginzburg E, Schulman CI, Lineen EB, Namias N, Proctor KG. Surveillance and Early Management of Deep Vein Thrombosis Decreases Rate of Pulmonary Embolism in High-Risk Trauma Patients. J Am Coll Surg. 2016 Jan;222(1):65-72. doi: 10.1016/j.jamcollsurg.2015.10.014. Epub 2015 Nov 4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6852	Allen TL, Carter JL, Morris BJ, Harker CP, Stevens MH. Retrievable vena cava filters in trauma patients for high-risk prophylaxis and prevention of pulmonary embolism. Am J Surg. 2005 Jun;189(6):656-61.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6853	Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary embolism. JAMA 1976;236(13):1477-1480.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6854	American Venous Forum. Upcoming IVC Filter Data From the American Venous Registry [not a peer-reviewed article]	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6855	Amole AO, Kathuria MK, Ozkan OS, Gill AS, Ozkan EO. Lumbar artery laceration with retroperitoneal hematoma after placement of a G-2 inferior vena cava filter. Cardiovasc Intervent Radiol. 2008 Nov-Dec;31(6):1257-9. doi: 10.1007/s00270-008-9365-x. Epub 2008 Jun 10.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6856	An T, Moon E, Bullen J, Kapoor B, Wu A, Sands M, Wang W. Prevalence and Clinical Consequences of Fracture and Fragment Migration of the Bard G2 Filter: Imaging and Clinical Follow-up in 684 Implantations. J Vasc Interv Radiol. 2014 Jun;25(6):941-8. doi: 10.1016/j.jvir.2014.01.035. Epub 2014 Mar 18.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6857	Anderson FA Jr, Spencer FA. Risk Factors for Venous Thromboembolism. Circulation. 2003 Jun 17;107(23 Suppl 1):I9-16.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6858	Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr; Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest 124 (Suppl): S349-S356, 2003	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6859	Anderson FA, Jr, Wheeler HB, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6860	Andreoli JM, Lewandowski RJ, Vogelzang RL, Ryu RK. Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database. J Vasc Interv Radiol. 2014 Aug;25(8):1181-5. doi: 10.1016/j.jvir.2014.04.016. Epub 2014 Jun 11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6861	Andreoli JM, Thornburg BG, Hickey RM. Inferior Vena Cava Filter Related Thrombus Deep Vein Thrombosis Data and Management. Semin Intervent Radiol. 2016 Jun;33(2):101-4. doi: 10.1055/s-0036-1581087.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6862	Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufman J. Systematic Review of the Use of Retrievable Inferior Vena Cava Filters. J Vasc Interv Radiol. 2011 Nov;22(11):1522-1530.e3. doi: 10.1016/j.jvir.2011.08.024.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6863	Antevil JL, Sise MJ, Sack DI, Sasadeusz KJ, Swanson SM, Rivera L, Lome BR, Weingarten KE, Kaminski SS. Retrievable Vena Cava Filters for Preventing Pulmonary Embolism in Trauma Patients: A Cautionary Tale. J Trauma. 2006 Jan;60(1):35-40.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6864	Araki T, Ishihara C. Images in cardiovascular medicine. Retroperitoneal Hematoma After Inferior Vena Cava Filter Insertion. Circulation. 2007 Sep 11;116(11):e345.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6865	Arjomand H, Surabhi S, Wolf NM. Right ventricular foreign body: percutaneous transvenous retrieval of a Greenfield filter from the right ventricle--a case report. Angiology. 2003. 54(1): 109-13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6866	Aryafar H, Kinney TB. Optional inferior vena cava filters in the trauma patient. Semin Intervent Radiol. 2010 Mar;27(1):68-80. doi: 10.1055/s-0030-1247890.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6867	Asch MR. Initial experience in humans with a new retrievable inferior vena cava filter. Radiology. 2002 Dec;225(3):835-44.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6868	Assifi MM, Bagameri G, Dimuzio PJ, Eisenberg JA. Management of infected caval filter with simultaneous aortic pseudoaneurysm and retroperitoneal perforation: a case report and literature review. Vascular. 2012 Aug;20(4):225-8. doi: 10.1258/vasc.2011.cr0310. Epub 2012 Jun 11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6869	Athanasoulis CA, Kaufman JA, Halpern EF, Waltman AC, Geller SC, Fan CM. Inferior vena caval filters: review of a 26-year single-center clinical experience. Radiology. 2000 Jul;216(1):54-66.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6870	Attar S, Boyd D, Layne E, McLaughlin J, Mansberger AR, Cowley RA. Alterations in coagulation in coagulation and fibrinolytic systems following trauma. J Trauma 1969; 9:939-965.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6871	Avgerinos ED, Bath J, Stevens J, McDaniel B, Marone L, Dillavou E, Cho JS, Makaroun MS, Chaer RA. Technical and patient-related characteristics associated with challenging retrieval of inferior vena cava filters. Eur J Vasc Endovasc Surg. 2013 Sep;46(3):353-9. doi: 10.1016/j.ejvs.2013.06.007. Epub 2013 Jul 5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6872	Aw-Zoretic J, Collins JD. Considerations for Imaging the Inferior Vena Cava (IVC) with without IVC Filters. Semin Intervent Radiol. 2016 Jun;33(2):109-21. doi: 10.1055/s-0036-1583207.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6873	Bach JR, Zaneuski R, Lee H. Cardiac arrhythmias from a malpositioned Greenfield filter in a traumatic quadriplegic. Am J Phys Med Rehabil. 1990 Oct;69(5):251-3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6874	Balas EA. Information Systems Can Prevent Errors and Improve Quality. J Am Med Inform Assoc. 2001 Jul-Aug;8(4):398-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6875	Ballew KA, Philbrick JT, Becker DM. Vena cava filter devices. Clin Chest Med. 1995 Jun;16(2):295-305.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6876	Bandle J, Shackford SR, Sise CB, Knudson MM; CLOTT Study Group. Variability is the Standard: The management of Venous Thromboembolic Disease Following Trauma. J Trauma Acute Care Surg. 2014 Jan;76(1):213-6. doi: 10.1097/TA.0b013e3182aa2fa9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6877	Bard Denali Vena Cava Filter. Femoral Vein Approach. Instructions for Use. http://www.bardpv.com/wp-content/uploads/2014/02/DenaliBAW5410500-US-FEM.pdf Accessed on January 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6878	Bard Eclipse Vena Cava Filter. Femoral Vein Approach. Instructions for Use. http://www.bardpv.com/wp-content/uploads/2014/02/EclipseVenaCavaFilterFemIFU.pdf Accessed on January 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6879	Bard G2 Filter System. Femoral Vein Approach. Instructions for Use. http://www.bardpv.com/filterfacts/pdf/ifus/G2-Fem-BAW5250500-R2.pdf Accessed September 1, 2016.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6880	Bariatric Surgery Guidelines, Medical Guidelines for Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Patient - 2013 Update	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6881	Barral FG. Vena cava filters: why, when, what and how? J Cardiovasc Surg (Torino). 2008 Feb;49(1):35-49.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6882	Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960;1(7138):1309-1312.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6883	Bauer G. The introduction of heparin therapy in cases of early thrombosis. Circulation 1959;19(1):108-109.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6884	Becattini C, Agnelli G. Acute pulmonary embolism: risk stratification in the emergency department. Intern Emerg Med 2007;2(2):119-129.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6885	Becker DM, Philbrick JT, Selby JB. Inferior Vena Cava Filters. Indications, safety, effectiveness. Arch Intern Med. 1992 Oct;152(10):1985-94.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6886	Bélénotti P, Sarlon-Bartoli G, Bartoli MA, Benyamine A, Thevenin B, Muller C, Serratrice J, Magnan PE, Weiller PJ. Vena cava filter migration: an unappreciated complication. About four cases and review of the literature. Ann Vasc Surg. 2011 Nov;25(8):1141.e9-14. doi: 10.1016/j.avsg.2011.03.016.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6887	Benenati, Society of Interventional Radiology letter re: FDA Public Health Notification - Removing Retrievable Inferior Vena Cava Filters: Initial Communication	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6888	Benenati, Society of Interventional Radiology Responds to FDA Blood Clot Device (IVC Filter) Advisory	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6889	Berczi V, Bottomley JR, Thomas SM, Taneja S, Gaines PA, Cleveland TJ. Long-term retrievability of IVC filters: should we abandon permanent devices? Cardiovasc Intervent Radiol. 2007 Sep-Oct;30(5):820-7. Epub 2007 Sep 1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6890	Bikdeli B, Ross JS, Krumholz HM. Data Desert for Inferior Vena Caval Filters: Limited Evidence, Supervision, and Research. JAMA Cardiol. 2017 Jan 1;2(1):3-4. doi: 10.1001/jamacardio.2016.3764.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6891	Billett H.H., Jacobs L.G., Madsen E.M., Giannattasio E.R., Mahesh S., Cohen H.W. Efficacy of inferior vena cava filters in anticoagulated patients. J Thromb Haemost. 2007;5:1848-1853.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6892	Binkert CA, Drooz AT, Caridi JG, Sands MJ, Bjarnason H, Lynch FC, Rilling WS, Zambuto DA, Stavropoulos SW, Venbrux AC, Kaufman JA. Technical success and safety of retrieval of the G2 filter in a prospective, multicenter study. J Vasc Interv Radiol. 2009 Nov;20(11):1449-53. doi: 10.1016/j.jvir.2009.08.007.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6893	Binkert CA, Sasadeusz K, Stavropoulos SW. Retrievability of the Recovery Vena Cava Filter after Dwell Times Longer than 180 Days. J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):299-302.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6894	Birkmeyer NJ, Finks JF, English WJ, Carlin AM, Hawasli AA, Genaw JA, Wood MH, Share DA, Birkmeyer JD; Michigan Bariatric Surgery Collaborative. Risks and Benefits of Prophylactic Inferior Vena Cava Filters in Patients Undergoing Bariatric Surgery. J Hosp Med. 2013 Apr;8(4):173-7. doi: 10.1002/jhm.2013. Epub 2013 Feb 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6895	Birkmeyer NJ, Share D, Baser O, Carlin AM, Finks JF, Pesta CM, Genaw JA, Birkmeyer JD: Michigan Bariatric Surgery Collaborative. Preoperative placement of inferior vena cava filters and outcomes after gastric bypass surgery. Ann Surg. 2010 Aug;252(2):313-8. doi: 10.1097/SLA.0b013e3181e61e4f.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6896	Bjarnason H, Yedlicka JW Jr, Hunter DW, Castañeda-Zuñiga WR, Amplatz K. In vitro metal fatigue testing of inferior vena cava filters. Invest Radiol. 1994 Sep;29(9):817-21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6897	Błaszyk H, Wollan PC, Witkiewicz AK, Björnsson J. Death from pulmonary thromboembolism in severe obesity: lack of association with established genetic and clinical risk factors. Virchows Arch. 1999 Jun;434(6):529-32.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6898	Blebea J, Wilson R, Waybill P, Neumyer MM, Blebea JS, Anderson KM, Atnip RG. Deep Vein Thrombosis After Percutaneous Insertion of Vena Caval Filters. J Vasc Surg. 1999 Nov;30(5):821-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6899	Bochenek KM, Aruny JE, Tal MG. Right Atrial Migration and percutaneous retrieval of a Gunther Tulip inferior vena cava filter. J Vasc Interv Radiol. 2003 Sep;14(9 Pt 1):1207-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6900	Bos A, Van Ha T, van Beek D, Ginsburg M, Zangan S, Navuluri R, Lorenz J, Funaki B. Strut Penetration: Local Complications, Breakthrough Pulmonary Embolism, and Retrieval Failure in Patients with Celect Vena Cava Filters. J Vasc Interv Radiol. 2015 Jan;26(1):101-6. doi: 10.1016/j.jvir.2014.09.010. Epub 2014 Oct 29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6901	Bos AS, Tullius T, Patel M, Leef JA, Navuluri R, Lorenz JM, Van Ha TG. Indwelling and Retrieval Complications of Denali and Celect Infraarenal Vena Cava Filters. J Vasc Interv Radiol. 2016 Jul;27(7):1021-6. doi: 10.1016/j.jvir.2016.03.034.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6902	Brathwaite CE, Mure AJ, O'Malley KF, Spence RK, Ross SE. Complications of Anticoagulation for Pulmonary Embolism in Low Risk Trauma Patients. Chest. 1993 Sep;104(3):718-20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6903	Braun MA, Collins MB, Sarrafzadeh M, Koslow AR. Percutaneous retrieval of tandem right atrial Greenfield filters. AJR Am J Roentgenol. 1991 Jul;157(1):199.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6904	Brenner DJ, Hall EJ. Computed tomography – an increasing source of radiation exposure. N Engl J Med 2007; 357:2277-84.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6905	Brotman DJ, Shihab HM, Prakasa KR, Kebede S, Haut ER, Sharma R, Shermock K, Chelladurai Y, Singh S, Segal JB. Pharmacologic and Mechanical Strategies for Preventing Venous Thromboembolism After Bariatric Surgery A Systematic Review and Meta-analysis. JAMA Surg. 2013 Jul;148(7):675-86. doi: 10.1001/jamasurg.2013.72.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6906	Brown AP, Miller MJ, Smith TP. Caval Penetration with Retroperitoneal Hemorrhage Following Placement of an Inferior Vena Cava (IVC) Filter. Semin Intervent Radiol. 2007 Sep;24(3):312-5. doi: 10.1055/s-2007-985741.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6907	Brown SL, Bright RA, Tavis DR. Medical Device Epidemiology and Surveillance – Patient Safety is the Bottom Line. Expert Rev Med Devices. 2004 Sep;1(1):1-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6908	Buckley O, DeVore A, Ersoy H, Sobieszczyk P, Auger W, Kwong R, Rybicki F, Goldhaber S. "Embolism after Inferior Vena Cava Filter Mesh Fragmentation," Letter to the Editor, November 2010 JVIR, Vol. 21, Number 11, 1782-3, DOI: 10.1016/j.jvir.2010.07.021.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6909	Bull PG, Mendel H, Schlegl A. Günther vena caval filter: clinical appraisal. J Vasc Interv Radiol. 1992 May;3(2):395-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6910	Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovela F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med. 2004 Jun 1;140(11):867-73.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6911	Burge AJ, Freeman KD, Klapper PJ, Haramati LB. Increased diagnosis of pulmonary embolism without a corresponding decline in mortality during the CT era. Clin Radiol 2008;63(4):381-386.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6912	Bustamante M, Abascal F, Garcia-Valtuille R, González-Tutor A, Gómez JM. Sudden death in a patient caused by migration of an Antheor vena cava filter to the heart. J Vasc Interv Radiol. 1998. 9(3): 521-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6913	Cain PG. Comment on "Treatment of venous disease--the innovators". J Vasc Surg. 1995 Sep;22(3):341-3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6914	Cantwell CP, Pennypacker J, Singh H, Scorza LB, Waybill PN, Lynch FC. Comparison of the recovery and G2 filter as retrievable inferior vena cava filters. J Vasc Interv Radiol. 2009 Sep;20(9):1193-9. doi: 10.1016/j.jvir.2009.05.037. Epub 2009 Jul 29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6915	Caplin DM, Nikolic B, Kalva SP, Ganguli S, Saad WE, Zuckerman DA. Quality Improvement Guidelines for the Performance of Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism. J Vasc Interv Radiol. 2011 Nov;22(11):1499-506. doi: 10.1016/j.jvir.2011.07.012. Epub 2011 Sep 3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6916	Cappelli F, Vignini S, Baldereschi GJ. ALN inferior vena cava filter upside down rotation with chest caval migration in an asymptomatic patient. J Invasive Cardiol. 2010 Aug;22(8):E153-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6917	Carabasi RA 3rd, Moritz MJ, Jarrell BE. Complications encountered with the use of the Greenfield filter. Am J Surg. 1987 Aug;154(2):163-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6918	Carlin AM, Tyburski JG, Wilson RF, Steffes C. Prophylactic and therapeutic inferior vena cava filters to prevent pulmonary emboli in trauma patients. Arch Surg. 2002 May;137(5):521-5; discussion 525-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6919	Carman TL, Alahmad A. Update on vena cava filters. Curr Treat Options Cardiovasc Med. 2008 Apr;10(2):101-11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6920	Castaneda F, Herrera M, Cragg AH, Salamonowitz E, Lund G, Castaneda-Zuniga WR, Amplatz K. Migration of a Kimray-Greenfield filter to the right ventricle. Radiology. 1983 Dec;149(3):690.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6921	Center for Devices and Radiological Health. Food and Drug Administration. The MAUDE - Manufacturer and User Facility Device Experience Web Homepage. Available from: 142. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM .	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6922	Centers for Disease Control and Prevention. Principles of Epidemiology in Public Health Practice, Third Edition An Introduction to Applied Epidemiology and Biostatistics https://www.cdc.gov/ophs/csels/dsepd/ss1978/lesson3/section2.html accessed on March 6, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6923	Chana-Rodríguez F, Mañanes RP, Rojo-Manaute J, Haro JAC, Vaquero-Martín J. Methods and Guidelines for Venous Thromboembolism Prevention in Polytrauma Patients with Pelvic and Acetabular Fractures. Open Orthop J. 2015; 9: 313-320.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6924	Charalel RA, Durack JC, Mao J, Ross JS, Meltzer AJ, Sedrakyan A. Statewide Inferior Vena Cava Filter Placement, Complications, and Retrievals: Epidemiology and Recent Trends. Med Care. 2018 Mar;56(3):260-265. doi: 10.1097/MLR.0000000000000867.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6925	Charles HW, Black M, Kovacs S, Gohari A, Arampulikan J, McCann JW, Clark TW, Bashar M, Steiger D. G2 Inferior Vena Cava Filter: Retrievability and Safety. J Vasc Interv Radiol. 2009 Aug;20(8):1046-51. doi: 10.1016/j.jvir.2009.03.046. Epub 2009 Jun 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6926	Charlton-Ouw KM, Leake SS, Sola CN, Sandhu HK, Albarado R, Holcomb JB, Miller CC 3rd, Safi HJ, Azizzadeh A. Technical and financial feasibility of an inferior vena cava filter retrieval program at a level one trauma center. Ann Vasc Surg. 2015 Jan;29(1):84-9. doi: 10.1016/j.avsg.2014.05.018. Epub 2014 Jun 12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6927	Chen D, Apple DF Jr, Hudson LM, Bode R. Medical Complications During Acute Rehabilitation Following Spinal Cord Injury – Current Experience of the Model Systems. Arch Phys Med Rehabil. 1999 Nov;80(11):1397-401.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6928	Cherry RA, Nichols PA, Snavelly TM, David MT, Lynch FC. Prophylactic inferior vena cava filters: do they make a difference in trauma patients? J Trauma. 2008 Sep;65(3):544-8. doi: 10.1097/TA.0b013e31817f980f.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6929	Cheung MC, Asch MR, Gandhi S, Kingdom JC. Temporary Inferior Vena Cava Filter Use in Pregnancy. J Thromb Haemost. 2005 May;3(5):1096-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6930	Chitwood WR Jr, Chiang KS, Williams JM, Zeri RS, Semer DA. Embolectomy of a Bird's Nest vena cava filter. Ann Thorac Surg. 1994 Dec;58(6):1766-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6931	Cipolla J, Weger NS, Sharma R, Schrag SP, Sarani B, Truitt M, Lorenzo M, Sims CA, Kim PK, Torigian D, Temple-Lyken B, Sicoutris CP, Stawicki SP. Complications of vena cava filters: A comprehensive clinical review. OPUS 12 Scientist 2008 Vol. 2, No. 2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6932	CIRA, CIRA Statement on IVC Filter Safety Concern Noted by Health Canada	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6933	CLOTS, Effectiveness of intermittent pneumatic compression in reduction of risk of DVT	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6934	Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006 Feb 11;332(7537):325-9. Epub 2006 Jan 26.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6935	Connolly PH, Balachandran VP, Trost D, Bush HL Jr. Open Surgical Inferior Vena Cava Filter Retrieval for Caval Perforation and a Novel Technique for minimal cavotomy filter extraction. J Vasc Surg. 2012 Jul;56(1):256-9; discussion 259. doi: 10.1016/j.jvs.2011.12.065. Epub 2012 Apr 12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6936	Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6937	Cook AD, Gross BW, Osler TM, Rittenhouse KJ, Bradburn EH, Shackford SR, Rogers FB. Vena Cava Filter Use in Trauma and Rates of Pulmonary Embolism, 2003-2015. JAMA Surg. 2017 Aug 1;152(8):724-732. doi: 10.1001/jamasurg.2017.1018.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6938	Corriere, M.A., et al., Vena cava filters and inferior vena cava thrombosis. J Vasc Surg. 2007. 45(4): 789-94.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6939	Cura, M., Computed tomography evaluation of inferior vena cava Bard G2 filters. (Meeting Abstract). 2010: S3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6940	Cuschieri, Inflammation and the Host Response to Injury a Large Scale Collaborative Project: Patient-Oriented Research Core Standard Operating Procedure for Clinical Care X. Guidelines for Venous Thromboembolism Prophylaxis in the Trauma Patient	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6941	Cynamon J, Bakal CW, Epstein SB, Gabelman G. Percutaneous removal of a titanium Greenfield filter. AJR Am J Roentgenol. 1992 Oct;159(4):777-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6942	Damascelli B, Ticha V, Patelli G, et al. Use of a retrievable vena cava filter with low-intensity anticoagulation for prevention of pulmonary embolism in patients with cancer: an observational study in 106 cases. J Vasc Interv Radiol 2011; 22:1312-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6943	Dardik A, Campbell KA, Yeo CJ, Lipsett PA. Vena cava filter ensnarement and delayed migration: an unusual series of cases. J Vasc Surg. 1997 Nov;26(5):869-74.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6944	Das M, Panter L, Wynn GJ, Taylor RM, Connor N, Mills JD, Kirchhof P, Gupta D. Primary Care Atrial Fibrillation Service – Outcomes from Consultant-Led Anticoagulation Assessment Clinics in the Primary Care Setting in the UK. BMJ Open. 2015 Dec 9;5(12):e009267. doi: 10.1136/bmjopen-2015-009267.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6945	Davies MG, Hart JP, El-Sayed HF. Efficacy of prophylactic inferior vena caval filters in prevention of pulmonary embolism in the absence of deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2016 Jan;4(1):127-130.e1. doi: 10.1016/j.jvsv.2015.05.008. Epub 2015 Jul 16	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6946	Davison BD, Grassi CJ. TrapEase Inferior Vena Cava Filter Placed via the Basilic Arm Vein: A New Antecubital Access. J Vasc Interv Radiol. 2002 Jan;13(1):107-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6947	Dazley JM, Wain R, Vellinga RM, Cohen B, Agulnick MA. Prophylactic Inferior Vena Cava Filters Prevent Pulmonary Embolisms in High- Risk Patients Undergoing Major Spinal Surgery. J Spinal Disord Tech. 2012 Jun;25(4):190-5. doi: 10.1097/BSD.0b013e31821532bd.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6948	de Gonzalez AB, Mahesh M, Kim K-P; et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009; 169(22):2071-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6949	de Villiers L, Mackenzie S, Gibbs H, Leggett D, Neels M, Harper J., Initial Australian Experience with the Recovery Inferior Vena Cava Filter in Patients with Increased Risk of thromboembolic disease. J Med Imaging Radiat Oncol. 2008 Apr;52(2):124-9. doi: 10.1111/j.1440-1673.2008.01929.x.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6950	De Waele JJ, De Pauw M, Van Belleghem Y, Van Nooten G., Diagnosis of myocardial perforation by a Greenfield filter made by transesophageal echocardiography. J Am Soc Echocardiogr. 2002 Apr;15(4):374-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6951	Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338:409-415.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6952	Defraigne JO, Vahdat O, Lacroix H, Limet R. Proximal migration of vena caval filters: report of two cases with operative retrieval. Ann Vasc Surg. 1995 Nov;9(6):571-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6953	Deitelzweig S.B., Johnson B.H., Lin J., Schulman K.L.; Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol. 2011;86:217-220.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6954	Dennis JW, Menawat S, Von Thron J, Fallon WF Jr, Vinsant GO, Laneve LM, Jagger C, Frykberg ER. Efficacy of Deep Venous Thrombosis Prophylaxis in Trauma Patients and Identification of High-Risk Groups. J Trauma. 1993 Jul;35(1):132-8; discussion 138-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6955	Desai KR, Errea M, Ryu RK, Lewandowski RJ. Extraordinary Cases in Inferior Vena Cava Filter Retrieval. Semin Intervent Radiol. 2016 Jun;33(2):149-56. doi: 10.1055/s-0036-1582120.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6956	Desai KR, Lewandowski RJ, Salem R, Mouli SK, Karp JK, Laws JL, Ryu RK. Retrieval of Inferior Vena Cava Filters With Prolonged Dwell Time: A Single-Center Experience in 648 Retrieval Procedures. JAMA Intern Med. 2015 Sep;175(9):1572-4. doi: 10.1001/jamainternmed.2015.2561.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6957	Desai SS, Naddaf A, Pan J, Hood D, Hodgson KJ. Impact of Consensus Statements and Reimbursement on Vena Cava Filter Utilization. J Vasc Surg. 2016 Aug;64(2):425-429. doi: 10.1016/j.jvs.2016.01.046. Epub 2016 Mar 4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6958	Desai TR, Morcos OC, Lind BB, Schindler N, Caprini JA, Hahn D, Warner D, Gupta N. Complications of indwelling retrievable versus permanent inferior vena cava filters. J Vasc Surg Venous Lymphat Disord. 2014 Apr;2(2):166-73. doi: 10.1016/j.jvsv.2013.10.050. Epub 2014 Jan 16.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6959	Desai KR, Pandhi MB, Seedial SM, Errea MF, Salem R, Ryu RK, Lewandowski RJ. Retrievable IVC Filters: Comprehensive Review of Device-related Complications and Advanced Retrieval Techniques. Radiographics. 2017 Jul-Aug;37(4):1236-1245. doi: 10.1148/rg.2017160167.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6960	Desjardins B, Kamath SH, Williams D. Fragmentation, embolization, and left ventricular perforation of a recovery filter. J Vasc Interv Radiol. 2010 Aug;21(8):1293-6. doi: 10.1016/j.jvir.2010.04.019. Epub 2010 Jul 3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6961	Deso SE, Idakoji IA, Muelly MC, Kuo WT. Creation of an iOS and Android Mobile Application for Inferior Vena Cava (IVC) Filters. Semin Intervent Radiol. 2016 Jun;33(2):137-43. doi: 10.1055/s-0036-1583206.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6962	Deso SE, Idakoji IA, Kuo WT. Evidence-Based Evaluation of Inferior Vena Cava Filter Complications Based on Filter Type. Semin Intervent Radiol. 2016 Jun;33(2):93-100. doi: 10.1055/s-0036-1583208.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6963	DeVivo MJ, Krause JS, Lammertse DP. Recent Trends in Mortality and Causes of Death Among Persons with Spinal Cord Injury. Arch Phys Med Rehabil. 1999 Nov;80(11):1411-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6964	DeYoung E, Minocha J. Inferior Vena Cava Filters: Guidelines, Best Practice, and Expanding Indications. Semin Intervent Radiol. 2016 Jun;33(2):65-70. doi: 10.1055/s-0036-1581088.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6965	Dhand S, Stulberg SD, Puri L, Karp J, Ryu RK, Lewandowski RJ. The Role of Potentially Retrievable Inferior Vena Cava Filters in High-Risk Patients Undergoing Joint Arthroplasty. J Clin Diagn Res. 2015 Dec;9(12):TC01-3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6966	Dimick, J.B., D.O. Staiger and J.D. Birkmeyer, Ranking hospitals on surgical mortality: the importance of reliability adjustment. Health Serv Res, 2010. 45(6 Pt 1): 1614-29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6967	Dinglasan LA, Oh JC, Schmitt JE, Trerotola SO, Shlansky-Goldberg RD, Stavropoulos SW. Radiology. Complicated inferior vena cava filter retrievals: associated factors identified at preretrieval CT. 2013 Jan;266(1):347-54. doi: 10.1148/radiol.12120372. Epub 2012 Oct 9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6968	Dinglasan LA, Trerotola SO, Shlansky-Goldberg RD, Mondschein J, Stavropoulos SW. Removal of Fractured Inferior Vena Cava Filters: Feasibility and Outcomes. J Vasc Interv Radiol. 2012 Feb;23(2):181-7. doi: 10.1016/j.jvir.2011.10.023. Epub 2011 Dec 16.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6969	Doe C, Ryu RK. Anatomic and Technical Considerations: Inferior Vena Cava Filter Placement. Semin Intervent Radiol. 2016 Jun;33(2):88-92. doi: 10.1055/s-0036-1581089.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6970	Dorsey, Migrated Kimray-Greenfield filter lodged in the right ventricle: surgical removal and transatrial reinsertion	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6971	Dossett, Unwarranted National Variation in the Use of Prophylactic Inferior Vena Cava Filters After Trauma: An analysis of the National Trauma Databank	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6972	Dowell, Celect Inferior Vena Cava Wall Strut Perforation Begets Additional Strut Perforation	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6973	Dreyer, Inferior vena cava filter migration to the right ventricle: a case report and review of filter migration and misdeployment	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6974	Duffett L, Carrier M. Inferior vena cava filters. J Thromb Haemost. 2017 Jan;15(1):3-12. doi: 10.1111/jth.13564. Epub 2016 Dec 26.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6975	Duffett LD, Gándara E, Cheung A, Bose G, Forster AJ, Wells PS. Outcomes of patients requiring insertion of an inferior vena cava filter: a retrospective observational study. Blood Coagul Fibrinolysis, 2014. 25(3): 266-71.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6976	Duggirala HJ, Herz ND, Caños DA, Sullivan RA, Schaaf R, Pinnow E, Marinac-Dabic D. Disproportionality analysis for signal detection of implantable cardioverter-defibrillator-related adverse events in the Food and Drug Administration Medical Device Reporting System. Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):87-93. doi: 10.1002/pds.2261. Epub 2011 Nov 18.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6977	Duperier, Acute Complications Associated with Greenfield Filter Insertion in High-Risk Trauma Patients	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6978	Durack JC, Westphalen AC, Kekulawela S, Bhanu SB, Avrin DE, Gordon RL, Kerlan RK. Perforation of the IVC, Rule Rather Than Exception, After Longer Indwelling Times for the Gunther Tulip and Celect Retrievable Filters. Cardiovasc Intervent Radiol. 2012 Apr;35(2):299-308. doi: 10.1007/s00270-011-0151-9. Epub 2011 Mar 30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6979	Duszak Jr R, Parker L, Levin DC, Rao VM. Placement and removal of inferior vena cava filters: national trends in the Medicare population. Am Coll Radiol 2011; 8 (7) 483-489.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6980	Eifler AC, Lewandowski RJ, Gupta R, Karp J, Salem R, Lee J, Ryu RK. Optional or Permanent: Clinical Factors that Optimize Inferior Vena Cava Filter Utilization. J Vasc Interv Radiol. 2013 Jan;24(1):35-40. doi: 10.1016/j.jvir.2012.09.021. Epub 2012 Nov 22.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6981	EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6982	EINSTEIN-PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6983	Emamina A, Fedoruk LM, Hagspiel KD, Bozlar U, Kron IL. Inferior vena cava filter migration to the heart. Ann Thorac Surg. 2008 Nov;86(5):1664-5. doi: 10.1016/j.athoracsur.2008.04.063.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6984	Engmann E, Asch MR. Clinical experience with the antecubital Simon nitinol IVC filter. J Vasc Interv Radiol. 1998 Sep-Oct;9(5):774-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6985	Eriksson, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6986	Errea M, Lewandowski R, Salem R, Karp J, Desai K. Device-specific adverse event rates in retrievable inferior vena cava filters: a systematic review and meta-analysis. Abstract 205. J VIR Scientific Session, March 7, 2017, S90-S91.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6987	Esparez, Fibrin Cap Disruption: An Adjunctive Technique for Inferior Vena Cava Filter Retrieval	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6988	Ezekowitz, Comparison of Dabigatran and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6989	Falck-Ytter, Prevention of VTE in orthopedic surgery patients	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6990	Fan, K., et al., High-Performance Signal Detection for Adverse Drug Events using MapReduce Paradigm. AMIA Annu Symp Proc, 2010. 2010: 902-6	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6991	FDA Safety - Inferior Vena Cava (IVC) Filters: Initial Communication: Risk of Adverse Events with Long Term Use, 08/09/2010.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6992	FDA Safety Communications, Removing Retrievable Inferior Vena Cava Filters. 05/06/2014. http://wayback.archive-it.org/7993/20170722215731/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm396377.htm	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6993	FDA Safety Communications, Removing Retrievable Inferior Vena Cava Filters: Initial Communication. 08/09/2010. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm221676.htm	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6994	FDA, Device Post Market Surveillance. http://www.fda.gov/MedicalDevices/Safety/CDRHPostmarketSurveillance/default.htm Accessed on January 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6995	FDA, MAUDE: Manufacturer and user facility device experience. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6996	FDA, National Evaluation System for health Technology. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm301912.htm Accessed on January 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6997	Fedullo PF, Roberts A. Placement of vena cava filters and their complications. UpToDate 2017. https://www.uptodate.com/contents/placement-of-vena-cava-filters-and-their-complications	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6998	Feezor RJ, Huber TS, Welborn MB 3rd, Schell SR. Duodenal perforation with an inferior vena cava filter- an unusual cause of abdominal pain. J Vasc Surg. 2002 May;35(5):1010-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6999	Feigal DW, Gardner SN, McClellan M. Ensuring Safe and Effective Medical Devices. N Engl J Med. 2003 Jan 16;348(3):191-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7000	Ferguson EJ, Lurie F, Brown M. Low Retrieval Rates of Temporary Inferior Vena Cava Filters in Trauma Patients. Am Surg. 2015 Apr;81(4):428-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7001	Ferreiro C, Abad-Cervero JF, Lopez-Pino MA. Fracture and migration of an Antheor vena cava filter. J Vasc Interv Radiol. 1996 Jan-Feb;7(1):149-50.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7002	Ferris EJ, McCowan TC, Carver DK, McFarland DR. Percutaneous inferior vena caval filters: follow-up of seven designs in 320 patients. Radiology. 1993 Sep;188(3):851-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7003	Fotiadis NI, Sabharwal T, Dourado R, Fikrat S, Adam A. Technical error during deployment leads to vena cava filter migration and massive pulmonary embolism. Cardiovasc Intervent Radiol. 2008 Jul;31 Suppl 2:S174-6. Epub 2007 Aug 29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7004	Frezza EE, Wachtel MS. A Simple Venous Thromboembolism Prophylaxis Protocol for Patients Undergoing Bariatric Surgery. Obesity (Silver Spring). 2006 Nov;14(11):1961-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7005	Friedell ML, Goldenkranz RJ, Parsonnet V, Alpert J, Brief DK, Brener BJ, Auerson FM. Migration of a Greenfield filter to the pulmonary artery: a case report. J Vasc Surg. 1986 Jun;3(6):929-31.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7006	Friese J, Leake B, Fleming CJ, Woodrum, DA, Bjarnason H, Misra S, McKusick MA, McPhail I, Stockland A. Increased in-hospital mortality in patients with pe/DVT and IVC filter. Abstract No. 53. JVIR Scientific Session, S26	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7007	Frisbie JH, Sharma GV, Brahma P, Hess MJ, Hayes JA. Recurrent Pulmonary Embolism and Pulmonary Hypertension in Chronic Tetraplegia. Spinal Cord. 2005 Oct;43(10):625-30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7008	Frisbie JH, Sharma GV. The Prevalence of Pulmonary Embolism in Chronically Paralyzed Subjects: A Review of Available Evidence. Spinal Cord. 2012 Jun;50(6):400-3. doi: 10.1038/sc.2011.154. Epub 2011 Dec 13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7009	Funaki B, Funaki C. Embolization of High Flow Arteriovenous Malformation. Semin Intervent Radiol. 2016 Jun;33(2):157-60. doi: 10.1055/s-0036-1582125.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7010	Funaki, B. Filter migration to right heart. Semin Intervent Radiol. 2007 Sep;24(3):356-60. doi: 10.1055/s-2007-985751.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7011	Furtado CD, Aguirre DA, Sirlin CB, et al. Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. Radiology 2005; 237(2):385-94.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7012	Galanaud JP, Laroche JP, Righini M. The history and historical treatments of deep vein thrombosis. J Thromb Haemost. 2013 Mar;11(3):402-11. doi: 10.1111/jth.12127.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7013	Galhotra S, Amesur NB, Zajko AB, Simmons RL. Migration of the Gunther Tulip inferior vena cava filter to the chest. J Vasc Interv Radiol. 2007 Dec;18(12):1581-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7014	Gargiulo NJ 3rd, O'Connor DJ, Veith FJ, Lipsitz EC, Vemulapalli P, Gibbs K, Suggs WD. Long-Term Outcome of Inferior Vena Cava Filter Placement in Patients Undergoing Gastric Bypass. Ann Vasc Surg. 2010 Oct;24(7):946-9. doi: 10.1016/j.avsg.2010.05.004.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7015	Gargiulo NJ 3rd, Veith FJ, Lipsitz EC, Suggs WD, Ohki T, Goodman E. Experience with inferior vena cava filter placement in patients undergoing open gastric bypass procedures. J Vasc Surg. 2006 Dec;44(6):1301-5. Epub 2006 Oct 20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7016	Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filters Are Rarely Removed. Am Surg. 2009 May;75(5):426-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7017	Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:34S-8S.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7018	Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospective Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7019	Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7020	Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7021	Gelzins, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth. 2009. 23(3): 381-3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7022	Ghanim A.J., Daskalakis C., Eschelman D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7023	Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the "One-Filter-for-All" Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7024	Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7025	Giroux M-F. Ask the experts: what is your practice's current IVC filter retrieval protocol, and in which cases do you deviate from it? Endovascular Today October 2015, pp. 53-58.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7026	Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7027	Godat LN, Kobayashi L, Chang D, Coimbra R: Can We Ever Stop Worrying About Venous Thromboembolism After Trauma? <i>Trauma</i> 2015; 78: 475-481.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7028	Goei AD, Josephs SC, Kinney TB, Ray CE Jr, Sacks D. Improving the tracking and removal of retrievable inferior vena cava filters. Semin Intervent Radiol. 2011 Mar;28(1):118-27. doi: 10.1055/s-0031-1273946.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7029	Goldhaber SZ, et al: A prospective study of risk factors for pulmonary embolism in women. JAMA 277:642-645. 1997.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7030	Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2014 Oct;134(4):774-82. doi: 10.1016/j.thromres.2014.06.020. Epub 2014 Jul 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7031	Gosin JS, Graham AM, Ciocca RG, Hammond JS. Efficacy of Prophylactic Vena Cava Filters in High-Risk Trauma Patients. Ann Vasc Surg. 1997 Jan;11(1):100-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7032	Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JL, Heit JA, Samama CM. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e227S-e277S. doi: 10.1378/chest.11-2297.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7033	Grande WJ, Trerotola SO, Reilly PM. et al. Experience with the Recovery Filter as a Retrievable Inferior Vena Cava Filter. J Vasc Interv Radiol. 2005;16:1189 – 1193.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7034	Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Ghera BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7035	Granke K, Abraham FM, McDowell DE. Vena cava filter disruption and central migration due to accidental guidewire manipulation: a case report. Ann Vasc Surg. 1996 Jan;10(1):49-53.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7036	Grassi CJ, Goldhaber SZ. Interruption of the inferior vena cava for prevention of pulmonary embolism: transvenous filter devices. Herz. 1989 Jun;14(3):182-91.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7037	Grassi CJ, Matsumoto AH, Teitelbaum GP. Vena Caval Occlusion after Simon Nitinol Filter Placement: Identification with MR Imaging in Patients with Malignancy. J Vasc Interv Radiol. 1992 Aug;3(3):535-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7038	Grassi CJ, Swan TL, Cardella JF, Meranze SG, Oglevie SB, Omary RA, Roberts AC, Sacks D, Silverstein MI, Towbin RB, Lewis CA. Quality improvement guidelines for percutaneous permanent inferior vena cava filter placement for the prevention of pulmonary embolism. J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S271-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7039	Grassi CJ. Inferior Vena Caval Filters Analysis of Five Currently Available Devices. AJR Am J Roentgenol. 1991 Apr;156(4):813-21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7040	Greenfield LJ, Cho KJ, Proctor M, Bonn J, Bookstein JJ, Castaneda-Zuniga WR, Cutler B, Ferris EJ, Keller F, McCowan T, et al. Results of a multicenter study of the modified hook titanium Greenfield filter. J Vasc Surg. 1991 Sep;14(3):253-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7041	Greenfield LJ, Cho KJ, Tauscher JR. Evolution of Hook Design for Fixation of the Titanium Greenfield Filter. J Vasc Surg. 1990 Sep;12(3):345-53.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7042	Greenfield LJ, Proctor MC, Cho KJ, Cutler BS, Ferris EJ, McFarland D, Sobel M, Tisnado J. Extended Evaluation of the Titanium Greenfield Vena Caval Filter. J Vasc Surg. 1994 Sep;20(3):458-64; discussion 464-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7043	Greenfield LJ, Proctor MC. The Percutaneous Greenfield Filter- Outcomes and Practice Patterns. J Vasc Surg. 2000 Nov;32(5):888-93.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7044	Greenfield LJ, Proctor MC. Twenty Year Clinical Experience with Greenfield Filter. 1995; Cardiovasc. Surg. 3:199-205.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7045	Greenfield LJ, Zocco J, Wilk J, Schroeder TM, Elkins RC. Clinical experience with the Kim-Ray Greenfield vena caval filter. Ann Surg. 1977 Jun;185(6):692-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7046	Greenfield LJ. Historical Reminiscence: Origin of the Greenfield Filter. Am Surg. 2010 Dec;76(12):1319-20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7047	Groom H, Hopkins DP, Pabst LJ, Murphy Morgan J, Patel M, Calonge N, Coyle R, Dombkowski K, Groom AV, Kurilo MB, Rasulnia B, Shefer A, Town C, Wortley PM, Zucker J; Community Preventive Services Task Force. Immunization Information Systems to Increase Vaccination Rates – A Community Guide Systematic Review. J Public Health Manag Pract. 2015 May-Jun;21(3):227-48. doi: 10.1097/PHH.0000000000000069.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7048	Guidance for the Industry - Good Pharmacovigilance Practices and Pharmacoeconomic assessment, March 2005 https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071696.pdf	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7049	Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb. 141 (2 Suppl):7S-47S.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7050	Guyatt GH, et al: Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: antithrombotic therapy and prevention of thrombosis, 9th Ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (Suppl):3185S-3194S, 2012.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7051	Haddadian, B., et al., Sudden cardiac death caused by migration of a TrapEase inferior vena cava filter: case report and review of the literature. Clin Cardiol. 2008. 31(2): 84-7	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7052	Hahn D. Retrievable Filter Update: The Denali Vena Cava Filter Semin Intervent Radiol. 2015;32(4): 379–383.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7053	Halkett GK, Jiwa M, Lobb EA. Patients' Perspectives on the Role of Their General Practitioner After Receiving an Advanced Cancer Diagnosis. Eur J Cancer Care (Engl). 2015 Sep;24(5):662-72. doi: 10.1111/ecc.12224. Epub 2014 Aug 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7054	Halmi, Preoperative placement of retrievable inferior vena cava filters in bariatric surgery	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7055	Hammond, Audit of the use of IVC filters in the UK: experience from three centres over 12 years	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7056	Harries SR, Wells IP, Roobottom CA. Long-term follow-up of the antheor inferior vena cava filter. Clin Radiol. 1998 May;53(5):350-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7057	Hauben, M., Signal detection in the pharmaceutical industry: integrating clinical and computational approaches. Drug Saf. 2007. 30(7): 627-30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7058	Haut ER, Garcia LJ, Shihab HM, Brotman DJ, Stevens KA, Sharma R, Chelladurai Y, Akande TO, Shermock KM, Kebede S, Segal JB, Singh S. The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis. JAMA Surg. 2014 Feb;149(2):194-202. doi: 10.1001/jamasurg.2013.3970.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7059	Headrick JR Jr, Barker DE, Pate LM, Horne K, Russell WL, Burns RP. The Role of Ultrasonography and Inferior Vena Cava Filter Placement in High-Risk Trauma Patients. Am Surg. 1997 Jan;63(1):1-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7060	Health Canada, Inferior Vena Cava Filters - Risk of Serious Complications	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7061	Heit JA, et al: The epidemiology of venous thromboembolism in the community. Thrombi Haemost 86:452-463, 2001.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7062	Helling TS, Kaswan S, Miller SL. Practice patterns in the use of retrievable inferior vena cava filters in a trauma population: A single-center experience. J Trauma 2009; 67:1293-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7063	Hemmila MR, Osborne NH, Henke PK, Kepros JP, Patel SG, Cain-Nielsen AH, Birkmeyer NJ. Prophylactic Inferior Vena Cava Filter Placement Does Not Result in a Survival Benefit for Trauma Patients. Ann Surg. 2015 Oct;262(4):577-85. doi: 10.1097/SLA.0000000000001434.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7064	Ho KM, Tan JA, Burrell M, Rao S, Misur P. Venous Thrombotic, Thromboembolic, and Mechanical Complications After Retrievable Inferior Vena Cava Filters for Major Trauma. Br J Anaesth. 2015 Jan;114(1):63-9. doi: 10.1093/bja/aeu195. Epub 2014 Jun 30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7065	Hoff WS, Hoey BA, Wainwright GA, Reed JF, Ball DS, Ringold M, Grossman MD. Early Experience with Retrievable Inferior Vena Cava Filters in High-Risk Trauma Patients. J Am Coll Surg. 2004 Dec;199(6):869-74.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7066	Hoffer, E.K., et al., Safety and efficacy of the Gunther Tulip retrievable vena cava filter: midterm outcomes. Cardiovasc Intervent Radiol. 2013. 36(4): 998-1005	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7067	Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwöcho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7068	Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):652-60. doi: 10.1161/CIRCOUTCOMES.110.957712. Epub 2010 Oct 5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7069	Hull JE, Han J, Giessel GM. Retrieval of the recovery filter after arm perforation, fracture, and migration to the right ventricle. J Vasc Interv Radiol. 2008 Jul;19(7):1107-11. doi: 10.1016/j.jvir.2008.03.011. Epub 2008 May 2. Review.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7070	Hull JE, Robertson SW. Bard Recovery filter: evaluation and management of vena cava limb perforation, fracture, and migration. J Vasc Interv Radiol. 2009 Jan;20(1):52-60. doi: 10.1016/j.jvir.2008.09.032. Epub 2008 Nov 21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7071	Iliescu B, Haskal ZJ. Advanced Techniques for Removal of Retrievable Inferior Vena Cava Filters. Cardiovasc Intervent Radiol. 2012 Aug;35(4):741-50. doi: 10.1007/s00270-011-0205-z. Epub 2011 Jun 15.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7072	Image Wisely. http://www.imagewisely.org Accessed on February 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7073	IMS Health. IMS Health Hospital Supply Index. Available from: http://www.imshealth.com/deployedfiles/imshealth/Global/North%20America/United%20States/Medical Device US/IMS Hospital Supply Index.pdf .	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7074	Inuzuka, K., et al., Hemorrhagic shock with delayed retroperitoneal hemorrhage after deployment of an inferior vena cava filter: report of a case. Surg Today, 2007. 37(7): 618-21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7075	Irwin E, Byrnes M, Schultz S, et al. A systematic method for follow-up improves removal rates for retrievable inferior vena cava filters in a trauma patient population. J Trauma 2010; 69:866-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7076	Izutani, H., et al., Migration of an inferior vena cava filter to the right ventricle and literature review. Can J Cardiol. 2004. 20(2): 233-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7077	Jaff M.R., McMurtry M.S., Archer S.L., Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123:1788-1830.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7078	Jaff MR, Kaufman J. A measured approach to vena cava filter use – respect rather than regret. JAMA Cardiol. 2017; 2(1):5-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7079	James KV, Sobolewski AP, Lohr JM, Welling RE. Tricuspid insufficiency after intracardiac migration of a Greenfield filter: case report and review of the literature. J Vasc Surg. 1996 Sep;24(3):494-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7080	Jassar AS, Nicotera SP, Levin N, Vernick WJ, Szeto WY. Inferior vena cava filter migration to the right ventricle. J Card Surg. 2011 Mar;26(2):170-2. doi: 10.1111/j.1540-8191.2010.01194.x. Epub 2011 Feb 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7081	Jia Z, Fuller TA, McKinney JM, Paz-Fumagalli R, Frey GT, Sella DM, Van Ha T, Wang W. Utility of Retrievable Inferior Vena Cava Filters: A Systematic Literature Review and Analysis of the Reasons for Nonretrieval of Filters with Temporary Indications. Cardiovasc Intervent Radiol. 2018 Jan 22. doi: 10.1007/s00270-018-1880-9. [Epub ahead of print].	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7082	Jia Z, Wu A, Tam M et al. Caval Penetration by Inferior Vena Cava Filters: A Systematic Literature Review of Clinical Significance and Management. Circulation. 2015;132:944-52.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7083	Joels CS, Sing RF, Heniford BT. Complications of Inferior Vena Cava Filters. Am Surg. 2003 Aug;69(8):654-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7084	Johnson MS. Vena cava filter fracture: unplanned obsolescence. J Vasc Interv Radiol. 2012 Feb;23(2):196-8. doi: 10.1016/j.jvir.2011.12.004.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7085	Jones T, Ugalde V, Franks P, Zhou H, White RH. Venous Thromboembolism After Spinal Cord Injury: Incidence, Time Course, and Associated Risk Factors in 16,240 Adults and Children. Arch Phys Med Rehabil. 2005 Dec;86(12):2240-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7086	Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-e226S. doi: 10.1378/chest.11-2296.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7087	Kakkar V.V., Howe C.T., Flanc C., Clarke M.B.; Natural history of postoperative deep-vein thrombosis. Lancet. 1969;2:230-232.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7088	Kalva SP, Athanasoulis CA, Fan CM, Curvelo M, Geller SC, Greenfield AJ, Waltman AC, Wisky S. Recovery Vena Cava Filter: Experience in 96 Patients. Cardiovasc Intervent Radiol (2006) 29:559-564.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7089	Kalva SP, Chlapoutaki C, Wicky S, Greenfield AJ, Waltman AC, Athanasoulis CA. Suprarenal Inferior Vena Cava Filters: A 20 Year Single Center Experience. J Vasc Interv Radiol. 2008 Jul;19(7):1041-7. doi: 10.1016/j.jvir.2008.03.026. Epub 2008 May 27.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7090	Kamath SD, McMahon BJ. Update on Anticoagulation: What the Interventional Radiologist Needs to Know. Semin Intervent Radiol. 2016 Jun;33(2):122-31. doi: 10.1055/s-0036-1582124.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7091	Kardys CM, Stoner MC, Manwaring ML, Barker M, Macdonald KG, Pender JR, Chapman WH 3rd. Safety and efficacy of intravascular ultrasound-guided inferior vena cava filter in super obese bariatric patients. Surg Obes Relat Dis. 2008 Jan-Feb;4(1):50-4. Epub 2007 Dec 11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7092	Kardys CM, Stoner MC, Manwaring ML, Bogey WM, Parker FM, Powell S. The Use of Intravascular Ultrasound Imaging to Improve Use of Inferior Vena Cava Filters in a High-Risk Bariatric Population. J Vasc Surg. 2007 Dec;46(6):1248-52. Epub 2007 Oct 24.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7093	Karmy-Jones R, Jirkovich GJ, Velmahos GC, Burdick T, Spaniolas K, Todd SR, McNally M, Jacoby RC, Link D, Janczyk RJ, Ivascu FA, McCann M, Obeid F, Hoff WS, McQuay N Jr, Tieu BH, Schreiber MA, Nirula R, Brasel K, Dunn JA, Gambrell D, Huckfeldt R, Harper J, Schaffer KB, Tominaga GT, Vines FY, Sperling D, Hoyt D, Coimbra R, Rosengart MR, Forsythe R, Cothren C, Moore EE, Haut ER, Hayanga AJ, Hird L, White C, Grossman J, Nagy K, Livaudais W, Wood R, Zengerink I, Kortbeek JB. Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. J Trauma. 2007 Jan;62(1):17-24; discussion 24-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7094	Karp JK, Desai KR, Salem R, et al. A dedicated inferior vena cava filter service line: how to optimize your practice. Semin Intervent Radiol 2016; 33:105-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7095	Katsamouris AA, Waltman AC, Delichatsios MA, Athanasoulis CA. Inferior vena cava filters: in vitro comparison of clot trapping and flow dynamics. Radiology. 1988 Feb;166(2):361-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7096	Kaufman JA, Kinney TB, Streiff MB, Sing RF, Proctor MC, Becker D, Cipolle M, Comerota AJ, Millward SF, Rogers FB, Sacks D, Venbrux AC. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol. 2006 Mar;17(3):449-59.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7097	Kaufman JA, Rundback JH, Kee ST, Geerts W, Gillespie D, Kahn SR, Kearon C, Rectenwald J, Rogers FB, Stavropoulos SW, Streiff M, Vedantham S, Venbrux A. Development of a Research Agenda for Inferior Vena Cava Filters: Proceedings from a Multidisciplinary Research Consensus Panel. J Vasc Interv Radiol. 2009 Jun;20(6):697-707. doi: 10.1016/j.jvir.2009.03.007.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7098	Kaufman JA. Optional Vena Cava Filters: What, Why, and When. Vascular. 2007 Sep-Oct;15(5):304-13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7099	Kazmers A, Jacobs LA, Perkins AJ. Pulmonary embolism in Veterans Affairs Medical Centers: is vena cava interruption underutilized? Am Surg. 1999; 65:1171-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7100	Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JR, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-52.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7101	Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic Therapy for Venous Thromboembolism Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):454S-545S. doi: 10.1378/chest.08-0658.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7102	Kearon C., Akl E.A., Comerota A.J., American College of Chest Physicians Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141 :e419S-e494S.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7103	Keeling WB, Haines K, Stone PA, Armstrong PA, Murr MM, Shames ML. Current Indications for Preoperative Inferior Vena Cava Filter Insertion in Patients Undergoing Surgery for Morbid Obesity. Obes Surg. 2005 Aug;15(7):1009-12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7104	Keller EJ, Vogelzang RL. Providing Context: Medical Device Litigation and Inferior Vena Cava Filters. Semin Intervent Radiol. 2016 Jun;33(2):132-6. doi: 10.1055/s-0036-1581086.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7105	Khansarinia S, Dennis JW, Veldenz HC, Butcher JL, Hartland L. Prophylactic Greenfield Filter Placement in Selected High-Risk Trauma Patients. J Vasc Surg. 1995 Sep;22(3):231-5; discussion 235-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7106	Kiefer RM, Pandey N, Trerotola SO, Nadolski GJ, Stavropoulos SW. The Value of Rotational Venography Versus Antero Posterior Venography in 100 Consecutive IVC Filter Retrievals. Cardiovasc Interv Radiol. 2016 Mar;39(3):394-9. doi: 10.1007/s00270-015-1183-3. Epub 2015 Jul 29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7107	Kiguchi MM, Dillavou ED. IVC filters: challenges and future directions. Adv Vasc Med 2014; 2014:1-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7108	Kim H, Sarg I, Jang JH. Outcomes of Retrievable Inferior Vena Cava Filters in Patients with Deep Vein Thrombosis and Transient Contraindication for Anticoagulation. 2015; Ann. Of Surgical Treatment and Research; 89(1):30-36.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7109	Kim, H.S., et al., A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters. J Vasc Interv Radiol. 2008. 19(3): 393-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7110	Kinney TB, Rose SC, Valji K, Oglevie SB, Roberts AC. Does Cervical Spinal Cord Injury Induce a Higher Incidence of Complications after prophylactic Greenfield inferior vena cava filter usage? J Vasc Interv Radiol. 1996 Nov-Dec;7(6):907-15.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7111	Kinney TB. Primum non nocere. J Vasc Interv Radiol. 2012 Dec;23(12):1564-5. doi: 10.1016/j.jvir.2012.10.003.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7112	Kinney TB. Update on inferior vena cava filters. J Vasc Interv Radiol. 2003 Apr;14(4):425-40.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7113	Kitchens CS, Konkle BA and Kessler CM. Consultative Hemostasis and Thrombosis, 3rd Edition.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7114	Knudson MM, Ikossi DG. Thromboembolism After Trauma. Curr Opin Crit Care. 2004 Dec;10(6):539-48.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7115	Ko SH, Reynolds BR, Nicholas DH, et al. Institutional protocol improves retrievable inferior vena cava filter recovery rate. Surgery 2009; 146:809-16.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7116	KrauthD et al: Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer 59:983-985, 1987.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7117	Kuo W, Robertson S. Bard Denali Inferior Vena Cava Filter Fracture and Embolization Resulting in Cardiac Tamponade: A Device Failure Analysis. J Vasc Interv Radiol. 2015 Jan;26(1):111-5.e1. doi: 10.1016/j.jvir.2014.08.001.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7118	Kuo WT, Cupp JS, Louie JD, Sze DY, Kothary N, Hwang GL, Hofmann L. Retrieval of permanently-embedded IVC filters and description of the laser-assisted sheath technique: Radiographic-histopathologic correlation (Abstract No. 4). Journal of Vascular and Interventional Radiology, Feb. 2010, Volume 21, Issue 2, Suppl., Page S4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7119	Kuo WT, Cupp JS. The Excimer Laser Sheath Technique for Embedded Inferior Vena Cava Filter Removal. J Vasc Interv Radiol. 2010 Dec;21(12):1896-9. doi: 10.1016/j.jvir.2010.08.013. Epub 2010 Nov 3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7120	Kuo WT, Odegaard JI, Rosenberg JK, Hofmann LV. Laser Assisted Removal of Embedded Vena Cava Filters: A 5 Year First in Human Study. Chest. 2017 Feb;151(2):417-424. doi: 10.1016/j.chest.2016.09.029. Epub 2016 Oct 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7121	Kuo WT, Robertson SW, Odegaard JI, Hofmann LV. Complex retrieval of fractured, embedded, and penetrating inferior vena cava filters: a prospective study with histologic and electron microscopic analysis. J Vasc Interv Radiol. 2013 May;24(5):622-630.e1; quiz 631. doi: 10.1016/j.jvir.2013.01.008. Epub 2013 Mar 21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7122	Kuo WT, Tong RT, Hwang GL, Louie JD, Lebowitz EA, Sze DY, Hofmann LV. High-risk retrieval of adherent and chronically implanted IVC filters: techniques for removal and management of thrombotic complications. J Vasc Interv Radiol. 2009 Dec;20(12):1548-56. doi: 10.1016/j.jvir.2009.08.024. Epub 2009 Oct 27.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7123	Kuo, W.T. and Robertson, S.W. Bard Denali inferior vena cava filter fracture and embolization resulting in cardiac tamponade: a device failure analysis. J Vasc Interv Radiol. 2015; 26: 111–115.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7124	Kuo, W.T., C.T. Loh and D.Y. Sze, Emergency retrieval of a G2 filter after complete migration into the right ventricle. J Vasc Interv Radiol, 2007. 18(9): 1177-82.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7125	Kuy S, Dua A, Lee CJ, Patel B, Desai SS, Dua A, Szabo A, Patel PJ. National Trends in Utilization of Inferior Vena Cava Filters in the United States, 2000-2009. J Vasc Surg Venous Lymphat Disord. 2014 Jan;2(1):15-20. doi: 10.1016/j.jvsv.2013.08.007. Epub 2013 Dec 12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7126	Laborda A, Sierre S, Malvè M, De Blas I, Ioakeim I, Kuo WT, De Gregorio MA. Influence of Breathing Movements and Valsalva Maneuver on Vena Caval Dynamics. World J Radiol. 2014 Oct 28;6(10):833-9. doi: 10.4329/wjr.v6.i10.833.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7127	Lampert R. Managing with Pacemakers and Implantable Cardioverter Defibrillators. Circulation. 2013 Oct 1;128(14):1576-85. doi: 10.1161/CIRCULATIONAHA.113.001555.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7128	Lang W, Schweiger H, Hofmann-Preiss K. Results of Long-Term Venacavography Study After Placement of a Greenfield Vena Caval Filter. J Cardiovasc Surg (Torino). 1992 Sep-Oct;33(5):573-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7129	Langan EM 3rd, Miller RS, Casey WJ 3rd, Carsten CG 3rd, Graham RM, Taylor SM. Prophylactic Inferior Vena Cava Filters in Trauma Patients at High Risk: Follow-up Examination and Risk/Benefit Assessment. J Vasc Surg. 1999 Sep;30(3):484-88.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7130	Laplante JS, Contractor FM, Kiproff PM, Khoury MB. Migration of the Simon nitinol vena cava filter to the chest. AJR Am J Roentgenol 1993; 160(2):385-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7131	Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa1006885.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7132	Lavan O, Rimón U, Simon D, et al: The use of optional inferior vena cava filters of type Optease in trauma patients — a single type of filter in a single medical center. 2015 Thromb. Res. 135:873-876.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7133	Laws JL, Lewandowski RJ, Ryu RK, Desai KR. Retrieval of Inferior Vena Cava Filters: Technical Considerations. Semin Intervent Radiol. 2016 Jun;33(2):144-8. doi: 10.1055/s-0036-1582119.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7134	Leach TA, Pastena JA, Swan KG, Tikellis JJ, Blackwood JM, Odom JW. Surgical Prophylaxis for Pulmonary Embolism. Am Surg. 1994 Apr;60(4):292-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7135	Leask RL, Johnston KW, Ojha M. In Vitro Hemodynamic Evaluation of a Simon Nitinol Vena Cava Filter: Possible Explanation of IVC Occlusion. J Vasc Interv Radiol. 2001 May;12(5):613-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7136	Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul 10;349(2):146-53.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7137	Lee MJ, Valenti D, deGregorio MA, et al. The CIRSE retrievable IVC filter registry: retrieval success rates in practice. Cardiovasc Intervent Radiol 2015; 38:1502-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7138	Leeper WR, Murphy PB, Vogt KN, et al: Are Retrievable Vena Cava Filters Placed in Trauma Patients Really Retrievable. Eur. J. Trauma Emergency Surg. 2016; 42:459-464.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7139	LeFevre ML; U.S. Preventive Services Task Force. Screening for Abdominal Aortic Aneurysm – US Preventative Services Task Force Recommendation Statement. <i>Ann Intern Med.</i> 2014 Aug 19;161(4):281-90. doi: 10.7326/M14-1204.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7140	Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. <i>Circulation.</i> 2004 Aug 17;110(7):874-9. Epub 2004 Aug 2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7141	Lessne ML, Sing RF. Counterpoint: Do the Benefits Outweigh the Risks for Most Patients Under Consideration for Inferior Vena Cava Filters? <i>No. Chest.</i> 2016 Dec;150(6):1182-1184. doi: 10.1016/j.chest.2016.08.1477. Epub 2016 Oct 20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7142	Lewandowski, R.J., et al., Abstract No. 54: A prospective study of 467 IVC filter placements: is there a difference between optional and permanent filters? <i>J Vasc Interv Radiol.</i> 2012. 23(3): S25	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7143	Li W, Gorecki P, Semaan E, Briggs W, Tortolani AJ, D'Ayala M. Concurrent prophylactic placement of inferior vena cava filter in gastric bypass and adjustable banding operations in the Bariatric Outcomes Longitudinal Database. <i>J Vasc Surg.</i> 2012 Jun;55(6):1690-5. doi: 10.1016/j.jvs.2011.12.056. Epub 2012 Feb 22.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7144	Li W, Gorecki P, Semaan E, Briggs W, Tortolani AJ, D'Ayala M. Concurrent prophylactic placement of inferior vena cava filter in gastric bypass and adjustable banding operations in the Bariatric Outcomes Longitudinal Database. <i>J Vasc Surg.</i> 2012 Jun;55(6):1690-5. doi: 10.1016/j.jvs.2011.12.056. Epub 2012 Feb 22.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7145	Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012 Feb;141(2 Suppl):e495S-e530S. doi: 10.1378/chest.11-2303. Review. Erratum in: <i>Chest.</i> 2015 Dec;148(6):1529.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7146	Lloyd GL, Singh MJ, Messing EM. An Unusual Cause of an Enhancing Retroperitoneal Mass. <i>Urology.</i> 2012 Apr;79(4):e61-2. doi: 10.1016/j.urology.2011.06.042. Epub 2011 Sep 25.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7147	Lynch FC, Kekulawela S. Removal of the G2 Filter: Differences between Implantation Times Greater and Less than 180 Days. <i>J Vasc Interv Radiol.</i> 2009 Sep;20(9):1200-9. doi: 10.1016/j.jvir.2009.05.039. Epub 2009 Jul 29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7148	Lynch FC. A method for following patients with retrievable inferior vena cava filters: results and lessons learned from the first 1,100 patients. <i>J Vasc Interv Radiol</i> 2011; 22:1507-12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7149	Lynch FC. Balloon-assisted Removal of Tilted Inferior Vena Cava Filters with Embedded Tips. <i>J Vasc Interv Radiol.</i> 2009; 20: 1210-1214.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7150	Lyon SM, Riojas GE, Ueroi R, Patel J, Lipp ME, Plant GR, De Gregorio MA, Günther RW, Voorhees WD, McCann-Brown JA. Short- and Long-term Retrievability of the Celect Vena Cava Filter: Results from a Multi-institutional Registry. <i>J Vasc Interv Radiol.</i> 2009 Nov;20(11):1441-8. doi: 10.1016/j.jvir.2009.07.038.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7151	Majdalany BS, Khaja MS, Williams DM. Bard Denali filter fractures. <i>J Vasc Interv Radiol.</i> 2016; 27: 1099–1101.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7152	Malgor RD, Hines GL, Terrana L, Labropoulos N. Persistent Abdominal Pain Caused by an Inferior Vena Cava Filter Protruding into the Duodenum and the Aortic Wall. <i>Ann Vasc Surg.</i> 2012 Aug;26(6):858.e3-6. doi: 10.1016/j.avsg.2011.11.038. Epub 2012 May 23.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7153	Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA. Collaborative Modeling of the Benefits and Harms Associated with Different US Breast Cancer Screening Strategies. <i>Ann Intern Med</i> . 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536. Epub 2016 Jan 12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7154	MAUDE Manufacturer and User Facility Device Experience. U.S. Food & Drug Administration. Accessible via: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm . Accessed April 4, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7155	Maxwell RA, Chavarria-Aguilar M, Cockerham WT, Lewis PL, Barker DE, Durham RM, Ciraulo DL, Richart CM. Routine Prophylactic Vena Cava Filtration Is Not Indicated after Acute Spinal Cord Injury. <i>J Trauma</i> . 2002 May;52(5):902-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7156	McCowan TC, Ferris EJ, Carver DK, Molpus WM. Complications of the nitinol vena caval filter. <i>J Vasc Interv Radiol</i> . 1992 May;3(2):401-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7157	McKenney K, Boneva D, Deeter M, Barquist E, Ang D, Kaye M. Trauma Admission CT as a Road Map for IVC Filters. <i>Int Surg</i> . 2014 Nov-Dec;99(6):734-8. doi: 10.9738/INTSURG-D-13-00192.1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7158	McLoney ED, Krishnasamy VP, Castle JC, Yang X, Guy G. Complications of Elect, Günther tulip, and Greenfield inferior vena cava filters on CT follow-up: a single-institution experience. <i>J Vasc Interv Radiol</i> . 2013 Nov;24(11):1723-9. doi: 10.1016/j.jvir.2013.07.023. Epub 2013 Sep 13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7159	McMurry AL, Owings JT, Anderson JT, Battistella FD, Gosselin R. Increased Use of Prophylactic Vena Cava Filters in Trauma Patients Failed to Decrease Overall Incidence of Pulmonary Embolism. <i>J Am Coll Surg</i> . 1999 Sep;189(3):314-20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7160	Mehanni, S., M. Higley and R.C. Schenning. Expectoration of an inferior vena cava filter strut. <i>BMJ Case Rep</i> . 2016. 2016.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7161	Melinek J, Livingston E, Cortina G, Fishbein MC. Autopsy Findings Following Gastric Bypass Surgery for Morbid Obesity. <i>Arch Pathol Lab Med</i> . 2002 Sep;126(9):1091-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7162	Meyer A, Schönleben F, Heinz M, Lang W. Perforated Inferior Vena Cava Filters as the Cause of Unclear Abdominal Pain. <i>Ann Vasc Surg</i> . 2013 Apr;27(3):354.e9-354.e12. doi: 10.1016/j.avsg.2012.08.006.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7163	Michetti CP, Franco E, Coleman J, Bradford A, Trickey AW. Deep Vein Thrombosis Screening and Risk Factors in a High-Risk Trauma Population. <i>J Surg Res</i> . 2015 Dec;199(2):545-51. doi: 10.1016/j.jss.2015.04.069. Epub 2015 Apr 27.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7164	Miller KE. Indications for Vena Cava Filters for Recurrent DVT. <i>Am Fam Physician</i> . 2003 Feb 1;67(3):593.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7165	Miller, C.L. and R.J. Wechsler. CT evaluation of Kimray-Greenfield filter complications. <i>AJR Am J Roentgenol</i> . 1986. 147(1): 45-50.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7166	Millward SF, Grassi CJ, Kinney TB, Kundu S, Becker GJ, Cardella JF, Martin LG, Silberzweig JE, Sacks D. Reporting standards for inferior vena caval filter placement and patient follow-up: supplement for temporary and retrievable/optional filters. <i>J Vasc Interv Radiol</i> . 2009 Jul;20(7 Suppl):S374-6. doi: 10.1016/j.jvir.2009.04.009.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7167	Millward SF. Temporary and Retrievable Inferior Vena Cava Filters: Current Status. <i>J Vasc Interv Radiol</i> . 1998 May-Jun;9(3):381-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7168	Minocha J, Idakoji I, Riaz A, Karp J, Gupta R, Chrisman HB, Salem R, Ryu RK, Lewandowski RJ. Improving inferior vena cava filter retrieval rates: impact of a dedicated inferior vena cava filter clinic. <i>J Vasc Interv Radiol</i> . 2010 Dec;21(12):1847-51. doi: 10.1016/j.jvir.2010.09.003. Epub 2010 Oct 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7169	Mismetti P, Laporte S, Pellerin O, Ennezat PV, Couturaud F, Elias A, Falvo N, Meneveau N, Quere I, Roy PM, Sanchez O, Schmidt J, Seinturier C, Sevestre MA, Beregi JP, Tardy B, Lacroix P, Presles E, Leizorovicz A, Decousus H, Barral F, Meyer G; PREPIC2 Study Group. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA. 2015 Apr 28;313(16):1627-35. doi: 10.1001/jama.2015.3780.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7170	Mitchell WB, Bonn J. Percutaneous retrieval of a Greenfield filter after migration to the left pulmonary artery. J Vasc Interv Radiol. 2005 Jul;16(7):1013-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7171	Mitsunaga, M.M. and H.-C. Yoon, Fracture Rate and Serious Complications of Vena Cava Filters. Open Journal of Radiology, 2013. 03(02): 85-90	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7172	Mohan G, Kasmani R, Okoli K, Elkambergy H. Right atrial foreign body: transvenous migration of Greenfield filter. Interact Cardiovasc Thorac Surg. 2009 Feb;8(2):245-6. doi: 10.1510/icvts.2008.189605. Epub 2008 Nov 17.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7173	Montgomery JP, Kaufman JA. A Critical Review of Available Retrievable Inferior Vena Cava Filters and Future Directions. Semin Intervent Radiol. 2016 Jun;33(2):79-87. doi: 10.1055/s-0036-1582121.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7174	Montgomery JP, Kaufman JA. Inferior Vena Cava Filters: Indications, Outcomes, and Evidence. Curr Treat Options Cardiovasc Med. 2015 Sep;17(9):401. doi: 10.1007/s11936-015-0401-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7175	Moore FD, et al: Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 116:405-407, 1981	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7176	Moore R, Dagher FJ, Tavares S, Attar S. Migration of Kim-Ray Greenfield Umbrella to the heart. South Med J. 1983 Jul;76(7):946-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7177	Moore, Feliciano, Mattox. Trauma, Fifth Edition	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7178	Morales JP, Li X, Irony TZ, Ibrahim NG, Moynahan M, Cavanaugh KJ. Decision analysis of retrievable inferior vena cava filters in patients with pulmonary embolism. J Vasc Surg Venous Lymphat Disord. 2013 Oct;1(4):376-84. doi: 10.1016/j.jvsv.2013.04.005. Epub 2013 Jul 4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7179	Morris CS, Cushman M. Perforation of the inferior vena cava by a Greenfield filter. Journal of Thrombosis and Haemostasis 2008; 6:1835-1836.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7180	Morris CS, LaRosa J, and VanAman ME. Technically difficult percutaneous Kimray-Greenfield filter insertions. Presented at the 48th annual meeting, Ohio State Radiological Society; 1988 May 13; Toledo, OH.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7181	Morris CS, Rogers FB, Najarian KE, Bhavé AD, Shackford SR. Current trends in vena caval filtration with the introduction of a retrievable filter at a level I trauma center. J Trauma 2004; 57:32-36	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7182	Muriel A, Jimenez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol 2014; 63:1675-83.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7183	Mutyalu, Realistic expectations and candidate selection for entry level vascular technologist in a busy laboratory	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7184	Myerburg RJ, Feigl DW Jr, Lindsay BD. Life threatening Malfunction of Implanatable Cardiac Devices. N Engl J Med. 2006 Jun 1;354(22):2309-11. Epub 2006 May 15.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7185	Narayan A, Hong K, Streiff M, Kim HS. (2008). Abstract No. 68: Safety and Efficacy of Retrievable vs Permanent IVC Filters in Oncology Patients – A Case Control Study. Journal of Vascular and Interventional Radiology - J VASC INTERVEN RADIOLOG. 19. . 10.1016/j.jvir.2007.12.076.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7186	Nathani N, Barzallo M, Mungee S. Myopericarditis secondary to embolization of fractured inferior vena cava filter limbs. J Invasive Cardiol. 2010 Dec;22(12):E225-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7187	National Cancer Institute. https://www.cancer.gov/about-cancer/diagnosis-staging/ct-scans-fact-sheet Accessed on February 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7188	Nazzal M, Abbas J, Nazzal M. A complication of a G2 Bard filter. J Vasc Interv Radiol. 2010 Nov;21(11):1784-5. doi: 10.1016/j.jvir.2010.07.010. Epub 2010 Sep 29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7189	Nazzal M, Chan E, Nazzal M, Abbas J, Erikson G, Sedique S, Gohara S. Complications related to inferior vena cava filters: a single-center experience. Ann Vasc Surg. 2010 May;24(4):480-6. doi: 10.1016/j.avsg.2009.07.015. Epub 2009 Nov 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7190	NCRP Report No. 160, Ionizing Radiation Exposure of the Population of the United States. http://ncrponline.org/publications/reports/ncrp-report-160/ Accessed on March 15, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7191	Nelson HD, Cantor A, Humphrey L, Fu R, Pappas M, Daeges M, Griffin J. Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation [Internet]. Agency for Healthcare Research and Quality (US); 2016 Jan. Report No.: 14-05201-EF-1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7192	Nicholson AA, Ettles DF, Paddon AJ, Dyet JF. Long-term Follow-up of the Bird's Nest IVC Filter. Clin Radiol. 1999 Nov;54(11):759-64.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7193	Nicholson W, Nicholson WJ, Tolerico P, Taylor B, Solomon S, Schryver T, McCullum K, Goldberg H, Mills J, Schuler B, Shears L, Siddoway L, Agarwal N, Tuohy C. Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade. Arch Intern Med. 2010 Nov 8;170(20):1827-31. doi: 10.1001/archinternmed.2010.316. Epub 2010 Aug 9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7194	Nicholson W. Refrain, Recover, Replace. J Vasc Interv Radiol 2012; 23:195-196.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7195	Nicholson W. Correction to Article About Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters. ARCH INTERN MED/VOL 172 (NO. 12), June 25, 2012.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7196	Nissim L, Romano W. Successful Retrieval from Right Ventricular Wall of an Embolized Bard Meridian Filter Fragment. J Vasc Interv Radiol. 2013 Dec;24(12):1933-4. doi: 10.1016/j.jvir.2013.09.001.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7197	Obeid FN, et al: Efficacy of prophylactic inferior vena cava filter placement in bariatric surgery. Sug Obes Relat Dis 3:606-610, 2007.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7198	Offner PJ, Hawkes A, Madayag R, Seale F, Maines C. The Role of Temporary Inferior Vena Cava Filters in Critically Ill Surgical Patients. Arch Surg. 2003 Jun;138(6):591-4; discussion 594-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7199	Oh J, Stavropoulos SW, Trerotola S, Soulen MC, Shlansky-Goldberg R, Nemeth A, Mondschein J, Solomon JA. Removal of retrievable IVC filters with CT findings indicating filter strut perforation. Abstract No. 5. Journal of Vascular and Interventional Radiology, February 2010, Volume 21, Issue 2, Supplement, Page S4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7200	Oh JC, Trerotola SO, Dagli M, Shlansky-Goldberg RD, Soulen MC, Itkin M, Mondschein J, Solomon J, Stavropoulos SW. Removal of retrievable inferior vena cava filters with computed tomography findings indicating tenting or penetration of the inferior vena cava wall. J Vasc Interv Radiol. 2011 Jan;22(1):70-4. doi: 10.1016/j.jvir.2010.09.021. Epub 2010 Nov 24.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7201	Oliva VL, Perreault P, Giroux MF, Bouchard L, Therasse E, Soulez G. Recovery G2 inferior vena cava filter: technical success and safety of retrieval. J Vasc Interv Radiol. 2008 Jun;19(6):884-9. doi: 10.1016/j.jvir.2008.02.025. Epub 2008 Apr 18.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7202	Oliva VL, Soulez G, Therasse E, Giroux M, Perreault P, Bouchard L, Denbow N. Recovery G2 vena cava filter retrievability study. Scientific Poster, Cardiovascular and Interventional Radiological Society of Europe, P235.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7203	Olorunsola OG, Kohi MP, Fidelman N, et al. Caval penetration by retrievable inferior vena cava filters: a retrospective comparison of Option and Günther Tulip filters. J Vasc Interv Radiol 2013;24:566-571.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7204	Olorunsola OG, Kohi MP, Fidelman N, Westphalen AC, Kolli PK, Taylor AG, Gordon RL, LaBerge JM, Kerlan RK. Caval Penetration by Retrievable Inferior Vena Cava Filters: A Retrospective Comparison of Option and Gunther Tulip Filters. J Vasc Interv Radiol. 2013 Apr;24(4):566-71. doi: 10.1016/j.jvir.2012.12.024. Epub 2013 Feb 23.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7205	O'Malley KF, Ross SE. Pulmonary Embolism in Major Trauma Patients. J Trauma 1990; 30:748-750.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7206	Osker T, Rogers FB: 1997: Prophylaxis after Major Trauma. Letter to the Editor. N. Eng. J. Med. Pg 586.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7207	Ota, S., et al., The Gunther-Tulip retrievable IVC filter: clinical experience in 118 consecutive patients. Circ J, 2008. 72(2): 287-92.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7208	Overby DW, Kohn GP, Cahan MA, Dixon RG, Stavas JM, Moll S, Burke CT, Colton KJ, Farrell TM. Risk-Group Targeted Inferior Vena Cava Filter Placement in Gastric Bypass Patients. Obes Surg. 2009 Apr;19(4):451-5. doi: 10.1007/s11695-008-9794-2. Epub 2009 Jan 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7209	Owens CA, Bui JT, Knuttinen MG, Gaba RC, Carrillo TC, Hoefling N, Layden-Almer JE. Intracardiac migration of inferior vena cava filters: review of published data. Chest. 2009 Sep;136(3):877-887. doi: 10.1378/chest.09-0153. Epub 2009 Apr 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7210	Owens, C.A., et al., Endovascular retrieval of intracardiac inferior vena cava filters: a review of published techniques. J Vasc Interv Radiol, 2009. 20(11): 1418-28	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7211	Oxford Centre for Evidence-based Medicine http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ (https://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/uspstf/index.html) accessed on March 6, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7212	Palestrant AM, Prince M, Simon M. Comparative in vitro evaluation of the nitinol inferior vena cava filter. Radiology. 1982 Nov;145(2):351-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7213	Pan Y, Zhao J, Mei J, Shao M, Zhang J, Wu H. Retrievable Inferior Vena Cava Filters in Trauma Patients: Prevalence and Management of Thrombus Within the Filter. Eur J Vasc Endovasc Surg. 2016 Dec;52(6):830-837. doi: 10.1016/j.ejvs.2016.08.012. Epub 2016 Sep 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7214	Pandhi MB, Desai KR, Ryu RK, Lewandowski RJ. The Role of Inferior Vena Cava Filters in Cancer Patients. Semin Intervent Radiol. 2016 Jun;33(2):71-4. doi: 10.1055/s-0036-1581090.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7215	Parker, N.A., et al., Complication and Retrieval Rates of Inferior Vena Cava Filters, a Single-Center Retrospective Study. Journal of Vascular Surgery, 2016. 64(3): 868-869.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7216	Passman M. Vena Cava Interruption and Pulmonary Embolism. In: Rutherford's Vascular Surgery, Cronenwett JL (ed). Elsevier 2014. 816.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7217	Patel A, Cholanikeril J. Case of the migrating embolic filter. Hosp Pract (Off Ed). 1991 Apr 15;26(4):129-32.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7218	Patton JH Jr, Fabian TC, Croce MA, Minard G, Pritchard FE, Kudsk KA. Prophylactic Greenfield Filters: Acute Complications and Long-Term Follow-up. J Trauma. 1996 Aug;41(2):231-6; discussion 236-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7219	Peters, M.N., et al., Inferior vena cava filter migration to the right ventricle causing nonsustained ventricular tachycardia. Tex Heart Inst J, 2013. 40(3): 316-9	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7220	Peterson EA, Yenson PR, Liu D, Lee AYY. Predictors of attempted inferior vena cava filters retrieval in a tertiary care centre. <i>Thromb Res</i> 2014; 134:300-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7221	Piano G, Ketteler ER, Prachand V, Devalk E, Van Ha TG, Gewertz BL, Alverdy JC. Safety, feasibility, and outcome of retrievable vena cava filters in high-risk surgical patients. <i>J Vasc Surg.</i> 2007 Apr;45(4):784-8; discussion 788.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7222	Piercechi, C.W., et al., Cardiac Perforation by Migrated Fractured Strut of Inferior Vena Cava Filter Mimicking Acute Coronary Syndrome. <i>Heart Lung Circ.</i> 2017. 26(2): e11-e13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7223	Pierfitte C, Bégaud B, Lagnaoui R, Moore ND. Is Reporting Rate a Good Predictor of Risks Associated with Drugs? <i>Br J Clin Pharmacol.</i> 1999 Mar;47(3):329-31.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7224	Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-Effectiveness Analyses of Colorectal Cancer Screening – A Systematic Review for the US Preventative Services Task Force. <i>Ann Intern Med.</i> 2002 Jul 16;137(2):96-104.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7225	Piotrowski, Is Deep Vein Thrombosis Surveillance Warranted in High-Risk Trauma Patients?	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7226	Poletti PA, Becker CD, Prina L, Ruijs P, Bounameaux H, Didier D, Schneider PA, Terrier F. Long-term results of the Simon nitinol inferior vena cava filter. <i>Eur Radiol.</i> 1998;8(2):289-94.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7227	Porcellini, M., et al., Intracardiac migration of nitinol TrapEase vena cava filter and paradoxical embolism. <i>Eur J Cardiothorac Surg.</i> 2002. 22(3): 460-1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7228	Prasad V, Rho J, Cifu, A. The Inferior Vena Cava Filter, How Could a Medical Device Be So Well Accepted Without Any Evidence of Efficacy? <i>JAMA Intern Med.</i> 2013;173(7):493-495. doi:10.1001/jamainternmed.2013.2725	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7229	Pratt WB, MD, Leake SS, Afaq S, Sandhu HK, Safi HJ, Azizzadeh A, Charlton-Ouw KM. Asymptomatic Patients With Inferior Vena Cava Filter Penetration Through the Wall May be Managed Conservatively. <i>Journal of Vascular Surgery.</i> March 2017, Volume 65, Issue 3, Pages e7-e8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7230	PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. <i>Circulation.</i> 2005 Jul 19;112(3):416-22. Epub 2005 Jul 11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7231	PRESERVE Trial (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters) http://www.preservetrial.com/Study-Design accessed on February 26, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7232	Proctor MC, Cho KJ, Greenfield LJ. In Vivo Evaluation of Vena Caval Filters-Can Function Be Linked to Design Characteristics? <i>Cardiovasc Intervent Radiol.</i> 2000 Nov-Dec;23(6):460-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7233	Proctor MC, Greenfield LJ. Pulmonary embolism: diagnosis, incidence and implications. <i>Cardiovasc Surg.</i> 1997; 5:77-81.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7234	Pryor HI 2nd, Singleton A, Lin E, Lin P, Vaziri K. Practice Patterns in High-Risk Bariatric Venous Thromboembolism Prophylaxis. <i>Surg Endosc.</i> 2013 Mar;27(3):843-8. doi: 10.1007/s00464-012-2521-z. Epub 2012 Oct 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7235	Prystowsky JB, Morasch MD, Eskandari MK, Hungness ES, Nagle AP. Prospective Analysis of the Incidence of Deep Venous Thrombosis in Bariatric Surgery Patients. <i>Surgery.</i> 2005 Oct;138(4):759-63; discussion 763-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7236	Puram B, Maley TJ, White NM, Rotman HH, Miller G. Acute myocardial infarction resulting from a migration of a Greenfield filter. Chest. 1990 Dec;98(6):1510-1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7237	Purcell, S.T., et al., PS232. Complications Associated With IVC Filters: A large, Single Institution Review. Journal of Vascular Surgery, 2014. 59(6): 88S	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7238	Putterman D, Niman D, Cohen G. Aortic Pseudoaneurysm after Penetration by a Simon Nitinol Inferior Vena Cava Filter. J Vasc Interv Radiol. 2005 Apr;16(4):535-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7239	Queiroz R, Waldman DL. Transvenous retrieval of a Greenfield filter lodged in the tricuspid valve. Cathet Cardiovasc Diagn. 1998 Jul;44(3):310-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7240	Radiation Dose in X-ray and CT Exams. http://www.radiologyinfo.org/en/info.cfm?pg=safety-xray Accessed on February 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7241	Raghavan S, Akhtar A, Bastani B. Migration of inferior vena cava filter into renal hilum. Nephron. 2002 Jun;91(2):333-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7242	Rajasekhar A, Elmariyah H, Lottenberg L, et al: Inferior Vena Cava Filters in Trauma Patients: A National Practice Patterns Survey of US Trauma Centers: The American Surgeon 2014; 80: 1237-1244.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7243	Rajasekhar A, Crowther MA. ASH evidence-based guidelines: what is the role of inferior vena cava filters in the perioperative prevention of venous thromboembolism in bariatric surgery patients? Hematology Am Soc Hematol Educ Program. 2009:302-4. doi: 10.1182/asheducation-2009.1.302.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7244	Rajasekhar A, Lottenberg L, Lottenberg R, Feezor RJ, Armen SB, Liu H, Efron PA, Crowther M, Ang D. A pilot study on the randomization of inferior vena cava filter placement for venous thromboembolism prophylaxis in high-risk trauma patients. J Trauma. 2011 Aug;71(2):323-8; discussion 328-9. doi: 10.1097/TA.0b013e318226e1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7245	Rajasekhar A, Lottenberg R, Lottenberg L, Liu H, Ang D. Pulmonary embolism prophylaxis with inferior vena cava filters in trauma patients: a systemic review using the meta-analysis of observational studies in epidemiology (MOOSE) guidelines. J Thromb Thrombolysis. 2011; 32(1):40-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7246	Rajasekhar A, Streiff MB. Vena cava filters for management of venous thromboembolism: a clinical review. Blood Rev. 2013 Sep;27(5):225-41. doi: 10.1016/j.blre.2013.07.001. Epub 2013 Aug 7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7247	Rajasekhar A., Crowther M. Inferior vena caval filter insertion prior to bariatric surgery: a systematic review of the literature. J Thromb Haemost. 2010;8:1266-1270.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7248	Rao KM, Simons AJ, Hare CL, Smulyan H. Migration of a Kimray-Greenfield filter into the pulmonary artery: localization by transesophageal echocardiography. Am Heart J. 1993 Feb;125(2 Pt 1):543-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7249	Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993;119(9):874-881.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7250	Rasuli P, Mehran R, French G, Turek M, Lalonde KA, Cardinal P. Percutaneous retrieval of a vena cava filter from the right atrium: case report. Can Assoc Radiol J. 2000 Feb;51(1):30-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7251	Rasuli P. Inferior vena cava penetration by g�nther tulip filter? J Vasc Interv Radiol. 2013 May;24(5):752. doi: 10.1016/j.jvir.2013.01.501.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7252	Ray CE Jr, Kaufman JA. Complications of inferior vena cava filters. Abdom Imaging. 1996 Jul-Aug;21(4):368-74.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7253	Ray CE Jr, Mitchell E, Zipser S, Kao EY, Brown CF, Moneta GL. Outcomes with retrievable inferior vena cava filters: a multicenter study. <i>J Vasc Interv Radiol</i> . 2006 Oct;17(10):1595-604.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7254	Redberg R. Continued High Rates of IVC Filter Use After US Food and Drug Safety Warning. <i>JAMA Intern Med</i> . 2017 Sep 1;177(9):1374-1375. doi: 10.1001/jamainternmed.2017.2724.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7255	Redberg, R.F. Medical devices and the FDA approval process: balancing safety and innovation; comment on "prevalence of fracture and fragment embolization of bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade". <i>Arch Intern Med</i> , 2010. 170(20): 1831-3	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7256	Redberg, Rita F., "Comment on 'Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Tamponade'", <i>Archives of Internal Medicine</i> 2010; 170(20):1827-1831	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7257	Reis SP, Kovoor J, Sutphin PD, Toomay S, Trimmer C, Pillai A, Reddick M, Kalva SP. Safety and Effectiveness of the Denali Inferior Vena Cava Filter: Intermediate Follow-Up Results. <i>Vasc Endovascular Surg</i> . 2016 Aug;50(6):385-90. doi: 10.1177/1538574416666223. Epub 2016 Aug 31.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7258	Renno, A., et al., A single center experience with retrievable IVC filters. <i>Vascular</i> , 2015. 23(4): 350-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7259	Ritchie AJ, Mitchell L, Forty J. Migration of a vena caval filter to the pulmonary artery. <i>Br J Surg</i> . 1995 Feb;82(2):207.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7260	Roberts AC. Inferior Vena Cava Filters, Today's clot filtration technologies offer a variety of options. <i>Endovascular Today</i> , February 2003.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7261	Roberts PR. Follow up and optimization of cardiac pacing. <i>Heart</i> . 2005; 91(9):1229-34.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7262	Rodriguez JL, Lopez JM, Proctor MC, Conley JL, Gerndt SJ, Marx MV, Taheri PA, Greenfield LJ. Early Placement of Prophylactic Vena Cava Filters in Injured Patients at High Risk for Pulmonary Embolism. <i>J Trauma</i> . 1996 May;40(5):797-802; discussion 802-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7263	Rodriguez LF, Saltiel FS. Long-term follow-up of ectopic intracardiac Greenfield filter. <i>Chest</i> . 1993 Aug;104(2):611-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7264	Rogers FB, Cipolle MD, Velmahos G, Luchette F. Practice Management Guidelines for the Prevention of Venous Thromboembolism in Trauma Patients. The EAST Practice Management Guidelines Work Group. <i>J Trauma Acute Care Surg</i> . 2002; 53:142-164.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7265	Rogers FB, Osler TM, Shackford SR: Immediate Pulmonary Embolism after Trauma. <i>Trauma</i> 2000; 48:146-148.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7266	Rogers FB, Shackford SR, Horst MA, Miller JA, Wu D, Bradburn E, Rogers A, Krasne M. Determining venous thromboembolic risk assessment for patients with trauma: The Trauma Embolic Scoring System. <i>J Trauma Acute Care Surg</i> . 2012; 73(2):511-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7267	Rogers FB, Shackford SR, Miller JA, et al. Improved recovery of prophylactic inferior vena cava filters in trauma patients: the results of a dedicated filter registry and critical pathway for filter removal. <i>J Trauma</i> 2012; 72:381-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7268	Rogers FB, Shackford SR, Miller JA, Wu D, Rogers A, Gambler A. Improved Recovery of Prophylactic Inferior Vena Cava Filters in Trauma Patients: The Results of a Dedicated Filter Registry and Critical Pathway for Filter Removal. <i>J Trauma Acute Care Surg</i> . 2012 Feb;72(2):381-4. doi: 10.1097/TA.0b013e3182447811.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7269	Rogers FB, Shackford SR, Wilson J, Ricci MA, Morris CS. Prophylactic vena cava filter insertion in severely injured trauma patients: Indications and preliminary results. <i>J Trauma</i> 1993; 35:637-641.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7270	Rogers FB, Strindberg G, Shackford SR, Osler TM, Morris CS, Ricci MA, Najarian KE, D'Agostino R, Pilcher DB. Five-year follow-up of prophylactic vena cava filters in high-risk trauma patients. Arch Surg 1998; 133:406-411.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7271	Rogers FB, Strindberg G, Shackford SR, Osler TM, Morris CS, Ricci MA, Najarian KE, D'Agostino R, Pilcher DB. Five-year Follow-up of Prophylactic Vena Cava Filters in High-Risk Trauma Patients. Arch Surg. 1998 Apr;133(4):406-11; discussion 412.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7272	Rogoff, P.A., et al., Cephalic migration of the bird's nest inferior vena caval filter: report of two cases. Radiology, 1992. 184(3): 819-22.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7273	Rose SC, Kinney TB, Valji K, Winchell RJ. Placement of Inferior Vena Caval Filters in the Intensive Care Unit. J Vasc Interv Radiol. 1997 Jan-Feb;8(1 Pt 1):61-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7274	Rosenthal D, Kochupura PV, Wellons ED, Burkett AB, Methodius-Rayford WC. Gunther Tulip and Celect IVC Filters in Multiple-Trauma Patients. J Endovasc Ther. 2009 Aug;16(4):494-9. doi: 10.1583/09-2728.1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7275	Rosenthal D, McKinsey JF, Levy AM, Lamis PA, Clark MD. Use of Greenfield filter in patients with major trauma. Cardiovasc Surg. 1994 Feb;2(1):52-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7276	Rosenthal D, Wellons ED, Levitt AB, Shuler FW, O'Conner RE, Henderson VJ. Role of prophylactic temporary inferior vena cava filters placed at the ICU bedside under intravascular ultrasound guidance in patients with multiple trauma. J Vasc Surg. 2004 Nov;40(5):958-64.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7277	Rossi, P., et al., Fatal outcome in atrial migration of the Tempofilter. Cardiovasc Intervent Radiol, 1999. 22(3): 227-31.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7278	Rozin L, Perper JA. Spontaneous Fatal Perforation of Aorta and Vena Cava by Mobin-Uddin Umbrella. Am J Forensic Med Pathol. 1989 Jun;10(2):149-51.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7279	Rubenstein L, Chun AK, Chew M, Binkert CA. Loop Snare Technique for Difficult Inferior Vena Cava Filter Retrievals. J Vasc Interv Radiol. 2007 Oct;18(10):1315-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7280	Ryu RK, Desai K, Karp J, et al. A comparison of retrievability: Celect versus Option filter. J Vasc Interv Radiol 2015;26:865-869.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7281	Saeed, I., M. Garcia and K. McNicholas, Right ventricular migration of a recovery IVC filter's fractured wire with subsequent pericardial tamponade. Cardiovasc Intervent Radiol, 2006. 29(4): 685-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7282	Sag AA, Stavas JM, Burke CT, Dixon RG, Marquess JS, Mauro MA. Analysis of Tilt of the Gunther Tulip Filter. J Vasc Interv Radiol. 2008 May;19(5):669-76. doi: 10.1016/j.jvir.2008.01.020. Epub 2008 Mar 24.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7283	Sagai HC, Ahn J, Cresla D, et al: Venous Thromboembolism in Orthopedic Patients: A Survey of OTA Member Practice Patterns and OTA Expert Panel Recommendations: 2015; J Orthop Trauma 29(10) e355-e362.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7284	Sakuma M, Nakamura M, Nakanishi N, et al. Inferior vena cava filter is a new additional therapeutic option to reduce mortality from acute pulmonary embolism. Circ J. 2004; 68:816-21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7285	Sangwaiya MJ, Marentis TC, Walker TG, Stecker M, Wicky ST, Kalva SP. Safety and Effectiveness of the Celect Inferior Vena Cava Filter: Preliminary Results. J Vasc Interv Radiol. 2009 Sep;20(9):1188-92. doi: 10.1016/j.jvir.2009.05.033. Epub 2009 Jul 23.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7286	Sano M, Unno N, Yamamoto N, Tanaka H, Konno H. Frequent fracture of TrapEase inferior vena cava filters: a long-term follow-up assessment. Arch Intern Med. 2012 Jan 23;172(2):189-91. doi: 10.1001/archinternmed.2011.548. Epub 2011 Nov 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7287	Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. Fatal Pulmonary Embolism after Bariatric Operations for Morbid Obesity: A 24-yr retro analysis. Obes Surg. 2003 Dec;13(6):819-25.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7288	Sarosiek (2016)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7289	Sarosiek S, Crowther M, Sloan JM. Indications, complications, and management of inferior vena cava filters: The experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med 2013; 173:513-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7290	Sarosiek S, Rybin D, Weinberg J, Burke PA, Kasotakis G, Sloan JM. Association Between Inferior Vena Cava Filter Insertion in Trauma Patients and In Hospital and Overall Mortality. JAMA Surg. 2017 Jan 1;152(1):75-81. doi: 10.1001/jamasurg.2016.3091.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7291	Sathyanarayana R, Tan GX, Van Tonder F, Szikla C, Jhamb A. Bard DENALI Inferior Vena Cava Filter Another "Arm" Fracture. J Vasc Interv Radiol. 2016 Nov;27(11):1722-1724. doi: 10.1016/j.jvir.2016.05.025.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7292	Satya R, Anderson J, Lievano G, Satya RJ. Inferior Vena Cava (IVC) Rupture and Retroperitoneal Hemorrhage Caused by IVC Filter Migration. J Vasc Interv Radiol. 2009 Aug;20(8):1102-4. doi: 10.1016/j.jvir.2009.05.001.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7293	Schmidt U, Anderson BL, Chen JP, Maul KI: D-dimer levels correlate with pathologic thrombosis in trauma patients. J Trauma 1992; 33:312-320.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7294	Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52. doi: 10.1056/NEJMoa0906598.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7295	Schuster R, Hagedorn JC, Curet MJ, Morton JM. Retrievable inferior vena cava filters may be safely applied in gastric bypass surgery. Surg Endosc. 2007 Dec;21(12):2277-9. Epub 2007 Apr 13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7296	Scientific Session 1 IVC Filters, Venous Thromboembolic Disease	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7297	Seyfer AR, Saeber AV, Dambrose FA, et al: Coagulation changes after elective surgery and trauma. Ann. Surg. 1981; 193:210-213.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7298	Shackford SR, Cook A, Rogers FB, Littenberg B, Osler T. The Increasing Use of Vena Cava Filters in Adult Trauma Victims: Data From the American College of Surgeons National Trauma Data Bank. J Trauma. 2007 Oct;63(4):764-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7299	Shackford SR, Mackersic RC, Holbrook TL, et al: The Epidemiology of Trauma Death: A Population-Based Analysis. Arch Surg. 1993;128:571-575.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7300	Shah AH, Lichtner A, Cura M. Inferior Vena Cava Filter Removal After Prolonged Dwell Time of 2310 Days. Proc (Bayl Univ Med Cent). 2016 Jul;29(3):292-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7301	Shamian B, Chamberlain RS. The role for prophylaxis inferior vena cava filters in patients undergoing bariatric surgery: Replacing Anecdote with Evidence. Am Surg. 2012 Dec;78(12):1349-61.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7302	Shang EK, Nathan DP, Carpenter JP, Fairman RM, Jackson BM. Delayed Complications of Inferior Vena Cava Filters: Case Report and Literature Review. Vasc Endovascular Surg. 2011 Apr;45(3):290-4. doi: 10.1177/1538574410395038. Epub 2011 Jan 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7303	Sharifi M, Bay C, Skrocki L, Lawson D, Mazdeh S. Role of IVC filters in endovenous therapy for deep venous thrombosis: the FILTER-PEVI (filter implantation to lower thromboembolic risk in percutaneous endovenous intervention) trial. Cardiovasc Intervent Radiol. 2012 Dec;35(6):1408-13. doi: 10.1007/s00270-012-0342-z. Epub 2012 Jan 20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7304	Shaw, C.M., et al., Optional vena cava filter use in the elderly population. J Vasc Interv Radiol, 2011. 22(6): 824-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7305	Shimizu, M., et al., Retrievable Gunther Tulip filter complicated by sepsis and retroperitoneal hemorrhage: successful management by filter retrieval. Intern Med, 2005. 44(6): 593-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7306	Simon M, Athanasoulis CA, Kim D, Steinberg FL, Porter DH, Byse BH, Kleshinski S, Geller S, Orron DE, Waltman AC. Simon nitinol inferior vena cava filter: initial clinical experience. Work in progress. Radiology. 1989 Jul;172(1):99-103.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7307	Simon M, Athanasoulis CA, Kim D, Steinberg FL, Porter DH, Byse BH, Kleshinski S, Geller S, Orron DE, Waltman AC. Simon nitinol inferior vena cava filter: initial clinical experience. Work in progress. Radiology. 1989 Jul;172(1):99-103.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7308	Sing RF, Fischer PE. Inferior Vena Cava Filters: Indications and Management. Curr Opin Cardiol. 2013 Nov;28(6):625-31. doi: 10.1097/HCO.0b013e3283655b97.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7309	Sing RF, Rogers FB, Novitsky YW, Heniford T. Optional vena cava filters for patients with high thromboembolic risk: questions to be answered. Surgical Innovation 2005; 12:195-202.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7310	Singer MA, Wang SL. Modeling blood flow in a tilted inferior vena cava filter: does tilt adversely affect hemodynamics? J Vasc Interv Radiol. 2011 Feb;22(2):229-35. doi: 10.1016/j.jvir.2010.09.032. Epub 2011 Jan 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7311	Singh S, Haut ER, Brotman DJ, Sharma R, Chelladurai Y, Shermock KM, Kebede S, Stevens KA, Prakasa KR, Shihab HM, Akande TO, Zeidan AM, Garcia LJ, Segal JB. Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations [Internet]. Agency for Healthcare Research and Quality (US); 2013 May. Report No.: 13-EHC082-1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7312	2001 SIR Guidelines for IVC filters, Grassi et al., J Vasc Interv Radiol.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7313	Smith A, Adrahtas D, Elitharp D, Gasparis A, Labropoulos N, Tassiopoulos A. Changes in the Rate of Prophylactic Vena Cava Filter Insertion at a University Hospital. Phlebology. 2016 Jul;31(6):403-8. doi: 10.1177/0268355115592769. Epub 2015 Jun 19.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7314	Smith BA, Vena Caval Filters. Emerg Med Clin North Am. 1994 Aug;12(3):645-56.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7315	Smouse B, Johar A. Is Market Growth of Vena Cava Filters Justified? A review of indications, use, and market analysis. Endoscopy Today, Feb. 2010.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7316	Smouse HB, Rosenthal D, Thuong VH, Knox MF, Dixon RG, Voorhees WD 3rd, McCann-Brown JA. Long-term Retrieval Success Rate Profile for the Gunther Tulip Vena Cava Filter. J Vasc Interv Radiol. 2009 Jul;20(7):871-7; quiz 878. doi: 10.1016/j.jvir.2009.03.033. Epub 2009 May 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7317	Smouse HB, Trost D, Rectenwald JE, Arko FR, Kaufman JA, Plant G, Atkins MD, Razavi MK, Uberoi R. One Question...How Have Your Protocols for IVC Filter Placement, Monitoring, and Retrieval Changed in the Past Several Years? Endovascular Today, July 2012. [not a peer-reviewed article]	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7318	Society of Interventional Radiology Responds to FDA Blood Clot Device (IVC Filter) Advisory	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7319	Society of Interventional Radiology Responds to FDA Blood Clot Device (IVC Filter) Advisory, 08/12/2010.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7320	Spencer FA, Bates SM, Goldbert RJ. A population-based study of inferior vena cava filters in patients with acute venous thromboembolism. Arch Intern Med 2010; 170:1456-62.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7321	Spinal Cord Injury Thromboprophylaxis Investigators, Prevention of Venous Thromboelism in the Acute Treatment Phase after Spinal Cord Injury: A Randomized, Multicenter Trial Comparing Low-Dose Heparin Plus Intermittent Pneumatic Compression with Enoxaparin. J Trauma. 2003 Jun;54(6):1116-24; discussion 1125-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7322	Stavropoulos SW, Dixon RG, Burke CT, Stavas JM, Shah A, Shlansky-Goldberg RD, Trerotola SO. Embedded inferior vena cava filter removal: use of endobronchial forceps. J Vasc Interv Radiol. 2008 Sep;19(9):1297-301. doi: 10.1016/j.jvir.2008.04.012. Epub 2008 Jun 2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7323	Stavropoulos, S.W., Chen, J.X., Sing, R.F. et al. Analysis of the final DENALI trial data: a prospective, multicenter study of the DENALI inferior vena cava filter. J Vasc Interv Radiol. 2016; 27: 1531–1538.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7324	Stavropoulos, S.W., et al., Retrieval of Tip-embedded Inferior Vena Cava Filters by Using the Endobronchial Forceps Technique: Experience at a Single Institution. Radiology, 2015. 275(3): 900-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7325	Stavropoulos, S.W., et al., The DENALI Trial: an interim analysis of a prospective, multicenter study of the Denali retrievable inferior vena cava filter. J Vasc Interv Radiol. 2014. 25(10): 1497-505, 1505 e1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7326	Steele JR, Wallace MJ, Hovsepian DM, James BC, Kundu S, Miller DL, Rose SC, Sacks D, Shah SS, Cardella JF. Guidelines for Establishing a Quality Improvement Program in Interventional Radiology. J Vasc Interv Radiol. 2010 May;21(5):617-25. doi: 10.1016/j.jvir.2010.01.010. Epub 2010 Mar 17.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7327	Stein PD, Alnas M, Skaf E, Kayali F, Siddiqui T, Olson RE, Patel K. Outcome and Complications of Retrievable Inferior Vena Cava Filters. Am J Cardiol. 2004 Oct 15;94(8):1090-3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7328	Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004; 164:1541-1545.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7329	Stein PD, Matta F, Huges MJ. Inferior Vena Cava Filters in Stable Patients with Acute Pulmonary Embolism Who Receive Thrombolytic Therapy. Am J Med. 2018 Jan;131(1):97-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7330	Stein PD, Matta F, Jull RD. Increasing use of vena cava filters for prevention of pulmonary embolism. Am J Med 2011; 124:655-61.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7331	Stein PD, Matta F, Keyes DC, Willyerd G. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med 2012; 125:478-84.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7332	Stein PD, Matta F, Lawrence FR, Huges MJ. Inferior Vena Cava Filters in Patients with Acute Pulmonary Embolism and Cancer. Am J Med. Epub 2017 Nov10.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7333	Stein PD, Matta F, Lawrence FR, Huges MJ. Usefulness of Inferior Vena Cava Filters in Unstable Patients With Acute Pulmonary Embolism and Patients Who Underwent Pulmonary Embolectomy. Am J Cardio. 2018 Jan;121(4):495-00.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7334	Stein PD, Matta F, Sabra MJ. Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism. Am J Med. 2013; 126:819-24.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7335	Stein PD, Matta F. Vena cava filters in unstable elderly patients with acute pulmonary embolism. Am J Med 2014; 127:222-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7336	Stösslein F, Altmann E. A rare complication with an Antheor cava filter. Cardiovasc Interv Radiol. 1998 Mar-Apr;21(2):165-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7337	Streib EW, Wagner JW. Complications of vascular access procedures in patients with vena cava filters. J Trauma. 2000 Sep;49(3):553-7; discussion 557-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7338	Streiff MB. Vena Caval Filters: A Comprehensive Review. Blood. 2000 Jun 15;95(12):3669-77.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7339	Sudheendra D, Giroux MF, Johnson MS, Murphy E, Garcia, MJ. Ask the Experts: What is your practice's current IVC filter retrieval protocol, and in which cases do you deviate from it? [not a peer-reviewed article]	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7340	Sutphin PD, Reis SP, McKune A, et al. Improving inferior vena cava filter retrieval rates with the define, measure, analyze, improve, control methodology. J Vasc Interv Radiol 2015; 26:491-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7341	Swami, U., G. Annunziata and I. Fulger, Experience with vena cava filters at a large community hospital and level-I trauma center: indications, complications, and compliance barriers. Clin Appl Thromb Hemost, 2014. 20(5): 546-52	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7342	Sweeney TJ, Van Aman ME. Deployment Problems with the Titanium Greenfield Filter. J Vasc Interv Radiol. 1993 Sep-Oct;4(5):691-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7343	Sweet PH III, Armstrong T, Chen J, Masliah E, Witucki P. Fatal pulmonary embolism update: 10 years of autopsy experience at an academic medical center. JRSJ Short Rep. 2013; 4(9):204253313489824.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7344	Świątkowska B, Szeszenia-Dąbrowska N, Wilczyńska U. Medical Monitoring of Asbestos-Exposed Workers – Experience from Poland. Bull World Health Organ. 2016 Aug 1;94(8):599-604. doi: 10.2471/BLT.15.159426. Epub 2016 Jun 2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7345	Taksler GB, Keshner M, Fagerlin A, Hajizadeh N, Braithwaite RS. Personalized Estimates of Benefit from Preventative Care Guidelines – A Proof of Concept. Ann Intern Med. 2013 Aug 6;159(3):161-8. doi: 10.7326/0003-4819-159-3-201308060-00005.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7346	Tam MD, Spain J, Lieber M, Geisinger M, Sands MJ, Wang W. Fracture and distant migration of the Bard Recovery filter: a retrospective review of 363 implantations for potentially life-threatening complications. J Vasc Interv Radiol. 2012 Feb;23(2):199-205.e1. doi: 10.1016/j.jvir.2011.10.017. Epub 2011 Dec 20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7347	Tam MD, Zhu X, McLennan G, Sands MJ, W. Wang. Complications of the Bard Recovery Filter and Their Effect on Attempted Retrieval in 107 Patients. Abstract No. 2. Journal of Vascular and Interventional Radiology, February 2010Volume 21, Issue 2, Supplement, Page S3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7348	Tan XL, Tam C, McKellar R, Nandurkar H, Bazargan A. Out of sight, out of mind: an audit of inferior vena cava filter insertion and clinical follow up in an Australian institution and literature review. Intern Med J 2013; 43(4):365-72.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7349	Tanner L, FDA clot device advisory tells of patients' risks. The San Diego Union-Tribune, August 9, 2010.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7350	Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7351	Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc, 2012. 19(1): 79-85	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7352	Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7353	The Guide to Clinical Preventative Services. US Preventative Services Task Force.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7354	The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7355	Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3 Suppl):S24-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7356	Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J 2008;29(18):2276–2315.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7357	Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7358	Tribe CR. Causes of Death in the Early and Late Stages of Paraplegia. Paraplegia. 1963 May;1:19-47.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7359	Trigilio-Black CM, Ringley CD, McBride CL, Sorensen VJ, Thompson JS, Longo GM, Pipinos II, Johanning JM. Inferior Vena Cava Filter Placement for Pulmonary Embolism Risk Reduction in Super Morbidly Obese Undergoing Bariatric Surgery. Surg Obes Relat Dis. 2007 Jul-Aug;3(4):461-4. Epub 2007 Jun 4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7360	Tschoe M, Kim HS, Brotman DJ, Streiff MB. Retrievable Vena Cava Filters: A Clinical Review. J Hosp Med. 2009 Sep;4(7):441-8. doi: 10.1002/jhm.439.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7361	Tse G, Cleveland T, Goode S. Ten-Year Experience of Retrievable Inferior Vena Cava Filters in a Tertiary Referral Center. Diagn Interv Radiol. 2017 Mar-Apr;23(2):144-149. doi: 10.5152/dir.2016.16022.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7362	Turba UC, Glaiberman C, Picus D, Arslan B, Angle JF, Matsumoto AH. Management of severe vena cava filter tilting: experience with Bard G-2 filters. J Vasc Interv Radiol. 2008 Mar;19(3):449-53. doi: 10.1016/j.jvir.2007.11.020.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7363	U.S. Preventive Services Task Force https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions accessed on March 6, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7364	Uberoi R, Tapping CR, Chalmers N, Allgar V. British Society of Interventional Radiology (BSIR) Inferior Vena Cava (IVC) Filter Registry. Cardiovasc Interv Radiol. 2013 Dec;36(6):1548-1561. doi: 10.1007/s00270-013-0606-2. Epub 2013 Mar 20. Erratum in: Cardiovasc Interv Radiol. 2017 Dec 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7365	Urbankova J, Quiroz R, Kucher N, Goldhaber SZ. Intermittent pneumatic compression and DVT prevention in postoperative patients. Thromb Haemost. 2005 Dec;94(6):1181-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7366	Urena, R. and L. Greenwood. Bird's nest filter migration to the right atrium. AJR Am J Roentgenol. 2004. 183(4): 1037-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7367	Urias D, Silvis J, Mesropyan L, Oberlander E, Simunich T, Tretter J. Retrievable Inferior Vena Cava Filters in Geriatric Trauma: Is There an Age Bias? Injury. 2017 Jan;48(1):148-152. doi: 10.1016/j.injury.2016.07.008. Epub 2016 Jul 15.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7368	Van Ha, T.G., Complications of inferior vena caval filters. Semin Intervent Radiol. 2006. 23(2): 150-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7369	Vaziri K, Bhanot P, Hungness ES, Morasch MD, Prystowsky JB, Nagle AP. Retrievable IVC Filters in High Risk Patients Undergoing Bariatric Surgery. Surg Endosc. 2009 Oct;23(10):2203-7. doi: 10.1007/s00464-008-0307-0. Epub 2009 Jan 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7370	Veerapong J, Wahlgren CM, Jolly N, Bassiouny H. Successful percutaneous retrieval of an inferior vena cava filter migrating to the right ventricle in a bariatric patient. Cardiovasc Interv Radiol. 2008 Jul;31 Suppl 2:S177-81. doi: 10.1007/s00270-007-9278-0. Epub 2008 Jan 17.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7371	Velmahos GC, et al: Prevention of venous thromboembolism after injury: an evidence-based report: part II: analysis of risk factors and evaluation of the role of vena caval filters. J Trauma 49:140-144, 2000	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7372	Vena Caval Filter Consensus Conference. Recommended reporting standards for vena caval filter placement and patient follow-up. The Participants in the Vena Caval Filter Consensus Conference. J Vasc Surg 1999;30:573-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7373	Vergara, G.R., W.F. Wallace and K.R. Bennett, Spontaneous migration of an inferior vena cava filter resulting in cardiac tamponade and percutaneous filter retrieval. Catheter Cardiovasc Interv. 2007. 69(2): 300-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7374	Vijay K, Hughes JA, Burdette AS, et al. Fractured Bard Recovery, G2, and G2 express inferior vena cava filters: incidence, clinical consequences, and outcomes of removal attempts. J Vasc Interv Radiol 2012; 23:188-94.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7375	Vladimir, F.G., et al., Complications and Outcomes Associated With the Use Of Retrievable Vena Cava Filters: A Review of the Manufacturer and User Facility Device Experience Database (MAUDE) Database. NESVS: 2005 Annual Meeting - 2005 Abstracts, 2005.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7376	Vossen, J.A., et al., Recurrent fracture of a recovery inferior vena cava filter with pulmonary migration. Yale J Biol Med, 2012. 85(2): 255-9	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7377	Walsh J, Safety and Effectiveness of Inferior Vena Cava Filters Used to Protect Against Pulmonary Embolus: A Technology Assessment. http://ctaf.org/sites/default/files/assessments/1247_file_IVC_Filters_final_W.pdf	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7378	Waltz P, Zuckerbraun BS. Commentary – Inferior Vena Cava Filters in Trauma Patients – For Whom the Benefit Tolls? JAMA Surg. 2017 Jan 1;152(1):81. doi: 10.1001/jamasurg.2016.3121.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7379	Wang SL, Lloyd AJ. Clinical review: inferior vena cava filters in the age of patient-centered outcomes. Ann Med. 2013 Nov;45(7):474-81.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7380	Wang W, Spain J, Tam MD. Acute Abdominal Pain After Retrievable Inferior Vena Cava Filter Insertion: Case Report of Caval Perforation by an Option Filter. Cardiovasc Intervent Radiol. 2011 Aug;34(4):883-5. doi: 10.1007/s00270-010-0080-z.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7381	Wang W, Zhou D, Obuchowski N et al. Fracture and Migration of Celect Inferior Vena Cava Filters: A Retrospective Review of 741 Consecutive Implantations. J Vasc Interv Radiol. 2013;24:1710-1722.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7382	Waring WP, Karunas RS. Acute Spinal Cord Injuries and the Incidence of Clinically Occurring Thromboembolic Disease. Paraplegia. 1991 Jan;29(1):8-16.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7383	Webb LX, Rush PT, Fuller SB, Meredith JW. Greenfield Filter Prophylaxis of Pulmonary Embolism in Patients Undergoing Surgery for Acetabular Fracture. J Orthop Trauma. 1992;6(2):139-45.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7384	Wehrenberg-Klee E, Stavropoulos SW. Inferior Vena Cava Filters for Primary Prophylaxis: When are they indicated? Semin Intervent Radiol. 2012 Mar;29(1):29-35. doi: 10.1055/s-0032-1302449.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7385	Weinberg I, Abtathian F, Debiosi R, et al: Effect of Delayed Inferior Vena Cava Filter Retrieval after Early Initiation of Anticoagulation. 2014 Am. J. Cardiology; 113:389-394.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7386	Weinberg I, Kaufman J, Jaff MR. Inferior vena cava filters. JACC Cardiovasc Interv. 2013;6(6):539-547.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7387	Whedon JM, Beaver TA, Hernandez RA, Burchard KW. Paradoxical Thromboembolism After Blunt Lower Extremity Trauma: A Management Strategy to Prevent Additional Sequelae Where Anticoagulation is Contraindicated. Am Surg. 2014 Nov;80(11):E309-11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7388	White RH, Brunson A, Romano PS, Li Z, Wun T. Outcomes after vena cava filter use in noncancer patients with acute venous thromboembolism: A Population-Based Study. Circulation. 2016 May 24;133(21):2018-29. doi: 10.1161/CIRCULATIONAHA.115.020338. Epub 2016 Apr 5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7389	White RH, Geraghty EM, Brunson A, Murin S, Wun T, Spencer F, Romano PS. High Variation Between Hospitals in Vena Cava Filter Use for Venous Thromboembolism. JAMA Intern Med. 2013 Apr 8;173(7):506-12. doi: 10.1001/jamainternmed.2013.2352.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7390	White RH: The epidemiology of venous thromboembolism. Circulation 107:14-18, 2003.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7391	Wicky S, Doenz F, Meuwly JY, Portier F, Schnyder P, Denys A. Clinical Experience with Retrievable Gunther Tulip Vena Cava Filters. J Endovasc Ther. 2003 Oct;10(5):994-1000.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7392	Winters JP, Morris CS, Holmes CE, Lewis P, Bhavé AD, Najarian KE, Shields JT, Charash W, Cushman M. A multidisciplinary quality improvement program increases the inferior vena cava filter retrieval rate. Vasc Med. 2017 Feb;22(1):51-56. doi: 10.1177/1358863X16676658. Epub 2016 Nov 3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7393	Wojcik R, Cipolle MD, Fearen I, Jaffe J, Newcomb J, Pasquale MD. Long-Term Follow-up of Trauma Patients with a Vena Caval Filter. J Trauma. 2000 Nov;49(5):839-43.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7394	Wones R, Pinney SM, Buckholz JM, Deck-Tebbe C, Freyberg R, Pesce A. Medical Monitoring – A Beneficial Remedy for Residents Living Near an Environmental Hazard Site. J Occup Environ Med. 2009 Dec;51(12):1374-83. doi: 10.1097/JOM.0b013e3181c558f1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7395	Wood, E.A., et al., Reporting the Impact of Inferior Vena Cava Perforation by Filters. (Abstract from the 2012 American Venous Forum Annual Meeting). J Vasc Surg. 2012. 55(1): 301	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7396	Woodward, E.B., et al., Delayed retroperitoneal arterial hemorrhage after inferior vena cava (IVC) filter insertion: case report and literature review of caval perforations by IVC filters. Ann Vasc Surg. 2002. 16(2): 193-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7397	Wu A, Moon E, Wang DS, Hertz B, Wang W. Bard Meridian Filter Fracture. Cardiovasc Intervent Radiol. 2015 Feb;38(1):251-2. doi: 10.1007/s00270-014-0935-9. Epub 2014 Jun 20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7398	Wu EC, Barba CA. Current Practices in the Prophylaxis of Venous Thromboembolism in Bariatric Surgery. Obes Surg. 2000 Feb;10(1):7-13; discussion 14.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7399	Wu EC, Barba CA. Endovascular Treatment of Late Aortic Perforation due to Vena Cava Filter. Obes Surg. 2000 Feb;10(1):7-13; discussion 14.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7400	Wu, G.S., et al., Inferior vena cava filter migration with severe deformity of filter. J Vasc Interv Radiol. 2009. 20(9): 1257-9	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7401	Yamagami T., Kato T., Hirota T., Yoshimatsu R., Matsumoto T., Nishimura T. Prophylactic implantation of inferior vena cava filter during interventional radiological treatment for deep venous thrombosis of the lower extremity. Br J Radiol. 2006;79:584-591.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7402	Young T, Tang H, Hughes R. Vena caval filters for the prevention of pulmonary embolism. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD006212. doi: 10.1002/14651858.CD006212.pub4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7403	Zektser M, Bartal C, Zeller L et al. Effectiveness of inferior vena cava filters without anticoagulation therapy for prophylaxis of recurrent pulmonary embolism. Rambam Maimonides Med J. 2016 Jul 28;7(3).	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7404	Zhou, D., et al., Penetration of Celect inferior vena cava filters: retrospective review of CT scans in 265 patients. AJR Am J Roentgenol. 2014. 202(3): 643-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7405	Zhou, D., et al., Retrospective review of 120 celect inferior vena cava filter retrievals: experience at a single institution. J Vasc Interv Radiol. 2012. 23(12): 1557-63	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7406	Zhu Indications, complications and outcomes of G2 retrievable IVC filters in 765 patients: A single institute experience. Abstract No. 3. Journal of Vascular and Interventional Radiology. February 2010 Volume 21, Issue 2, Supplement, Pages S3-S4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7407	Zhu X, Tam MD, Bartholomew J, Newman JS, Sands MJ, Wang W. Retrievability and device-related complications of the G2 filter: a retrospective study of 139 filter retrievals. J Vasc Interv Radiol. 2011 Jun;22(6):806-12. doi: 10.1016/j.jvir.2011.01.430. Epub 2011 Apr 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7408	Zolfaghari D, Johnson B, Weireter LJ, Britt LD. Expanded Use of Inferior Vena Cava Filters in the Trauma Population. Surg Annu. 1995;27:99-105.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7409	Goldman, Limitations and Strengths of Spontaneous Reports Data (1998)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7410	1997 GAO Report Excerpt (Medical Device Reporting: Improvements Needed in FDA's System for Monitoring Problems With Approved Devices)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7411	2008 Surgeon General's Call to Action re PE and DVT	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7412	April 14, 2017 Report of Dr. Fasching, Medical Literature - James, B, Medical Device Failure Analysis, ASM Handbook, Volume 23, Materials for Medical Devices, ASM International, Materials Park, OH, 2012, p. 346.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7413	April 14, 2017 Report of Dr. Fasching, Medical Literature - Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufman J. Systematic Review of the use of Retrievable Inferior Vena Cava Filters. J Vasc Interv Radiol 2011; 22:1522-1530.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7414	April 14, 2017 Report of Dr. Fasching, Medical Literature - Hull JE, Robertson SW. Bard Recovery Filter: Evaluation and Management of vena Cava Limb Perforation, Fracture, and Migration. J Vasc Interv Radiol 2009; 20:52-60.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7415	April 14, 2017 Report of Dr. Fasching, Medical Literature - Tam MD, Spain J, Lieber M, Geisinger M, Sands MJ, Wang W. Fracture and Distant Migration of the Bard Recovery Filter: A Retrospective Review of 363 Implantations for Potentially Life-Threatening Complications. J Vasc Interv Radiol 2013; 23:199-205.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7416	April 14, 2017 Report of Dr. Fasching, Medical Literature - Kuo WT, Robertson SW, Odegaard JI, Hofmann LV. Complex Retrieval of Fractured, Embedded, and Penetrating Inferior Vena Cava Filters: A prospective Study with Histologic and Electron Microscopic Analysis. J Vasc Interv Radiol 2013; 24:622-630.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7417	April 14, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Assessment of the Designs of Bard Inferior Vena Cava Filters: The Recovery, G2, G2 Express, Eclipse, Meridian, and Denali Models, Re: MDL3.3.17.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7418	April 14, 2017 Report of Dr. Fasching, Medical Literature - Hodgson DE. Fabrication, Heat Treatment and Joining of Nitinol Components. SMST-2000 Proceedings of the International Conference on Shape Memory and Superelastic Technologies (Pacific Grove, CA, April 30 to May 4, 2000), P. 11-24.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7419	April 14, 2017 Report of Dr. Fasching, Medical Literature - Trepanier C, Tabrizian M, Yahia LH, Bilodeau L, Piron DL. Improvement of the Corrosion Resistance of NiTi Stents by Surface Treatments. Mat. Res. Soc. Symp. Proc. Vol. 459 (1997). 363-368.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7420	April 14, 2017 Report of Dr. Fasching, Medical Literature - Trepanier C, Tabrizian M, Yahia LH, Bilodeau L, Piron DL. Effect of Modification of Oxide Layer on NiTi Stent Corrosion Resistance. J. Biomed. Mat. Research, 1998; 43:433-440.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7421	April 14, 2017 Report of Dr. Fasching, Medical Literature - Steegmueller R, Fleckenstein T, Schuessler A. Is Electropolishing equal Electropolishing? A Comparison Study for Nitinol Stents. Proceed. Mat. & Proc. for Med. Dev. Conf., November 14-16, Boston, MA, 2006, p. 163-168.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7422	April 14, 2017 Report of Dr. Fasching, Medical Literature - https://emea.cordis.com/ma/product/smart-control-self-expanding-nitinol-stent#overview	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7423	April 14, 2017 Report of Dr. Fasching, Medical Literature - Patel MM, Gordon RF. An Investigation of Diverse Surface Finishes on Fatigue Properties of Superelastic Nitinol Wire, Proceedings of International Conference on Shape Memory and Superelastic Technology, ASM International, 2006, p. 61-70.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7424	April 14, 2017 Report of Dr. Fasching, Medical Literature - Kuo WT Robertson SW, Odegaard JI Hofmann LV. Complex Retrieval of Fractured, Embedded, and Penetrating Inferior Vena Cava Filters: A prospective Study with Histologic and Electron Microscopic Analysis. J Vasc Interv Radiol 2013; 24:622-630.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7425	April 14, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Begley MR, Mechanical Reliability Assessment of the Bard G2 Filter, Re: Ebert v CR Bard, January 2014.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7426	April 14, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Begley MR, Finite Element Modeling of the Bard Filters, June 2011.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7427	April 14, 2017 Report of Dr. Fasching, Medical Literature - Gong XY, Pelton AR, Finite Element Analysis on Nitinol Medical Applications, Proceedings of IMECE-2002, Vol. 53, 2002.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7428	April 14, 2017 Report of Dr. Fasching, Medical Literature - Rebelo N, Gong XY, Hall A, Pelton AR, Duerig TW, Finite Element Analysis on the Cyclic Properties of Superelastic Nitinol, Proceedings 2004 ABAQUS Users' Conference, p. 601-613.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7429	April 14, 2017 Report of Dr. Fasching, Medical Literature - Pelton AR, Schroeder V, Mitchell MR, Gong XY, Barney M, Robertson SW, Fatigue and Durability of Nitinol Stents, J of Mech Behavior Biomed Mater, 1, 153-164 (2008)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7430	April 14, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Begley MR, Mechanical Reliability Assessment of the Bard IVC Recovery Filters, Re: Katrina Newton et. al. v CR Bard, March 2011.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7431	March 17, 2017 Report of Dr. Fasching, Medical Literature - R. Ritchie, Assessment of the Structural Integrity of Bard IVC Filters: Recovery, G2, G2-Express and Eclipse, March 2, 2017, Re: MDL 3.2.17	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7432	March 17, 2017 Report of Dr. Fasching, Medical Literature - Lin ZC, Denison A, Nitinol Fatigue Resistance – A Strong Function of Surface Quality, Proceedings from the Materials & Processes for Medical Devices Conference, 8-10 Sept 2003, ASM International, 2003.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7433	March 17, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Assessment of the Designs of Bard Inferior Vena Cava Filters: The Recovery, G2, G2 Express, Eclipse, Meridian, and Denali Models, Re: MDL3.3.17.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7434	Vogelzang, Providing Context: Medical Device Litigation and Inferior Vena Cava Filters (2016)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7435	Greenfield, et al., Recommended reporting standards for vena cava filter placement and patient follow-up (1999)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7436	Hull, Bard Recovery Filter Evaluation and Management (2009)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7437	"Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database."	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7438	Looby, S., Cardiovascular Interventional Radiology, 2007 Jan – Feb 30(1): 59 – 65. "Gunther Tulip retrievable inferior vena caval filters, indications, efficacy, retrieval, and complications". Study of 147 patients with Tulip filter 2001 to 2005, failed retrievals in 20%	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7449	Attorney John A. Dalimonte Answers to Defendants' Interrogatories and Response to Production of Documents			FRE 401, 402, 403, 602, 801, 802	401; 402; 403; 801; 802
7450	Emails produced by John Dalimonte re communications with the FDA			FRE 401, 402, 403, 602, 801, 802	401; 402; 403; 801; 802; 407; MIL 1; MIL 2
7459	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit A			FRE 401, 402, 403, 602, 801, 802	
7460	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit B			FRE 401, 402, 403, 602, 801, 802	
7461	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit C			FRE 401, 402, 403, 602, 801, 802	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7462	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit D			FRE 401, 402, 403, 602, 801, 802	
7463	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit E			FRE 401, 402, 403, 602, 801, 802	
7464	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit F			FRE 401, 402, 403, 602, 801, 802	
7465	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 1			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7466	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 2			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7467	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 3			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7468	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 4			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7469	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 5			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7470	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 6			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7471	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 7			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7472	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 8			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7473	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 9			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7474	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 1			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7475	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 2			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7476	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 3			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7477	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 4			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7478	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 5			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7479	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 6			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7480	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 7			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7481	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 8			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7482	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 9			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7483	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7484	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7485	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7486	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7487	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7488	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7489	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7490	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7491	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 18			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7492	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 19			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7493	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 20			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7494	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 21			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7495	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 22			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7496	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 23			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7497	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 24			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7498	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 25			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7499	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 26			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7500	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 27			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7501	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 28			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7502	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 29			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7503	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 30			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7504	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 31			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7505	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 32			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7506	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 33			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7507	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 34			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7508	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 35			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7509	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 36			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7510	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 37			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7511	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 38			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7512	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 39			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7513	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 40			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7514	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 41			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7515	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 42			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7516	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 43			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7517	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 44			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7518	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 45			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7519	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 46			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7520	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 47			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7521	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 48			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7522	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 49			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7523	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 50			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7524	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 51			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7525	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 52			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7526	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 53			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7527	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 54			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7528	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 55			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7529	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 56			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7530	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 57			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7531	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 58			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7532	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 59			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7533	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 60			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7534	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 61			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7535	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 62			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7536	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 63			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7537	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 64			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7538	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 65			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7539	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 66			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7540	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 67			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7541	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 68			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7542	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 69			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7543	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 70			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7544	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 71			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7545	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 72			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7546	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 73			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7547	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 74			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7548	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 75			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7549	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 76			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7550	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 77			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7551	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 78			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7552	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 79			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7553	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 80			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7554	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 81			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7555	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 82			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7556	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 83			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7557	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 84			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7558	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 85			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7559	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 86			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7560	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 87			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7561	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 88			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7562	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 89			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7563	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 90			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7564	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 91			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7565	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 92			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7566	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 93			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7567	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 94			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7568	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 95			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7569	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 96			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7570	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 97			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7571	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 98			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7572	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 99			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7573	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 100			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7574	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 101			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7575	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 102			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7576	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 103			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7577	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 104			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7578	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 105			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7579	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 106			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7580	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 107			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7581	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 108			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7582	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 109			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7583	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 110			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7584	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 111			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7585	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 112			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7586	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 113			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7587	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 114			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7588	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 115			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7589	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 116			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7590	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 117			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7591	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 118			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7592	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 119			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7593	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 120			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7594	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 121			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7595	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 122			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7596	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 123			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7597	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 124			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7598	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 125			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7599	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 126			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7600	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 127			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7601	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 128			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7602	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 129			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7603	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 130			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7604	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 131			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7605	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 132			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7606	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 133			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7607	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 134			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7608	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 135			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7609	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 136			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7610	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 137			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7611	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 138			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7612	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 139			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7613	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 140			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7614	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 141			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7615	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 142			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7616	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 143			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7617	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 144			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7618	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 145			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7619	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 146			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7620	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 147			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7621	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 148			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7622	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 149			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7623	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 148			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7624	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 149			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7625	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 150			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7626	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 151			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7627	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 152			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7628	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 153			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7629	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 154			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7630	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 155			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7631	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 156			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7632	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 157			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7633	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 158			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7634	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 159			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7635	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 160			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7636	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 161			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7637	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 162			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7638	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 163			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7639	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 164			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7640	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 165			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7641	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 166			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7642	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 167			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7643	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 168			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7644	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 169			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7645	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 170			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7646	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 171			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7647	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 172			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7648	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 173			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7649	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 174			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7650	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 175			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7651	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 176			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7652	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 177			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7653	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 178			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7654	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 179			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7655	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 180			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7656	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 181			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7657	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 182			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7658	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 183			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7659	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 184			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7660	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 185			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7661	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 186			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7662	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 187			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7663	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 188			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7664	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 189			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7665	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 190			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7666	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 191			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7667	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 192			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7668	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 193			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7669	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 194			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7670	Fasching MDL Report dated May 11, 2017; Interaction with sharp chamfer, Figures 14a, 17a, 85a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7671	Fasching MDL Report dated May 11, 2017; Fracture of outside of a high stress area, Figures 63a (Arm 2), 94 (Arm 1), 156 (Arm 1)			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7672	Fasching MDL Report dated May 11, 2017; Inclusions at initiation site: Figures 83 a & b, 44 b, and 123 b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7673	Fasching MDL Report dated May 11, 2017 ; Initiations not at surface defect, Figures 142 a & b; 146 a & b, 65 b.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7674	April 14, 2017 Report of Dr. Briant, Pictures from Figure 1			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7675	April 14, 2017 Report of Dr. Briant, Pictures from Figure 2			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7676	April 14, 2017 Report of Dr. Briant, Pictures from Figure 3			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7677	April 14, 2017 Report of Dr. Briant, Pictures from Figure 4			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7678	April 14, 2017 Report of Dr. Briant, Pictures from Figure 5			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7679	April 14, 2017 Report of Dr. Briant, Pictures from Figure 6			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7680	April 14, 2017 Report of Dr. Briant, Pictures from Figure 7			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7681	April 14, 2017 Report of Dr. Briant, Pictures from Figure 8			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7682	April 14, 2017 Report of Dr. Briant, Pictures from Figure 9			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7683	April 14, 2017 Report of Dr. Briant, Pictures from Figure 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7684	April 14, 2017 Report of Dr. Briant, Pictures from Figure 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7685	April 14, 2017 Report of Dr. Briant, Pictures from Figure 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7686	April 14, 2017 Report of Dr. Briant, Pictures from Figure 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7687	April 14, 2017 Report of Dr. Briant, Pictures from Figure 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7688	April 14, 2017 Report of Dr. Briant, Pictures from Figure 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7689	April 14, 2017 Report of Dr. Briant, Pictures from Figure 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7690	April 14, 2017 Report of Dr. Briant, Pictures from Figure 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7691	April 14, 2017 Report of Dr. Briant, Pictures from Figure 18			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7692	April 14, 2017 Report of Dr. Briant, Pictures from Figure 19			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7693	April 14, 2017 Report of Dr. Briant, Pictures from Figure 20			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7694	April 14, 2017 Report of Dr. Briant, Pictures from Figure 21			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7695	April 14, 2017 Report of Dr. Briant, Pictures from Figure 22			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7696	April 14, 2017 Report of Dr. Briant, Pictures from Figure 23			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7697	April 14, 2017 Report of Dr. Briant, Pictures from Figure 24			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7698	April 14, 2017 Report of Dr. Briant, Pictures from Figure 25			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7699	April 14, 2017 Report of Dr. Briant, Pictures from Figure 26			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7700	April 14, 2017 Report of Dr. Briant, Pictures from Figure 27			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7701	April 14, 2017 Report of Dr. Briant, Pictures from Figure 28			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7702	April 14, 2017 Report of Dr. Briant, Pictures from Figure 29			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7703	April 14, 2017 Report of Dr. Briant, Pictures from Figure 30			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7704	April 14, 2017 Report of Dr. Briant, Pictures from Figure 31			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7705	April 14, 2017 Report of Dr. Briant, Pictures from Figure 32			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7706	April 14, 2017 Report of Dr. Briant, Pictures from Figure 33			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7707	April 14, 2017 Report of Dr. Briant, Pictures from Figure 34			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7708	April 14, 2017 Report of Dr. Briant, Pictures from Figure 35			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7709	April 14, 2017 Report of Dr. Briant, Pictures from Figure 36			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7710	April 14, 2017 Report of Dr. Briant, Pictures from Table 1			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7711	April 14, 2017 Report of Dr. Briant, Pictures from Table 2			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7712	April 14, 2017 Report of Dr. Briant, Pictures from Table 3			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7713	April 14, 2017 Report of Dr. Briant, Pictures from Table 4			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7714	April 14, 2017 Report of Dr. Briant, Pictures from Table 5			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7715	April 14, 2017 Report of Dr. Briant, Pictures from Table 6			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7716	April 14, 2017 Report of Dr. Briant, Pictures from Table 7			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7717	April 14, 2017 Report of Dr. Briant, Pictures from Table 8			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7718	http://www.preservetrial.com			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7719	https://clinicaltrials.gov/ct2/show/study/NCT02381509			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7720	July 12, 2017, Expert Report of Paul Briant, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7721	June 29, 2017, Expert Report of Daniel Cousin, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7722	July 31, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7723	July 10, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7724	July 9, 2017, Expert Report of Piotr Sobieszczyk, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7725	April 13, 2017, Expert Report of Christine L. Brauer			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7726	April 14, 2017, Expert Report of Paul Briant, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7727	April 14, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7728	April 14, 2017, Expert Report of David W. Fiegall, Jr., M.D., M.P.H.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7729	April 14, 2017, Expert Report of Clement J. Grassi, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7730	April 14, 2017, Expert Report of Christopher S. Morris, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7731	April 14, 2017, Expert Report of Ronald A. Thisted, Ph.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7732	April 14, 2017, Expert Report of Donna-Bea Tillman, Ph.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7733	May 12, 2017, Expert Report of Christine L. Brauer			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7734	May 12, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7735	May 12, 2017, Expert Report of Donna-Bea Tillman, Ph.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7736	CV of Christine L. Brauer			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7737	CV of Paul Briant, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7738	CV of Daniel Cousin, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7739	CV of Audrey Fasching, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7740	CV of David W. Fiegall, Jr., M.D., M.P.H.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7741	CV of Clement J. Grassi, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7742	CV of Christopher S. Morris, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7743	CV of Piotr Sobieszczyk, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7744	CV of Ronald A. Thisted, Ph.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7745	CV of Donna-Bea Tillman, Ph.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7746	Photos from Dr. Morris re SNF			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7747	Bard Filter Complication Rates			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7748	NMT's 510(k) (K963014) for modifications to the SNF/Straight Line System (Summary)			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
7749	FDA concurrence letter for K963014			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
7750	FDA concurrence letter for K970099			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
7751	1989 FDA Guidance re Medical Device Labeling			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7752	2005 FDA Guidance re Good Pharmacovigilance Practices and Pharmacoeconomic Assessment			FRE 801; 802	
7753	2014 Draft FDA Guidance re Benefit-Risk Factors When Determining Substantial Equivalence in Premarket Notifications 510k with Different Technological Characteristics			FRE 801; 802	
7754	2014 FDA Guidance re Distinguishing Medical Device Recalls from Medical Device Enhancements			FRE 801; 802	
7755	2011 Draft FDA Guidance re Responding to Unsolicited Requests for Off-Label Information			FRE 801; 802	
7756	2017 FDA Guidance Deciding When to Submit a 510k for a Change to an Existing Device			FRE 801; 802	
7757	2002 FDA Guidance re Determination of Intended Use for 510k Devices			FRE 801; 802	
7758	2014 FDA Guidance re 510k Evaluating Substantial Equivalence in Premarket Notifications			FRE 801; 802	
7759	CDRH Preliminary Internal Evaluations - Volume I			FRE 801; 802	
7760	2017 Public Health Interests and First Amendment Consideration Related to Manufacturer Communications			FRE 801; 802	
7761	2015 Draft Public Notification of Emerging Postmarket Medical Device Signals			FRE 801; 802	
7762	2016 FDA Guidance Medical Device Reporting for Manufacturers			FRE 801; 802	
7763	Braun Vena Tech Jugular – 2010			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7764	Braun Vena Tech Jugular – 2015			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7765	Braun Vena Tech Femoral – 2015			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7766	Cook Celect Platinum Jugular and Femoral – 2015 deployment guide			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7767	Boston Scientific Greenfield Stainless Steel and Titanium – 2011 brochure with performance stats			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7768	Cordis Optease Femoral Jugular Antecubital – 2017			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7769	ALN Jugular-Brachial and Femoral-Popliteal – 2013 procedure guide			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7770	Braun Vena Tech Convertible Femoral & Jugular – February 2016			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7771	Braun Vena Tech LP Femoral – October 2010			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7772	Greenfield Stainless Steel – November 2001			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7773	Argon Option IFU - 2017			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7774	Argon Option Elite IFU - 2017			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7775	Cook Celect Femoral 2008			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7776	Cook Celect Femoral & Jugular 2009			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7777	Cook Celect Platinum Femoral & Jugular 2012			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7778	Cool Giantruco-Roehm Bird's Nest Femoral & Jugular 2008			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7779	Cool Giantruco-Roehm Bird's Nest Radoipaque band Femoral & Jugular 2008			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7780	Cook Gunther Tulip Jugular 2003			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7781	Cook Gunther Tulip Jugular 2005			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7782	Cook Gunther Tulip Jugular & Femoral 2006			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7783	Cook Gunther Tulip Femoral 2006			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7784	Cook Gunther Tulip Jugular 2008			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7785	Cook Gunther Tulip Jugular & Femoral 2009			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7786	Greenfield Over the Wire Femoral & Jugular 2004			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7787	Cordis Optease Femoral Jugular Antecubital – 2013			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7788	ALN Filter with Hook Jugular 2014			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7789	Volcano Crux VCF Femoral Jugular 2016			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7790	Coumadin Package Inserts			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7791	Lovenox Package Inserts			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7792	Various Anticoagulant Package Inserts			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7793	G2 Filter exemplar			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7794	Screenshot from FDA, Manufacturer and User Facility Device Experience Database - (MAUDE), available online at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/ReportingAdverseEvents/ucm127891.htm			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7795	Screenshot from FDA, MAUDE - Manufacturer and User Facility Device Experience, available online at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7796	Removable Embolus Blood Clot Filter and Filter Delivery System, January 1, 2008, US Patent No. 7,314,477 B1			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7797	G2 Bench testing videos			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7798	2010 FDA Safety Communication: Removing Retrievable Inferior Vena Cava Filters			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
7799	2014 FDA Safety Communication: Removing Retrievable Inferior Vena Cava Filters			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
7800	Kessler Invoices			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7801	Demonstrative (Chart of Complication Rates)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7802	Demonstrative (IVC Filter Implant and Explant Animations)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7803	Demonstrative (IVC Filter Clot Trapping Animations)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7804	Demonstrative (Diagram of Venous System)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7805	Demonstrative (Picture of Bard G2 Filter)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7806	Demonstrative (Pulmonary Embolism Statistics)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7807	Demonstrative (Animations of Plaintiff's Medical Course)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7808	Demonstrative (Timeline of Plaintiff's Medical Course)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7809	Demonstrative Slides for Dr. Paul Briant			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7810	Flip Chart and/or demonstrative exhibit describing reporting trends for Dr. Ronald Thisted			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7811	Briant Demonstrative Exhibit, Definitions – Stress, Strain and Stiffness			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7812	Briant Demonstrative Exhibit, Exponent and McMeeking Calculation Approach Comparison			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7813	Briant Demonstrative Exhibit, IVC and Surrounding Tissues			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7814	Briant Demonstrative Exhibit, Exponent and McMeeking Strain Calculation Input Comparison			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7815	Briant Demonstrative Exhibit, Exponent Model Validation			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7816	Briant Demonstrative Exhibit, Exponent and McMeeking Strain Results Comparison			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7817	Briant Demonstrative Exhibit, Summary of Exponent versus McMeeking Analysis			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7818	US Patent No. 6,007,558 titled "Removable Embolus Blood Clot Filter" assigned on 12/28/1999			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7819	G2 technical drawings			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7820	American National Standard ANSI AAMI ISO 25539-3 (2011)			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7821	Demonstrative depiction of inferior vena cava			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7822	Demonstrative depiction of dynamic environment of inferior vena cava			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7823	Demonstrative depiction of pulmonary embolism			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7824	Demonstrative depiction of IVC filter catching a clot			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7825	Demonstrative depiction of the development of a deep vein thrombosis			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7826	Demonstrative depiction of abdominal anatomy			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7827	Demonstrative depiction of IVC filter placement			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7828	Demonstrative depiction of IVC filter retrieval			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7829	Demonstrative depiction of CT scans			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7830	Demonstrative depiction of IVC filter migration			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7831	Demonstrative depiction of IVC filter appearing to migrate			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7857	Demonstrative depiction of endothelialization of filter strut			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7858	Demonstrative depiction of leads in the heart			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7859	Demonstrative depiction of non-filter mechanical devices in the heart			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7860	Demonstrative depiction of kidney stones			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7861	Demonstrative depiction of abdominal hernias			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7862	Demonstrative depiction of colitis			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7863	Demonstrative depiction of pericarditis			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7864	Demonstrative depiction of costochondritis			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7865	Demonstrative depiction of medical literature regarding complications of IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7866	Demonstrative depiction of medical literature regarding efficacy of IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7867	Demonstrative depiction of the medical literature regarding complications associated with the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7868	Demonstrative depiction of the medical literature regarding complications associated with the Simon Nitinol Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7869	Demonstrative depiction of the medical literature regarding complications associated with the Recovery Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7870	Demonstrative depiction of the medical literature regarding complications associated with non-Bard IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7871	Demonstrative depiction of IVC filter design considerations			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7872	Demonstrative depiction of the Recovery Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7873	Demonstrative depiction of the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7874	Demonstrative depiction of the Simon Nitinol Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7875	Demonstrative depiction of differences between the Recovery Filter and the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7876	Demonstrative depiction of Instructions for Use regarding non-Bard IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7877	Demonstrative depiction of the G2 Filter Instructions for Use			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7878	Demonstrative depiction of MAUDE database disclaimers			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7879	Demonstrative depiction of spontaneous adverse event reporting biases and limitations			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7880	Demonstrative depiction of errors in Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7881	Demonstrative depiction of errors in Fracture and distant migration of the Bard Recovery filter: a retrospective review of 363 implantations for potentially life-threatening complications			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7882	Demonstrative depiction of errors in Prevalence and clinical consequences of fracture and fragment migration of the Bard G2 filter: imaging and clinical follow-up in 684 implantations			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7883	Demonstrative depiction regarding hierarchy of scientific evidence			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7884	Demonstrative depiction of where the medical literature regarding IVC filters falls within the hierarchy of scientific evidence			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7885	Demonstrative depiction comparing the medical literature regarding the G2 Filter and the Simon Nitinol Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7886	Demonstrative depiction comparing the medical literature regarding the Recovery Filter and the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7887	Demonstrative depiction comparing the medical literature regarding the G2 Filter and non-Bard IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7888	Demonstrative depiction comparing complication rates of the G2 Filter to rates of complication identified in the 2001 "SIR Guidelines"			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7889	Demonstrative depiction comparing complication rates of the G2 Filter to rates of complication identified in the 2017 "SIR Guidelines"			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7890	Demonstrative depiction of the process by which the 2001 Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism were created			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7891	Demonstrative depiction of the process by which the 2003 Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism were created			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7892	Demonstrative depiction regarding the 2011 Quality Improvement Guidelines for the Performance of Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7893	Demonstrative depiction regarding the 2014 ACR-SIR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7894	Demonstrative depiction regarding the 2016 ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7895	Demonstrative depiction regarding the 2017 ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7896	Demonstrative depiction of Bard's internal complication rates for the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7897	Demonstrative depiction of Bard's internal complication rates for the Recovery Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7898	Demonstrative depiction of sales of the Simon Nitinol Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7899	Demonstrative depiction of sales of the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7900	Demonstrative depiction of sales of Bard's retrievable IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7901	Demonstrative depiction of bench testing regarding the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7902	Demonstrative depiction of animal testing regarding the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7903	Demonstrative depiction of clinical trial testing regarding the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7904	Demonstrative depiction of Bard's interaction with the FDA regarding the G2 Filter before clearance on August 29, 2005			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7905	Demonstrative depiction of Bard's interaction with the FDA regarding the G2 Filter after clearance on August 29, 2005			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7906	Demonstrative depiction of Bard's interaction with the FDA regarding the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7907	Demonstrative depiction of Bard's interaction with the FDA regarding the clinical trial EVEREST			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7908	Demonstrative depiction regarding EVEREST clinical trial material			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7909	Demonstrative depiction of post-market adverse event tracking regarding the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7910	Demonstrative depiction of Bard's actions concerning caudal migration investigation			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7911	Demonstrative depiction of Weber effect			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7912	Demonstrative depiction of adverse event reporting trends			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7913	Demonstrative depiction of the physicians who read imaging regarding the plaintiff's G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7914	Demonstrative regarding mission statement / core values			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7915	Placeholder/demonstrative for Bard's community activities/engagement			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7916	21 CFR 803.50 - Individual adverse event reports; manufacturers			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7917	Dr. Vogelzang's invoices			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7918	Dr. Desai's invoices			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7919	Screenshots of NWIR Filter Clinic website - http://ivcfilter.nm.org/about-ivc-filters.html			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7920	Screenshots of NWIR Filter Clinic website - http://ivcfilter.nm.org/for-physicians.html			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7921	Screenshots of NWIR Filter Clinic website - http://ivcfilter.nm.org/after-placement.html			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7922	NWIR Calculator Screenshots - http://ivcfilter.nm.org/calculator.html			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7923	Meridian Femoral IFU, 10/10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7924	2017 Arizona Bioindustry Association Publication			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7925	Bard Filter Rate information for Recovery, G2, and G2X			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7926	Demonstrative depiction of permanent IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7927	Demonstrative depiction of retrievable IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7928	Demonstrative: Tillman- 2004-2005 recovery filter regulatory history			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7929	Demonstrative: Tillman- regulatory process			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7930	Demonstrative: Tillman Opinions			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7931	Demonstrative: Everest			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7932	Demonstrative: The Design Environment			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7933	Demonstrative: Powerpoint slides prepared by Dr Morris			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7934	Demonstrative: Summary of TR EX 5022			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7935	Demonstrative: Briant- compilation of exhibits 7708 and 7717			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7936	Demonstrative: Briant- compilation of exhibits 7703 and 7704			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7937	Fasching Demonstrative – Recovery & G2 Filter Fracture Data Summary			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7938	Overview of Dr. Grassi's opinions			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7939	Description of the process by which the 2001 SIR Guidelines were written			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7940	Table 1 from the 2001 SIR Guidelines			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7941	Table 2 from the 2001 SIR Guidelines			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7942	Complication rates through 2016			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7943	Demonstrative - SIR Guidelines			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7944	Demonstrative - Briant Opinions Summary			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7945	Demonstrative- Briant- Tissue Stress-Strain Response			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7946	Demonstrative- Briant- Bard Analysis and Testing Summary			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7947	Demonstrative- Briant- animation of filter pulsation			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7952	G2 Platinum, Project #8088- Meeting Minutes- 4/14/09			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7957	Whitehall, T.; Caval Interruption Method: Comparison of Options, Seminary in Vascular Surgery, Vol. 9, No 1 (March), 1966: pp 59-69			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7960	Chart: IVC Filters, Clinical Overview	BPV-17-01-00255260	BPV-17-01-00255261	Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7961	Coroporate Quality Assurance Manual, Standard for Product Complaint Handling	BPV-17-01-00200167	BPV-17-01-00200187	Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7962	Coroporate Quality Assurance Manual, Standard for Medical Device Reporting	BPV-17-01-002022921	BPV-17-01-002022934	Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7963	G2 Filter FAQ's	BPV-17-01-00060150	BPV-17-01-00060153	Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7964	Exhibit Placeholder			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7965	Exhibit Placeholder			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7966	Exhibit Placeholder			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7967	Exhibit Placeholder			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7968	2017.07.12 - Deposition of Michael Streiff Exhibit 04			401; 402; 403; 801; 802	801; 802
7969	2017.07.12 - Deposition of Michael Streiff Exhibit 05			401; 402; 403; 801; 802	801; 802
7970	2017.07.12 - Deposition of Michael Streiff Exhibit 07			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7971	Aujesky, A prediction rule to identify low risk patients with pulmonary embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7972	Goldhaber, Acute pulmonary embolism clinical outcomes in the International Cooperative Pulmonary Embolism Registry			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7973	Soloff, Acute pulmonary embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7974	Trujillo-Santos, Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7975	Shoeb, Assessing Bleeding Risk in Patients Taking Anticoagulants			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7976	Carson, Clinical Course of PE			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7977	Coon, Deep venous thrombosis and pulmonary embolism prediction prevention and treatment			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7978	Nieto, Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7979	Levine, Hemorrhagic Complications of Anticoagulant Treatment			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7980	Rubboli, Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7981	Horlander, Pulmonary Embolism Mortality in the United States 1979 to 1998			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7982	Streiff 2000 - Vena Caval Filters- A comprehensive review			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7983	Streiff 2003 - Outpatient therapy with low molecular weight heparin for treatment of venous thromboembolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7984	Streiff 2003 - Vena Caval Filters- A Review for Intensive Care Specialists			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7985	Streiff 2003 -Diagnosis and treatment of deep venous thrombosis and pulmonary embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7986	Streiff 2005 Hann 2005 - The role of vena caval filters in the management of venous thromboembolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7987	Streiff 2006 - Kaufman 2006 - Guidelines for the use of retrievable and convertible vena cava filters - SIR			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7988	Streiff 2006 - Kaufman Guidelines for the use of retrievable and convertible vena cava filters - SIR Multidisciplinary Consensus Conference			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7989	Streiff 2007 - A Management of Venous Thromboembolism A Systematic Review for Practice Guidelines			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7990	Streiff 2007 - Segal - Management of Venous Thromboembolism A Systematic Review for a Practice Guideline			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7991	Streiff 2007 - The NCCN guidelines on venous thromboembolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7992	Streiff 2008 - Kim A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7993	Streiff 2008 Catheter-directed thrombolysis of inferior vena cava thrombosis in a 13-day old neonate and review of literature			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7994	Streiff 2009 - Development of a research agenda for inferior vena cava filters-multidisciplinary research consensus panel.			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7995	Streiff 2009 - Tschoe 2009 - Retrievable vena cava filters- A clinical review			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7996	Streiff 2010 -Raman Inferior vena cava filters in the management of cancer-associated venous thromboembolism- a systematic review			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7997	Streiff 2012 - Thromboprophylaxis in nonsurgical patients			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7998	Streiff 2013 - Rajasekhar 2013 - Use of vena cava filters and venous access devices			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7999	Streiff 2013 - Rajasekhar 2013 - Vena cava filters for management of venous thromboembolism- A clinical review			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8000	Streiff 2013 - Thromboprophylaxis in nonsurgical patients			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8001	Streiff 2015 - Predicting the risk of recurrent venous thromboembolism (VTE)			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8002	Nijkeuter, The Natural Course of Hemodynamically Stable Pulmonary Embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8003	Konstantinides, Trends in incidence versus case fatality rates of pulmonary embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8004	Jimenez, Trends in the Management and Outcomes of Acute Pulmonary Embolism Analysis From Acute Pulmonary Embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8005	Nieto, Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8006	Witt, What to do after the bleed resuming anticoagulation after major bleeding			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8007	Marconi - Five year follow up of pulmonary embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8008	Kuo - Image Guided Interventions			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8009	Olin - Pulmonary Embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8010	Wood - Major Pulmonary Embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8011	Gerber - The incidence of and risk factors for venous thromboembolism and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8012	Petty - Complications of Long Term Anticoagulation			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8013	Lankiewicz - Urgent reversal of warfarin with prothrombin complex concentrate			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8014	Schulman - Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8140	Darren Hurst, 11/1/16 deposition Exhibit 10			801; 802	801; 802
8141	Darren Hurst, 11/1/16 deposition Exhibit 11			801; 802	801; 802
8142	Darren Hurst, 11/1/16 deposition Exhibit 12			801; 802	801; 802
8143	Darren Hurst, 11/1/16 deposition Exhibit 13			801; 802	801; 802
8144	Darren Hurst, 11/1/16 deposition Exhibit 14			801; 802	801; 802
8145	Darren Hurst, 11/1/16 deposition Exhibit 15			801; 802	801; 802
8146	Darren Hurst, 11/1/16 deposition Exhibit 16			801; 802	801; 802
8147	Darren Hurst, 11/1/16 deposition Exhibit 17			801; 802	801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8148	Darren Hurst, 11/1/16 deposition Exhibit 18			801; 802	801; 802
8149	Darren Hurst, 11/1/16 deposition Exhibit 19			801; 802	801; 802
8150	Darren Hurst, 11/1/16 deposition Exhibit 20			801; 802	801; 802
8151	Darren Hurst, 11/1/16 deposition Exhibit 21			801; 802	801; 802
8152	Darren Hurst, 11/1/16 deposition Exhibit 22			801; 802	801; 802
8153	Darren Hurst, 11/1/16 deposition Exhibit 23			801; 802	801; 802
8154	Darren Hurst, 11/1/16 deposition Exhibit 24			801; 802	801; 802
8155	Darren Hurst, 11/1/16 deposition Exhibit 25			801; 802	801; 802
8156	Darren Hurst, 11/1/16 deposition Exhibit 26			801; 802	801; 802
8157	Darren Hurst, 11/1/16 deposition Exhibit 27			801; 802	801; 802
8158	Darren Hurst, 7/21/17 deposition Exhibit 01			801; 802	801; 802
8159	Darren Hurst, 7/21/17 deposition Exhibit 02			801; 802	801; 802
8160	Darren Hurst, 7/21/17 deposition Exhibit 03			801; 802	801; 802
8161	Darren Hurst, 7/21/17 deposition Exhibit 04			801; 802	801; 802
8162	Darren Hurst, 7/21/17 deposition Exhibit 05			801; 802	801; 802
8163	Darren Hurst, 7/21/17 deposition Exhibit 06			801; 802	801; 802
8164	Darren Hurst, 7/21/17 deposition Exhibit 07			801; 802	801; 802
8165	Darren Hurst, 7/21/17 deposition Exhibit 08			801; 802	801; 802
8166	Darren Hurst, 7/21/17 deposition Exhibit 09			801; 802	801; 802
8167	Darren Hurst, 7/21/17 deposition Exhibit 10			801; 802	801; 802
8168	Darren Hurst, 7/21/17 deposition Exhibit 11			801; 802	801; 802
8169	Darren Hurst, 7/21/17 deposition Exhibit 12			801; 802	801; 802
8170	Darren Hurst, 7/21/17 deposition Exhibit 13			801; 802	801; 802
8171	Darren Hurst, 7/21/17 deposition Exhibit 14			801; 802	801; 802
8172	Darren Hurst, 7/21/17 deposition Exhibit 15			801; 802	801; 802
8173	Darren Hurst, 8/19/16 deposition Exhibit 01			801; 802	801; 802
8174	Darren Hurst, 8/19/16 deposition Exhibit 02			801; 802	801; 802
8175	Darren Hurst, 8/19/16 deposition Exhibit 03			801; 802	801; 802
8176	Darren Hurst, 8/19/16 deposition Exhibit 04			801; 802	801; 802
8177	Darren Hurst, 8/19/16 deposition Exhibit 05			801; 802	801; 802
8178	Darren Hurst, 8/19/16 deposition Exhibit 06			801; 802	801; 802
8179	Darren Hurst, 8/19/16 deposition Exhibit 07			801; 802	801; 802
8180	Darren Hurst, 8/19/16 deposition Exhibit 08			801; 802	801; 802
8181	Darren Hurst, 8/19/16 deposition Exhibit 09			801; 802	801; 802
8182	Darren Hurst, 8/7/17 deposition Exhibit 16			801; 802	801; 802
8183	Darren Hurst, 8/7/17 deposition Exhibit 17			801; 802	801; 802
8184	Darren Hurst, 8/7/17 deposition Exhibit 18			801; 802	801; 802
8185	Darren Hurst, 8/7/17 deposition Exhibit 19			801; 802	801; 802
8186	Darren Hurst, 8/7/17 deposition Exhibit 20			801; 802	801; 802
8187	Darren Hurst, 8/7/17 deposition Exhibit 21			801; 802	801; 802
8188	Darren Hurst, 8/7/17 deposition Exhibit 22			801; 802	801; 802
8189	Darren Hurst, 8/7/17 deposition Exhibit 23			801; 802	801; 802
8190	Darren Hurst, 8/7/17 deposition Exhibit 24			801; 802	801; 802
8191	Darren Hurst, 8/7/17 deposition Exhibit 25			801; 802	801; 802
8192	Darren Hurst, 8/7/17 deposition Exhibit 26			801; 802	801; 802
8196	David Garcia, 6/21/2017 deposition Exhibit 01			801; 802	801; 802
8197	David Garcia, 6/21/2017 deposition Exhibit 02			801; 802	801; 802
8198	David Garcia, 6/21/2017 deposition Exhibit 02a			801; 802	801; 802
8199	David Garcia, 6/21/2017 deposition Exhibit 03			801; 802	801; 802
8200	David Garcia, 6/21/2017 deposition Exhibit 04			801; 802	801; 802
8201	David Garcia, 6/21/2017 deposition Exhibit 05			801; 802	801; 802
8202	David Garcia, 6/21/2017 deposition Exhibit 06			801; 802	801; 802
8203	David Garcia, 6/21/2017 deposition Exhibit 07			801; 802	801; 802
8204	David Garcia, 6/21/2017 deposition Exhibit 08			801; 802	801; 802
8205	David Garcia, 6/21/2017 deposition Exhibit 09			801; 802	801; 802
8206	David Garcia, 6/21/2017 deposition Exhibit 10			801; 802	801; 802
8207	David Garcia, 6/21/2017 deposition Exhibit 11			801; 802	801; 802
8208	David Garcia, 6/21/2017 deposition Exhibit 12			801; 802	801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8209	Derek Muehrcke, 7/21/15 deposition Exhibit 01			801; 802	801; 802
8210	Derek Muehrcke, 7/21/15 deposition Exhibit 02			801; 802	801; 802
8211	Derek Muehrcke, 7/21/15 deposition Exhibit 03			801; 802	801; 802
8212	Derek Muehrcke, 7/21/15 deposition Exhibit 04			801; 802	801; 802
8213	Derek Muehrcke, 7/21/15 deposition Exhibit 05			801; 802	801; 802
8214	Derek Muehrcke, 7/21/15 deposition Exhibit 06			801; 802	801; 802
8215	Derek Muehrcke, 7/21/15 deposition Exhibit 07			801; 802	801; 802
8216	Derek Muehrcke, 7/21/15 deposition Exhibit 08			801; 802	801; 802
8217	Derek Muehrcke, 7/21/15 deposition Exhibit 09			801; 802	801; 802
8218	Derek Muehrcke, 7/21/15 deposition Exhibit 10			801; 802	801; 802
8219	Derek Muehrcke, 7/21/15 deposition Exhibit 11			801; 802	801; 802
8220	Derek Muehrcke, 7/21/15 deposition Exhibit 12			801; 802	801; 802
8221	Derek Muehrcke, 7/21/15 deposition Exhibit 13			801; 802	801; 802
8222	Derek Muehrcke, 7/21/15 deposition Exhibit 14			801; 802	801; 802
8223	Derek Muehrcke, 7/21/15 deposition Exhibit 15			801; 802	801; 802
8224	Derek Muehrcke, 7/21/15 deposition Exhibit 16			801; 802	801; 802
8225	Derek Muehrcke, 7/21/15 deposition Exhibit 17			801; 802	801; 802
8226	Derek Muehrcke, 7/21/15 deposition Exhibit 18			801; 802	801; 802
8227	Derek Muehrcke, 7/21/15 deposition Exhibit 19			801; 802	801; 802
8228	Derek Muehrcke, 7/21/15 deposition Exhibit 20			801; 802	801; 802
8229	Derek Muehrcke, 7/24/17 deposition Exhibit 01			801; 802	801; 802
8230	Derek Muehrcke, 7/24/17 deposition Exhibit 02			801; 802	801; 802
8231	Derek Muehrcke, 7/24/17 deposition Exhibit 03			801; 802	801; 802
8232	Derek Muehrcke, 7/24/17 deposition Exhibit 04			801; 802	801; 802
8233	Derek Muehrcke, 7/24/17 deposition Exhibit 05			801; 802	801; 802
8234	Derek Muehrcke, 7/24/17 deposition Exhibit 06			801; 802	801; 802
8235	Derek Muehrcke, 7/24/17 deposition Exhibit 07			801; 802	801; 802
8236	Derek Muehrcke, 7/24/17 deposition Exhibit 08			801; 802	801; 802
8237	Derek Muehrcke, 7/24/17 deposition Exhibit 09			801; 802	801; 802
8238	Derek Muehrcke, 7/24/17 deposition Exhibit 10			801; 802	801; 802
8239	Derek Muehrcke, 7/24/17 deposition Exhibit 11			801; 802	801; 802
8240	Derek Muehrcke, 7/24/17 deposition Exhibit 12			801; 802	801; 802
8241	Derek Muehrcke, 7/24/17 deposition Exhibit 13			801; 802	801; 802
8242	Derek Muehrcke, 7/24/17 deposition Exhibit 14			801; 802	801; 802
8243	Derek Muehrcke, 7/24/17 deposition Exhibit 15			801; 802	801; 802
8247	James Matthew Sims, 7/26/17 deposition Exhibit 01			801; 802	801; 802
8248	James Matthew Sims, 7/26/17 deposition Exhibit 02			801; 802	801; 802
8249	James Matthew Sims, 7/26/17 deposition Exhibit 03			801; 802	801; 802
8250	James Matthew Sims, 7/26/17 deposition Exhibit 04			801; 802	801; 802
8251	James Matthew Sims, 7/26/17 deposition Exhibit 05			801; 802	801; 802
8252	James Matthew Sims, 7/26/17 deposition Exhibit 06			801; 802	801; 802
8253	James Matthew Sims, 7/26/17 deposition Exhibit 07			801; 802	801; 802
8254	James Matthew Sims, 7/26/17 deposition Exhibit 08			801; 802	801; 802
8255	James Matthew Sims, 7/26/17 deposition Exhibit 09			801; 802	801; 802
8256	James Matthew Sims, 7/26/17 deposition Exhibit 10			801; 802	801; 802
8257	James Matthew Sims, 7/26/17 deposition Exhibit 11			801; 802	801; 802
8258	James Matthew Sims, 7/26/17 deposition Exhibit 12			801; 802	801; 802
8259	Kenneth Herbst, 10/7/14 deposition Exhibit 01			801; 802	801; 802
8260	Kenneth Herbst, 10/7/14 deposition Exhibit 02			801; 802	801; 802
8261	Kenneth Herbst, 10/7/14 deposition Exhibit 03			801; 802	801; 802
8262	Kenneth Herbst, 10/7/14 deposition Exhibit 04			801; 802	801; 802
8263	Kenneth Herbst, 10/7/14 deposition Exhibit 05			801; 802	801; 802
8264	Kenneth Herbst, 10/7/14 deposition Exhibit 06			801; 802	801; 802
8265	Kenneth Herbst, 10/7/14 deposition Exhibit 07			801; 802	801; 802
8266	Kenneth Herbst, 7/26/17 deposition Exhibit 1018			801; 802	801; 802
8267	Kenneth Herbst, 7/26/17 deposition Exhibit 1019			801; 802	801; 802
8268	Kenneth Herbst, 7/26/17 deposition Exhibit 1022			801; 802	801; 802
8274	Michael Streiff, 7/12/17 deposition Exhibit 01			801; 802	801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8275	Michael Streiff, 7/12/17 deposition Exhibit 02			801; 802	801; 802
8276	Michael Streiff, 7/12/17 deposition Exhibit 03			801; 802	801; 802
8277	Michael Streiff, 7/12/17 deposition Exhibit 04			801; 802	801; 802
8278	Michael Streiff, 7/12/17 deposition Exhibit 05			801; 802	801; 802
8279	Michael Streiff, 7/12/17 deposition Exhibit 06			801; 802	801; 802
8280	Michael Streiff, 7/12/17 deposition Exhibit 07			801; 802	801; 802
8281	Michael Streiff, 7/12/17 deposition Exhibit 08			801; 802	801; 802
8282	Michael Streiff, 7/12/17 deposition Exhibit 09			801; 802	801; 802
8283	Michael Streiff, 7/12/17 deposition Exhibit 10			801; 802	801; 802
8284	Michael Streiff, 7/12/17 deposition Exhibit 11			801; 802	801; 802
8285	Michael Streiff, 7/12/17 deposition Exhibit 12			801; 802	801; 802
8286	Michael Streiff, 7/12/17 deposition Exhibit 13			801; 802	801; 802
8287	Moni Stein, 7/31/17 deposition Exhibit 1023			801; 802	801; 802
8288	Moni Stein, 7/31/17 deposition Exhibit 1024			801; 802	801; 802
8289	Moni Stein, 7/31/17 deposition Exhibit 1025			801; 802	801; 802
8290	Moni Stein, 7/31/17 deposition Exhibit 1026			801; 802	801; 802
8291	Moni Stein, 7/31/17 deposition Exhibit 1027			801; 802	801; 802
8292	Moni Stein, 7/31/17 deposition Exhibit 1028			801; 802	801; 802
8312	Affidavit of Marlene Bobka, FOI Services			801; 802	
8313	Photo of filter catching clot			801; 802	
8314	2016.05.02 - Filter MDL - Deposition of Murray Asch - Exhibit 206			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8315	2016.05.02 - Filter MDL - Deposition of Murray Asch - Exhibit 213			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8316	2016.05.02 - Filter MDL - Deposition of Murray Asch - Exhibit 214			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8317	2016.05.02 - Filter MDL - Deposition of Murray Asch - Exhibit 215			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8318	2016.05.02 - Filter MDL - Deposition of Murray Asch - Exhibit 216			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8319	2016.05.02 - Filter MDL - Deposition of Murray Asch - Exhibit 219			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8320	Poruk, et al., Functioning inferior vena cava filter caught in the act, J. Vasc. Surg., 2015			401; 402; 403; 801; 802	801; 802
8321	Invoices of Dr. Kinney			401; 402; 403; 801; 802	801; 802
8322	Invoices of Dr. Hurst			401; 402; 403; 801; 802	801; 802
8323	Bard filter rates through September 2010			401; 402; 403; 801; 802	801; 802
8324	March 24, 2005 FDA Meeting PPT	BPV-17-01-00098020	BPV-17-01-00098076	401; 402; 403; 801; 802	801; 802
8325	Eclipse IFU 02.2010 PK5100600 Rev. 1	BPVEFILTER-20-00001738	BPVEFILTER-20-00001749	401; 402; 403; 801; 802	
8326	August 31, 2010, Bard Letter to Clinical Care Givers Folder - G62243	BPV-17-01-00255229	BPV-17-01-00255248	401; 402; 403; 801; 802	801; 802
8327	IVC Filters Clinical Overview Folder - G62244	BPV-17-01-00255249	BPV-17-01-00255378	401; 402; 403; 801; 802	801; 802
8328	Sept 2, 2010, Dear Sales Rep Letter Folder - G62247	BPV-17-01-00257454	BPV-17-01-00257489	401; 402; 403; 801; 802	801; 802
8329	Sept 7, 2010 International Dear Clinical Care Giver Folder - G62252	BPV-17-01-00257490	BPV-17-01-00257510	401; 402; 403; 801; 802	801; 802
8330	Bard Position Statement & Key Points / Talking Points Folder - G62234	BPV-17-01-00255007	BPV-17-01-00255055	401; 402; 403; 801; 802	801; 802
8331	Chum/Everest/Charles Clinical overview Folder - G61745	BPV-17-01-00256022	BPV-17-01-00256191	401; 402; 403; 801; 802	801; 802
8332	Eclipse Patient Q&A Rev 1 Folder - S11733	BPV-17-01-00251429	BPV-17-01-00251468	401; 402; 403; 801; 802	801; 802
8333	Eclipse Patient Q&A Rev 2 Folder - S11733	BPV-17-01-00251469	BPV-17-01-00251509	401; 402; 403; 801; 802	801; 802
8334	August 31, 2010, Bard Letter to Clinical Care Givers Distribution Email	BPVEFILTER-05-00054173	BPVEFILTER-05-00054175	401; 402; 403; 801; 802	801; 802
8335	CQA-STD-24 Rev 12 -- Standard for Product Complaint Handling	BPV-17-01-00200167	BPV-17-01-00200184	401; 402; 403; 801; 802	801; 802
8336	CQA-STD-54 Rev. 04 (Standard for Medical Device Reporting	BPV-17-01-00202921	BPV-17-01-00202934	401; 402; 403; 801; 802	801; 802
8337	Eclipse™ Filter Design History File	BPV-17-01-00108342	BPV-17-01-00109314	401; 402; 403; 801; 802	801; 802
8338	Eclipse Design History File Index	BPV-17-01-00108342	BPV-17-01-00108344	401; 402; 403; 801; 802	801; 802
8339	Eclipse Concept Product Opportunity Appraisal POA	BPV-17-01-00108346	BPV-17-01-00108353	401; 402; 403; 801; 802	801; 802
8340	Eclipse MS&S TD-01304	BPV-17-01-00108355	BPV-17-01-00108360	401; 402; 403; 801; 802	801; 802
8341	Eclipse Field Assurance Training	BPV-17-01-00108362	BPV-17-01-00108383	401; 402; 403; 801; 802	801; 802
8342	Eclipse Design and Development Plan DDP-8113 FM1160805	BPV-17-01-00108384	BPV-17-01-00108410	401; 402; 403; 801; 802	801; 802
8343	Eclipse Corporate Labeling Approval Form Brochure	BPV-17-01-00108412	BPV-17-01-00108420	401; 402; 403; 801; 802	801; 802
8344	Eclipse Launch Plan, TD-01289	BPV-17-01-00108422	BPV-17-01-00108433	401; 402; 403; 801; 802	801; 802
8345	Eclipse DIS Design Input Summary	BPV-17-01-00108435	BPV-17-01-00108438	401; 402; 403; 801; 802	801; 802
8346	Eclipse Product Performance Specification PPS	BPV-17-01-00108440	BPV-17-01-00108508	401; 402; 403; 801; 802	801; 802
8347	Eclipse Risk Analysis RA070079	BPV-17-01-00108510	BPV-17-01-00108529	401; 402; 403; 801; 802	801; 802
8348	Eclipse Design Failure Mode and Effects Analysis DFMEA070077 Rev 1	BPV-17-01-00108532	BPV-17-01-00108578	401; 402; 403; 801; 802	801; 802
8349	Eclipse Process Failure Mode and Effects Analysis PFMEA070069 Rev 1	BPV-17-01-00108580	BPV-17-01-00108598	401; 402; 403; 801; 802	801; 802
8350	Eclipse Risk Management Report TR-09-11-16	BPV-17-01-00108600	BPV-17-01-00108605	401; 402; 403; 801; 802	801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8351	Eclipse Technical Drawings	BPV-17-01-00108623	BPV-17-01-00108624	401; 402; 403; 801; 802	801; 802
8352	Eclipse IFUs from DHF	BPV-17-01-00108694	BPV-17-01-00108730	401; 402; 403; 801; 802	801; 802
8353	Eclipse Packaging and Labeling Review TD-01318	BPV-17-01-00108732	BPV-17-01-00108739	401; 402; 403; 801; 802	801; 802
8354	Eclipse TD-01249 (Eclipse Test Method Matrix)	BPV-17-01-00108839	BPV-17-01-00108844	401; 402; 403; 801; 802	801; 802
8355	Eclipse Biocompatibility Requirements	BPV-17-01-00108862	BPV-17-01-00108891	401; 402; 403; 801; 802	801; 802
8356	Comparison of G2 Express Filter Snare Tip and Vail Filter Wire	BPV-17-01-00108894	BPV-17-01-00108968	401; 402; 403; 801; 802	801; 802
8357	TR-09-11-08 Eclipse (Corrosion Testing of the Vail Filter (Eclipse)	BPV-17-01-00108994	BPV-17-01-00109014	401; 402; 403; 801; 802	801; 802
8358	TR-09-10-15 -- Eclipse Flat Plate Fatigue and Corrosion Examination of the Vail (Eclipse) Filter	BPV-17-01-00109017	BPV-17-01-00109024	401; 402; 403; 801; 802	801; 802
8359	TR-09-10-16 DV&V Eclipse Filter Arm Fatigue Comparison Study (Project #8113)	BPV-17-01-00109027	BPV-17-01-00109036	401; 402; 403; 801; 802	801; 802
8360	Eclipse Process Validation	BPV-17-01-00109065	BPV-17-01-00109082	401; 402; 403; 801; 802	801; 802
8361	Eclipse™ Filter Vail Phase Review Books	BPV-17-01-00145634	BPV-17-01-00146922	401; 402; 403; 801; 802	801; 802
8362	Eclipse Filter Patient Questions & Answers	BPV-17-01-00142907	BPV-17-01-00142909	401; 402; 403; 801; 802	801; 802
8363	Eclipse Filter Patient Card	BPV-17-01-00142910	BPV-17-01-00142911	401; 402; 403; 801; 802	801; 802
8364	Eclipse Post-Market Design Review Customer Complaint Review and Risk Assessment	BPV-17-01-00170317	BPV-17-01-00170348	401; 402; 403; 801; 802	801; 802
8365	Eclipse Post-Market Review Regulatory TD-01619 Sept 27, 2010	BPV-17-01-00170349	BPV-17-01-00170355	401; 402; 403; 801; 802	801; 802
8366	Eclipse Post-Market Manufacturing Assessment TD-01620	BPV-17-01-00170356	BPV-17-01-00170357	401; 402; 403; 801; 802	801; 802
8367	Eclipse Post-Market Design Review Marketing TD-01621	BPV-17-01-00170358	BPV-17-01-00170361	401; 402; 403; 801; 802	801; 802
8368	TP-09-10-15 Rev. 0 - Eclipse DV&V Flat Plate Fatigue and Corrosion Test Protocol	BPVEFILTER-42-00017728	BPVEFILTER-42-00017743	401; 402; 403; 801; 802	801; 802
8369	TR-09-10-16 Rev. 0 - Eclipse Filter Arm Fatigue Comparison Study Test Report	BPVEFILTER-20-00129357	BPVEFILTER-20-00129366	401; 402; 403; 801; 802	801; 802
8370	TM1133800 Rev. 4 - Recovery Filter Diaphragmatic Arm Fatigue Test	BPVEFILTER-20-00039457	BPVEFILTER-20-00039465	401; 402; 403; 801; 802	801; 802
8371	TM1141700 Rev. 1 - Flat Plate Filter Fatigue and Corrosion Examination Test Method	BPVEFILTER-20-00124281	BPVEFILTER-20-00124297	401; 402; 403; 801; 802	801; 802
8372	TM1141300 Rev. 4 - Filter Wire Weld Tensile Strength Test Method	BPVEFILTER-20-00124229	BPVEFILTER-20-00124236	401; 402; 403; 801; 802	801; 802
8373	TP-09-10-16 Rev. 0 - Eclipse Filter DV&V Arm Fatigue Evaluation Test Protocol	BPVEFILTER-20-00043369	BPVEFILTER-20-00043377	401; 402; 403; 801; 802	801; 802
8374	TP-09-11-08 Rev. 0 (Test Protocol for Corrosion Testing of the Vail Filter)	BPVEFILTER-20-00043399	BPVEFILTER-20-00043404	401; 402; 403; 801; 802	801; 802
8375	Eclipse DFMEA Rev. 0	BPV-17-01-00191079	BPV-17-01-00191122	401; 402; 403; 801; 802	801; 802
8376	Eclipse DFMEA Rev. 1	BPV-17-01-00191123	BPV-17-01-00191166	401; 402; 403; 801; 802	801; 802
8377	Eclipse DFMEA Rev. 2	BPV-17-01-00191167	BPV-17-01-00191229	401; 402; 403; 801; 802	801; 802
8378	Eclipse DFMEA Rev. 3	BPV-17-01-00223323	BPV-17-01-00223383	401; 402; 403; 801; 802	801; 802
8379	Expert Report from Dr. Garcia in Cook litigation			401; 402; 403; 801; 802	801; 802
8394	Demonstrative depiction of the IVC filter fragment in the plaintiff's artery			Plaintiffs reserve the right to object until the demonstrative is produced.	
8395	Demonstrative depiction of the procedure to remove the plaintiff's IVC filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8396	Demonstrative depiction of endothelialization of filter strut			Plaintiffs reserve the right to object until the demonstrative is produced.	
8397	Demonstrative depiction of peptic ulcer disease			Plaintiffs reserve the right to object until the demonstrative is produced.	
8398	Demonstrative depiction of lap band procedure			Plaintiffs reserve the right to object until the demonstrative is produced.	
8399	Demonstrative depiction of afferent loop syndrome			Plaintiffs reserve the right to object until the demonstrative is produced.	
8400	Demonstrative depiction of duodenal ulcers			Plaintiffs reserve the right to object until the demonstrative is produced.	
8408	Demonstrative depiction of medical literature regarding complications of IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8409	Demonstrative depiction of medical literature regarding efficacy of IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8410	Demonstrative depiction of the medical literature regarding complications associated with the G2 Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8411	Demonstrative depiction of the medical literature regarding complications associated with the Simon Nitinol Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8412	Demonstrative depiction of the medical literature regarding complications associated with the Recovery Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8413	Demonstrative depiction of the medical literature regarding complications associated with the G2X Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8414	Demonstrative depiction of the medical literature regarding complications associated with the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8415	Demonstrative depiction of the medical literature regarding complications associated with non-Bard IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8416	Demonstrative depiction of IVC filter design considerations			Plaintiffs reserve the right to object until the demonstrative is produced.	
8417	Demonstrative depiction of the Recovery Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8418	Demonstrative depiction of the G2 Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8419	Demonstrative depiction of the G2X Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8420	Demonstrative depiction of the Simon Nitinol Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8421	Demonstrative depiction of the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8422	Demonstrative depiction of differences between generations of Bard's filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8423	Demonstrative depiction of Instructions for Use regarding non-Bard IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8424	Demonstrative depiction of the Eclipse Filter Instructions for Use			Plaintiffs reserve the right to object until the demonstrative is produced.	
8425	Demonstrative depiction of MAUDE database disclaimers			Plaintiffs reserve the right to object until the demonstrative is produced.	
8426	Demonstrative depiction of spontaneous adverse event reporting biases and limitations			Plaintiffs reserve the right to object until the demonstrative is produced.	
8427	Demonstrative depiction of errors in Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade			Plaintiffs reserve the right to object until the demonstrative is produced.	
8428	Demonstrative depiction of errors in Fracture and distant migration of the Bard Recovery filter: a retrospective review of 363 implantations for potentially life-threatening complications			Plaintiffs reserve the right to object until the demonstrative is produced.	
8429	Demonstrative depiction of errors in Prevalence and clinical consequences of fracture and fragment migration of the Bard G2 filter: imaging and clinical follow-up in 684 implantations			Plaintiffs reserve the right to object until the demonstrative is produced.	
8430	Demonstrative depiction regarding hierarchy of scientific evidence			Plaintiffs reserve the right to object until the demonstrative is produced.	
8431	Demonstrative depiction of where the medical literature regarding IVC filters falls within the hierarchy of scientific evidence			Plaintiffs reserve the right to object until the demonstrative is produced.	
8432	Demonstrative depiction comparing the medical literature regarding the Eclipse and/or G2/G2X Filters and the Simon Nitinol Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8433	Demonstrative depiction comparing the medical literature regarding the Recovery Filter and the G2 Filter and/or G2X and/or Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8434	Demonstrative depiction comparing the medical literature regarding the G2 Filter and/or Eclipse Filter and non-Bard IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8435	Demonstrative depiction comparing complication rates of the Eclipse Filter to rates of complication identified in the 2001 "SIR Guidelines"			Plaintiffs reserve the right to object until the demonstrative is produced.	
8436	Demonstrative depiction comparing complication rates of the Eclipse Filter to rates of complication identified in the 2017 "SIR Guidelines"			Plaintiffs reserve the right to object until the demonstrative is produced.	
8437	Demonstrative depiction of the process by which the 2001 Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism were created			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8438	Demonstrative depiction of the process by which the 2003 Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism were created			Plaintiffs reserve the right to object until the demonstrative is produced.	
8439	Demonstrative depiction regarding the 2011 Quality Improvement Guidelines for the Performance of Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism			Plaintiffs reserve the right to object until the demonstrative is produced.	
8440	Demonstrative depiction regarding the 2014 ACR-SIR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiffs reserve the right to object until the demonstrative is produced.	
8441	Demonstrative depiction regarding the 2016 ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiffs reserve the right to object until the demonstrative is produced.	
8442	Demonstrative depiction regarding the 2017 ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiffs reserve the right to object until the demonstrative is produced.	
8443	Demonstrative depiction of Bard's internal complication rates for the G2 Filter and/or G2X Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8444	Demonstrative depiction of Bard's internal complication rates for the Recovery Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8445	Demonstrative depiction of Bard's internal complication rates for the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8446	Demonstrative depiction of sales of the Simon Nitinol Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8447	Demonstrative depiction of sales of the G2 and/or G2X and/or Eclipse Filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8448	Demonstrative depiction of sales of Bard's retrievable IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8449	Demonstrative depiction of bench testing regarding the G2 Filter and/or G2X and/or Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8450	Demonstrative depiction of animal testing regarding the G2 Filter and/or G2X and/or Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8451	Demonstrative depiction of clinical trial testing regarding the G2 Filter and/or G2X and/or Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8452	Demonstrative depiction of Bard's interaction with the FDA before clearance of the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8453	Demonstrative depiction of Bard's interaction with the FDA after clearance of the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8454	Demonstrative depiction of Bard's interaction with the FDA regarding the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8455	Demonstrative depiction of Bard's interaction with the FDA regarding the clinical trial EVEREST			Plaintiffs reserve the right to object until the demonstrative is produced.	
8456	Demonstrative depiction regarding EVEREST clinical trial material			Plaintiffs reserve the right to object until the demonstrative is produced.	
8457	Demonstrative depiction of post-market adverse event tracking regarding the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8458	Demonstrative depiction of Bard's actions concerning caudal migration investigation			Plaintiffs reserve the right to object until the demonstrative is produced.	
8459	Demonstrative depiction of Weber effect			Plaintiffs reserve the right to object until the demonstrative is produced.	
8460	Demonstrative depiction of adverse event reporting trends			Plaintiffs reserve the right to object until the demonstrative is produced.	
8461	Demonstrative depiction of the physicians who read imaging regarding the plaintiff's Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8462	Demonstrative Slides with Attorney Advertising Information			Plaintiffs reserve the right to object until the demonstrative is produced.	
8463	Demonstrative regarding electropolishing for Dr. Briant			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8464	Demonstrative regarding electropolishing for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8465	Demonstrative regarding Eclipse filter for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8466	Demonstrative regarding Eclipse filter for Dr. Briant			Plaintiffs reserve the right to object until the demonstrative is produced.	
8467	Demonstrative regarding Eclipse filter for Dr. Feigal			Plaintiffs reserve the right to object until the demonstrative is produced.	
8468	Demonstrative regarding Eclipse filter for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8469	Demonstrative regarding Eclipse filter for Dr. Brauer			Plaintiffs reserve the right to object until the demonstrative is produced.	
8470	Demonstrative regarding Eclipse filter for Dr. Tillman			Plaintiffs reserve the right to object until the demonstrative is produced.	
8471	Demonstrative regarding Eclipse filter for Dr. Stein			Plaintiffs reserve the right to object until the demonstrative is produced.	
8472	Demonstrative regarding Eclipse filter for Dr. Herbst			Plaintiffs reserve the right to object until the demonstrative is produced.	
8473	Demonstrative regarding MAUDE search data for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8474	Demonstrative regarding MAUDE search screenshots for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8475	MAUDE search data for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8476	MAUDE search screenshots for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8477	Exemplar nitinol wire for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8478	Demonstrative regarding figures 180, 191 -193 for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8479	Demonstrative regarding figures 179a, 190a, 186-187 for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8480	Demonstrative regarding Recovery cross-section photos for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8481	Demonstrative regarding warning timeline			Plaintiffs reserve the right to object until the demonstrative is produced.	
8482	Bard IVC Filter Design/Development Timeline			Plaintiffs reserve the right to object until the demonstrative is produced.	
8483	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8484	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8485	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8486	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8487	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8488	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8489	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8490	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8491	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8492	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8493	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8494	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8495	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8496	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8497	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8498	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8499	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8500	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8501	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8502	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8503	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8504	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8505	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8506	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8507	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8508	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8509	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8510	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8511	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8512	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8513	Exhibit Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8514	Exhibit Placeholder				
8515	Exhibit Placeholder				
8516	Exhibit Placeholder				
8517	Exhibit Placeholder				
8518	Exhibit Placeholder				
8519	Exhibit Placeholder				
8520	Exhibit Placeholder				
8521	Exhibit Placeholder				
8522	Exhibit Placeholder				
8523	Exhibit Placeholder				
8524	Exhibit Placeholder				
8525	Exhibit Placeholder				
8526	Exhibit Placeholder				
8527	Exhibit Placeholder				
8528	Exhibit Placeholder				
8529	Exhibit Placeholder				

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8530	Exhibit Placeholder				
8531	Exhibit Placeholder				
8532	Exhibit Placeholder				
8533	Exhibit Placeholder				
8534	Exhibit Placeholder				
8535	Exhibit Placeholder				
8536	Exhibit Placeholder				
8537	Exhibit Placeholder				
8538	Exhibit Placeholder				
8539	Exhibit Placeholder				
8540	Exhibit Placeholder				
8541	Exhibit Placeholder				
8542	Exhibit Placeholder				
8545	BS EN 12006-3:1999 - Non-active surgical implants - Particular requirements for ca	BPV-17-01-00001518	BPV-17-01-00001542	401; 402; 403; 801; 802	
8546	Draft Test Report re Rotary Beam Fatigue of Nitinol Wire	BPV-17-01-00188406	BPV-17-01-00188410	801; 802	801; 802
8547	Legal Website Customer Letter Folder	BPV-17-01-00254787	BPV-17-01-00254814	401; 402; 403; 801; 802	801; 802
8548	Legal Website Customer Letter	BPV-17-01-00254796	BPV-17-01-00254796	401; 402; 403; 801; 802	801; 802
8549	Clinical Trial Update Poster - Everest	BPV-17-01-00248313	BPV-17-01-00248313	401; 402; 403; 801; 802	801; 802
8550	Laboratory Notebooks	BPV-17-01-00004138	BPV-17-01-00004333	401; 402; 403; 801; 802	801; 802
8551	Laboratory Notebooks	BPV-17-01-00006967	BPV-17-01-00007034	401; 402; 403; 801; 802	801; 802
8552	Laboratory Notebooks	BPV-17-01-00009320	BPV-17-01-00009730	401; 402; 403; 801; 802	801; 802
8553	Laboratory Notebooks	BPV-17-01-00010780	BPV-17-01-00011204	401; 402; 403; 801; 802	801; 802
8554	Laboratory Notebooks	BPV-17-01-00012931	BPV-17-01-00012949	401; 402; 403; 801; 802	801; 802
8555	Laboratory Notebooks	BPV-17-01-00013210	BPV-17-01-00013319	401; 402; 403; 801; 802	801; 802
8556	Laboratory Notebooks	BPV-17-01-00014825	BPV-17-01-00014891	401; 402; 403; 801; 802	801; 802
8557	Laboratory Notebooks	BPV-17-01-00015195	BPV-17-01-00015302	401; 402; 403; 801; 802	801; 802
8558	Laboratory Notebooks	BPV-17-01-00015312	BPV-17-01-00015592	401; 402; 403; 801; 802	801; 802
8559	Laboratory Notebooks	BPV-17-01-00021974	BPV-17-01-00022106	401; 402; 403; 801; 802	801; 802
8560	Laboratory Notebooks	BPV-17-01-00026094	BPV-17-01-00026096	401; 402; 403; 801; 802	801; 802
8561	Laboratory Notebooks	BPV-17-01-00069840	BPV-17-01-00069885	401; 402; 403; 801; 802	801; 802
8562	Laboratory Notebooks	BPV-17-01-00069978	BPV-17-01-00070029	401; 402; 403; 801; 802	801; 802
8563	Laboratory Notebooks	BPV-17-01-00070073	BPV-17-01-00070087	401; 402; 403; 801; 802	801; 802
8564	Laboratory Notebooks	BPV-17-01-00070109	BPV-17-01-00070331	401; 402; 403; 801; 802	801; 802
8565	Laboratory Notebooks	BPV-17-01-00070515	BPV-17-01-00070528	401; 402; 403; 801; 802	801; 802
8566	Laboratory Notebooks	BPV-17-01-00082934	BPV-17-01-00082998	401; 402; 403; 801; 802	801; 802
8567	Laboratory Notebooks	BPV-17-01-00110519	BPV-17-01-00110542	401; 402; 403; 801; 802	801; 802
8568	Laboratory Notebooks	BPV-17-01-00167143	BPV-17-01-00169112	401; 402; 403; 801; 802	801; 802
8569	Laboratory Notebooks	BPV-17-01-00236651	BPV-17-01-00237044	401; 402; 403; 801; 802	801; 802
8570	TD-00429 G3 Concept Testing, Project 8049	BPV-17-01-00180270	BPV-17-01-00180273	401; 402; 403; 801; 802	801; 802
8571	G3 DDP Design and Development Plan	BPV-17-01-00180367	BPV-17-01-00180391	401; 402; 403; 801; 802	801; 802
8572	G3 Meeting Minutes July 25, 2006	BPV-17-01-00181762	BPV-17-01-00181763	401; 402; 403; 801; 802	801; 802
8573	G3 Meeting Minutes Nov 27, 2007	BPV-17-01-00181911	BPV-17-01-00181914	401; 402; 403; 801; 802	801; 802
8574	TR 09-10-10, Test Report Cyclic Fatigue Testing of Electropolished Vail Filter Wire	BPVEFILTER-11-00027094	BPVEFILTER-11-00027103	401; 402; 403; 801; 802	801; 802
8575	TP 09-10-10, Test Protocol Cyclic Fatigue Testing of Electropolished Vail Filter Wire	BPVE-01-00930038	BPVE-01-00930050	401; 402; 403; 801; 802	801; 802
8576	TM1144600 G2 Filter Ground Wire Fatigue Test Rev 0	BPVEFILTER-20-00124452	BPVEFILTER-20-00124459	401; 402; 403; 801; 802	801; 802
8577	TM1144600 Filter Ground Wire Fatigue Test Rev 1	BPVEFILTER-20-00040092	BPVEFILTER-20-00040099	401; 402; 403; 801; 802	801; 802
8578	TR-06-12-04, Rotary Beam Fatigue Test of G2 Filter Wire Test Report	BPVEFILTER-20-00126862	BPVEFILTER-20-00126873	401; 402; 403; 801; 802	801; 802
8579	TPR 06-05-17 Rotary Beam Fatigue Testing of G2 Filter Wire	BPVEFILTER-20-00046856	BPVEFILTER-20-00046882	401; 402; 403; 801; 802	801; 802
8580	Project Platinum Project Status Report July 2009	BPVE-01-00699498	BPVE-01-00699499	401; 402; 403; 801; 802	801; 802
8581	Project Platinum Project Status Report Nov. 2008	BPV-17-01-00188798	BPV-17-01-00188798	401; 402; 403; 801; 802	801; 802
8582	G2 Platinum Project Launch Presentation, April 23, 2009	BPV-17-01-00188634	BPV-17-01-00188634	401; 402; 403; 801; 802	801; 802
8583	G3 Project Status Report April 19, 2006	BPV-17-01-00183521	BPV-17-01-00183521	401; 402; 403; 801; 802	801; 802
8584	G3 Project Plan Aug. 1, 2006	BPV-17-01-00183502	BPV-17-01-00183507	401; 402; 403; 801; 802	801; 802
8585	May 6, 2008, Filter Franchise Review Presentation, Deposition of Brett Baird, Exhibit 301			401; 402; 403; 801; 802	801; 802
8586	FOIA Affidavits			401; 402; 403; 801; 802	801; 802
8587	Karnath (2004) - Anemia in the Adult Patient			401; 402; 403; 801; 802	801; 802
8588	NIH - Anemia			401; 402; 403; 801; 802	801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8589	American Society of Hematology - Anemia & Shortness of Breath			401; 402; 403; 801; 802	801; 802
8590	Byrnes (2017) - Red Blood Cells in Thrombosis			401; 402; 403; 801; 802	801; 802
8591	Franchini (2008) - Iron and Thrombosis			401; 402; 403; 801; 802	801; 802
8592	Hung (2015) - Association Between VTE and Iron Deficiency Anemia			401; 402; 403; 801; 802	801; 802
8593	Potaczek (2016) - Iron Deficiency A Novel Risk Factor of Recurrence in Patients After Unprovoked VTE			401; 402; 403; 801; 802	801; 802
8594	An (2014) -- Prevalence and Clinical Consequences of Fracture and Fragment Migration of the Bard G2 Filter			401; 402; 403; 801; 802	801; 802
8595	Dinglasan (2011) -- Removal of Fractured Inferior Vena Cava Filters Feasibility and Outcomes			401; 402; 403; 801; 802	801; 802
8596	Hudali (2015) --A Fractured IVC Filter Strut Migrating to the Left Pulmonary Artery			401; 402; 403; 801; 802	801; 802
8597	Kuo (2009) -- High Risk Retrieval of Adherent and Chronically Implanted IVC Filters			401; 402; 403; 801; 802	801; 802
8598	Kuo (2013) -- Complex Retrieval of Fractured, Embedded, and Penetrating IVC Filters			401; 402; 403; 801; 802	801; 802
8599	Mehanni (2016) -- Expectoration of an Inferior Vena Cava Filter Strut			401; 402; 403; 801; 802	801; 802
8600	Owens (2009) -- Intracardiac Migration of Inferior Vena Cava Filters			401; 402; 403; 801; 802	801; 802
8601	Tam (2011) -- Fracture and Distant Migration of the Bard Recovery Filter			401; 402; 403; 801; 802	801; 802
8602	Trerotola (2017) -- Management of Fractured Inferior Vena Cava Filters- Outcomes by Fragment Location			401; 402; 403; 801; 802	801; 802
8603	Unai (2017) -- Nonthrombotic Pulmonary Artery Embolism			401; 402; 403; 801; 802	801; 802
8604	Vijay (2012) -- Fractured Bard Recovery G2 and G2 Express Inferior Vena Cava Filters			401; 402; 403; 801; 802	801; 802
8605	American Thyroid Association - Hypothyroidism			401; 402; 403; 801; 802	801; 802
8606	Harrison's 19th ed (2015) - Hypothyroidism Symptoms			401; 402; 403; 801; 802	801; 802
8607	Schmidt (2011) - NSAID Use and Risk of VTE			401; 402; 403; 801; 802	801; 802
8608	Ungprasert (2015) - NSAIDs and the Risk of VTE			401; 402; 403; 801; 802	801; 802
8609	American College of Gastroenterology - Understanding Ulcers, NSAIDs & GI Bleeding			401; 402; 403; 801; 802	801; 802
8610	Harrison's 19th ed (2015) - NSAIDs & GI Bleeding			401; 402; 403; 801; 802	801; 802
8611	Harrison's 19th ed (2015) - NSAID-Induced GI Bleed & PUD			401; 402; 403; 801; 802	801; 802
8612	Hernandez-Diaz (2000) - Association Between NSAIDs and Upper GI Tract Bleeding Perforation			401; 402; 403; 801; 802	801; 802
8613	Mellemkjaer (2002) - Upper GI Bleeding Among Users of NSAIDs			401; 402; 403; 801; 802	801; 802
8614	Sostres (2013) - NSAIDs and Upper and Lower GI Mucosal Damage			401; 402; 403; 801; 802	801; 802
8615	American Heart Association - Smoking Risk for Blood Clot			401; 402; 403; 801; 802	801; 802
8616	American Society of Hematology - Smoking Risk for Blood Clot			401; 402; 403; 801; 802	801; 802
8617	Cheng (2013) - Current and Former Smoking and Risk for VTE			401; 402; 403; 801; 802	801; 802
8618	Enga (2012) - Cigarette Smoking and the Risk of VTE			401; 402; 403; 801; 802	801; 802
8619	Harrison's 19th ed (2015) - Smoking Risk for Thrombosis			401; 402; 403; 801; 802	801; 802
8620	Lutsey (2010) - Correlates and Consequences of VTE The Iowa Women's Health Study			401; 402; 403; 801; 802	801; 802
8621	Pomp (2007) - Smoking Increases the Risk of Venous Thrombosis			401; 402; 403; 801; 802	801; 802
8622	Sweetland (2013) - Smoking, Surgery, and VTE Risk in Women			401; 402; 403; 801; 802	801; 802
8623	Tapson (2005) - The Role of Smoking in Coagulation and Thromboembolism			401; 402; 403; 801; 802	801; 802
8624	American Lung Association - Smoking & Shortness of Breath			401; 402; 403; 801; 802	801; 802
8625	Liu (2015) - Smoking Duration, Respiratory Symptoms, and COPD in Adults			401; 402; 403; 801; 802	801; 802
8626	Harrison's Principles of Internal Medicine, 19th ed (2015)			401; 402; 403; 801; 802	801; 802
8627	Original certificate and affidavit of FDA enclosing FDA FOIA Request 2013-5061			401; 402; 403; 801; 802	
8628	Associated Pathologists Chartered Legal Department	HYDEL_APCLD_PAT00001	HYDEL_APCLD_PAT00001	401; 402; 403; 801; 802	801; 802
8629	Ati Physical Therapy	HYDEL_ATIPT_MDR00001	HYDEL_ATIPT_MDR00031	401; 402; 403; 801; 802	801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8630	Aurora Medical Group Obstetrics and Gynecology - Billing	HYDEL_AMGOBG_BIL00001	HYDEL_AMGOBG_BIL00007	401; 402; 403; 801; 802	801; 802
8631	Aurora Medical Group Obstetrics and Gynecology - Medical	HYDEL_AMGOG_MDR00001	HYDEL_AMGOG_MDR00046	401; 402; 403; 801; 802	801; 802
8632	Aurora St. Luke's Medical Center - Medical	HYDEL_ASLMC_MDR00001	HYDEL_ASLMC_MDR00003	401; 402; 403; 801; 802	801; 802
8633	Aurora St. Luke's Medical Center - Billing	HYDEL_ASLMC_BIL00001	HYDEL_ASLMC_BIL00006	401; 402; 403; 801; 802	801; 802
8634	Aurora St. Luke's Medical Center - Radiology	HYDEL_ASLMC_RAD00001	HYDEL_ASLMC_RAD00001	401; 402; 403; 801; 802	801; 802
8635	Aurora St. Luke's Medical Center - Pathology	HYDEL_ASLMC_PAT00001	HYDEL_ASLMC_PAT00004	401; 402; 403; 801; 802	801; 802
8636	Aurora West Allis Medical Center - Medical	HYDEL_AWAMC_MDR00001	HYDEL_AWAMC_MDR00046	401; 402; 403; 801; 802	801; 802
8637	Aurora West Allis Medical Center - Billing	HYDEL_AWAMC_BIL00001	HYDEL_AWAMC_BIL00001	401; 402; 403; 801; 802	801; 802
8638	Aurora West Allis Medical Center - Radiology	HYDEL_AWAMC_RAD00001	HYDEL_AWAMC_RAD00002	401; 402; 403; 801; 802	801; 802
8639	Aurora West Allis Medical Center - Pathology	HYDEL_AWAMC_PAT00001	HYDEL_AWAMC_PAT00003	401; 402; 403; 801; 802	801; 802
8640	Center for Colon and Digestive Diseases - Medical	HYDEL_CCDD_MDR00001	HYDEL_CCDD_MDR00022	401; 402; 403; 801; 802	801; 802
8641	Center for Colon and Digestive Diseases - Billing	HYDEL_CCDD_BIL00001	HYDEL_CCDD_BIL00005	401; 402; 403; 801; 802	801; 802
8642	Centers for Medicare & Medicaid Services (Region 9)	HYDEL_CMS9_INS00001	HYDEL_CMS9_INS00002	401; 402; 403; 801; 802	801; 802
8643	Comprehensive and Interventional Pain Management - Medical	HYDEL_CIPM_MDR00001	HYDEL_CIPM_MDR00004	401; 402; 403; 801; 802	801; 802
8644	Comprehensive and Interventional Pain Management - Billing	HYDEL_CIPM_BIL00001	HYDEL_CIPM_BIL00002	401; 402; 403; 801; 802	801; 802
8645	Comprehensive Cancer Centers of Nevada - Billing	HYDEL_CCCN_BIL00001	HYDEL_CCCN_BIL00015	401; 402; 403; 801; 802	801; 802
8646	Comprehensive Cancer Centers of Nevada - Medical	HYDEL_CCCN_MDR00001	HYDEL_CCCN_MDR00103	401; 402; 403; 801; 802	801; 802
8647	D. Keith Klewin Institute	HYDEL_DKKI_MDR00001	HYDEL_DKKI_MDR00066	401; 402; 403; 801; 802	801; 802
8648	Laboratory Medicine Consultants	HYDEL_LABMC_PAT00001	HYDEL_LABMC_PAT00006	401; 402; 403; 801; 802	801; 802
8649	Las Vegas Immediate Care	HYDEL_LVIC_MDR00001	HYDEL_LVIC_MDR00083	401; 402; 403; 801; 802	801; 802
8650	Las Vegas Radiology-Smoke Ranch - Medical	HYDEL_LVRSR_MDR00001	HYDEL_LVRSR_MDR00006	401; 402; 403; 801; 802	801; 802
8651	Las Vegas Radiology-Smoke Ranch - Radiology	HYDEL_LVRSR_RAD00001	HYDEL_LVRSR_RAD00006	401; 402; 403; 801; 802	801; 802
8652	Las Vegas Urology - Billing	HYDEL_LVU_BIL00001	HYDEL_LVU_BIL00002	401; 402; 403; 801; 802	801; 802
8653	Las Vegas Urology-Northwest - Medical	HYDEL_LVUN_MDR00001	HYDEL_LVUN_MDR00004	401; 402; 403; 801; 802	801; 802
8654	Lasik Vision Institute	HYDEL_LVI_MDR00001	HYDEL_LVI_MDR00052	401; 402; 403; 801; 802	801; 802
8655	Lehrner, Stephanie, D.O.	HYDEL_SLEHR_MDR00001	HYDEL_SLEHR_MDR00017	401; 402; 403; 801; 802	801; 802
8656	Molin, Clifford, M.D.	HYDEL_CMOLI_MDR00001	HYDEL_CMOLI_MDR00019	401; 402; 403; 801; 802	801; 802
8657	Moss, Nicole J., M.D.	HYDEL_NMOSS_MDR00001	HYDEL_NMOSS_MDR00007	401; 402; 403; 801; 802	801; 802
8658	Nevada Heart & Vascular Center - Medical	HYDEL_NHVC_MDR00001	HYDEL_NHVC_MDR00010	401; 402; 403; 801; 802	801; 802
8659	Nevada Heart & Vascular Center - Radiology	HYDEL_NHVC_RAD00001	HYDEL_NHVC_RAD00003	401; 402; 403; 801; 802	801; 802
8660	Silver State Neurology	HYDEL_SSN_MDR00001	HYDEL_SSN_MDR00001	401; 402; 403; 801; 802	801; 802
8661	Social Security Administration	HYDEL_SOSA_SSA00001	HYDEL_SOSA_SSA00002	401; 402; 403; 801; 802	801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8662	Sparks Family Medicine, Ltd	HYDEL_SPARKFM_MDR00001	HYDEL_SPARKFM_MDR00134	401; 402; 403; 801; 802	801; 802
8663	Stanford Hospitals & Clinics - Billing	HYDEL_SHC_BIL00001	HYDEL_SHC_BIL00001	401; 402; 403; 801; 802	801; 802
8664	Stanford Hospitals & Clinics - Echo	HYDEL_SHC_ECH00001	HYDEL_SHC_ECH00002	401; 402; 403; 801; 802	801; 802
8665	Stanford Hospitals & Clinics - Medical	HYDEL_SHC_MDR00001	HYDEL_SHC_MDR00237	401; 402; 403; 801; 802	801; 802
8666	Stanford Hospitals & Clinics - Pathology	HYDEL_SHC_PAT00001	HYDEL_SHC_PAT00002	401; 402; 403; 801; 802	801; 802
8667	Stanford Hospitals & Clinics - Radiology	HYDEL_SHC_RAD00001	HYDEL_SHC_RAD00008	401; 402; 403; 801; 802	801; 802
8668	Steinberg Diagnostic Medical Imaging Center - Medical	HYDEL_SDMIC_MDR00001	HYDEL_SDMIC_MDR00003	401; 402; 403; 801; 802	801; 802
8669	Steinberg Diagnostic Medical Imaging Center - Radiology	HYDEL_SDMIC_RAD00001	HYDEL_SDMIC_RAD00028	401; 402; 403; 801; 802	801; 802
8670	Summerlin Hospital Medical Center - Medical	HYDEL_SHMC_MDR00001	HYDEL_SHMC_MDR00316	401; 402; 403; 801; 802	801; 802
8671	Summerlin Hospital Medical Center - Billing	HYDEL_SHMC_BIL00001	HYDEL_SHMC_BIL00008	401; 402; 403; 801; 802	801; 802
8672	Summerlin Hospital Medical Center - Radiology	HYDEL_SHMC_RAD00001	HYDEL_SHMC_RAD00002	401; 402; 403; 801; 802	801; 802
8673	Touro University Health Center	HYDEL_TUHC_MDR00001	HYDEL_TUHC_MDR00016	401; 402; 403; 801; 802	801; 802
8674	Werner Institute of Balance & Dizziness c/o Kolesar and Leatham, CHTD	HYDEL_WIBD_MDR00001	HYDEL_WIBD_MDR00001	401; 402; 403; 801; 802	801; 802
8675	West Valley Imaging - Medical	HYDEL_WVI_MDR00001	HYDEL_WVI_MDR00018	401; 402; 403; 801; 802	801; 802
8676	West Valley Imaging - Radiology	HYDEL_WVI_RAD00001	HYDEL_WVI_RAD00005	401; 402; 403; 801; 802	801; 802
8677	Wheaton Franciscan Healthcare Corporate Services Office/Business Office	HYDEL_WHEFH_BIL00001	HYDEL_WHEFH_BIL00015	401; 402; 403; 801; 802	801; 802
8678	Wheaton Franciscan Healthcare-All Saints - Medical	HYDEL_WFHAS_MDR00001	HYDEL_WFHAS_MDR00001	401; 402; 403; 801; 802	801; 802
8679	Wheaton Franciscan Healthcare-All Saints - Radiology	HYDEL_WFHAS_RAD00001	HYDEL_WFHAS_RAD00007	401; 402; 403; 801; 802	801; 802
8680	Wheaton Franciscan Healthcare-All Saints - Pathology	HYDEL_WFHAS_PAT00001	HYDEL_WFHAS_PAT00002	401; 402; 403; 801; 802	801; 802
8681	Wheaton Franciscan Healthcare-Franklin - Medical	HYDEL_WFHF_MDR00001	HYDEL_WFHF_MDR00292	401; 402; 403; 801; 802	801; 802
8682	Wheaton Franciscan Healthcare-Franklin - Billing	HYDEL_WFHF_BIL00001	HYDEL_WFHF_BIL00006	401; 402; 403; 801; 802	801; 802
8683	Wheaton Franciscan Healthcare-Franklin - Pathology	HYDEL_WFHF_PAT00001	HYDEL_WFHF_PAT00003	401; 402; 403; 801; 802	801; 802
8684	Wheaton Franciscan Healthcare-Franklin - Radiology	HYDEL_WFHF_RAD00001	HYDEL_WFHF_RAD00026	401; 402; 403; 801; 802	801; 802
8685	Wheaton Franciscan Medical Group - Medical	HYDEL_WFMG_MDR00001	HYDEL_WFMG_MDR00171	401; 402; 403; 801; 802	801; 802
8686	Wheaton Franciscan Medical Group - Billing	HYDEL_WFMG_BIL00001	HYDEL_WFMG_BIL00011	401; 402; 403; 801; 802	801; 802
8687	Wheaton Franciscan St. Joseph Hospital	HYDEL_WFSTJH_PAT00001	HYDEL_WFSTJH_PAT00002	401; 402; 403; 801; 802	801; 802
8688	Right Lower Extremity Venous Ultrasound	HYDEL_WFMG_MDR00037	HYDEL_WFMG_MDR00037	401; 402; 403; 801; 802	801; 802
8689	Office Visit (PCP) - Dr Weiderhold	HYDE_WFMG_MDR00107	HYDE_WFMG_MDR00108	401; 402; 403; 801; 802	801; 802
8690	CT of Chest	HYDEL_WFMG_MDR00035	HYDEL_WFMG_MDR00036	401; 402; 403; 801; 802	801; 802
8691	Office Visit (PCP) - Dr Stineman	HYDE_WFMG_MDR00045	HYDE_WFMG_MDR00045	401; 402; 403; 801; 802	801; 802
8692	ER Visit	HYDEL_WFHF_MDR00091	HYDEL_WFHF_MDR00097	401; 402; 403; 801; 802	801; 802
8693	Right Lower Extremity Venous Ultrasound	HYDEL_WFHF_MDR00169	HYDEL_WFHF_MDR00169	401; 402; 403; 801; 802	801; 802
8694	CT of Chest	HYDEL_WFHF_MDR00170	HYDEL_WFHF_MDR00171	401; 402; 403; 801; 802	801; 802
8695	History and Physical	HYDEL_WFHF_MDR00099	HYDEL_WFHF_MDR00101	401; 402; 403; 801; 802	801; 802
8696	Echocardiogram	HYDEL_WFHF_MDR00176	HYDEL_WFHF_MDR00177	401; 402; 403; 801; 802	801; 802
8697	Consent - Filter Placement - F/U with Wheaton to get consent signed by Hyde	HYDEL_WFHF_MDR00098	HYDEL_WFHF_MDR00098	401; 402; 403; 801; 802	801; 802
8698	Inferior Venacavagram and IVC Filter Placement	HYDEL_WFHF_MDR00172	HYDEL_WFHF_MDR00173	401; 402; 403; 801; 802	801; 802
8699	Interventional Radiology Post-Procedure Note	HYDEL_WFHF_MDR00118	HYDEL_WFHF_MDR00118	401; 402; 403; 801; 802	801; 802
8700	IR Tech Note	HYDEL_WFHF_MDR00109	HYDEL_WFHF_MDR00109	401; 402; 403; 801; 802	801; 802
8701	Hematology Consultation	HYDEL_WFHF_MDR00105	HYDEL_WFHF_MDR00107	401; 402; 403; 801; 802	801; 802
8702	Pulmonary Consultation	HYDEL_WFHF_MDR00102	HYDEL_WFHF_MDR00104	401; 402; 403; 801; 802	801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8703	Discharge Summary	HYDEL_WFHF_MDR00083	HYDEL_WFHF_MDR00084	401; 402; 403; 801; 802	801; 802
8704	Clinical History Profile	HYDEL_WFHF_MDR00070	HYDEL_WFHF_MDR00073	401; 402; 403; 801; 802	801; 802
8705	ER Visit	HYDEL_WFHF_MDR00055	HYDEL_WFHF_MDR00060	401; 402; 403; 801; 802	801; 802
8706	CTA of Chest	HYDEL_WFHF_MDR00064	HYDEL_WFHF_MDR00065	401; 402; 403; 801; 802	801; 802
8707	Neurology Consultation - Sleep Evaluation	HYDE_WFMG_MDR00072	HYDE_WFMG_MDR00073	401; 402; 403; 801; 802	801; 802
8708	Pulmonary Visit	HYDE_WFMG_MDR00068	HYDE_WFMG_MDR00069	401; 402; 403; 801; 802	801; 802
8709	Abdominal Ultrasound	HYDEL_LVRSR_MDR00001	HYDEL_LVRSR_MDR00000	401; 402; 403; 801; 802	801; 802
8710	CT of Abdomen and Pelvis	HYDEL_LVRSR_MDR00005	HYDEL_LVRSR_MDR00000	401; 402; 403; 801; 802	801; 802
8711	X-ray of Abdomen (KUB)	HYDEL_LVRSR_MDR00007	HYDEL_LVRSR_MDR00000	401; 402; 403; 801; 802	801; 802
8712	Hematology Consultation - Dr Thummala	HYDEL_CCCN_MDR00031	HYDEL_CCCN_MDR00033	401; 402; 403; 801; 802	801; 802
8713	Office Visit (PCP) - Dr Sparks	HYDEL_SPARKFM_MDR00009	HYDEL_SPARKFM_MDR00009	401; 402; 403; 801; 802	801; 802
8714	Office Visit (PCP) - Jennifer Powers, APN	HYDEL_SPARKFM_MDR00009	HYDEL_SPARKFM_MDR00009	401; 402; 403; 801; 802	801; 802
8715	ER Visit	HYDEL_SHMC_MDR00251	HYDEL_SHMC_MDR00257	401; 402; 403; 801; 802	801; 802
8716	X-ray of Ribs and Chest	HYDEL_SHMC_MDR00303	HYDEL_SHMC_MDR00303	401; 402; 403; 801; 802	801; 802
8717	Rheumatology Consultation - Dr Grant	HYDEL_TUHC_MDR00003	HYDEL_TUHC_MDR000006	401; 402; 403; 801; 802	801; 802
8718	Office Visit (PCP) - Dr Sparks	HYDEL_SPARKFM_MDR00009	HYDEL_SPARKFM_MDR00009	401; 402; 403; 801; 802	801; 802
8719	Pain Consultation - Dr Reyes	HYDEL_CIPM_MDR00001	HYDEL_CIPM_MDR00004	401; 402; 403; 801; 802	801; 802
8720	CT of Abdomen and Pelvis	HYDEL_WVI_RAD00002	HYDEL_WVI_RAD00003	401; 402; 403; 801; 802	801; 802
8721	Office Visit (PCP) - Jay Cology, PA	HYDEL_SPARKFM_MDR00009	HYDEL_SPARKFM_MDR00009	401; 402; 403; 801; 802	801; 802
8722	CT of Abdomen and Pelvis	HYDEL_SDMIC_RAD00018	HYDEL_SDMIC_RAD00019	401; 402; 403; 801; 802	801; 802
8723	Telephone Notes (PCP) - Jay Cology, PA	HYDE_LISA_000448	HYDE_LISA_000448	401; 402; 403; 801; 802	801; 802
8724	Office Visit (Heme) - Dr Thummala	HYDEL_CCCN_MDR00026	HYDEL_CCCN_MDR00028	401; 402; 403; 801; 802	801; 802
8725	X-ray of Chest	HYDEL_SDMIC_RAD00027	HYDEL_SDMIC_RAD00027	401; 402; 403; 801; 802	801; 802
8726	Office Visit (PCP) - Jay Cology, PA	HYDEL_SPARKFM_MDR00009	HYDEL_SPARKFM_MDR00009	401; 402; 403; 801; 802	801; 802
8727	Telephone Note (PCP) - Dr Sparks	HYDE_LISA_000438	HYDE_LISA-000438	401; 402; 403; 801; 802	801; 802
8728	CT of Chest	HYDEL_LVRSR_MDR00009	HYDEL_LVRSR_MDR000010	401; 402; 403; 801; 802	801; 802
8729	Cardiology Consultation - Dr Shehane	HYDEL_NHVC_MDR00002	HYDEL_NHVC_MDR00005	401; 402; 403; 801; 802	801; 802
8730	Echocardiogram	HYDEL_NHVC_RAD00003	HYDEL_NHVC_RAD00003	401; 402; 403; 801; 802	801; 802
8731	Cardiology Visit - Dr Shehane	HYDEL_NHVC_MDR00006	HYDEL_NHVC_MDR00008	401; 402; 403; 801; 802	801; 802
8732	Office Visit (PCP) - Dr Lehrner	HYDEL_SLEHR_MDR00088	HYDEL_SLEHR_MDR00092	401; 402; 403; 801; 802	801; 802
8733	Office Visit (Heme) - Dr Thummala	HYDEL_CCCN_MDR00023	HYDEL_CCCN_MDR00025	401; 402; 403; 801; 802	801; 802
8734	Interventional Radiology Consult - Dr Kuo	HYDEL_SHC_MDR00017	HYDEL_SHC_MDR00020	401; 402; 403; 801; 802	801; 802
8735	History and Physical	HYDEL_SHC_MDR00037	HYDEL_SHC_MDR00040	401; 402; 403; 801; 802	801; 802
8736	Echocardiogram	HYDEL_SHC_MDR00009	HYDEL_SHC_MDR00012	401; 402; 403; 801; 802	801; 802
8737	Consent (1) - Filter Retrieval	HYDEL_SHC_MDR00214	HYDEL_SHC_MDR00214	401; 402; 403; 801; 802	801; 802
8738	Consent (2) - Filter Retrieval	HYDEL_SHC_MDR00228	HYDEL_SHC_MDR00229	401; 402; 403; 801; 802	801; 802
8739	Filter Retrieval Note	HYDEL_SHC_MDR00054	HYDEL_SHC_MDR00056	401; 402; 403; 801; 802	801; 802
8740	Filter Procedure Log	HYDEL_SHC_MDR00219	HYDEL_SHC_MDR00225	401; 402; 403; 801; 802	801; 802
8741	IR Post-Operative Note	HYDEL_SHC_MDR00044	HYDEL_SHC_MDR00044	401; 402; 403; 801; 802	801; 802
8742	Pathology Request Form	HYDEL_SHC_MDR00236	HYDEL_SHC_MDR00236	401; 402; 403; 801; 802	801; 802
8743	Filter Pathology Report	HYDEL_SHC_MDR00061	HYDEL_SHC_MDR00062	401; 402; 403; 801; 802	801; 802
8744	Discharge Summary	HYDEL_SHC_MDR00035	HYDEL_SHC_MDR00037	401; 402; 403; 801; 802	801; 802
8745	Office Visit (PCP) - Dr Lehrner	HYDEL_SLEHR_MDR00093	HYDEL_SLEHR_MDR00096	401; 402; 403; 801; 802	801; 802
8746	Office Visit (Heme) - Dr Thummala	HYDEL_CCCN_MDR00020	HYDEL_CCCN_MDR00022	401; 402; 403; 801; 802	801; 802
8747	CT of Chest - original report	HYDEL_SDMIC_RAD00026	HYDEL_SDMIC_RAD00026	401; 402; 403; 801; 802	801; 802
8748	CT of Chest - corrected report [only added asthma history]	HYDEL_SDMIC_RAD00007	HYDEL_SDMIC_RAD00007	401; 402; 403; 801; 802	801; 802
8749	Office Visit (PCP) - Dr Lehrner	HYDEL_SLEHR_MDR00106	HYDEL_SLEHR_MDR00109	401; 402; 403; 801; 802	801; 802
8750	Office Visit (Heme) - Dr Thummala	HYDEL_CCCN_MDR00017	HYDEL_CCCN_MDR00019	401; 402; 403; 801; 802	801; 802
8751	Office Visit (Heme) - Dr Thummala	HYDEL_CCCN_MDR00014	HYDEL_CCCN_MDR00016	401; 402; 403; 801; 802	801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8752	Office Visit (PCP) - Dr Lehrner	HYDEL_SLEHR_MDR00138	HYDEL_SLEHR_MDR00142	401; 402; 403; 801; 802	801; 802
8753	Office Visit (Sleep Apnea) - Dr Molin	HYDEL_SLEHR_MDR00143	HYDEL_SLEHR_MDR00146	401; 402; 403; 801; 802	801; 802
8754	Office Visit (PCP) - Dr Lehrner	HYDEL_SLEHR_MDR00147	HYDEL_SLEHR_MDR00151	401; 402; 403; 801; 802	801; 802
8755	X-ray of Chest	HYDEL_SHMC_MDR00217	HYDEL_SHMC_MDR00217	401; 402; 403; 801; 802	801; 802
8756	History and Physical	HYDEL_SHMC_MDR00076	HYDEL_SHMC_MDR00079	401; 402; 403; 801; 802	801; 802
8757	CTA of Chest	HYDEL_SHMC_MDR00216	HYDEL_SHMC_MDR00216	401; 402; 403; 801; 802	801; 802
8758	Myocardial Perfusion Scan	HYDEL_SHMC_MDR00218	HYDEL_SHMC_MDR00218	401; 402; 403; 801; 802	801; 802
8759	Lexiscan Stress Test	HYDEL_SHMC_MDR00023	HYDEL_SHMC_MDR00023	401; 402; 403; 801; 802	801; 802
8760	Discharge Summary	HYDEL_SHMC_MDR00038	HYDEL_SHMC_MDR00042	401; 402; 403; 801; 802	801; 802
8761	Office Visit (Sleep Apnea) - Dr Molin	HYDEL_SLEHR_MDR00010	HYDEL_SLEHR_MDR00013	401; 402; 403; 801; 802	801; 802
8762	Office Visit (PCP) - Dr Lehrner	HYDEL_SLEHR_MDR00040	HYDEL_SLEHR_MDR00044	401; 402; 403; 801; 802	801; 802
8763	Office Visit (Heme) - Dr Thummala	HYDEL_CCCN_MDR00002	HYDEL_CCCN_MDR00004	401; 402; 403; 801; 802	801; 802
8764	Lisa Hyde's Answers to Bard's First Set of Non-Uniform Interrogatories (7/28/17)			401; 402; 403; 801; 802	801; 802
8765	Lisa Hyde's Response to Bard's First Request for Production of Documents (7/28/17)			401; 402; 403; 801; 802	801; 802
8766	Lisa Hyde's Answers to Bard's Supplemental of Non-Uniform Interrogatories (8/15/17)			401; 402; 403; 801; 802	801; 802
8767	Lisa Hyde's Response to Bard's Supplemental Request for Production of Documents (8/15/17)			401; 402; 403; 801; 802	801; 802
8768	Henry, MD, David A Deposition, 2017.04.06 Exhibit 2128			401; 402; 403; 801; 802	801; 802
8769	Henry, MD, David A Deposition, 2017.04.06 Exhibit 2129			401; 402; 403; 801; 802	801; 802
8770	Hyde, Lisa Deposition, 2017.01.25 Exhibit A			401; 402; 403; 801; 802	801; 802
8771	Hyde, Lisa Deposition, 2017.01.25 Exhibit B			401; 402; 403; 801; 802	801; 802
8772	Hyde, Lisa Deposition, 2017.01.25 Exhibit C			401; 402; 403; 801; 802	801; 802
8773	Hyde, Lisa Deposition, 2017.01.25 Exhibit D			401; 402; 403; 801; 802	801; 802
8774	Hyde, Lisa Deposition, 2017.01.25 Exhibit E			401; 402; 403; 801; 802	801; 802
8775	Hyde, Mark Deposition, 2017.01.25 Exhibit A			401; 402; 403; 801; 802	801; 802
8776	Hyde, Mark Deposition, 2017.01.25 Exhibit B			401; 402; 403; 801; 802	801; 802
8777	Hyde, Mark Deposition, 2017.01.25 Exhibit C			401; 402; 403; 801; 802	801; 802
8778	Kuo, MD, William Deposition, 2017.03.23 Exhibit 01			401; 402; 403; 801; 802	801; 802
8779	Kuo, MD, William Deposition, 2017.03.23 Exhibit 02			401; 402; 403; 801; 802	801; 802
8780	Kuo, MD, William Deposition, 2017.03.23 Exhibit 03			401; 402; 403; 801; 802	801; 802
8781	Kuo, MD, William Deposition, 2017.03.23 Exhibit 04			401; 402; 403; 801; 802	801; 802
8782	Kuo, MD, William Deposition, 2017.03.23 Exhibit 05			401; 402; 403; 801; 802	801; 802
8783	Kuo, MD, William Deposition, 2017.03.23 Exhibit 06			401; 402; 403; 801; 802	801; 802
8784	Kuo, MD, William Deposition, 2017.03.23 Exhibit 07			401; 402; 403; 801; 802	801; 802
8785	Kuo, MD, William Deposition, 2017.03.23 Exhibit 08			401; 402; 403; 801; 802	801; 802
8786	Kuo, MD, William Deposition, 2017.03.23 Exhibit 09			401; 402; 403; 801; 802	801; 802
8787	Kuo, MD, William Deposition, 2017.03.23 Exhibit 10			401; 402; 403; 801; 802	801; 802
8788	Poll, MD, David Deposition, 2017.08.03 Exhibit 1053			401; 402; 403; 801; 802	801; 802
8789	Poll, MD, David Deposition, 2017.08.03 Exhibit 1054			401; 402; 403; 801; 802	801; 802
8790	Poll, MD, David Deposition, 2017.08.03 Exhibit 1055			401; 402; 403; 801; 802	801; 802
8791	Poll, MD, David Deposition, 2017.08.03 Exhibit 1056			401; 402; 403; 801; 802	801; 802
8792	Sparks, MD, Amy R Deposition, 2017.07.07 Exhibit 01			401; 402; 403; 801; 802	801; 802
8793	Sparks, MD, Amy R Deposition, 2017.07.07 Exhibit 02			401; 402; 403; 801; 802	801; 802
8794	Defense Fact Sheet served 8/29/16			401; 402; 403; 801; 802	801; 802
8795	Supplemental Defense Fact Sheet served 8/1/17			401; 402; 403; 801; 802	801; 802
8796	Bard Miscellaneous Income form for Kuo	DFS_HydeL_CV-16-00893_000001	DFS_HydeL_CV-16-00893_000002	401; 402; 403; 801; 802	801; 802
8797	Bard complaint file	DFS_HydeL_CV-16-00893_000003	DFS_HydeL_CV-16-00893_000028	401; 402; 403; 801; 802	801; 802
8798	Tim Hug Resume	DFS_HydeL_CV-16-00893_000029	DFS_HydeL_CV-16-00893_000030	401; 402; 403; 801; 802	801; 802
8799	Matthew Fermanich Resume	DFS_HydeL_CV-16-00893_000031	DFS_HydeL_CV-16-00893_000033	401; 402; 403; 801; 802	801; 802

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8800	Physician search results- Kuo	DFS_HydeL_CV-16-00893_000034	DFS_HydeL_CV-16-00893_000073	401; 402; 403; 801; 802	801; 802
8801	Physician search results- Shehane	DFS_HydeL_CV-16-00893_000074		401; 402; 403; 801; 802	801; 802
8802	Physician search results- Reyes	DFS_HydeL_CV-16-00893_000075		401; 402; 403; 801; 802	801; 802
8803	Facility sales information	DFS_HydeL_CV-16-00893_000076	DFS_HydeL_CV-16-00893_000077	401; 402; 403; 801; 802	801; 802
8804	Bard complaint file	DFS_HydeL_CV-16-00893_000078	DFS_HydeL_CV-16-00893_000113	401; 402; 403; 801; 802	801; 802
8805	Defense Profile Form served 6/2/2016			401; 402; 403; 801; 802	801; 802
8806	Kuo Bard consulting agreement amendment	DPF-HydeL_CV-16-00893_000001		401; 402; 403; 801; 802	801; 802
8807	Kuo consulting agreement with Bard	DPF-HydeL_CV-16-00893_000002	DPF-HydeL_CV-16-00893_000007	401; 402; 403; 801; 802	801; 802
8808	Bard complaint file	DPF-HydeL_CV-16-00893_000008	DPF-HydeL_CV-16-00893_000021	401; 402; 403; 801; 802	801; 802
8809	Physician search results- Henry	DPF-HydeL_CV-16-00893_000022	DPF-HydeL_CV-16-00893_000023	401; 402; 403; 801; 802	801; 802
8810	Plaintiff Fact Sheet, verified 7/19/16			401; 402; 403; 801; 802	801; 802
8811	Social Media produced with Plaintiff Fact Sheet			401; 402; 403; 801; 802	801; 802
8812	Medical records produced with Plaintiff Fact Sheet			401; 402; 403; 801; 802	801; 802
8813	Plaintiff Profile Form and accompanying medical record, verified 5/5/16			401; 402; 403; 801; 802	801; 802
8814	Social Media- Mrs Hyde			401; 402; 403; 801; 802	801; 802
8815	Social Media- Mr Hyde			401; 402; 403; 801; 802	801; 802
8816	Exemplar Eclipse filter			401; 402; 403; 801; 802	
8817	Exemplar G2X filter			401; 402; 403; 801; 802	
8818	Exemplar SNF filter			401; 402; 403; 801; 802	
8819	MAUDE reports regarding permanent filters			401; 402; 403; 801; 802	801; 802
8820	Expert Report from Dr. Morris for Plaintiff Hyde			401; 402; 403; 801; 802	801; 802
8821	Expert Report from Dr. Poll for Plaintiff Hyde			401; 402; 403; 801; 802	801; 802
8822	10/14/15 Medication List	HYDEL_LVRSR_MDR00098	HYDEL_LVRSR_MDR00098	401; 402; 403; 801; 802	801; 802
8823	10/20/16 Office Visit	HYDEL_CCDD_MDR00015	HYDEL_CCDD_MDR00016	401; 402; 403; 801; 802	801; 802
8824	11/07/17 Office Visit	HYDEL_SLEHR_MDR00200	HYDEL_SLEHR_MDR00201	401; 402; 403; 801; 802	801; 802
8825	June 19, 2006 EVEREST Medical Monitor Meeting Powerpoint	BPV-17-01-00155189	BPV-17-01-00155204	401; 402; 403; 801; 802	801; 802
8826	Product identification sales document	BPV-17-01-00262748	BPV-17-01-00262748	401; 402; 403; 801; 802	801; 802
8827	Product identification invoice documents	BPV-17-01-00262749	BPV-17-01-00262756	401; 402; 403; 801; 802	801; 802
8828	Defendants' Exhibit 1 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8829	Defendants' Exhibit 2 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8830	Defendants' Exhibit 3 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8831	Defendants' Exhibit 4 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8832	Defendants' Exhibit 5 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8833	Defendants' Exhibit 6 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8834	Defendants' Exhibit 7 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8835	Defendants' Exhibit 8 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8836	Defendants' Exhibit 9 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8837	Defendants' Exhibit 10 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8838	Defendants' Exhibit 11 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8839	Defendants' Exhibit 12 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8840	Defendants' Exhibit 13 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8841	Defendants' Exhibit 14 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8842	Demonstrative depiction of timeline of plaintiff's relevant medical events			Plaintiffs reserve the right to object until the demonstrative is produced.	
8843	Demonstrative depiction of the plaintiff's IVC filter at placement			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Hyde v. C.R. Bard, et al.

Exhibit	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8844	Demonstrative depiction of the plaintiff's IVC filter at retrieval			Plaintiffs reserve the right to object until the demonstrative is produced.	
8845	Demonstrative depiction of the plaintiff's IVC filter in 2011			Plaintiffs reserve the right to object until the demonstrative is produced.	
8846	Demonstrative depiction of the plaintiff's IVC filter in 2012			Plaintiffs reserve the right to object until the demonstrative is produced.	
8847	Demonstrative depiction of the plaintiff's IVC filter in 2013			Plaintiffs reserve the right to object until the demonstrative is produced.	
8848	Demonstrative depiction of the plaintiff's IVC filter in 2014			Plaintiffs reserve the right to object until the demonstrative is produced.	
8849	Demonstrative depiction of fragment of the plaintiff's IVC filter in 2014			Plaintiffs reserve the right to object until the demonstrative is produced.	
8850	Demonstrative depiction of the plaintiff's heart post-retrieval in 2015			Plaintiffs reserve the right to object until the demonstrative is produced.	
8851	Demonstrative depiction of the plaintiff's heart post-retrieval in 2016			Plaintiffs reserve the right to object until the demonstrative is produced.	
8852	Demonstrative depiction of the plaintiff's heart post-retrieval in 2017			Plaintiffs reserve the right to object until the demonstrative is produced.	
8853	Demonstrative depiction of the plaintiff's heart post-retrieval in 2018			Plaintiffs reserve the right to object until the demonstrative is produced.	
8854	Demonstrative depiction of the IVC filter fragment in the plaintiff's heart			Plaintiffs reserve the right to object until the demonstrative is produced.	
8855	Demonstrative depiction of the procedure to remove the plaintiff's IVC filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8856	Demonstrative depiction of the percutaneous procedure to remove the IVC filter strut from the plaintiff's heart			Plaintiffs reserve the right to object until the demonstrative is produced.	
8857	Demonstrative depiction of timeline of plaintiff's relevant medical events			Plaintiffs reserve the right to object until the demonstrative is produced.	
8858	Demonstrative regarding G2X and/or Eclipse filter for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8859	Demonstrative regarding G2X and/or Eclipse filter for Dr. Briant			Plaintiffs reserve the right to object until the demonstrative is produced.	
8860	Demonstrative regarding G2X and/or Eclipse filter for Dr. Feigal			Plaintiffs reserve the right to object until the demonstrative is produced.	
8861	Demonstrative regarding G2X and/or Eclipse filter for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8862	Demonstrative regarding G2X and/or Eclipse filter for Dr. Brauer			Plaintiffs reserve the right to object until the demonstrative is produced.	
8863	Demonstrative regarding G2X and/or Eclipse filter for Dr. Tillman			Plaintiffs reserve the right to object until the demonstrative is produced.	
8864	Demonstrative regarding G2X and/or Eclipse filter for Dr. Stein			Plaintiffs reserve the right to object until the demonstrative is produced.	
8865	Demonstrative regarding G2X and/or Eclipse filter for Dr. Herbst			Plaintiffs reserve the right to object until the demonstrative is produced.	
8866	Demonstrative regarding G2X and/or Eclipse filter for Dr. Morris			Plaintiffs reserve the right to object until the demonstrative is produced.	
8867	Demonstrative regarding G2X and/or Eclipse filter for Dr. Poll			Plaintiffs reserve the right to object until the demonstrative is produced.	
8868	Demonstrative regarding the plaintiff's medical care for Dr. Morris			Plaintiffs reserve the right to object until the demonstrative is produced.	
8869	Demonstrative regarding the plaintiff's medical care for Dr. Poll			Plaintiffs reserve the right to object until the demonstrative is produced.	
8870	Demonstrative regarding timeline of the plaintiff's medical course			Plaintiffs reserve the right to object until the demonstrative is produced.	
8871	Demonstrative depiction of Ms. Hyde's 02/24/11 CT scan			Plaintiffs reserve the right to object until the demonstrative is produced.	
8872	Demonstrative depiction of Ms. Hyde's 02/25/11 echocardiogram			Plaintiffs reserve the right to object until the demonstrative is produced.	

[illegible]

[illegible]